



*advances into transforming challenges*

That's  
the history,  
and  
the future,  
of  
Eli Lilly  
and Company.

2011 Annual Report  
Notice of 2012 Annual Meeting  
Proxy Statement

## Transforming

*As we enter 2012, Eli Lilly and Company comes face to face with the most challenging period in its 135-year history. A series of patent expirations for some of our largest products place downward pressure on our revenue at a time when we must invest to deliver the full promise of our pipeline, including 12 molecules—the most ever—in Phase III testing.*

*Yet we remain confident in our time-tested ability to transform this significant challenge into advances—new medicines that will push forward the frontiers of science and provide hope, healing, and health to the millions of people who depend on us.*

*The foundation of our success, as always, will be our talented Lilly associates, whose dedication and commitment to our important mission have never wavered. Working with partners around the world, we will forge ahead in our quest to find solutions for some of our most vexing health care challenges, including cancer, Alzheimer's disease, diabetes, and mental illness.*

*Transforming challenges into advances: This is the subtitle of our company's proud history. We're doing it still today. We'll be doing it tomorrow.*

## The Lilly Promise

### Our Mission

Lilly makes medicines that help people live longer, healthier, more active lives.

### Our Values

#### Integrity | Excellence | Respect for People

We promise to operate our business with absolute integrity and earn the trust of all, set the highest standards for our performance and for the performance of our products, and demonstrate caring and respect for all those who share in our mission and are touched by our work.

### Our Vision

We will make a significant contribution to humanity by improving global health in the 21st century. Starting with the work of our scientists, we will place improved outcomes for individual patients at the center of what we do. We will listen carefully to understand patient needs and work with health care partners to provide meaningful benefits for the people who depend on us.

### Our Strategy

We will create value for all our stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients.

## Year in Review

- 1 Financial Highlights
- 2 Letter to Shareholders
- 6 Transforming Challenges into Advances: Lilly People in Action
- 9 Pipeline of Molecules in Clinical Development

## Form 10-K

- 2 Products
- 17 Results of Operations
- 31 Consolidated Statements of Operations
- 32 Consolidated Statements of Comprehensive Income
- 33 Consolidated Balance Sheets
- 34 Consolidated Statements of Cash Flows
- 35 Segment Information
- 36 Selected Quarterly Data
- 37 Selected Financial Data
- 39 Notes to Consolidated Financial Statements
- 66 Management's Reports
- 67 Reports of Independent Registered Public Accounting Firm

For more information on Lilly's commitment to corporate responsibility, please see the inside back cover of this report.

## Proxy Statement

- 1 Notice of 2012 Annual Meeting and Proxy Statement
- 2 Proxy Statement Overview
- 4 Board of Directors
- 11 Highlights of the Company's Corporate Governance Guidelines
- 16 Committees of the Board of Directors
- 17 Membership and Meetings of the Board and Its Committees
- 18 Director Compensation
- 20 Directors and Corporate Governance Committee Matters
- 21 Audit Committee Matters
- 23 Compensation Committee Matters
- 25 Compensation Discussion and Analysis
- 39 Executive Compensation
- 39 Summary Compensation Table
- 49 Ownership of Company Stock
- 51 Items of Business To Be Acted Upon at the Meeting
- 57 Meeting and Voting Logistics
- 60 Other Matters
- 61 Appendix A

## Corporate Information

- 1 Executive Committee and Senior Leadership
- 2 Corporate Information
- 5 Annual Meeting Admission Ticket

## 2011 Financial Highlights


Eli Lilly and Company and Subsidiaries (Dollars in millions, except per-share data)	Year Ended December 31	2011	2010	Change %
Revenue		\$24,286.5	\$23,076.0	5
Research and development		5,020.8	4,884.2	3
Research and development as a percent of revenue		20.7%	21.2%	
Net income		\$4,347.7	\$ 5,069.5	(14)
Earnings per share—diluted		3.90	4.58	(15)
Reconciling items <sup>1</sup> :				
Acquired in-process research and development (IPR&D)		.23	.03	
Asset impairments, restructuring, and other special charges		.29	.13	
Non-GAAP earnings per share—diluted		<u>4.41<sup>2</sup></u>	<u>4.74</u>	(7)
Dividends paid per share		1.96	1.96	—
Capital expenditures		672.0	694.3	(3)
Employees		38,080	38,350	(1)

<sup>1</sup> For more information on these reconciling items, see the Financial Results section of the Executive Overview on page 17 of the Form 10-K.

<sup>2</sup> Numbers in the 2011 column do not add due to rounding.


### Revenue Growth Across Business Areas (\$ millions, percent growth)

Revenue in Neuroscience, led by Zyprexa and Cymbalta, increased 3 percent compared with 2010. Endocrinology, led by Humalog and Humulin, grew 11 percent and represents 28 percent of total revenue. Cardiovascular increased by 15 percent, and Animal Health grew 21 percent. Oncology declined 11 percent due to generic competition in most major markets for Gemzar.




### Return on Assets and Shareholders' Equity

ROA and ROE decreased from 2010 primarily due to lower net income attributable to lower gross margin as a percent of sales and higher operating expenses.



### Total Shareholder Return

In 2011, the steady dividend stream and a 19 percent increase in the stock price contributed to Lilly's total shareholder return of 24.9 percent, which compared favorably against the S&P 500 benchmark.



## To Our Shareholders

Out of more than 5,000 publicly traded U.S. companies, only six companies as big as Lilly have operated under the same name longer than we have. We're very proud of our heritage, but we know that longevity provides no guarantee of future success. Not for Lilly, not for anybody.

It's not the strongest who survive; it's those who are able to adapt to change. We must continue to do just that, as we have for 135 years, with a sense of urgency befitting the challenge we face in the current period of major patent expirations—the period we call YZ.

But YZ is just the most immediate hurdle. Change is all around us: increasing demands from patients, payers, regulators, and governments; an abundance of low-cost generic medicines; economic turmoil; and higher hurdles for drug discovery and development. These combine to set the bar for pharmaceutical innovation higher than it's ever been.

Despite these challenges, we can remain certain of the many important unmet medical needs, particularly as societies grow older; of the crucial role played by modern medicines in the provision of high-quality and cost-effective health care; and of rising global living standards that are the direct result of our work and serve to increase the demand for our medicines.

We're confident that we can transform our challenges into advances—for patients, and for our company. That's what we've done throughout our history, and it's what we're doing today. On the pages following this letter, we highlight five stories of employees who are transforming our company, the way we pursue science, and the way we do business. (See pages 6-8.)

Yet even as we carry out this transformation, we must continue to deliver solid results and execute on our strategy to bridge YZ and return to growth. In this letter I'll report on those efforts.

### Strong performance in 2011

In 2011, Lilly grew worldwide revenue by 5 percent, despite a 2 percent fourth-quarter decline in revenue. That decline reflects what we knew was coming—the initial impact of the Zyprexa® patent loss in both the U.S. and most major markets outside Japan, and continued erosion of Gemzar® sales due to generic competition.

For the year, revenue topped \$24 billion, as seven products and our animal health portfolio all exceeded \$1 billion in annual sales. Of note, Cymbalta® surpassed \$4 billion in sales, and our insulins—Humalog® and Humulin®—together achieved their first-ever billion-dollar quarter as we closed the year.

The counter-cyclical growth engines we described last year—Japan, emerging markets, and our Elanco animal health business—delivered, too. For the full year, revenues in Japan grew by 31 percent. Animal health turned in its

best growth—21 percent—in at least a decade. And though growth has moderated a bit in our emerging markets, China was a standout with 31 percent revenue growth.

Now let me look ahead. First, I'll review our plans to bridge the YZ period of patent expirations from now through 2014. Then, I'll turn to our long-term strategy for resuming growth coming out of YZ.

### Bridging YZ

Our strategy for YZ is to continue to grow sales volumes of our currently marketed products, harvest the fruits of our investments in

our counter-cyclical growth engines, and supplement our internal growth with business development—while improving productivity. This will allow us to fund our innovation-based strategy and, specifically, a pipeline that can deliver long-term growth.

Since 2004, we've doubled productivity as measured by sales per employee. And beginning in 2009, we stepped up the pace of resizing our organization for the post-Zyprexa period, reducing senior management by a quarter and significantly restructuring everything from our support operations to our sales and marketing organization.

We met the goals we committed to reach by the end of 2011—reducing our projected expenses by more than \$1 billion, and reducing staff by more than 5,500, excluding strategic additions from acquisitions and in high-growth emerging markets and Japan.

As a result, each year through 2014, we expect revenue to be at least \$20 billion, net income to be at least \$3 billion, and operating cash flow to be at least \$4 billion. Given our strategy, we will continue to have ample cash to meet our needs throughout this period. And we will continue to

*We're confident that we can transform our challenges into advances—for patients, and for our company. That's what we've done throughout our history, and it's what we're doing today.*



*John C. Lechleiter, Ph.D., chairman, president, and chief executive officer (center), meets with employees at Lilly's biotechnology manufacturing facility in Sesto Fiorentino, Italy. The state-of-the-art operations at Sesto include formulating, filling, and packaging Humalog and Humulin cartridges and pens. The site has achieved a dramatic transformation from a historical focus on antibiotics to a mission that today has insulin manufacturing and diabetes treatment at its core. The transformation at Sesto is part of an ongoing effort to expand manufacturing capacity to meet growing demand for Lilly's diabetes-care portfolio. (See page 8.)*

*During a visit in June 2011, Lechleiter toured the insulin cartridge-filling operations at Sesto, and reviewed progress toward further expansion of Sesto's insulin pen assembly capabilities. Lilly employees with John in a soon-to-be-opened area of the facility are (left to right) Cristina Lastrucci, biological laboratory specialist; Giovanni Fiesoli, manufacturing junior technician; Cristiana Fracassini, leader insulin line 2 project; Andrea Froio, utilities and maintenance junior manager.*

pay the dividend at least at its current level. It's critically important to management, our board of directors, and shareholders—and we have no intention of cutting it.

### Innovation for the long run

As we look to the future beyond YZ, Lilly remains firmly committed to innovation. Our company is not shifting its focus to generics or consumer products. And we're not pursuing a big merger. We're committed to maintaining our investment in R&D through the current period of patent expirations, and we're keeping our focus on the keys to Lilly's long-term success:

- a pipeline that reflects successful and productive pursuit of innovation,
- an external environment that enables medical innovation to flourish, and
- the transformation of our own company to ensure that we can continue to deliver innovative medicines valued by our customers.

### Replenishing and advancing our pipeline

The future growth—indeed, the very survival—of our company depends on a robust pipeline of innovative medicines that meet the needs of patients. We ended 2011 with the highest number of molecules we've ever had in Phase III development, and through the year we sustained a strong flow of new molecules into the pipeline. Overall, since our 2010 annual report, we've moved 13 new assets into Phase I, eight into Phase II, and four into Phase III, and we've launched one new medicine, while terminating the development of 12 molecules. (See page 9.)

With the addition of these molecules, we have 12 potential new medicines in Phase III testing, surpassing our goal of 10 by the end of 2011. The large majority of the molecules in our Phase III portfolio come with convincing Phase II clinical data. And I'm pleased to note that 11 of the 12 assets come from our own labs, including ImClone.


New entries into Phase III since our 2010 annual report include mGlu2/3 receptor agonist, now known as pomaglumetad methionil, for schizophrenia; the anti-IL-17 monoclonal antibody, now ixekizumab, for psoriasis; and two potential treatments for diabetes—a novel basal insulin analog and a new insulin glargine product.

Two Phase III trials for solanezumab, our monoclonal antibody being studied as a potential treatment to slow the

progression of mild to moderate Alzheimer's disease, are scheduled to be completed in the second half of 2012. We have additional molecules in our pipeline for Alzheimer's, including our oral BACE inhibitor, which will initiate a Phase Ia/Iib study this year.

Another late-stage molecule, ramucirumab from our ImClone unit, reached full enrollment in a Phase III breast cancer trial in November 2011. This is one of six ongoing Phase III trials with ramucirumab—as a single agent or in combination with chemotherapy—in five different tumor types: liver, gastric, colorectal, non-small cell lung, and breast cancers.

Yet another molecule that we expect to advance into Phase III testing in 2012 is our CETP inhibitor, evacetrapib. At the American Heart Association meeting in November 2011, we shared encouraging Phase II data showing that evacetrapib, in combination with each of three commonly used statins, increased HDL cholesterol and also incrementally decreased LDL cholesterol, both in a statistically significant manner. It's important to note that Phase III studies will still take years to complete and this is a very competitive area of research.



These molecules exemplify the progress we've made in building a robust, high-quality, mid- to late-stage pipeline, with an even mix of large and small molecules. We believe our current pipeline includes many potential opportunities to treat diseases with large unmet need, as well as significant commercial opportunity, and provides the foundation for Lilly to return to growth after 2014. This year, we'll begin to generate and disseminate important data that should help you better gauge our growth potential.

### Advocating for an environment for innovation

The second key to our long-term strategy is fostering an external environment supportive of the pursuit of innovation. We remain vigilant in advocating policies that are essential to the continued viability of our innovation model and essential for the discovery and development of new medicines.

In 2011, we saw some positive developments, most notably comprehensive patent reform in the United States and important progress in the area of international trade, including the U.S. trade agreement with South Korea.

We also avoided a serious threat, when the Congressional deficit-reduction committee failed to adopt a proposal to implement Medicaid-like rebates in the Medicare Part D prescription drug program. These rebates would have amounted to a new \$100 billion tax on the biopharmaceutical industry, and would severely hamper our industry's ability to innovate. Still, given our nation's ongoing debt crisis, we do not expect these kinds of risks to go away. And the challenges in Washington mirror those around the world, as health care budget pressures are compounded by financial crises.

We know that health care reform will be a perennial issue globally. Here in the U.S., the Supreme Court will issue a ruling in June on the health care reform law passed in 2009. No matter how the Court decides, the debate will continue.

We believe it's essential that health care policy appropriately reflect the value that innovative pharmaceuticals provide in meeting the growing health care needs of aging populations and helping patients avoid more costly interventions.

### ***Transforming the way we work***

We'll continue to make the case for policies that enable us to carry on the work of pharmaceutical innovation, but we know we can't control or often predict the environment. And because we can't, we must also focus on what we can control: the ongoing transformation of our company to succeed and thrive in the face of growing challenges.

This transformation goes on everywhere within our company, alongside the indispensable work of delivering strong performance day by day. Last year, we completed the restructuring we announced in 2009 and delivered the savings we promised by year-end 2011. Today, the work of transformation continues. The five stories that follow exemplify those efforts, but only scratch the surface of all that is going on across our company.

### **Innovation—Our heritage and our future**

Building on a heritage of transforming challenges into advances, and guided by an unwavering commitment to innovation, we are transforming Lilly to succeed and grow in a demanding environment.

We're successfully pursuing a sound strategy to maintain a level of earnings and cash flow through the YZ period

that will allow us to make the investments necessary to resume and sustain growth in the years beyond. We must continue to deliver strong business results by generating new growth from our key brands, our counter-cyclical growth engines, and from every corner of our business, even as we control our costs.

We've replenished our late-stage pipeline, and we have the largest Phase III cohort of molecules in our history, many of them addressing significant unmet medical needs. As we develop our pipeline, we must continue to transform the way we do research to sustain the flow of innovation.

For 135 years, the people of Lilly have overcome barriers and transformed them into advances for patients and for our company. That's what we do, through a passion for innovation and an intense desire to persevere despite long odds. In the midst of the struggle, challenges may seem daunting and progress slow. Looking back, the transformation is dramatic and inspiring.


I'm privileged to work with Lilly people around the world who are adding to the long and proud history of Eli Lilly and Company, transforming our company for the future even as they deliver results here and now. Special thanks to Bryce Carmine, who led our Bio-Medicines organization, and Dr. Frank Deane, who led manufacturing—both of whom retired at year-end after 30-plus years of dedicated service to our company.

And thanks to you, our shareholders, for your continued trust and support as we transform challenges into advances in our quest for innovative medicines that can make a real difference for patients around the world.

For the Board of Directors,



John C. Lechleiter  
*Chairman, President, and Chief Executive Officer*



## *Transforming Challenges into Advances: Lilly People in Action*

Transformation is everywhere at Lilly. We're finding innovative ways to conduct research, to connect with customers, and to operate more efficiently in every area of our business. Each of the individuals pictured here represents the combined effort of a team of Lilly employees, and these stories are but examples of countless initiatives by their colleagues across the company. All these efforts support a common mission—to make medicines that help people live longer, healthier, more active lives.



### **DISCOVERY:** **Accessing molecules through open innovation**

*Marta Piñero-Núñez, Ph.D., director, open innovation drug discovery, builds relationships with academic scientists.*

We're opening the door for accessing promising molecules around the world with an innovative approach to collaborating with scientists in academia and small biotech companies.

In 2009, we launched the Lilly Phenotypic Drug Discovery Initiative, known as "PD<sup>2</sup>," and we expanded the program in 2011 under the banner of Open Innovation Drug Discovery.

Through this program, Lilly carries out screening tests—free of charge—on compounds submitted by outside researchers. In return, we retain first rights to negotiate an agreement with them. If no such agreement results, external researchers receive no-strings-attached ownership of the data report from Lilly to use as they see fit in publications, grant proposals, or further research.

By the end of 2011, more than 200 universities, research institutes, and small biotechs representing 25 countries were affiliated with the program, and we received some 84,000 chemical structures uploaded into our database for evaluation. Of these, we've evaluated more than 14,000 physical samples, the vast majority of which are structurally distinct from those in our compound collection. We've entered five collaborations, all ongoing.

We believe that open innovation significantly complements our internal efforts, leveraging our resources to discover potential new medicines.



**DEVELOPMENT:**  
**Overcoming delays in clinical trial enrollment**

*Jannell Franklin, consultant, critical chain project management, is helping cut the time for clinical trial sites to be ready to enroll patients.*

We're meeting ever-increasing clinical trial requirements for a growing pipeline and increasing regulatory demands, through a successful Six Sigma project to speed trial enrollment.

The Six Sigma project was aimed at getting clinical sites "regulatory ready"—completing the process to gain ethical review board and FDA authorization to enroll patients. To speed clinical trial readiness, the project applied a technique called critical chain project management (CCPM), and we established processes to ensure that gains would be sustained.

In the past, our key metric was reaching First Patient Visit (FPV) at any one site. While FPV remains a key milestone, we're now focusing on having *every* site ready to enroll patients. Achieving consistent and reliable readiness across all sites is key to reducing the overall time needed to complete a trial and obtain results.

Our clinical trial site services group has reduced time to reach "regulatory ready" by 25 percent at our North American clinical trial sites, and we've sustained those gains for three years. Based on that achievement, we began to replicate this process in other regions and among our clinical research partners in 2011. We're already seeing early success stories across regions, and we're now looking at other aspects of clinical trials where similar gains can be made.



**ADVANCED IT:**  
**Empowering global sales representatives**

*Richard Grogut, manager IT, global CRM implementation, is based in England as part of the team rolling out the mobile IT tool for Lilly sales reps worldwide.*


We're helping Lilly sales representatives around the world improve service to customers by equipping them with state-of-the-art mobile technologies.

In mid-2011, Lilly launched Veeva, the industry-leading customer relationship management (CRM) tool, to 2,500 field-based representatives in China—one of the largest corporate CRM deployments in the industry.

Lilly USA quickly followed, with Veeva deployed broadly across sales, managed health care, and its medical liaisons. Now the global CRM IT team is working with global commercial operations to ensure that all Lilly field personnel across all business organizations have access to Veeva—through PC, iPad, or BlackBerry—by the end of 2012.

This new cloud-based platform enables Lilly representatives to more easily enter and access information and to ensure that customers get the most out of their engagement with Lilly. The system is flexible and easy to navigate. So minimal training is required, thus allowing more time to be spent in face-to-face dialogue with customers—while helping to reduce implementation costs.

An unrelenting focus on standardizing global business processes and reporting is resulting in a single, mobile, and cost-effective solution for Lilly representatives around the world that combines a commitment to innovation with a focus on the customer.



The photo © Travis Dove for The Wall Street Journal.

**MANUFACTURING:**  
**Adding capacity without building new plants**

*Jim McDonough, Ph.D., senior research advisor, manufacturing science & technology, is helping to develop a new insulin manufacturing platform.*

We're meeting the challenge of achieving leadership in diabetes by expanding our capacity to satisfy increasing demand for our diabetes-care portfolio, while enhancing our cost position.

An ambitious technical agenda is in place to expand capacity and improve operating efficiency in insulin production. As a result, we expect to double manufacturing capacity in the coming years within our existing manufacturing footprint, which will support the needs of our customers while also improving our cost-competitiveness.

We're also enhancing our manufacturing capacity to enable expanded insulin cartridge production, for example, at our plant in Sesto Fiorentino, Italy (*see photo, page 3*).

A key to this technical agenda, in partnership with Lilly Diabetes and the Development Center of Excellence, is the adoption of common technology platforms across our manufacturing sites. In the coming years, we estimate that the cumulative economic benefit of our insulin manufacturing initiatives will equate to the value of a newly launched product.

Even more important is that these efforts to improve and standardize insulin production will also support our commitment to maintain our high standards of quality.

**SALES & MARKETING:**  
**Focusing on providing value to physicians**

*Michaelene Greenly, executive sales representative, neuroscience, Greensboro, N.C., was featured in The Wall Street Journal in January 2012.*

We're providing better support to physicians—while holding down costs—by transforming our approach to customer relationships.


With ever-growing demands on their time, physicians are limiting sales calls from pharmaceutical representatives. We've responded by transforming the role of Lilly representatives from selling to providing value as doctors themselves define it—completely changing our business model to build trust and improve satisfaction.

Our new Customer Engagement Model is based on research and insights into the challenges facing physicians. We've moved from a focus on reinforcing messages about our products to a genuine conversation with physicians about how we can help doctors better treat their patients.

In 2007, we launched pilots in Ohio and Wisconsin, and—based on improved customer ratings and sales in those states—we began restructuring and training our entire U.S. sales force in 2009. Today the sales force is one-third smaller than when we started—a recipe for shrinking market share under the old sales model—yet we have achieved continued growth in important Lilly brands.


Bottom line: We're using fewer resources to provide better service to physicians. And that, in turn, can lead to better patient outcomes.

# Pipeline of Molecules in Clinical Development



The Lilly Pipeline currently includes 67 molecules in clinical development. Since our 2010 annual report, 13 new molecules advanced into Phase I testing (including one currently in Phase III and one that has been terminated), eight molecules advanced into Phase II testing, and four molecules advanced into Phase III testing, and we launched one new medicine. We terminated development of 12 molecules, and one is currently on hold. We now have the largest Phase III pipeline in the history of the company, including eight new biotech entities and four new chemical entities. Additional information and updates are available on the Lilly Interactive Pipeline at [www.lilly.com](http://www.lilly.com).

In 2011, Elanco delivered eight new products from its pipeline with a number of regional approvals. In 2012, Elanco anticipates launching eight products from its pipeline and gaining 19 additional approvals globally. This includes products that augment the company's companion animal parasiticide franchise and products that will enhance food animals' productivity as well as food safety. Elanco continues to build a substantial development capability for animal health vaccines, and the recent acquisition of ChemGen will significantly accelerate Elanco's effort to develop in-feed enzymes.



Movement since 2010 Annual Report:  
 → Achieved Milestone  
 →→ Advanced Through Multiple Milestones  
 ↓ Attrition

\*Commercial Collaboration

†Development Currently On Hold

Information is current as of February 15, 2012. The search for new medicines is risky and uncertain, and there are no guarantees. Remaining scientific and regulatory hurdles may cause pipeline compounds to be delayed or to fail to reach the market.



*transforming challenges into advances*

*Lilly*

Form 10-K



**United States  
Securities and Exchange Commission  
Washington, D.C. 20549**

**Form 10-K**

**Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
for the fiscal year ended December 31, 2011**

Commission file number 001-06351

**Eli Lilly and Company**

An Indiana corporation

I.R.S. employer identification no. 35-0470950

Lilly Corporate Center, Indianapolis, Indiana 46285

(317) 276-2000

**Securities registered pursuant to Section 12(b) of the Act:**

<u>Title of Each Class</u>	<u>Name of Each Exchange On Which Registered</u>
Common Stock (no par value)	New York Stock Exchange
6.57% Notes Due January 1, 2016	New York Stock Exchange
7 1/8% Notes Due June 1, 2025	New York Stock Exchange
6.77% Notes Due January 1, 2036	New York Stock Exchange

**Securities registered pursuant to Section 12(g) of the Act: None**

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  No

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in the definitive proxy statement incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the Registrant is a shell company as defined in Rule 12b-2 of the Act: Yes  No

Aggregate market value of the common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of the last business day of the Registrant's most recently completed second fiscal quarter (Common Stock): approximately \$38,414,000,000

Number of shares of common stock outstanding as of February 15, 2012: 1,160,406,840

Portions of the Registrant's Proxy Statement to be filed on or about March 5, 2012 have been incorporated by reference into Part III of this report.

## Part I

### Item 1. Business

Eli Lilly and Company (the “company” or “registrant”) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and sell products in one significant business segment—pharmaceutical products. We also have an animal health business segment, whose operations are not material to our financial statements.

Our mission is to make medicines that help people live longer, healthier, more active lives. Our strategy is to create value for all our stakeholders by accelerating the flow of innovative new medicines that provide improved outcomes for individual patients. Most of the products we sell today were discovered or developed by our own scientists, and our success depends to a great extent on our ability to continue to discover, develop, and bring to market innovative new medicines.

We manufacture and distribute our products through facilities in the United States, Puerto Rico, and 15 other countries. Our products are sold in approximately 130 countries.

#### Products

Our products include:

**Neuroscience products**, our largest-selling product group, including:

- *Zyprexa*<sup>®</sup>, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance
- *Zyprexa Relprevv*<sup>™</sup> (*Zypadhera*<sup>®</sup> in the European Union), a long-acting intramuscular injection formulation of Zyprexa
- *Cymbalta*<sup>®</sup>, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the U.S. for the management of fibromyalgia and of chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis
- *Strattera*<sup>®</sup>, for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and in the U.S. in adults
- *Prozac*<sup>®</sup>, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder
- *Symbyax*<sup>®</sup>, for the treatment of bipolar depression and treatment-resistant depression.

**Endocrinology products**, including:

- *Humalog*<sup>®</sup>, *Humalog Mix 75/25*<sup>™</sup>, and *Humalog Mix 50/50*<sup>™</sup>, for the treatment of diabetes
- *Humulin*<sup>®</sup>, for the treatment of diabetes
- *Byetta*<sup>®</sup>, for the treatment of type 2 diabetes
- *Bydureon*<sup>®</sup>, approved in Europe in 2011 and in the U.S. in January 2012 for the treatment of type 2 diabetes (see “Pharmaceutical Marketing Collaborations” below for information about the termination of our collaboration with Amylin Pharmaceuticals for Byetta and Bydureon)
- *Actos*<sup>®</sup>, for the treatment of type 2 diabetes (marketed by us only in certain countries outside the U.S.)
- *Tradjenta*<sup>™</sup>, approved and launched in 2011 for the treatment of type 2 diabetes
- *Evista*<sup>®</sup>, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer
- *Forteo*<sup>®</sup>, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women
- *Humatrope*<sup>®</sup>, for the treatment of human growth hormone deficiency and certain pediatric growth conditions
- *Axiron*<sup>®</sup>, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone (launched in 2011).

**Oncology products**, including:

- *Alimta*<sup>®</sup>, for the first-line treatment, in combination with another agent, of non-small cell lung cancer for patients with non-squamous cell histology; for the second-line treatment of non-small cell lung cancer; in the European Union as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer in patients with non-squamous cell histology whose disease has not progressed immediately following platinum-based chemotherapy; and in combination with another agent, for the treatment of malignant pleural mesothelioma

- *Gemzar*<sup>®</sup>, for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, non-small cell lung cancer, and advanced or recurrent ovarian cancer; and in the European Union for the treatment of bladder cancer
- *Erbix*<sup>®</sup>, indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers; and as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers.

**Cardiovascular products**, including:

- *Cialis*<sup>®</sup>, for the treatment of erectile dysfunction, and approved in the U.S. for the treatment of benign prostatic hyperplasia
- *Effient*<sup>®</sup>, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or stent placement
- *ReoPro*<sup>®</sup>, for use as an adjunct to PCI for the prevention of cardiac ischemic complications
- *Adcirca*<sup>®</sup>, for the treatment of pulmonary arterial hypertension
- *Livalo*<sup>®</sup>, a statin medication for use as an adjunct to diet in the treatment of high cholesterol (primary hyperlipidemia or mixed dyslipidemia).

**Animal health products**, including:

- *Rumensin*<sup>®</sup>, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis
- *Tylan*<sup>®</sup>, an antibiotic used to control certain diseases in cattle, swine, and poultry
- *Micotil*<sup>®</sup>, *Pulmotil*<sup>®</sup>, and *Pulmotil AC*, antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively
- *Paylean*<sup>®</sup> and *Optaflexx*<sup>®</sup>, leanness and performance enhancers for swine and cattle, respectively
- *Posilac*<sup>®</sup>, a protein supplement to improve milk productivity in dairy cows
- *Coban*<sup>®</sup>, *Monteban*<sup>®</sup>, and *Maxiban*<sup>®</sup>, anticoccidial agents for use in poultry
- *Apralan*<sup>™</sup>, an antibiotic used to control enteric infections in calves and swine
- *Surmax*<sup>®</sup> (sold as *Maxus*<sup>®</sup> in some countries), a performance enhancer for swine and poultry
- *Comfortis*<sup>®</sup>, a chewable tablet that kills fleas and prevents flea infestations on dogs
- *Trifexis*<sup>®</sup>, a monthly chewable tablet for dogs that kills fleas, prevents flea infestations, prevents heartworm disease, and controls intestinal parasite infections
- *Reconcile*<sup>®</sup>, for treatment of canine separation anxiety in conjunction with behavior modification training.

**Other pharmaceuticals**, including:

- *Vancocin*<sup>®</sup> HCl, used primarily to treat staphylococcal infections
- *Ceclor*<sup>™</sup>, for the treatment of a wide range of bacterial infections.

## Marketing

We sell most of our products worldwide. We adapt our marketing methods and product emphasis in various countries to meet local needs.

### Pharmaceuticals—United States

In the United States, we distribute pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In 2011, 2010, and 2009, three wholesale distributors in the U.S.—AmerisourceBergen Corporation, McKesson Corporation, and Cardinal Health, Inc.—each accounted for between 11 percent and 17 percent of our worldwide consolidated total revenue. No other distributor accounted for more than 10 percent of consolidated total revenue in any of those years.

We promote our major pharmaceutical products in the United States through sales representatives who call upon physicians and other health care professionals. We advertise in medical journals, distribute literature and samples of certain products to physicians, and exhibit at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain web sites with information about our major products. We supplement our employee sales force with contract sales organizations as appropriate to leverage our own resources and the strengths of our partners in various markets.

We maintain special business groups to service wholesalers, pharmacy benefit managers, managed-care organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. In response to competitive pressures, we have entered into arrangements with some of these organizations providing for discounts or rebates on Lilly products.

### Pharmaceuticals—Outside the United States

Outside the United States, we promote our pharmaceutical products primarily through sales representatives. While the products marketed vary from country to country, neuroscience products constitute the largest single group in total revenue. Distribution patterns vary from country to country. In most countries, we maintain our own sales organizations, but in some countries we market our products through independent distributors.

### Pharmaceutical Marketing Collaborations

Certain of our products are marketed in arrangements with other pharmaceutical companies, including the following:

- We co-market Cymbalta in Japan with Shionogi & Co. Ltd.
- Evista is marketed in major European markets by Daiichi Sankyo Europe GmbH, a subsidiary of Daiichi Sankyo Co., Ltd. We co-market Evista in Japan with Chugai Pharmaceutical Co., Ltd.
- Byetta and Bydureon have been the subject of a collaboration with Amylin Pharmaceuticals, Inc., under which we co-promoted Byetta in the U.S. and Puerto Rico and have exclusive marketing rights to both products in other territories. In November 2011, we entered into agreement with Amylin to terminate the collaboration and resolve all outstanding litigation between the companies. The parties are transitioning full responsibility for the worldwide development and commercialization of both products to Amylin, starting in the U.S. on November 30, 2011, and progressing to all markets not earlier than mid-2012 and not later than the end of 2013. See Item 8, “Financial Statements and Supplementary Data” – Note 4, “Collaborations”, for more information on the November 2011 agreement.
- Erbitux is marketed in North America by Bristol-Myers Squibb. We have the option to co-promote Erbitux in North America. Outside North America, Erbitux is commercialized by Merck KGaA. We receive royalties from Bristol-Myers Squibb and Merck KGaA.
- Effient is co-promoted with us by Daiichi Sankyo in the U.S., major European markets, Brazil, Mexico, China and several other Asian countries. Daiichi Sankyo retains sole marketing rights in Japan, and we retain sole marketing rights in Canada, Australia, Russia, and certain other countries.
- Tradjenta is being jointly developed and commercialized with us by Boehringer Ingelheim pursuant to a collaboration agreement reached in 2011 under which both parties contributed certain mid- and late-stage development potential diabetes treatments to be jointly developed and commercialized by the parties.

### Animal Health Products

Our Elanco animal health business unit employs field salespeople throughout the United States. Elanco also has an extensive sales force outside the U.S. Elanco sells its products primarily to wholesale distributors.

### Competition

Our pharmaceutical products compete with products manufactured by many other companies in highly competitive markets throughout the world. Our animal health products compete globally with products of animal health care companies as well as pharmaceutical, chemical, and other companies that operate animal health businesses.

Important competitive factors include safety, effectiveness, and ease of use of our products; price and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products and processes. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors. If competitors introduce new products or delivery systems with therapeutic or cost advantages, our products can be subject to progressive price reductions, decreased sales volume, or both. Increasingly, to obtain favorable reimbursement and formulary positioning with government payers, managed care organizations, and pharmacy benefits managers, we must demonstrate that our products offer not only medical benefits but also more value as compared with other forms of care.

Manufacturers of generic pharmaceuticals invest far less than we do in research and development and therefore can price their products much lower than our branded products. Accordingly, when our branded pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product. In many countries outside the U.S., intellectual property protection is weak and we must compete with generic or counterfeit versions of our products.

We believe our long-term competitive success depends upon discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective medicines that provide improved outcomes to individual patients and deliver value to payers, together with our ability to continuously improve the productivity of our operations in a highly competitive environment. There can be no assurance that our research and development efforts will result in commercially successful products, and it is possible that our products will become uncompetitive from time to time as a result of products developed by our competitors.

### Patents, Trademarks, and Other Intellectual Property Rights

#### Overview

Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines. We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes.

The patent protection anticipated to be of most relevance to human pharmaceuticals is provided by national patents claiming the active ingredient (the compound patent), particularly those in major markets such as the U.S., various European countries and Japan. These patents may be issued based upon the filing of international patent applications, usually filed under the Patent Cooperation Treaty (PCT). Patent applications covering the compounds are generally filed during the Discovery Research Phase of the drug discovery process, which is described in the "Research and Development" section of Item 1, "Business." In general, national patents in each relevant country are available for a period of 20 years from the filing date of the PCT application, which is often years prior to the launch of a commercial product. Further patent term adjustments and restorations may extend the original patent term:

- Patent term adjustment is a statutory right available to all U.S. patent applicants to provide relief in the event that a patent is delayed during examination by the U.S. Patent and Trademark Office.
- Patent term restoration is a statutory right provided to U.S. patents that claim inventions subject to review by the FDA. A single patent for a pharmaceutical product may be eligible for patent term restoration, to make up for a portion of the time invested in clinical trials and the FDA review process. Patent term restoration is limited by a formula and cannot be calculated until product approval due to uncertainty about the duration of clinical trials and the time it takes the FDA to review an application. There is a five-year cap on any restoration, and no patent may be extended for more than 14 years beyond FDA approval. Some countries outside the U.S. also offer forms of patent term restoration. For example, Supplementary Protection Certificates are sometimes available to extend the life of a European patent an additional five years.

Loss of patent protection often results in the loss of effective market exclusivity for the product, which can result in severe and rapid decline in sales of the product. However, in some cases the innovator company may be protected from approval of generic or other follow-on versions of a new medicine beyond the expiry of the product patent through manufacturing trade secrets, later-expiring patents on methods of use or formulations, or data protection that may be available under pharmaceutical regulatory laws. The primary forms of data protection are as follows:

- Regulatory authorities in major markets generally grant data package protection for a period of years following new drug approvals in recognition of the substantial investment required to complete clinical trials. Data package protection prohibits other manufacturers from submitting regulatory applications based on the innovator company's regulatory submission data for the drug. For small molecule new molecular entities, the base period of data package protection is five years in the U.S., ten years in the European Union and eight years in Japan. The period begins on the date of product approval and runs concurrently with the patent term for any relevant patent.
- Some of our current products, including Erbitux and ReoPro, and many of the new molecular entities in our research pipeline are biological products ("biologics"). Based on the Biologics Price Competition and Innovation Act (enacted in the U.S. in 2010), the FDA has the authority to approve similar versions ("biosimilars") of innovative biologic products. A competitor seeking approval of a biosimilar must file an application to show its molecule is highly similar to an approved innovator biologic, address the challenges of biologics manufacturing, and include a certain amount of safety and efficacy data which the FDA will determine on a case-by-case basis. Under the data protection provisions of this law, the FDA cannot approve a biosimilar application until 12 years after initial marketing approval of the innovator biologic, subject to certain conditions. Regulators in the EU and other countries also have been given the authority to approve biosimilars. The specific requirements of these new approval processes, and the extent to which a biosimilar, once approved, will be substituted for the innovator biologic in a way that is similar to traditional generic substitution for non-biologic products, are not yet entirely clear, and will depend on a number of regulatory and marketplace factors that are still developing.
- In the U.S., the FDA has the authority to grant additional data protection for approved drugs where the sponsor conducts specified testing in pediatric or adolescent populations. If granted, this "pediatric exclusivity" provides an additional six months which are added to the term of data protection as well as to the term of any relevant patents, to the extent these protections have not already expired.
- The FDA also has authority to grant "orphan" status to a specific use of a drug. Under the U.S. orphan drug law, a drug or biological product can receive "orphan" designation if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or affecting more than 200,000 people but not reasonably expected to recover its development and marketing costs through U.S. sales. Among other benefits, orphan designation entitles the drug to seven years of market exclusivity, meaning that the FDA cannot (with limited exceptions) approve another marketing application for the same drug for the same indication until expiration of the seven-year period. Unlike pediatric exclusivity, the orphan exclusivity period is independent of and runs in parallel with any applicable patents.

Outside the major markets, the adequacy and effectiveness of intellectual property protection for pharmaceuticals varies widely. Under the Trade-Related Aspects of Intellectual Property Agreement (TRIPs) administered by the World Trade Organization (WTO), over 140 countries have now agreed to provide non-discriminatory protection for most pharmaceutical inventions and to assure that adequate and effective rights are available to patent owners. Because of TRIPs transition provisions, dispute resolution mechanisms, and substantive limitations, it is difficult to assess when and how much we will benefit commercially from this protection.

There is no assurance that the patents we are seeking will be granted or that the patents we hold would be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or

processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties sometimes may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property.

### Our Intellectual Property Portfolio

We consider intellectual property protection for certain products, processes, and uses—particularly those products discussed below—to be important to our operations. For many of our products, in addition to the compound patent we hold other patents on manufacturing processes, formulations, or uses that may extend exclusivity beyond the expiration of the product patent.

The most relevant U.S. patent protection or data package protection for our larger or recently launched patent-protected marketed products is as follows:

- *Alimta* is protected by a compound patent (2016), as extended by pediatric exclusivity (2017), and a concomitant nutritional supplement use patent (2021), as extended by pediatric exclusivity (2022).
- *Cialis* is protected by compound and use patents (2017).
- *Cymbalta* is protected by a compound patent (June 2013). We are seeking pediatric exclusivity which, if granted, would extend protection to December 2013.
- *Effient* is protected by a compound patent (2017).
- *Evista* is protected by patents on the treatment and prevention of osteoporosis (2014). *Evista* for use in breast cancer risk reduction is protected by orphan drug exclusivity (2014).
- *Humalog* is protected by a compound patent (May 2013).
- *Strattera* is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016), as extended by pediatric exclusivity (2017).
- *Tradjenta* is protected by a compound patent (2023), and Boehringer Ingelheim has applied for a patent extension to 2025 under the patent restoration laws.

U.S. patent protection or data package protection for our new molecular entities that have been submitted for regulatory review is as follows. Additional information about these molecules is provided in Item 7, Management's Discussion and Analysis under "Late Stage Pipeline." The dates below do not include any potential patent extensions or adjustments as described above:

- *Florbetapir* is covered by a compound patent (2025).
- *Liprotamase* is expected to be protected for at least the five-year data package protection period following U.S. regulatory approval.

Worldwide, we sell all of our major products under trademarks that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms.

### Patent Licenses

Most of our major products were discovered in our own laboratories and are not subject to significant license agreements. Two of our larger products, *Cialis* and *Alimta*, are subject to patent assignments or licenses granted to us by others.

- The compound patent for *Cialis* is the subject of a license agreement with Glaxo SmithKline which assigns to us exclusively all rights in the compound. The agreement calls for royalties of a single-digit percentage of net sales. The agreement is not subject to termination by Glaxo for any reason other than a material breach by Lilly of the royalty obligation, after a substantial cure period.
- The compound patent for *Alimta* is the subject of a license agreement with Princeton University, granting us an irrevocable exclusive worldwide license to the compound patents for the lives of the patents in the respective territories. The agreement calls for royalties of a single-digit percentage of net sales. The agreement is not subject to termination by Princeton for any reason other than a material breach by Lilly of the royalty obligation, after a substantial cure period. *Alimta* is also the subject of a worldwide, nonexclusive license to certain compound and process patents owned by Takeda Pharmaceutical Company Limited. The agreement calls for royalties of a single-digit percentage of net sales in countries covered by a relevant patent. The agreement is subject to termination for material default and failure to cure by Lilly and in the event that Lilly becomes bankrupt or insolvent.

### Patent Challenges

In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as "Hatch-Waxman," made a complex set of changes to both patent and new-drug-approval laws. Before Hatch-Waxman, no drug could be approved without providing the FDA complete safety and efficacy studies, *i.e.*, a complete New Drug Application (NDA). Hatch-Waxman authorizes the FDA to approve generic versions of innovative pharmaceuticals (other than biologics) without such information by filing an Abbreviated New Drug Application (ANDA). In an ANDA, the generic manufacturer must demonstrate only "bioequivalence" between the generic version and the NDA-approved drug—not safety and efficacy.

Absent a patent challenge, the FDA cannot approve an ANDA until after the innovator's patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA alleging that one or more of the patents listed in the innovator's NDA are invalid or not infringed. This allegation is commonly known as a "Paragraph IV certification." The innovator must then file suit against the generic manufacturer to protect its patents. The FDA is then prohibited from approving the generic company's application for a 30- to 42-month period (which can be shortened or extended by the trial court judge hearing the patent challenge). If one or more of the NDA-listed patents are challenged, the first filer(s) of a Paragraph IV certification may be entitled to a 180-day period of market exclusivity over all other generic manufacturers.

Generic manufacturers use Paragraph IV certifications extensively to challenge patents on a wide array of innovative pharmaceuticals. In addition, generic companies have shown an increasing willingness to launch "at risk," i.e., after receiving ANDA approval but before final resolution of their patent challenge. We are currently in litigation with numerous generic manufacturers arising from their Paragraph IV certifications on Alimta. For more information on this litigation, see Item 7, "Management's Discussion and Analysis—Legal and Regulatory Matters."

Outside the United States, the legal doctrines and processes by which pharmaceutical patents can be challenged vary widely. In recent years, we have experienced an increase in patent challenges from generic manufacturers in many countries outside the U.S., and we expect this trend to continue.

## Government Regulation

### Regulation of Our Operations

Our operations are regulated extensively by numerous national, state, and local agencies. The lengthy process of laboratory and clinical testing, data analysis, manufacturing development, and regulatory review necessary for governmental approvals is extremely costly and can significantly delay product introductions. Promotion, marketing, manufacturing, and distribution of pharmaceutical and animal health products are extensively regulated in all major world markets. We are required to conduct extensive post-marketing surveillance of the safety of the products we sell. In addition, our operations are subject to complex federal, state, local, and foreign laws and regulations concerning the environment, occupational health and safety, and privacy. The laws and regulations affecting the manufacture and sale of current products and the discovery, development, and introduction of new products will continue to require substantial effort, expense and capital investment.

Of particular importance is the FDA in the United States. Pursuant to the Federal Food, Drug, and Cosmetic Act, the FDA has jurisdiction over all of our products and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, advertising, dissemination of information, and post-marketing surveillance of our pharmaceutical products. The FDA, along with the U.S. Department of Agriculture (USDA), also regulates our animal health products. The U.S. Environmental Protection Agency also regulates some animal health products.

The FDA extensively regulates all aspects of manufacturing quality under its current Good Manufacturing Practices (cGMP) regulations. We make substantial investments of capital and operating expenses to implement comprehensive, company-wide quality systems in our manufacturing, product development, and process development operations to ensure sustained cGMP compliance. However, in the event we fail to adhere to cGMP requirements in the future, we could be subject to interruptions in production, fines and penalties, and delays in new product approvals.

Outside the U.S., our products and operations are subject to similar regulatory requirements, notably by the European Medicines Agency (EMA) in the European Union and the Ministry of Health, Labor and Welfare (MHLW) in Japan. Specific regulatory requirements vary from country to country.

The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers and prescribers, are subject to various other federal and state laws, including the federal anti-kickback statute and the False Claims Act and state laws governing kickbacks, false claims, unfair trade practices, and consumer protection. These laws are administered by, among others, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services, the Federal Trade Commission, the Office of Personnel Management, and state attorneys general. Over the past several years, the FDA, the Department of Justice, and many of these other agencies have increased their enforcement activities with respect to pharmaceutical companies and increased the inter-agency coordination of enforcement activities. Over this period, several claims brought by these agencies against Lilly and other companies under these and other laws have resulted in corporate criminal sanctions and very substantial civil settlements. See Item 3, "Legal Proceedings," for information regarding a Corporate Integrity Agreement entered into by Lilly in connection with the resolution of a U.S. federal marketing practices investigation and certain related state investigations involving Zyprexa.

The U.S. Foreign Corrupt Practices Act (FCPA) prohibits certain individuals and entities, including U.S. publicly traded companies, from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage. The FCPA also imposes specific recordkeeping and internal controls requirements on U.S. publicly traded companies. As noted above, outside the U.S., our business is heavily regulated and therefore involves significant interaction with foreign officials. Additionally, in many countries outside the U.S., the health care providers who prescribe pharmaceuticals are employed by the government and the purchasers of pharmaceuticals are government entities; therefore, our interactions with these prescribers and purchasers are subject to regulation under the FCPA. Recently the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ)

have increased their FCPA enforcement activities with respect to pharmaceutical companies. See Item 3, “Legal Proceedings,” for information about a currently pending SEC/DOJ investigation involving our operations in several countries.

In addition to the U.S. application and enforcement of the FCPA, the various jurisdictions in which we operate and supply our products have laws and regulations aimed at preventing and penalizing corrupt and anticompetitive behavior. In recent years, several jurisdictions have enhanced their laws and regulations in this area, increased their enforcement activities, and increased the level of cross-border coordination and information sharing.

It is possible that we could become subject to additional administrative and legal proceedings and actions, which could include claims for civil penalties (including treble damages under the False Claims Act), criminal sanctions, and administrative remedies, including exclusion from U.S. federal health care programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position.

### **Regulations Affecting Pharmaceutical Pricing, Reimbursement, and Access**

In the United States, we are required to provide rebates to state governments on their purchases of our products under state Medicaid programs and to private payers who cover patients in certain types of health care facilities that serve low-income and uninsured patients (known as 340B facilities). We also give rebates to private payers who provide prescription drug benefits to seniors covered by Medicare. Additional cost containment measures have been adopted or proposed by federal, state, and local government entities that provide or pay for health care. In most international markets, we operate in an environment of government-mandated cost containment programs, which may include price controls, reference pricing, discounts and rebates, restrictions on physician prescription levels, restrictions on reimbursement, compulsory licenses, health economic assessments, and generic substitution.

The enactment of the “Patient Protection and Affordable Care Act” and “The Health Care and Education Reconciliation Act of 2010” in March 2010 has brought significant changes to U.S. health care. Increases in the minimum statutory rebate for branded prescription drugs sold to Medicaid beneficiaries from 15.1 percent to 23.1 percent were generally effective in 2010. This rebate has been expanded to managed-Medicaid, a program that provides for the delivery of Medicaid benefits via managed care organizations, under arrangements between those organizations and state Medicaid agencies. Additionally, a prescription drug discount program for outpatient drugs in 340B facilities has been expanded. Beginning in 2011, drug manufacturers are required to provide a discount of 50 percent of the cost of branded prescription drugs for Medicare Part D participants who are in the “doughnut hole” (the coverage gap in Medicare prescription drug coverage). The doughnut hole is being phased out by the federal government between 2011 and 2020. Additionally, beginning in 2011, an annual fee is imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs. See Item 7, “Management’s Discussion and Analysis—Executive Overview—Legal, Regulatory, and Other Matters,” for more discussion of U.S. health care reform. At the state level, budget pressures are causing various states to impose cost-control measures such as higher rebates and more restrictive formularies.

International operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls, limit access to or reimbursement for our products, or reduce the value of our intellectual property protection. Recently, several governments have implemented across-the-board price cuts of branded pharmaceuticals as part of austerity measures in the face of the global financial crisis and severe national budget deficits.

We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, in general we expect that state, federal, and international legislative and regulatory developments could negatively affect our pricing and rebates.

### **Research and Development**

Our commitment to research and development dates back more than 100 years. Our research and development activities are responsible for the discovery and development of most of the products we offer today. We invest heavily in research and development because we believe it is critical to our long-term competitiveness. At the end of 2011, we employed approximately 7,500 people in pharmaceutical and animal health research and development activities, including a substantial number of physicians, scientists holding graduate or postgraduate degrees, and highly skilled technical personnel. Our research and development expenses were \$5.02 billion in 2011, \$4.88 billion in 2010, and \$4.33 billion in 2009.

Our pharmaceutical research and development focuses on five therapeutic categories: cancer; endocrine diseases, including diabetes, obesity, and musculoskeletal disorders; central nervous system and related diseases; autoimmune diseases; and cardiovascular diseases. However, we remain opportunistic, selectively pursuing promising leads in other therapeutic areas. We are also investing in molecules with multi-pathway pharmacological efficacy to expand the potential of our therapeutic portfolio. We have a strong biotechnology research program, with nearly half of our clinical stage pipeline, and more than half of our late-stage pipeline, currently consisting of biotechnology molecules. In addition to discovering and developing new molecular entities, we seek to expand the value of existing products through new uses, formulations, and therapeutic approaches that provide additional value to patients. Across all our therapeutic areas, we are increasingly focusing our efforts on tailored therapeutics, seeking to identify and use advanced diagnostic tools and other information to identify specific subgroups of patients for whom our medicines—or those of other companies—will be the best treatment option.

To supplement our internal efforts, we collaborate with others, including educational institutions and research-based pharmaceutical and biotechnology companies. We use the services of physicians, hospitals, medical schools, and other research organizations worldwide to conduct clinical trials to establish the safety and effectiveness of our pharmaceutical products. We actively seek out investments in external research and technologies that hold the promise to complement and strengthen our own research efforts. These investments can take many forms, including licensing arrangements, co-development and co-marketing agreements, co-promotion arrangements, joint ventures, and acquisitions.

Drug development is time-consuming, expensive, and risky. On average, only one out of many thousands of molecules discovered by researchers ultimately becomes an approved medicine. The process from discovery to regulatory approval can take 12 to 15 years or longer. Drug candidates can fail at any stage of the process, and even late-stage drug candidates sometimes fail to receive regulatory approval or achieve commercial success. After approval and launch of a product, we expend considerable resources on post-marketing surveillance and clinical studies to collect and understand the benefits and potential risks of medicines as they are used as therapeutics. The following describes the new drug research and development process in more detail:

## Phases of New Drug Development

### Discovery Research Phase

The earliest phase of new drug research and development, the discovery phase, can take many years. Scientists identify, design, and synthesize promising molecules, screening tens of thousands of molecules for their effect on biological “targets” that appear to play an important role in one or more diseases. Targets can be part of the body, such as a protein, receptor, or gene; or foreign, such as a virus or bacteria. Some targets have been proven to affect disease processes, but often the target is unproven and may later prove to be irrelevant to the disease. Molecules that have the desired effect on the target and meet other design criteria become “lead” molecules and go on to the next phase of development. The probability of any one such lead molecule completing the rest of the drug development process and becoming a product is extremely low.

### Early Development Phase

The early development phase involves refining lead molecules, understanding how to manufacture them efficiently, and completing initial testing for safety and efficacy. Safety testing is done first in laboratory tests and animals, to identify toxicity and other potential safety issues that would preclude use in humans. The first human tests (often referred to as Phase I) are normally conducted in small groups of healthy volunteers to assess safety and find the potential dosing range. After a safe dose has been established, the drug is administered to small populations of sick patients (Phase II) to look for initial signs of efficacy in treating the targeted disease and to continue to assess safety. In parallel, scientists work to identify safe, effective, and economical manufacturing processes. Long-term animal studies continue to test for potential safety issues. Of the molecules that enter the early development phase, typically less than 10 percent move on to the product phase. The early development phase normally takes several years to complete.

### Product Phase

Product phase (Phase III) molecules have already demonstrated safety and, typically, shown initial evidence of efficacy. As a result, these molecules generally have a higher likelihood of success. The molecules are now rigorously tested in much larger patient populations to demonstrate efficacy to a predetermined level of statistical significance and to continue to develop the safety profile. These trials are generally global in nature and are designed to generate the data necessary to submit the molecule to regulatory agencies for marketing approval. The potential new drug is generally compared with existing competitive therapies, placebo, or both. The resulting data is compiled and submitted to regulatory agencies around the world. Phase III testing varies by disease state, but can often last from two to four years.

### Submission Phase

Once a molecule is submitted, the time to final marketing approval can vary from six months to several years, depending on variables such as the disease state, the strength and complexity of the data presented, the novelty of the target or compound, and the time required for the agency(ies) to evaluate the submission. There is no guarantee that a potential medicine will receive marketing approval, or that decisions on marketing approvals or indications will be consistent across geographic areas.

We believe our investments in research, both internally and in collaboration with others, have been rewarded by the large number of new molecules and new indications for existing molecules that we have in all stages of development. We currently have approximately 65 drug candidates across all stages of human testing and a larger number of projects in preclinical development. Among our new investigational molecules in the product phase of development or awaiting regulatory approval are potential therapies for diabetes, various cancers, Alzheimer’s disease, rheumatoid arthritis, lupus, psoriasis, schizophrenia, depression, and pancreatic exocrine insufficiency, as well as an imaging agent for detecting beta-amyloid plaques (which are associated with Alzheimer’s disease) in the brain. We are studying many other drug candidates in the earlier stages of development, including molecules targeting various cancers, diabetes, obesity, Alzheimer’s disease, depression, bipolar disorder, migraine, atherosclerosis, anemia, rheumatoid arthritis, musculoskeletal disorders, and renal diseases. We are also developing new uses, formulations, or delivery methods for many of these molecules as well as several currently marketed products, including Alimta, Cialis, Effient, Erbitux, Forteo, and Humalog.

### Raw Materials and Product Supply

Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally have sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.

Our primary bulk manufacturing occurs at four owned sites in the U.S. as well as owned sites in Ireland, Puerto Rico, and the United Kingdom. Finishing operations, including labeling and packaging, take place at a number of sites throughout the world. In January 2010, we sold our Tippecanoe Laboratories manufacturing site in West Lafayette, Indiana, to an affiliate of Evonik Industries AG, and entered into a nine-year supply and services agreement whereby Evonik will manufacture final and intermediate-step active pharmaceutical ingredients for certain Lilly human and animal health products.

We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that should allow us to meet all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.

### Quality Assurance

Our success depends in great measure upon customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness. Product quality arises from a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, distribution, and dissemination of information about our medicines. We have implemented quality systems relating to the quality and integrity of scientific information and production processes.

Control of production processes involves rigid specifications for ingredients, equipment, facilities, manufacturing methods, packaging materials, and labeling. We perform tests at various stages of production processes and on the final product to assure that the product meets all regulatory requirements and our standards. These tests may involve chemical and physical chemical analyses, microbiological testing, testing in animals, or a combination. Additional assurance of quality is provided by a corporate quality-assurance group that monitors existing pharmaceutical and animal health manufacturing procedures and systems in the parent company, subsidiaries and affiliates, and third-party suppliers.

### Executive Officers of the Company

The following table sets forth certain information regarding our executive officers. Except as otherwise noted, all executive officers have been employed by the company in executive positions during the last five years.

The term of office for each executive officer expires on the date of the annual meeting of the Board of Directors, to be held on April 16, 2012, or on the date his or her successor is chosen and qualified. No director or executive officer has a "family relationship" with any other director or executive officer of the company, as that term is defined for purposes of this disclosure requirement. There is no understanding between any executive officer and any other person pursuant to which the executive officer was selected.

Name	Age	Offices and Business Experience
John C. Lechleiter, Ph.D.	58	Chairman (since January 2009), President (since October 2005), Chief Executive Officer (since April 2008) and a Director (since October 2005)
Robert A. Armitage	63	Senior Vice President and General Counsel (since January 2003)
Bryce D. Carmine	60	Executive Vice President and President, Lilly Bio-Medicines (since November 2009) (retired December 2011)
Enrique A. Conterno	45	Senior Vice President and President, Lilly Diabetes (since November 2009)
Maria A. Crowe	52	President, Manufacturing Operations (since January 2012)
Frank M. Deane, Ph.D.	62	President, Manufacturing Operations (since June 2007) (retired December 2011)
Stephen F. Fry	46	Senior Vice President, Human Resources and Diversity (since February 2011)
Jan M. Lundberg, Ph.D.	58	Executive Vice President, Science and Technology and President, Lilly Research Laboratories (since January 2010). From 2002 until he joined Lilly in January 2010, Dr. Lundberg was executive vice president and head of discovery research at AstraZeneca.

Name	Age	Offices and Business Experience
Susan Mahony, Ph.D.	47	Senior Vice President and President, Lilly Oncology (since February 2011)
Anne Nobles	55	Senior Vice President, Enterprise Risk Management (since April 2009) and Chief Ethics and Compliance Officer (since June 2007)
Barton R. Peterson	53	Senior Vice President, Corporate Affairs and Communications (since June 2009). Mr. Peterson served as mayor of Indianapolis, Indiana, from 2000 to 2007. From 2008 to 2009, he was managing director at Strategic Capital Partners, LLC, and distinguished visiting professor of public policy at Ball State University.
Derica W. Rice	47	Executive Vice President, Global Services (since January 2010) and Chief Financial Officer (since May 2006)
David A. Ricks	44	Senior Vice President and President, Lilly Bio-Medicines (since January 2012)
Jeffrey N. Simmons	44	Senior Vice President and President, Elanco Animal Health (since January 2008)
Jacques Tapiero	53	Senior Vice President and President, Emerging Markets (since January 2010)
Fionnuala M. Walsh	52	Senior Vice President, Global Quality (since July 2007)

### Employees

At the end of 2011, we employed approximately 38,080 people, including approximately 20,800 employees outside the United States. A substantial number of our employees have long records of continuous service.

### Financial Information Relating to Business Segments and Classes of Products

You can find financial information relating to our business segments and classes of products in Item 8 of this Form 10-K, "Segment Information." That information is incorporated here by reference.

The relative contribution of any particular product to our consolidated revenue changes from year to year. This is due to several factors, including the introduction of new products by us and by other manufacturers and the introduction of generic pharmaceuticals upon patent expirations. In addition, margins vary for our different products due to various factors, including differences in the cost to manufacture and market the products, the value of the products to the marketplace, and government restrictions on pricing and reimbursement. Our major product revenues are generally not seasonal.

### Financial Information Relating to Foreign and Domestic Operations

You can find financial information relating to foreign and domestic operations in Item 8, "Segment Information." That information is incorporated here by reference. To date, our overall operations abroad have not been significantly deterred by local restrictions on the transfer of funds from branches and subsidiaries located abroad, including the availability of U.S. dollar exchange. We cannot predict what effect these restrictions or the other risks inherent in foreign operations, including possible nationalization, might have on our future operations or what other restrictions may be imposed in the future. In addition, changing currency values can either favorably or unfavorably affect our financial position, liquidity, and results of operations. We mitigate foreign exchange risk through various hedging techniques including the use of foreign currency contracts.

### Available Information on Our Web Site

We make available through our company web site, free of charge, our company filings with the SEC as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. These include our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents. The company web site link to our SEC filings is <http://investor.lilly.com/sec.cfm>.

In addition, the Corporate Governance portion of our web site includes our corporate governance guidelines, board and committee information (including committee charters), and our articles of incorporation and by-laws. The link to our corporate governance information is <http://investor.lilly.com/governance.cfm>.

We will provide paper copies of our SEC filings free of charge upon request to the company's secretary at the address listed on the front of this Form 10-K.

## Item 1A. Risk Factors; Cautionary Statement Regarding Forward Looking Statements

In addition to the other information contained in this Form 10-K, the following risk factors should be considered carefully in evaluating our company. It is possible that our business, financial condition, liquidity, or results of operations could be materially adversely affected by any of these risks.

We make certain forward-looking statements in this Form 10-K, and company spokespersons may make such statements in the future. Where possible, we try to identify forward-looking statements by using such words as “expect,” “plan,” “will,” “estimate,” “forecast,” “project,” “believe,” and “anticipate”. Forward-looking statements do not relate strictly to historical or current facts. They are likely to address our growth strategy, sales of current and anticipated products, financial results, our research and development programs, the status of product approvals, legislative and regulatory developments, and the outcome of contingencies such as litigation and investigations. All forward-looking statements are based on our expectations at the time we make them. They are subject to risks and uncertainties, including those summarized below.

- *Pharmaceutical research and development is very costly and highly uncertain.* There are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products. There is a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market typically takes a decade or more and costs over \$1 billion. Failure can occur at any point in the process, including late in the process after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain necessary regulatory approvals and payer reimbursement, limited scope of approved uses, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Delays and uncertainties in the FDA approval process and the approval processes in other countries can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict sales growth rates of new products.
- *We face intense competition.* We compete with a large number of multinational pharmaceutical companies, biotechnology companies and generic pharmaceutical companies. To compete successfully, we must continue to deliver to the market innovative, cost-effective products that meet important medical needs. Our product revenues can be adversely affected by the introduction by competitors of branded products that are perceived as superior by the marketplace, by generic versions of our branded products, and by generic versions of other products in the same therapeutic class as our branded products. See Item 1, “Business—Competition,” for more details.
- *Our long-term success depends on intellectual property protection.* Our long-term success depends on our ability to continually discover, develop, and commercialize innovative new pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new drugs to the market.

Intellectual property protection varies throughout the world and is subject to change over time. In the U.S., the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our patents; as a result, we expect that our U.S. patents on major products will be routinely challenged, and there can be no assurance that our patents will be upheld. See Item 1, “Business—Patents, Trademarks, and Other Intellectual Property Rights,” for more details. We face generic manufacturer challenges to our patents outside the U.S. as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. See Item 1, “Business—Patents, Trademarks, and Other Intellectual Property Rights,” for more details.

- *We depend on patent-protected products for most of our revenues, cash flows, and earnings, and we will lose effective intellectual property protection for many of them in the next several years.* Seven significant patent-protected products, which together comprised 71 percent of our worldwide revenue in 2011, have lost or will lose their most significant remaining U.S. patent protection and data-based protection, as well as their intellectual property-based exclusivity in most countries outside the U.S., in the next several years:

Product	Worldwide Revenues (2011)	Percent of Total 2011 Revenues	Loss of Relevant U.S. Exclusivity
Zyprexa	\$4.62 billion	19	October 2011
Cymbalta	\$4.16 billion	17	2013
Alimta	\$2.46 billion	10	2017 (compound patent plus pediatric exclusivity); 2022 (concomitant nutritional supplement use patent plus pediatric exclusivity)
Humalog	\$2.37 billion	10	2013
Cialis	\$1.88 billion	8	2017
Evista	\$1.07 billion	4	2014
Strattera	\$620.1 million	3	2017

Loss of exclusivity, whether by expiration or as a consequence of litigation, typically results in a rapid and severe decline in sales. See Item 7, “Management’s Discussion and Analysis—Financial Condition,” and Item 1, “Business—Patents, Trademarks, and Other Intellectual Property Rights,” for more details.

- *Our business is subject to increasing government price controls and other health care cost-containment measures.* Government health care cost-containment measures can significantly affect our revenue and profitability. In many countries outside the U.S., government agencies strictly control, directly or indirectly, the prices at which our products are sold. In the U.S., we are subject to substantial pricing pressures from state Medicaid programs and private insurance programs and pharmacy benefit managers, including those operating under the Medicare Part D pharmaceutical benefit, and implementation of the recently-enacted U.S. health care reform legislation is increasing these pricing pressures. In addition, many state legislative proposals would further negatively affect our pricing and/or reimbursement for our products. We expect pricing pressures from both governments and private payers inside and outside the U.S. to become more severe. See Item 1, “Business—Regulations Affecting Pharmaceutical Pricing, Reimbursement, and Access,” for more details.
- *Pharmaceutical products can develop unexpected safety or efficacy concerns.* Unexpected safety or efficacy concerns can arise with respect to marketed products, leading to product recalls, withdrawals, or declining revenue, as well as costly product liability claims.
- *Regulatory compliance problems could be damaging to the company.* The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to extensive regulation. Many companies, including Lilly, have been subject to claims related to these practices asserted by federal, state and foreign governmental authorities, private payers, and consumers. These claims have resulted in substantial expense and other significant consequences to us. It is possible that we could become subject to such investigations and that the outcome could include criminal charges and fines, penalties, or other monetary or nonmonetary remedies, including exclusion from U.S. federal health care programs. In addition, regulatory issues concerning compliance with current Good Manufacturing Practice (cGMP) regulations for pharmaceutical products can lead to product recalls and seizures, interruption of production leading to product shortages, and delays in the approvals of new products pending resolution of the cGMP issues. We are now operating under a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services that requires us to maintain comprehensive compliance programs governing our research, manufacturing, and sales and marketing of pharmaceuticals. A material failure to comply with the Agreement could result in severe sanctions to the company. See Item 1, “Business—Regulation of our Operations,” for more details.
- *We face many product liability claims today, and future claims will be largely self-insured.* We are subject to a substantial number of product liability claims involving primarily Byetta, Zyprexa, diethylstilbestrol (DES), and Darvon®, and because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability claims for these or other products in the future. See Item 7, “Management’s Discussion and Analysis—Legal and Regulatory Matters,” and Item 3, “Legal Proceedings,” for more information on our current product liability litigation. Due to a very restrictive market for product liability insurance, we have been and will continue to be largely self-insured for future product liability losses for substantially all our currently marketed products. In addition, there is no assurance that we will be able to fully collect from our insurance carriers on past claims.
- *Manufacturing difficulties could lead to product supply problems.* Pharmaceutical manufacturing is complex and highly regulated. Manufacturing difficulties at our facilities or contracted facilities, or the failure or refusal of a contract manufacturer to supply contracted quantities, could result in product shortages, leading to lost revenue. See Item 1, “Business—Raw Materials and Product Supply,” for more details.
- *Worsening economic conditions could adversely affect our business and operating results.* While pharmaceuticals have not generally been sensitive to overall economic cycles, a prolonged economic downturn coupled with rising unemployment (and a corresponding increase in the uninsured and underinsured population) could lead to decreased utilization of drugs, affecting our sales volume. Declining tax revenues attributable to the downturn are increasing the pressure on governments to reduce health care spending, leading to increasing government efforts to control drug prices and utilization. Additionally, some customers, including governments or other entities reliant upon government funding, may be unable to pay in a timely manner for our products that they purchase. We have experienced delays in repayment from national health care systems in certain countries, including but not limited to regions within Spain and Italy. The ongoing euro area financial crisis has heightened our sensitivity to such trends, and we continue to monitor the countries’ and regions’ creditworthiness. A prolonged economic downturn could also adversely affect our investment portfolio, which could lead to the recognition of losses on our corporate investments and increased benefit expense related to our pension obligations. Also, if our customers, suppliers or collaboration partners experience financial difficulties, we could experience slower customer collections, greater bad debt expense, and performance defaults by suppliers or collaboration partners.
- *We are increasingly dependent on information technology systems and infrastructure.* We rely to a large extent on sophisticated information technology systems and infrastructure. The size and complexity of these systems make them potentially vulnerable to breakdown, malicious intrusion, and random attack. Likewise, confidentiality or data privacy breaches by employees or others with permitted access to our systems may pose a risk that trade secrets, personal information, or other sensitive data may be exposed to unauthorized persons

or to the public. While we have invested heavily in the protection of data and information technology, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business.

- *We face other risks to our business and operating results.* Our business is subject to a number of other risks and uncertainties, including:
  - Economic factors over which we have no control, including changes in inflation, interest rates, and foreign currency exchange rates, can affect our results of operations.
  - Changes in tax laws, including laws related to the remittance of foreign earnings or investments in foreign countries with favorable tax rates, and settlements of federal, state, and foreign tax audits, can affect our results of operations. The Obama Administration has proposed changes to the manner in which the U.S. would tax the international income of U.S.-based companies. There have also been tax proposals under discussion or introduced in the U.S. Congress that could change the manner in and rate at which income of U.S. companies would be taxed. While it is uncertain how the U.S. Congress may address U.S. tax policy matters in the future, reform of U.S. taxation, including taxation of international income, will continue to be a topic of discussion for the U.S. Congress and the Administration. A significant change to the U.S. tax system, including changes to the taxation of international income, could have a material adverse effect on our results of operations.
  - Changes in accounting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission can affect our financial statements.
  - Our financial statements can also be affected by internal factors, such as changes in business strategies and the impact of restructurings, asset impairments, technology acquisition and disposition transactions, and business combinations.

We undertake no duty to update forward-looking statements.

## ***Item 1B. Unresolved Staff Comments***

None.

## ***Item 2. Properties***

Our principal domestic and international executive offices are located in Indianapolis. At December 31, 2011, we owned 12 production and distribution sites in the U.S. and Puerto Rico. Together with the corporate administrative offices, these facilities contain an aggregate of approximately 13.4 million square feet of floor area dedicated to production, distribution, and administration. Major production sites include Indianapolis and Clinton, Indiana; Carolina, Puerto Rico; and Branchburg, New Jersey.

We own production and distribution sites in 11 countries outside the U.S. and Puerto Rico, containing an aggregate of approximately 3.4 million square feet of floor area. Major production sites include facilities in France, Ireland, the United Kingdom, Spain, Italy, Mexico, and Brazil.

Our U.S. research and development facilities consist of approximately 3.5 million square feet and are located primarily in Indianapolis, with smaller sites in San Diego and New York City. We also have smaller research and development facilities in the United Kingdom, Canada, and Spain.

We believe that none of our properties is subject to any encumbrance, easement, or other restriction that would detract materially from its value or impair its use in the operation of the business. The buildings we own are of varying ages and in good condition.

## ***Item 3. Legal Proceedings***

We are a party to various currently pending legal actions, government investigations, and environmental proceedings, and we anticipate that such actions could be brought against us in the future. The most significant of these matters are described below or, as noted, in Item 7, "Management's Discussion and Analysis—Legal and Regulatory Matters." While it is not possible to determine the outcome of the legal actions, investigations and proceedings brought against us, we believe that, except as otherwise specifically noted in Item 7, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could be material to our consolidated results of operations in any one accounting period.

### **Legal Proceedings Described in Management's Discussion and Analysis**

See Item 7, "Management's Discussion and Analysis—Legal and Regulatory Matters," for information on various legal proceedings, including but not limited to:

- The U.S. patent litigation involving Alimta and Strattera
- The Zyprexa product liability and related litigation, including claims brought on behalf of state Medicaid agencies and private healthcare payers
- The Byetta product liability litigation.

That information is incorporated into this Item by reference.

### Other Product Liability Litigation

We are currently a defendant in a variety of product liability lawsuits in the U.S. involving primarily Zyprexa, Byetta, diethylstilbestrol (DES), and Darvon.

In approximately 15 U.S. lawsuits against us involving approximately 90 claimants, plaintiffs seek to recover damages on behalf of children or grandchildren of women who were prescribed DES during pregnancy in the 1950s and 1960s. Approximately 65 of these claimants allege that they were indirectly exposed in utero to the medicine and later developed breast cancer as a consequence. In December 2009, a lawsuit was filed in U.S. District Court in Washington, D.C. against Lilly and other manufacturers (*Michele Fecho, et al v. Eli Lilly and Company, et al*) seeking to assert product liability claims on behalf of a putative class of men and women allegedly exposed to the medicine who claim to have later developed breast cancer. In January 2012, the judge in this case ordered the parties to proceed to mediation. We believe these claims are without merit and are prepared to defend against them vigorously.

Along with several other manufacturers, we have been named as a defendant in approximately 165 cases in the U.S. involving approximately 755 claimants related to the analgesic Darvon and related formulations of propoxyphene. These cases generally allege various cardiac injuries. In November 2011, a lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana (*Ballard, et al. v. Eli Lilly and Company et al.*) against Lilly and other manufacturers as a putative class action seeking to assert product liability claims on behalf of U.S. residents who ingested propoxyphene and allegedly sustained personal injuries. We transferred the U.S. regulatory approvals and all marketing rights to our propoxyphene products in 2002 to AAi Pharma, which subsequently transferred all such approvals and marketing rights to Xanodyne Pharmaceuticals, Inc. We believe these claims are without merit and are prepared to defend against them vigorously.

We have been named along with Takeda Chemical Industries, Ltd., and Takeda affiliates as a defendant in product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until September 2006. Under our agreement with Takeda, we will be indemnified by Takeda for our losses and expenses in accordance with the terms of the agreement.

### Other Marketing Practices Investigations

In August 2003, we received notice that the staff of the SEC is conducting an investigation into the compliance by Polish subsidiaries of certain pharmaceutical companies, including Lilly, with the U.S. Foreign Corrupt Practices Act of 1977. The staff has issued subpoenas to us requesting production of documents related to the investigation. In connection with that matter, staffs of the SEC and the Department of Justice (DOJ) have asked us to voluntarily provide additional information related to certain activities of Lilly affiliates in a number of other countries. The SEC staff has also issued subpoenas related to activities in these countries. We are cooperating with the SEC and the DOJ in this investigation and are in advanced discussions with the SEC to resolve their investigation.

In November 2008, we received a subpoena from the U.S. Department of Health and Human Services Office of Inspector General in coordination with the U.S. Attorney for the Western District of New York seeking production of a wide range of documents and information relating to reimbursement of Alimta. We are cooperating in this investigation.

In December 2010, we received a civil investigative demand from the Attorney General of Texas seeking production of a wide range of documents and information related to Actos. We are cooperating in this investigation.

In January 2009, as part of the resolution of a government investigation related to our U.S. marketing and promotional practices with respect to Zyprexa, we entered into a corporate integrity agreement with the Office of the Inspector General of the U.S. Department of Health and Human Services which requires us to maintain our compliance program and to undertake a set of defined corporate integrity obligations for five years. The agreement also provides for an independent third-party review organization to assess and report on the company's systems, processes, procedures, and practices related to compliance with health care laws.

### Employee Litigation

We have been named as a defendant in a lawsuit filed in the U.S. District Court for the Northern District of New York (*Schaefer-LaRose, et al. v. Eli Lilly and Company*, filed November 14, 2006) claiming that our pharmaceutical sales representatives should have been categorized as "non-exempt" rather than "exempt" employees, and claiming that the company owes them back wages for overtime worked, as well as penalties, interest, and attorneys' fees. Other pharmaceutical industry participants face similar lawsuits. The case was transferred to the U.S. District Court for the Southern District of Indiana and involves approximately 400 plaintiffs. In September 2009, the District Court granted our motion for summary judgment with regard to Ms. Schaefer-LaRose's claims and ordered the plaintiffs to demonstrate why the entire collective action should not be decertified within 30 days. Plaintiffs filed a motion for reconsideration of the summary judgment decision and also opposed decertification, and in October 2010, the court denied plaintiffs motion for reconsideration but decided not to decertify the collective action at this time. Plaintiffs' appeal of the summary judgment ruling was heard in October 2011, and we are waiting for a ruling. We believe this lawsuit is without merit and are prepared to defend against it vigorously.

We have been named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals. We have also been named in approximately 50 lawsuits filed in the same court by individual former employees making similar claims. We believe these lawsuits are without merit and are prepared to defend against them vigorously.

**Other Matters**

In May 2011, Amylin Pharmaceuticals, Inc., our collaboration partner with respect to Byetta and Bydureon, filed a lawsuit against us in the U.S. District Court for the Southern District of California alleging various antitrust and unfair competition law violations and breach of contract. In November 2011, we entered into an agreement that ended this litigation and provides for the transition of full responsibility for the worldwide development and commercialization of Byetta and Bydureon to Amylin, starting in the U.S. on November 30, 2011, and progressing to all markets by the end of 2013. See Item 8, "Financial Statements and Supplementary Data" – Note 4, "Collaborations", for more information on the November 2011 agreement.

In 2004 we, along with several other pharmaceutical companies, were named in a lawsuit in California state court brought by approximately 20 California pharmacies alleging that pharmaceutical companies prevented commercial importation of prescription drugs from outside the U.S. and used Canadian pharmaceutical prices as an agreed floor for prices in the U.S. in violation of antitrust laws. The case sought restitution for alleged overpayments for pharmaceuticals and an injunction against the allegedly violative conduct. Summary judgment was granted to us and the other defendants and in July 2008, the California Court of Appeal affirmed that decision. In July 2010, the California Supreme Court overturned the lower court decision and remanded the case to the state court. In March 2011, the state court again granted summary judgment for us and the other defendants. Plaintiffs have appealed this decision to the California Court of Appeal. We believe the lawsuit has no merit and are prepared to defend against it vigorously.

In June 2009, we received a Civil Investigative Demand from the office of the Attorney General of Texas requesting documents related to nominal pricing of Axid®; we divested the marketing rights for Axid in 2000. We are cooperating in this matter.

Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.

We are also a defendant in other litigation and investigations, including product liability, patent, employment, and premises liability litigation, of a character we regard as normal to our business.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Part II****Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities**

You can find information relating to the principal market for our common stock and related stockholder matters at Item 8 under "Selected Quarterly Data (unaudited)" and "Selected Financial Data (unaudited)." That information is incorporated here by reference.

The following table summarizes the activity related to repurchases of our equity securities during the fourth quarter ended December 31, 2011:

Period	Total Number of Shares Purchased (in thousands) (a)	Average Price Paid per Share (b)	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (c)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (dollars in millions) (d)
October 2011 .....	0	\$0.00	0.0	\$419.2
November 2011 .....	0	0.00	0.0	419.2
December 2011 .....	0	0.00	0.0	419.2
Total .....	0		0.0	

The amounts presented in columns (a) and (b) above represent purchases of common stock related to our stock-based compensation programs. The amounts presented in columns (c) and (d) in the above table represent activity related to our \$3.00 billion share repurchase program announced in March 2000. As of December 31, 2011, we have purchased \$2.58 billion related to this program. During 2011, no shares were repurchased under this program, and we do not anticipate any such purchases in 2012.

## Item 6. Selected Financial Data

You can find selected financial data for each of our five most recent fiscal years in Item 8 under “Selected Financial Data (unaudited).” That information is incorporated here by reference.

## Item 7. Management’s Discussion and Analysis of Results of Operations and Financial Condition

### RESULTS OF OPERATIONS

#### EXECUTIVE OVERVIEW

This section provides an overview of our financial results, recent product and late-stage pipeline developments, and legal, regulatory, and other matters affecting our company and the pharmaceutical industry.

#### Financial Results

We achieved revenue growth of 5 percent in 2011, which was primarily driven by the collective growth of Cymbalta, insulin products, animal health products, Alimta, Effient, and Cialis, offset by the decline in Gemzar and Zyprexa revenue due to the loss of patent exclusivity. This revenue growth, as well as a lower effective tax rate, was more than offset by lower gross margin percentage; increased marketing, selling, and administrative costs; higher other expense; and the increased impact in 2011 of the items noted below. As a result, net income decreased 14 percent to \$4.35 billion, and earnings per share decreased 15 percent to \$3.90 per share, in 2011 as compared to \$5.07 billion, or \$4.58 per share, in 2010.

#### 2011

##### U.S. Health Care Reform

- As a result of higher rebates and subsidies included in health care reform enacted in the U.S. during 2010, total revenue in 2011 was reduced by \$408.8 million (pretax), or \$.29 per share. Also, marketing, selling, and administrative expenses increased by \$178.0 million (pretax), or \$.16 per share, as a result of the mandatory pharmaceutical manufacturers’ fee.

##### Collaborations (Note 4)

- We incurred acquired in-process research and development (IPR&D) charges associated with the diabetes collaboration with Boehringer Ingelheim of \$388.0 million (pretax), which decreased earnings per share by \$.23.

##### Asset Impairments and Related Restructuring and Other Special Charges (Note 5)

- We recognized restructuring charges of \$316.4 million (pretax), or \$.24 per share, primarily related to severance costs from previously announced strategic actions that we are taking to reduce our cost structure and global workforce.
- We incurred a charge of \$85.0 million (pretax), or approximately \$.05 per share, in 2011 primarily for returned product and contractual commitments related to the withdrawal of Xigris.

#### 2010

##### U.S. Health Care Reform

- As a result of higher rebates included in health care reform enacted in the U.S. during 2010, total revenue in 2010 was reduced by \$229.0 million (pretax), or \$.16 per share. We also recorded a one-time non-cash deferred income tax charge in the first quarter of \$85.1 million, or \$.08 per share, associated with the imposition of tax on the prescription drug subsidy of our U.S. retiree health plan.

##### Acquisitions (Note 3)

- We incurred acquired IPR&D charges associated with the in-licensing arrangement with Acrux Limited (Acrux) of \$50.0 million (pretax), which decreased earnings per share by \$.03.

##### Asset Impairments and Related Restructuring and Other Special Charges (Note 5)

- We recognized asset impairments, restructuring, and other special charges of \$192.0 million (pretax), or \$.13 per share, primarily related to severance costs from previously announced strategic actions.

#### Late-Stage Pipeline

Our long-term success depends to a great extent on our ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies. We currently have approximately 65 potential new drugs in human testing and a larger number of projects in preclinical research.

There are many difficulties and uncertainties inherent in pharmaceutical research and development (R&D) and the introduction of new products. A high rate of failure is inherent in new drug discovery and development. The process to bring a drug from the discovery phase to regulatory approval can take 12 to 15 years or longer and cost more than

\$1 billion. Failure can occur at any point in the process, including late in the process after substantial investment. As a result, most research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain necessary regulatory approvals, limited scope of approved uses, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Delays and uncertainties in the U.S. Food and Drug Administration (FDA) approval process and the approval processes in other countries can result in delays in product launches and lost market opportunity. Consequently, it is very difficult to predict which products will ultimately be approved and the sales growth of those products.

We manage R&D spending across our portfolio of molecules, and a delay in, or termination of, any one project will not necessarily cause a significant change in our total R&D spending. Due to the risks and uncertainties involved in the R&D process, we cannot reliably estimate the nature, timing, completion dates, and costs of the efforts necessary to complete the development of our R&D projects, nor can we reliably estimate the future potential revenue that will be generated from a successful R&D project. Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated R&D expense. While we do accumulate certain R&D costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms. Therefore, we do not have sufficiently reliable data to report on total R&D costs by project, by preclinical versus clinical spend, or by therapeutic category.

The following new molecular entities (NMEs) are currently in Phase III clinical trial testing for potential use in the diseases described. The quarter in which the NME initially entered Phase III for any indication is shown in parentheses:

- Dulaglutide\* (Q3 2008)**—a glucagon-like peptide 1 analog for the treatment of type 2 diabetes
- Edivoxetine (Q4 2010)**—a norepinephrine reuptake inhibitor for the treatment of major depression
- Empagliflozin-BI10773 (Q3 2010)**—a sodium glucose co-transporter (SGLT-2) inhibitor for the treatment of type 2 diabetes (in collaboration with Boehringer Ingelheim)
- Enzastaurin (Q1 2006)**—a small molecule for the treatment of diffuse large B-cell lymphoma
- Ixekizumab—formerly IL-17 MAb\* (Q4 2011)**—a monoclonal antibody for the treatment of psoriasis
- Necitumumab\* (Q4 2009)**—a fully human monoclonal antibody for the treatment of squamous non-small cell lung cancer (NSCLC) (in collaboration with Bristol Myers Squibb)
- New insulin glargine product—formerly LY2963016 (Q3 2011)**—a new insulin glargine product for the treatment of type 1 and type 2 diabetes (in collaboration with Boehringer Ingelheim)
- Novel basal insulin analog\* (Q4 2011)**—a novel basal insulin for the treatment of type 1 and type 2 diabetes (in collaboration with Boehringer Ingelheim)
- Pomaglumetad Methionil (Q1 2011)**—a metabotropic glutamate 2/3 (mGlu 2/3) receptor agonist for the treatment of schizophrenia
- Ramucirumab\* (Q4 2009)**—a monoclonal antibody for the treatment of metastatic breast, gastric, liver, NSCLC, and colorectal cancers
- Solanezumab\* (Q2 2009)**—an amyloid beta (A $\beta$ ) antibody for the treatment of Alzheimer's disease.
- Tabalumab—formerly BAFF MAb\* (Q4 2010)**—an anti-BAFF monoclonal antibody for the treatment of lupus and rheumatoid arthritis

\* Biologic molecule subject to the U.S. Biologics Price Competition and Innovation Act

The following NMEs have been submitted for regulatory review for potential use in the disease described. The quarter the NME initially was submitted for any indication is shown in parentheses:

- Florbetapir (Q3 2010)**—a molecular imaging tool for the detection of beta-amyloid plaque in the brain
- Liprotamase (Q1 2010)**—a non-porcine pancreatic enzyme replacement therapy for the treatment of exocrine pancreatic insufficiency.

The following late-stage pipeline developments have occurred since January 1, 2011:

- Arxxant**—In December, we completed and evaluated the final clinical trial for Arxxant, the EYES study, which did not meet the primary study endpoint. We have opted not to re-submit Arxxant to the FDA for diabetic retinopathy.
- Bydureon**—In June, the European Commission granted marketing authorization for Bydureon, the first once-weekly treatment for type 2 diabetes in combination with certain oral therapies. European launches began in the third quarter of 2011, starting with the United Kingdom and Germany. In January 2012, the FDA approved Bydureon as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. We and Amylin terminated the collaboration in November 2011; refer to Note 4 of the Financial Statements for additional information.
- Florbetapir**—In March, we received a complete response letter from the FDA for the New Drug Application (NDA) for Amyvid (florbetapir) that was primarily focused on the need to establish a reader training program for market implementation that helps to ensure reader accuracy and consistency of interpretations of existing Amyvid scans. We submitted our response to the FDA's complete response letter.
- Ixekizumab**—In November, we began the first Phase III clinical trial for ixekizumab.

**Linagliptin and Empagliflozin**—In January 2011, we announced a global agreement with Boehringer Ingelheim (Boehringer) to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development, including Boehringer's two investigational oral diabetes agents, linagliptin and empagliflozin. In 2011, linagliptin was approved and launched in the U.S. (trade name Tradjenta), Japan (trade name Trazenta™), Europe (trade name Trajenta®), and other countries. In January 2012, the FDA approved Jentadueto™, a combination of linagliptin and metformin for the treatment of adults with type 2 diabetes.

**Liprotamase**—In April, we received a complete response letter from the FDA for the NDA for liprotamase that communicated the need for us to conduct an additional clinical trial prior to a re-submission. We are currently finalizing the study design and anticipate starting a clinical study in 2012.

**Necitumumab**—In February 2011, we and Bristol-Myers Squibb Company stopped enrollment in one of the two global Phase III studies. The decision to stop enrollment in the Phase III non-squamous NSCLC INSPIRE trial (combination treatment with Alimta) followed an independent Data Monitoring Committee recommendation that no new or recently enrolled patients continue treatment in the trial because of safety concerns related to thromboembolism (blood clots) in the experimental arm of the study. The second Phase III study in squamous NSCLC looking at the combination use of necitumumab with Gemzar is continuing.

**New insulin glargine product**—In September, we began the first Phase III clinical trial for our new insulin glargine product.

**Novel basal insulin analog**—In November, we began the first Phase III clinical trial for our novel basal insulin analog.

**Pomaglumetad Methionil**—In February 2011, we began the first Phase III clinical trial for pomaglumetad methionil.

**Solanezumab**—In January 2012, an independent Data Monitoring Committee (DMC) recommended that we continue the two ongoing Phase III randomized pivotal trials for solanezumab without modifications, based on pre-planned interim safety and futility analyses. The DMC also recommended that we make a protocol modification to EXPEDITION-XT, the open-label extension study of the two Phase III trials, making the protocol for the open-label extension more consistent with the current protocol for the pivotal studies.

### Acquisition

In February 2012, we acquired ChemGen Corp., a privately-held bioscience company specializing in the development and commercialization of innovative feed enzyme products that improve the efficiency of poultry, egg, and meat production. The transaction is not material to our consolidated financial statements.

### Legal, Regulatory, and Other Matters

In October 2011, we announced the withdrawal of our Xigris [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. We incurred a charge of \$85.0 million (pretax), or approximately \$.05 per share, for product returns and contractual commitments related to Xigris. Revenue related to Xigris has not been material to our consolidated financial statements.

The enactment of the "Patient Protection and Affordable Care Act" (PPACA) and "The Health Care and Education Reconciliation Act of 2010" in March 2010 brought significant changes to U.S. health care. These changes began to affect our financial results in the first quarter of 2010 and will continue to have significant impact on our results in the future. The U.S. Supreme Court has agreed to decide the constitutionality of the PPACA. Oral arguments will take place in March 2012 and a decision is expected in the summer of 2012.

Changes to the rebates for prescription drugs sold to Medicaid beneficiaries, which increase the minimum statutory rebate for branded drugs from 15.1 percent to 23.1 percent, became effective in the first quarter of 2010. This rebate has been expanded to managed Medicaid, a program that provides for the delivery of Medicaid benefits via managed care organizations, under arrangements between those organizations and state Medicaid agencies. Additionally, a prescription drug discount program for outpatient drugs in certain types of health care facilities that serve low-income and uninsured patients (known as 340B facilities) has been expanded.

Beginning in 2011, drug manufacturers provided a discount of 50 percent of the cost of branded prescription drugs for Medicare Part D participants who are in the "doughnut hole" (the coverage gap in Medicare prescription drug coverage). The doughnut hole will be phased out by the federal government between 2011 and 2020. Additionally, beginning in 2011, a non-tax-deductible annual fee is imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs. This fee is allocated to companies based on their prior-calendar-year market share for branded prescription drug sales into these government programs. In 2011, we recorded \$178.0 million related to this fee, which is included in marketing, selling, and administrative expense in our consolidated statement of operations.

Also, there are changes to the tax treatment of subsidies paid by the government to employers, such as us, who provide their retirees with a drug benefit at least equivalent to the Medicare Part D drug benefit. Beginning in 2013, the federal government will tax the subsidy it provides to such employers. While this tax will not take effect for two more years, accounting rules dictated that we adjust our deferred tax asset through a one-time non-cash charge of \$85.1 million upon enactment of the tax law change, which we recorded in the first quarter of 2010.

The continuing prominence of U.S. budget deficits as both a policy and political issue increases the risk that taxes, fees, rebates, or other measures that would further reduce pharmaceutical companies' revenue or increase

expenses may be enacted. Certain other federal and state health care proposals continue to be debated, and could place downward pressure on pharmaceutical industry sales or prices. We also expect pricing pressures at state levels could become more severe. These federal and state proposals, or state price pressures, could have a material adverse effect on our consolidated results of operations.

The Obama Administration has proposed changes to the manner in which the U.S. would tax the international income of U.S.-based companies. There also have been tax proposals under discussion or introduced in the U.S. Congress that could change the manner in which, and the rate at which, income of U.S. companies would be taxed. While it is uncertain how the U.S. Congress may address U.S. tax policy matters in the future, reform of U.S. taxation, including taxation of international income, will continue to be a topic of discussion for Congress and the Obama Administration. A significant change to the U.S. tax system, including changes to the taxation of international income, could have a material adverse effect on our consolidated results of operations. In October 2010, Puerto Rico enacted income and excise tax legislation affecting our operations. This tax is included in costs of sales in our consolidated statement of operations. We believe this tax should be creditable against our U.S. income taxes.

International operations also are generally subject to extensive price and market regulations, and several European countries have recently required either price decreases or rebate increases in response to economic pressures. We also anticipate an adverse effect from biennial pricing actions in Japan. There are proposals for cost-containment measures pending in a number of additional countries, including proposals that would directly or indirectly impose additional price controls, limit access to or reimbursement for our products, or reduce the value of our intellectual property protection. Such proposals are expected to increase in both frequency and impact, given the pressures on national and regional health care budgets as a result of austerity measures being pursued in a number of countries.

## OPERATING RESULTS—2011

### Revenue

Our worldwide revenue for 2011 increased 5 percent, to \$24.29 billion, driven by the collective growth of Cymbalta, insulin products, animal health products, Alimta, Effient, and Cialis, offset by the decline in Gemzar and Zyprexa revenue due to the loss of patent exclusivity. Worldwide sales volume increased 6 percent, and the favorable impact of foreign exchange rates contributed 2 percent of revenue growth, partially offset by a 3 percent decrease due to lower prices. The increase in volume and reduction in price were partially driven by the loss of U.S. patent exclusivity for Zyprexa and Gemzar and the agreements to supply authorized versions of olanzapine and gemcitabine. Revenue in the U.S. increased 1 percent, to \$12.98 billion, due to higher volume, partially offset by lower prices. Revenue outside the U.S. increased 11 percent, to \$11.31 billion, due to increased demand and the positive impact of foreign exchange rates, partially offset by lower prices. In 2011, total revenue was reduced by \$408.8 million due to the impact of U.S. health care reform.

The following table summarizes our revenue activity in 2011 compared with 2010:

Product	Year Ended December 31, 2011			Year Ended December 31, 2010 Total	Percent Change from 2010
	U.S. <sup>1</sup>	Outside U.S.	Total <sup>2</sup>		
	(Dollars in millions)				
Zyprexa	\$ 2,165.3	\$ 2,456.7	\$ 4,622.0	\$ 5,026.4	(8)
Cymbalta	3,173.4	988.4	4,161.8	3,459.2	20
Alimta	994.6	1,466.5	2,461.1	2,208.6	11
Humalog	1,398.9	968.7	2,367.6	2,054.2	15
Cialis	704.5	1,171.1	1,875.6	1,699.4	10
Animal health products	896.8	781.8	1,678.6	1,391.4	21
Humulin	588.1	660.7	1,248.8	1,088.9	15
Evista	707.5	359.4	1,066.9	1,024.4	4
Forteo	453.1	496.7	949.8	830.1	14
Strattera	392.2	227.9	620.1	576.7	8
Gemzar	70.6	381.5	452.1	1,149.4	(61)
Other pharmaceutical products	879.4	1,221.0	2,100.4	1,933.5	9
Total net product sales	12,424.4	11,180.4	23,604.8	22,442.2	5
Collaboration and other revenue <sup>3</sup>	552.8	128.9	681.7	633.8	8
Total revenue	\$12,977.2	\$11,309.3	\$24,286.5	\$23,076.0	5

<sup>1</sup>U.S. revenue includes revenue in Puerto Rico.

<sup>2</sup>Numbers may not add due to rounding.

<sup>3</sup>Collaboration and other revenue is primarily composed of Erbitux royalties and 50 percent of Byetta's gross margin in the U.S.

Zyprexa is a treatment for schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance. Zyprexa sales in the U.S. decreased 13 percent in 2011 due to the loss of patent exclusivity in

the U.S. on October 23, 2011. Despite a decline in demand for branded Zyprexa, U.S. volume increased in 2011 primarily as a result of sales of authorized olanzapine in connection with our six-month agreement with Prasco Laboratories. This volume increase was more than offset by significant price reductions attributable both to branded Zyprexa and authorized olanzapine. Sales outside the U.S. decreased 3 percent driven primarily by the loss of patent exclusivity throughout most major markets outside of Japan during 2011, partially offset by the favorable impact of foreign exchange rates and increased demand in Japan. In the five major European countries, which in the aggregate had approximately \$900 million in sales in 2011, we lost exclusivity in Spain in April 2011 and in France, Germany, Italy, and the United Kingdom in September 2011. Globally, upon loss of exclusivity, we are experiencing generic competition which is causing rapid and severe declines on our Zyprexa sales. In Japan, our second-largest market with approximately \$540 million in sales in 2011, our patent expires in December 2015. We anticipate worldwide sales of Zyprexa to decline by at least \$3 billion in 2012.

Sales of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the U.S. for the treatment of chronic musculoskeletal pain and the management of fibromyalgia, increased 14 percent in the U.S., driven primarily by increased demand and higher prices. Sales outside the U.S. increased 44 percent, driven primarily by increased demand and, to a lesser extent, the favorable impact of foreign exchange rates.

Sales of Alimta, a treatment for various cancers, increased 4 percent in the U.S., due primarily to higher prices and increased demand. Sales outside the U.S. increased 17 percent, due to increased demand and, to a lesser extent, the favorable impact of foreign exchange rates. We expect 2012 sales outside the U.S. to be negatively affected by significant government price reductions in Japan, which is our second largest market for Alimta, and the introduction of generic competition in certain markets.

Sales of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 14 percent in the U.S., due to increased demand and, to a lesser extent, higher prices. Sales outside the U.S. increased 16 percent, driven by increased demand and, to a lesser extent, the favorable impact of foreign exchange rates.

Sales of Cialis, a treatment for erectile dysfunction (also approved in October 2011 for benign prostatic hyperplasia in the U.S.), increased 7 percent in the U.S., primarily due to higher prices. Sales outside the U.S. increased 12 percent, driven by increased demand, the favorable impact of foreign exchange rates, and higher prices.

Sales of Humulin, an injectable human insulin for the treatment of diabetes, increased 25 percent in the U.S., driven primarily by higher prices for Humulin and increased demand attributable to Humulin ReliOn. Sales outside the U.S. increased 7 percent, due to increased demand and the favorable impact of foreign exchange rates, partially offset by lower prices.

Sales of Evista, a product for the prevention and treatment of osteoporosis in postmenopausal women and for reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, increased 4 percent in the U.S., due to higher prices partially offset by lower demand. Sales outside the U.S. increased 5 percent, driven by the favorable impact of foreign exchange rates and, to a lesser extent, increased demand, partially offset by lower prices.

Sales of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in postmenopausal women and men, decreased 9 percent in the U.S., driven by lower demand, partially offset by higher prices. Sales outside the U.S. increased 50 percent, primarily due to the increased demand in Japan.

Sales of Strattera, a treatment for attention-deficit hyperactivity disorder in children, adolescents, and in the U.S. in adults, increased 1 percent in the U.S., due primarily to higher prices, partially offset by lower demand. Sales outside the U.S. increased 22 percent, driven primarily by increased demand and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower prices.

Sales of Gemzar, a product approved to treat various cancers, decreased 90 percent in the U.S., due to a rapid and severe decline in sales as a result of generic competition, which began in November 2010, following the expiration of the compound patent. Sales outside the U.S. decreased 10 percent, due to generic competition in most major markets. We expect sales to continue to decline in 2012.

We report as revenue for Erbitux, a product approved to treat various cancers, the net royalties received from our collaboration partners and our product sales. Our revenues increased 6 percent to \$409.2 million in 2011.

Prior to the termination of our exenatide collaboration with Amylin in November 2011, we recognized in revenue our 50 percent share of Byetta's gross margin in the U.S. In December 2011, we recognized a pro rata portion of revenue resulting from the termination arrangement. We will continue to recognize 100 percent of Byetta and Bydureon sales outside the U.S. until those markets transition to Amylin on a market-by-market basis over a period beginning no earlier than the second half of 2012 and that will not extend beyond December 31, 2013. We also recognize our sales of Byetta pen delivery devices to Amylin which will continue until no later than the end of 2013. In 2011, we recognized total exenatide revenue of \$422.7 million, a decrease of 2 percent.

Animal health product sales in the U.S. increased 16 percent, due primarily to increased demand. Sales outside the U.S. increased 27 percent during 2011, driven primarily by the impact of the acquisition of certain Janssen and Pfizer animal health assets in Europe and, to a lesser extent, increased demand for other products and the favorable impact of foreign exchange rates.

### Gross Margin, Costs, and Expenses

Gross margin as a percent of total revenue decreased by 2.0 percentage points in 2011 to 79.1 percent. This decrease was due primarily to the effect of foreign exchange rates on international inventories sold, which significantly increased cost of sales in 2011, but led to a modest reduction to cost of sales in 2010. Patent expirations for Zyprexa and Gemzar also drove the reduction in gross margin percent.

Marketing, selling, and administrative expenses increased 12 percent in 2011 to \$7.88 billion. The increase was driven by the diabetes collaboration with Boehringer Ingelheim, as well as the effect of foreign exchange rates. In addition, higher administrative expenses in the U.S. included \$178.0 million related to the mandatory pharmaceutical manufacturers' fee associated with U.S. health care reform. Investment in research and development increased 3 percent, to \$5.02 billion, due primarily to increased late-stage clinical trial costs, including costs related to the diabetes collaboration with Boehringer Ingelheim.

We incurred an IPR&D charge of \$388.0 million in 2011, associated with our diabetes collaboration with Boehringer Ingelheim, compared with \$50.0 million in 2010 associated with the in-licensing agreement with Acrux. We recognized asset impairments, restructuring, and other special charges of \$401.4 million in 2011, including charges of \$316.4 million primarily related to severance costs from previously announced strategic actions that we are taking to reduce our cost structure and global workforce, and a special charge of \$85.0 million related to the withdrawal of Xigris. In 2010, we recognized charges totaling \$192.0 million for asset impairments, restructuring, and other special charges. See Notes 3 and 5 to the consolidated financial statements for additional information.

Other—net, expense increased \$174.0 million to a net expense of \$179.0 million in 2011, due primarily to the partial impairment of the acquired IPR&D assets related to liprotamase and Amyvid in 2011 and damages recovered in 2010 from generic pharmaceutical companies related to Zyprexa patent litigation in Germany.

Our effective tax rate was 18.7 percent in 2011, compared with 22.3 percent in 2010. The decrease was due to the tax benefit on the IPR&D charge associated with the Boehringer Ingelheim diabetes collaboration, as well as a benefit of \$85.3 million primarily from the resolution in 2011 of the IRS audits of tax years 2005-2007, along with certain matters related to 2008-2009. Additionally, the tax rate for 2010 was increased by a one-time charge of \$85.1 million associated with the imposition of tax on the prescription drug subsidy of our retiree health plan as part of U.S. health care reform.

## OPERATING RESULTS—2010

### Financial Results

We achieved revenue growth of 6 percent to \$23.08 billion in 2010, which was primarily driven by the collective growth of Alimta, Cymbalta, animal health products, insulin products, Cialis, and Zyprexa, offset by a decline in Gemzar revenue. Cost of sales and marketing, selling, and administrative expenses grew at a slower rate than revenue, while our investment in research and development grew at a greater rate than revenue and our effective tax rate increased. Net income increased 17 percent to \$5.07 billion, and earnings per share increased 16 percent to \$4.58 per share, in 2010, as compared to \$4.33 billion, or \$3.94 per share, in 2009. Net income comparisons between 2010 and 2009 are affected by the impact of several highlighted items. The highlighted items for 2010 are summarized in the Executive Overview. The 2009 highlighted items are summarized as follows:

#### Acquisitions (Note 3)

- We incurred acquired IPR&D charges associated with an in-licensing arrangement with Incyte Corporation (Incyte) of \$90.0 million (pretax), which decreased earnings per share by \$.05.

#### Asset Impairments and Related Restructuring and Other Special Charges (Notes 5 and 15)

- We recognized asset impairments, restructuring, and other special charges of \$462.7 million (pretax), which decreased earnings per share by \$.29, for asset impairments and restructuring primarily related to the sale of our Tiptecanoe Laboratories manufacturing site.
- We incurred pretax charges of \$230.0 million in connection with the claims of several states related to Zyprexa, which decreased earnings per share by \$.13.

### Revenue

Our worldwide revenue for 2010 increased 6 percent, to \$23.08 billion, driven by the collective growth of Alimta, Cymbalta, animal health products, insulin products, Cialis, and Zyprexa, offset by a decline in Gemzar revenue. Worldwide sales volume increased 3 percent, while selling prices contributed 2 percent of revenue growth, and the impact of foreign exchange rates was negligible. Revenue in the U.S. increased 5 percent, to \$12.87 billion, due to higher prices. Revenue outside the U.S. increased 7 percent, to \$10.21 billion, due to increased demand, partially offset by lower prices. In 2010, total revenue was reduced by \$229.0 million due to the impact of U.S. health care reform.

The following table summarizes our revenue activity in 2010 compared with 2009:

Product	Year Ended December 31, 2010			Year Ended December 31, 2009	Percent Change from 2010
	U.S. <sup>1</sup>	Outside U.S.	Total <sup>2</sup>	Total	
	(Dollars in millions)				
Zyprexa .....	\$ 2,495.5	\$ 2,530.9	\$ 5,026.4	\$ 4,915.7	2
Cymbalta .....	2,772.0	687.2	3,459.2	3,074.7	13
Alimta .....	957.1	1,251.5	2,208.6	1,706.0	29
Humalog .....	1,222.4	831.8	2,054.2	1,959.0	5
Cialis .....	658.1	1,041.4	1,699.4	1,559.1	9
Animal health products .....	775.1	616.3	1,391.4	1,207.2	15
Gemzar .....	723.3	426.1	1,149.4	1,363.2	(16)
Humulin .....	470.8	618.0	1,088.9	1,022.0	7
Evista .....	681.8	342.6	1,024.4	1,030.4	(1)
Forteo .....	499.0	331.0	830.1	816.7	2
Strattera .....	389.8	186.9	576.7	609.4	(5)
Other pharmaceutical products .....	737.4	1,196.3	1,933.5	1,908.1	1
Total net product sales .....	12,382.3	10,060.0	22,442.2	21,171.5	6
Collaboration and other revenue <sup>3</sup> .....	483.3	150.4	633.8	664.5	(5)
Total revenue .....	\$12,865.6	\$10,210.4	\$23,076.0	\$21,836.0	6

<sup>1</sup> U.S. revenue includes revenue in Puerto Rico.

<sup>2</sup> Numbers may not add due to rounding.

<sup>3</sup> Collaboration and other revenue is primarily composed of Erbitux royalties and 50 percent of Byetta's gross margin in the U.S.

Zyprexa sales in the U.S. increased 7 percent in 2010, driven by higher prices, partially offset by lower demand. Sales outside the U.S. decreased 2 percent driven by lower prices and decreased demand in Europe and Canada, partially offset by the favorable impact of foreign exchange rates and increased demand in Japan.

Sales of Cymbalta increased 9 percent in the U.S., driven primarily by higher prices. Sales outside the U.S. increased 31 percent, driven primarily by increased demand in Japan, Europe, and Canada.

Sales of Alimta increased 17 percent in the U.S., due primarily to increased demand. Sales outside the U.S. increased 41 percent, due to increased demand. Demand outside the U.S. was favorably affected by continued strong growth in Japan.

Sales of Humalog increased 1 percent in the U.S., due to higher prices, partially offset by the impact of wholesaler buying patterns. Sales outside the U.S. increased 11 percent, driven by increased demand primarily in Japan and China.

Sales of Cialis increased 6 percent in the U.S., due to higher prices. Sales outside the U.S. increased 11 percent, due primarily to increased demand and, to a lesser extent, higher prices.

Sales of Gemzar decreased 3 percent in the U.S., due to a rapid and severe decline in sales as a result of generic competition, which began in November 2010, following the expiration of the compound patent. Sales outside the U.S. decreased 31 percent, due primarily to generic competition in most major markets.

Sales of Humulin increased 17 percent in the U.S., driven primarily by higher prices and increased demand. Sales outside the U.S. remained essentially flat when compared to 2009, due to lower prices offset by increased demand and the favorable impact of foreign exchange rates.

Sales of Evista remained essentially flat in the U.S., due to decreased demand offset by increased prices. Sales outside the U.S. decreased 2 percent, driven by lower prices and lower demand, partially offset by a favorable impact of foreign exchange rates.

Sales of Forteo decreased 4 percent in the U.S., driven by lower demand, partially offset by higher prices. Sales outside the U.S. increased 11 percent, due to increased demand and, to a lesser extent, higher prices.

Sales of Strattera decreased 13 percent in the U.S., due primarily to lower demand, and to a lesser extent, lower net effective selling prices. Sales outside the U.S. increased 14 percent, driven by increased demand, partially offset by lower prices.

Worldwide sales of Byetta decreased 11 percent to \$710.2 million during 2010 due to competitive pressures in the U.S. and European markets. Our revenues decreased 4 percent to \$430.6 million in 2010.

Erbitux revenues were \$386.1 million in 2010, compared with \$390.8 million in 2009.

Animal health product sales in the U.S. and outside the U.S. increased 15 percent, due primarily to increased demand for our companion animal and feed additive products.

### Gross Margin, Costs, and Expenses

Gross margin as a percent of total revenue increased by 0.5 percentage points in 2010 to 81.1 percent. This increase was due to lower manufacturing costs and higher selling prices, partially offset by the negative effect of foreign exchange rates on international inventories sold.

Marketing, selling, and administrative expenses increased 2 percent in 2010 to \$7.05 billion. The increase was driven by higher marketing and selling expenses outside the U.S., partially offset by lower administrative and litigation expenses and company-wide cost containment efforts. Investment in research and development increased 13 percent, to \$4.88 billion, due primarily to charges related to pipeline molecules, including charges related to business development activities and termination of clinical trials.

We incurred an IPR&D charge of \$50.0 million in 2010, associated with the in-licensing agreement with Acrux, compared with \$90.0 million in 2009 resulting from the in-licensing agreement with Incyte. We recognized asset impairments, restructuring, and other special charges of \$192.0 million in 2010, primarily related to severance and other related costs from previously announced strategic actions we are taking to reduce our cost structure and global workforce. In 2009, we recognized charges totaling \$692.7 million for asset impairments, restructuring, and other special charges. See Notes 3, 5, and 15 to the consolidated financial statements for additional information.

Other—net, expense improved \$224.5 million to a net expense of \$5.0 million in 2010, due primarily to net gains on equity investments, lower net interest expense, damages recovered from generic pharmaceutical companies following Zyprexa patent litigation in Germany, and an insurance recovery associated with the theft of product at our Enfield, Connecticut, distribution center.

The effective tax rate was 22.3 percent for 2010, compared with 19.2 percent for 2009. The 2010 increase was driven by \$85.1 million in additional tax expense in the first quarter related to U.S. health care reform. The 2009 effective tax rate was reduced due to the tax benefit of asset impairment and restructuring charges associated with the sale of the Tiptecanoe Laboratories manufacturing site.

### FINANCIAL CONDITION

As of December 31, 2011, cash, cash equivalents, and short-term investments totaled \$6.90 billion compared with \$6.73 billion at December 31, 2010. The increase in cash was driven by cash from operations of \$7.23 billion, partially offset by net noncurrent investment activity (as cash was invested with maturities greater than one year) of \$2.32 billion, dividends paid of \$2.18 billion, business and product acquisitions of \$1.33 billion, and purchases of property and equipment of \$672.0 million.

Capital expenditures of \$672.0 million during 2011 were \$22.3 million less than in 2010. We expect 2012 capital expenditures to be approximately \$800 million as we invest in the long-term growth of our diabetes-care product portfolio and additional biotechnology capacity while continuing investments to improve the quality, productivity, and capability of our manufacturing, research, and development facilities.

Total debt at December 31, 2011, was \$6.99 billion, an increase of \$60.5 million from December 31, 2010, which was due primarily to the \$252.4 million increase in the fair value of hedged debt offset by the full repayment in 2011 of \$125.0 million of short-term floating rate debt and \$63.7 million in Employee Stock Ownership Plan debentures. In 2012, we plan to retire \$1.51 billion of our debt as it matures. Our current debt ratings from Standard & Poor's and Moody's remain AA- and A2, respectively. Our ratings outlook from both Moody's and Standard & Poor's is stable.

Dividends of \$1.96 per share were paid in 2011 and 2010. 2011 was the 127th consecutive year in which we made dividend payments. In the fourth quarter of 2011, effective for the dividend to be paid in the first quarter of 2012, the quarterly dividend was maintained at \$.49 per share, resulting in an indicated annual rate for 2012 of \$1.96 per share.

As of the fourth quarter of 2011, the U.S. economy continues to recover while concerns have grown regarding the health of the European economy. Worries in Europe have spread beyond the "peripheral" nations to encompass the entirety of the euro area, with many economists believing a recession in the euro area to be probable. Meanwhile, U.S. economic data in the fourth quarter generally exceeded expectations, with housing and employment indicators signaling a strengthening recovery. Still, given the fragility of the economic recovery and the heightened anxiety regarding Europe, the Federal Reserve has maintained its view that accommodative policy is likely to be warranted through 2014. Both domestically and abroad, high sovereign debt levels, sluggish growth, rating downgrades, and ongoing fiscal deficits have spurred efforts at fiscal austerity, notably in Spain, Italy, and Greece. We continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government backed agencies and suppliers; the uncertain impact of recent health care legislation; the federal government's involvement in the U.S. economy; and various international government funding levels. Currently, we believe economic conditions in Europe will not have a material impact on our liquidity.

We believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund our normal operating needs, including debt service, capital expenditures, and dividends in 2012. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowings. Because of the high credit quality of our short- and long-term debt, our access to credit markets has not been adversely affected. We currently have \$1.24 billion of unused committed bank credit facilities, \$1.20 billion of which backs our commercial paper program. Various risks and uncertainties, including those discussed in Item 1A, "Risk Factors," and the "Financial Expectations for 2012" section, may affect our operating results and cash generated from operations.

We depend on patents or other forms of intellectual property protection for most of our revenues, cash flows, and earnings. Through 2014, we expect to lose U.S. patent protection for Cymbalta (June 2013) and Evista (March 2014). Cymbalta could receive an additional six months of exclusivity, based on completion of pediatric studies.

Zyprexa and Gemzar have already lost exclusivity in the U.S. and Europe. In the U.S., Gemzar lost exclusivity in November 2010 and Zyprexa lost exclusivity in October 2011. In addition, we face U.S. patent litigation over Alimta, and it is possible we could lose our exclusivity prior to the expiration of the relevant patents. Refer to the Hatch-Waxman patent litigation discussion in Note 15 and in the "Legal and Regulatory Matters" section below. The loss of exclusivity for Alimta, Cymbalta, or Evista would likely result in generic competition, generally causing a rapid and severe decline in revenue from the affected product, which would have a material adverse effect on our results of operations. The U.S. patent for Humalog expires in May 2013. Humalog is currently protected in Europe only by formulation patents. We do not currently expect the loss of patent protection for Humalog to result in a rapid and severe decline in revenue. To date, no company has received approval to market a biosimilar version of Humalog; however, it is difficult to predict the likelihood and impact of biosimilars entering the market. Our goal is to mitigate the effect of these exclusivity losses on our operations, liquidity, and financial position through growth in our patent-protected products that do not lose exclusivity during this period, in emerging markets, in Japan, and in our animal health business. Our expected growth in the emerging markets and Japan is attributable to both the growth of these markets and launches of new products in these markets.

In the normal course of business, our operations are exposed to fluctuations in interest rates and currency values. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact on earnings of fluctuations in interest and currency exchange rates. All derivative activities are for purposes other than trading.

Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. Based on our overall interest rate exposure at December 31, 2011 and 2010, including derivatives and other interest rate risk-sensitive instruments, a hypothetical 10 percent change in interest rates applied to the fair value of the instruments as of December 31, 2011 and 2010, respectively, would have no material impact on earnings, cash flows, or fair values of interest rate risk-sensitive instruments over a one-year period.

Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and the Japanese yen, and the British pound against the euro. We face transactional currency exposures that arise when we enter into transactions, generally on an intercompany basis, denominated in currencies other than the local currency. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Our policy outlines the minimum and maximum hedge coverage of such exposures. Gains and losses on these derivative positions offset, in part, the impact of currency fluctuations on the existing assets, liabilities, commitments, and anticipated revenues. Considering our derivative financial instruments outstanding at December 31, 2011 and 2010, a hypothetical 10 percent change in exchange rates (primarily against the U.S. dollar) as of December 31, 2011 and 2010, respectively, would have no material impact on earnings, cash flows, or fair values of foreign currency rate risk-sensitive instruments over a one-year period. These calculations do not reflect the impact of the exchange gains or losses on the underlying positions that would be offset, in part, by the results of the derivative instruments.

### **Off-Balance Sheet Arrangements and Contractual Obligations**

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on assets still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product (e.g., approval of the product for marketing by the appropriate regulatory agency or upon the achievement of certain sales levels). If required by the arrangement, we may make royalty payments based upon a percentage of the sales of the pharmaceutical product in the event that regulatory approval for marketing is obtained. Because of the contingent nature of these payments, they are not included in the table of contractual obligations.

Individually, these arrangements are not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements would happen to be reached in the same reporting period, the aggregate charge to expense could be material to the results of operations in that period. These arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves milestone objectives. We also note that, from a business perspective, we view these payments as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flows from sales of products.

Our current noncancelable contractual obligations that will require future cash payments are as follows (in millions):

	Payments Due by Period				
	Total	Less Than 1 Year	1-3 Years	3-5 Years	More Than 5 Years
Long-term debt, including interest payments <sup>1</sup> . . . . .	\$ 9,127.8	\$ 1,672.0	\$ 1,323.5	\$ 519.5	\$ 5,612.8
Capital lease obligations . . . . .	60.8	8.0	12.5	11.5	28.8
Operating leases . . . . .	514.9	111.7	155.1	100.3	147.8
Purchase obligations <sup>2</sup> . . . . .	12,694.3	10,791.8	1,258.2	496.5	147.8
Other long-term liabilities reflected on our balance sheet <sup>3</sup> . .	1,679.7	0.0	549.0	233.0	897.7
Other <sup>4</sup> . . . . .	180.5	180.5	0.0	0.0	0.0
<b>Total . . . . .</b>	<b>\$24,258.0</b>	<b>\$12,764.0</b>	<b>\$3,298.3</b>	<b>\$1,360.8</b>	<b>\$6,834.9</b>

<sup>1</sup> Our long-term debt obligations include both our expected principal and interest obligations and our interest rate swaps. We used the interest rate forward curve at December 31, 2011, to compute the amount of the contractual obligation for interest on the variable rate debt instruments and swaps.

<sup>2</sup> We have included the following:

- Purchase obligations, consisting primarily of all open purchase orders at our significant operating locations as of December 31, 2011. Some of these purchase orders may be cancelable; however, for purposes of this disclosure, we have not distinguished between cancelable and noncancelable purchase obligations.
- Contractual payment obligations with each of our significant vendors, which are noncancelable and are not contingent.

<sup>3</sup> We have included long-term liabilities consisting primarily of our nonqualified supplemental pension funding requirements and deferred compensation liabilities. We excluded long-term liabilities for unrecognized tax benefits of \$1.09 billion, because we cannot reasonably estimate the timing of future cash outflows associated with those liabilities.

<sup>4</sup> This category consists of various miscellaneous items expected to be paid in the next year, none of which are individually material.

The contractual obligations table is current as of December 31, 2011. We expect the amount of these obligations to change materially over time as new contracts are initiated and existing contracts are completed, terminated, or modified.

## APPLICATION OF CRITICAL ACCOUNTING POLICIES

In preparing our financial statements in accordance with generally accepted accounting principles (GAAP), we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and consequently actual results could differ from those estimates. For any given individual estimate or assumption we make, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. We believe that, given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position, or liquidity for the periods presented in this report. Our most critical accounting policies have been discussed with our audit committee and are described below.

### Revenue Recognition and Sales Return, Rebate, and Discount Accruals

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, rebates, and discounts are established in the same period the related sales are recorded.

We regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements does not provide an incentive for speculative wholesaler buying and provides us with data on inventory levels at our wholesalers. When we believe wholesaler purchasing patterns have caused an unusual increase or decrease in the sales of a major product compared with underlying demand, we disclose this in our product sales discussion if we believe the amount is material to the product sales trend; however, we are not always able to accurately quantify the amount of stocking or destocking. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.

Consistent with revenue recognition accounting guidance, when sales occur we estimate a reserve for future product returns related to those sales. This estimate is primarily based on historical return rates as well as specifically identified anticipated returns due to known business conditions and product expiry dates. We record the return amounts as a deduction to arrive at our net product sales. Once the product is returned, it is destroyed. Actual product returns have been less than one percent of our net sales over the past three years and have not fluctuated significantly as a percent of sales.

We establish sales rebate and discount accruals in the same period as the related sales. The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include Medicaid, managed care, Medicare, chargebacks, long-term care, hospital, patient assistance programs, and various other government programs. We base these accruals primarily upon our historical rebate and discount payments made to our customer segment groups and the provisions of current rebate and discount contracts.

The largest of our sales rebate and discount amounts are rebates associated with sales covered by Medicaid. In determining the appropriate accrual amount, we consider our historical Medicaid rebate payments by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g. patent expiries), an evaluation of the current Medicaid rebate laws and interpretations, the percentage of our products that are sold to Medicaid recipients, and our product pricing and current rebate and discount contracts. Although we accrue a liability for Medicaid rebates at the time we record the sale (when the product is shipped), the Medicaid rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.

Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. A best estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale. If our estimates are not reflective of the actual pharmaceutical costs incurred by the government, we adjust our rebate reserves.

We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. U.S. sales returns, federally mandated Medicaid rebate and state pharmaceutical assistance programs (Medicaid), and Medicare rebates reduced sales by \$2.46 billion, \$1.66 billion, and \$1.20 billion in 2011, 2010, and 2009, respectively. A 5 percent change in the sales return, Medicaid, and Medicare rebate amounts we recognized in 2011 would lead to an approximate \$123 million effect on our income before income taxes. As of December 31, 2011, our sales returns, Medicaid, and Medicare rebate liability was \$1.23 billion.

Our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our global sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet. Approximately 82 percent and 83 percent of our global sales return, rebate, and discount liability resulted from sales of our products in the U.S. as of December 31, 2011 and 2010, respectively. The following represents a roll-forward of our most significant U.S. returns, rebate, and discount liability balances, including Medicaid (in millions):

	2011	2010
Sales return, rebate, and discount liabilities, beginning of year	\$ 1,155.3	\$ 963.6
Reduction of net sales due to sales returns, discounts, and rebates <sup>1</sup>	4,016.9	2,876.1
Cash payments of discounts and rebates	<u>(3,574.3)</u>	<u>(2,684.4)</u>
Sales return, rebate, and discount liabilities, end of year	<u>\$ 1,597.9</u>	<u>\$ 1,155.3</u>

<sup>1</sup> Adjustments of the estimates for these returns, rebates, and discounts to actual results were less than 0.3 percent of net sales for each of the years presented.

### Product Litigation Liabilities and Other Contingencies

Product litigation liabilities and other contingencies are, by their nature, uncertain and are based upon complex judgments and probabilities. The factors we consider in developing our product litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nature and the number of other similar current and past litigation cases, the nature of the product and the current assessment of the science subject to the litigation, and the likelihood of settlement and current state of settlement discussions, if any. In addition, we accrue for certain product liability claims incurred, but not filed, to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. We accrue legal defense costs expected to be incurred in connection with significant product liability contingencies when probable and reasonably estimable.

We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibility of and length of time for collection. Due to a very restrictive market for product liability insurance, we have been and will continue to be largely self-insured for future product liability losses for substantially all our currently marketed products. In addition, there is no assurance that we will be able to fully collect from our insurance carriers on past claims.

The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.

### Pension and Retiree Medical Plan Assumptions

Pension benefit costs include assumptions for the discount rate, retirement age, and expected return on plan assets. Retiree medical plan costs include assumptions for the discount rate, retirement age, expected return on plan

assets, and health-care-cost trend rates. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 14 to the consolidated financial statements for additional information regarding our retirement benefits.

Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating these assumptions, we consider many factors, including an evaluation of the discount rates, expected return on plan assets, and health-care-cost trend rates of other companies; our historical assumptions compared with actual results; an analysis of current market conditions and asset allocations (approximately 81 percent of which are growth investments); and the views of leading financial advisers and economists. We use an actuarially determined, company-specific yield curve to determine the discount rate. In evaluating our expected retirement age assumption, we consider the retirement ages of our past employees eligible for pension and medical benefits together with our expectations of future retirement ages.

If the health-care-cost trend rates were to be increased by one percentage point each future year, the aggregate of the service cost and interest cost components of the 2011 annual expense would increase by \$15.1 million. A one-percentage-point decrease would decrease the aggregate of the 2011 service cost and interest cost by \$12.3 million. If the 2011 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to be changed by a quarter percentage point, income before income taxes would change by \$28.4 million. If the 2011 expected return on plan assets for U.S. plans were to be changed by a quarter percentage point, income before income taxes would change by \$19.2 million. If our assumption regarding the 2011 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affected by \$35.3 million. The U.S. plans, including Puerto Rico, represent approximately 82 percent of the total accumulated postretirement benefit obligation and approximately 81 percent of total plan assets at December 31, 2011.

### **Impairment of Indefinite-Lived and Long-Lived Assets**

We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. We determine impairment by comparing the projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.

Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment.

There are several methods that can be used to determine the estimated fair value of the IPR&D acquired in a business combination, all of which require multiple assumptions. We utilize the "income method," which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently.

For IPR&D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in the "Late-Stage Pipeline" section. The nature of the pharmaceutical business is high-risk and requires that we invest in a large number of projects to build a successful portfolio of approved products. As such, it is likely that some IPR&D assets will become impaired at some time in the future.

The estimated future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management's judgment. Actual results could vary from these estimates.

### **Income Taxes**

We prepare and file tax returns based on our interpretation of tax laws and regulations and record estimates based on these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities, which may result in future tax, interest, and penalty assessments by these authorities. Inherent uncertainties exist in estimates of many tax positions due to changes in tax law resulting from legislation, regulation, and/or as concluded through the various jurisdictions' tax court systems. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. The amount of unrecognized tax benefits is adjusted for changes in facts and circumstances. For example, adjustments could result from significant amendments to existing tax law and the issuance of regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We believe that our estimates for uncertain tax positions are appropriate and sufficient to pay assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense.

We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses and tax credit carryforwards in certain taxing jurisdictions. In evaluating whether we would more likely than not recover these deferred tax assets, we have not assumed any future taxable

income or tax planning strategies in the jurisdictions associated with these carryforwards where history does not support such an assumption. Implementation of tax planning strategies to recover these deferred tax assets or future income generation in these jurisdictions could lead to the reversal of these valuation allowances and a reduction of income tax expense.

A 5 percent change in the amount of the uncertain tax positions and the valuation allowance would result in a change in net income of \$40.6 million and \$30.6 million, respectively.

### FINANCIAL EXPECTATIONS FOR 2012

For the full year of 2012, we expect earnings per share to be in the range of \$3.10 to \$3.20. We anticipate that total revenue will be between \$21.8 billion and \$22.8 billion. This includes an expected decline of more than \$3 billion in Zyprexa sales due to patent expirations in most markets outside of Japan. The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis, Humalog, Humulin, and Forteo, as well as continued growth of newer products such as Effient, Axiron, and Tradjenta. We also anticipate continued strong, double-digit revenue growth from our Elanco Animal Health business. Both Japan and emerging markets are expected to post continued strong underlying volume growth; however, overall revenue growth in these markets in 2012 will be adversely affected by anticipated pricing actions in Japan and by the expected impact of patent expirations, including Zyprexa, in some emerging market countries.

We anticipate that gross margin as a percent of revenue will be approximately 77 percent. Marketing, selling, and administrative expenses are expected to decline and be in the range of \$7.4 billion to \$7.8 billion. Research and development expense is expected to be flat to increasing and in the range of \$5.0 billion to \$5.3 billion. Other—net, expense is expected to be in a range between net expense of \$50 million and net income of \$100 million. Operating cash flows are expected to be more than sufficient to fund capital expenditures of approximately \$800 million, as well as anticipated business development activity and our current dividend.

### PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995— A CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, we caution investors that any forward-looking statements or projections made by us, including those above, are based on management's belief at the time they are made. However, they are subject to risks and uncertainties. Actual results could differ materially and will depend on, among other things, the continuing growth of our currently marketed products; developments with competitive products; the implementation of U.S. health care reform; the timing and scope of regulatory approvals and the success of our new product launches; asset impairments, restructurings, and acquisitions of compounds under development resulting in acquired IPR&D charges; foreign exchange rates and global macroeconomic conditions; changes in effective tax rates; wholesaler inventory changes; other regulatory developments, litigation, patent disputes, and government investigations; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals; and other factors that may affect our operations and prospects, which are discussed earlier in this section and in Item 1A, "Risk Factors." We undertake no duty to update these forward-looking statements.

### LEGAL AND REGULATORY MATTERS

We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.

#### Patent Litigation

We are engaged in the following U.S. patent litigation matters brought pursuant to procedures set out in the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984):

- Alimta: Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); and Barr Laboratories, Inc. (Barr) each submitted ANDAs seeking approval to market generic versions of Alimta prior to the expiration of the relevant U.S. patents and data-based pediatric exclusivity period (compound patent licensed from the Trustees of Princeton University and expiring in 2017, concomitant nutritional supplement use patent expiring in 2022) and alleging the patents are invalid. We, along with Princeton, filed lawsuits in the U.S. District Court for the District of Delaware against Teva, APP, and Barr seeking rulings that the compound patent is valid and infringed. In July 2011, the district court entered judgment in our favor, upholding that patent's validity. The generic manufacturers have appealed this decision. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our concomitant nutritional supplement use patent is valid and infringed. No trial date has yet been set. In January 2012, we filed a similar lawsuit against Accord Healthcare Inc.

We believe the Hatch-Waxman challenges to Alimta are without merit and expect to prevail in this litigation. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated

results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market.

- **Strattera:** Actavis Elizabeth LLC (Actavis), Apotex Inc. (Apotex), Aurobindo Pharma Ltd. (Aurobindo), Mylan Pharmaceuticals Inc. (Mylan), Sandoz Inc. (Sandoz), Sun Pharmaceutical Industries Limited (Sun Ltd.), and Teva Pharmaceuticals USA, Inc. (Teva USA) each submitted an ANDA seeking permission to market generic versions of Strattera prior to the expiration of our relevant U.S. patent and data-based pediatric exclusivity period (expiring in 2017), and alleging that this patent is invalid. In 2007, we brought a lawsuit against Actavis, Apotex, Aurobindo, Mylan, Sandoz, Sun Ltd., and Teva USA in the U.S. District Court for the District of New Jersey. In August 2010, the court ruled that our patent was invalid; however, in July 2011, the Court of Appeals for the Federal Circuit overturned that decision, upholding the patent. The Federal Circuit Court of Appeals denied the generic manufacturers' petition for rehearing en banc in October 2011, and the deadline for any further appeal has passed. Zydus Pharmaceuticals (Zydus) filed an action in the New Jersey district court in October 2010 seeking a declaratory judgment that it has the right to launch a generic atomoxetine product, based on the district court ruling. We believe that Zydus is subject to the injunction issued by the court of appeals in the Actavis case.

### Zyprexa Litigation

We are a defendant in approximately 40 Zyprexa product liability lawsuits in the U.S. covering approximately 120 plaintiffs. The lawsuits allege a variety of injuries from the use of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the claims also allege that we improperly promoted the drug. Approximately 25 of the lawsuits, covering about 30 plaintiffs, are part of a Multi-District Litigation (MDL) proceeding before The Honorable Jack Weinstein in the Federal District Court for the Eastern District of New York (EDNY) (MDL No. 1596). In October 2011, a jury trial in a California state court was decided in our favor. We are prepared to continue our vigorous defense of Zyprexa in all these lawsuits and claims.

We were served with lawsuits filed by 13 states alleging that Zyprexa caused or contributed to diabetes or high blood-glucose levels, and that we improperly promoted the drug. We settled the Zyprexa-related claims of all of these states, incurring pretax charges of \$230.0 million in 2009 and \$15.0 million in 2008.

In 2005 and 2006, four lawsuits were filed in the EDNY purporting to be nationwide class actions on behalf of all consumers and third-party payors, excluding governmental entities, which made or will make payments for their members or insured patients being prescribed Zyprexa. These actions were consolidated into a single lawsuit, brought under certain state consumer-protection statutes, the federal civil Racketeer Influenced and Corrupt Organizations Act, and common law theories, seeking a refund of the cost of Zyprexa, treble damages, punitive damages, and attorneys' fees. As with the product liability suits, these lawsuits allege that we inadequately tested for and warned about side effects of Zyprexa and improperly promoted the drug. In September 2008, Judge Weinstein certified a class consisting of third-party payors, excluding governmental entities and individual consumers, and denied our motion for summary judgment. In September 2010, both decisions were reversed by the Second Circuit Court of Appeals, which found that the case cannot proceed as a class action and entered a judgment in our favor on plaintiffs' overpricing claim. The U.S. Supreme Court denied plaintiffs' petition for certiorari. All remaining claims at issue in these cases have now been resolved.

### Byetta Litigation

We have been named as a defendant in approximately 120 lawsuits involving approximately 480 plaintiffs, primarily seeking to recover damages for pancreatitis experienced by patients prescribed Byetta. We are aware of approximately 530 additional claimants who have not yet filed suit. Approximately 100 of these lawsuits are filed in California and coordinated in a Los Angeles Superior Court.

### Other Product Liability Litigation

We have been named as a defendant in numerous other product liability lawsuits involving primarily diethylstilbestrol. These claims are covered by insurance, subject to deductibles and coverage limits.

### Product Liability Insurance

Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims for other products in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for future product liability losses. In addition, there is no assurance that we will be able to fully collect from our insurance carriers in the future.

## Item 7A. Quantitative and Qualitative Disclosures About Market Risk

You can find quantitative and qualitative disclosures about market risk (e.g., interest rate risk) in Item 7 at “Management’s Discussion and Analysis—Financial Condition.” That information is incorporated in this report by reference.

## Item 8. Financial Statements and Supplementary Data

### Consolidated Statements of Operations

ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, except per-share data)	Year Ended December 31	2011	2010	2009
Revenue .....		\$24,286.5	\$23,076.0	\$21,836.0
Cost of sales .....		5,067.9	4,366.2	4,247.0
Research and development .....		5,020.8	4,884.2	4,326.5
Marketing, selling, and administrative .....		7,879.9	7,053.4	6,892.5
Acquired in-process research and development (Notes 3 and 4) .....		388.0	50.0	90.0
Asset impairments, restructuring, and other special charges (Note 5) .....		401.4	192.0	692.7
Other—net, expense (Note 17) .....		179.0	5.0	229.5
		<u>18,937.0</u>	<u>16,550.8</u>	<u>16,478.2</u>
Income before income taxes .....		5,349.5	6,525.2	5,357.8
Income taxes (Note 13) .....		1,001.8	1,455.7	1,029.0
Net income .....		<u>\$ 4,347.7</u>	<u>\$ 5,069.5</u>	<u>\$ 4,328.8</u>
Earnings per share—basic and diluted (Note 12) .....		<u>\$ 3.90</u>	<u>\$ 4.58</u>	<u>\$ 3.94</u>

See notes to consolidated financial statements.

## Consolidated Statements of Comprehensive Income

ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions)	Year Ended December 31	2011	2010	2009
Net income .....		\$ 4,347.7	\$5,069.5	\$4,328.8
Other comprehensive income (loss)				
Foreign currency translation gains (losses) .....		(244.8)	(325.1)	284.9
Net unrealized gains (losses) on securities .....		(178.5)	80.8	289.8
Defined benefit pension and retiree health benefit plans (Note 14) .....		(1,240.2)	148.9	(280.3)
Effective portion of cash flow hedges .....		44.8	(26.6)	48.2
Other comprehensive income (loss) before income taxes .....		(1,618.7)	(122.0)	342.6
Provision for income taxes related to other comprehensive income (loss) items .....		430.2	(76.2)	(27.7)
Other comprehensive income (loss) (Note 16) .....		(1,188.5)	(198.2)	314.9
Comprehensive income .....		<u>\$ 3,159.2</u>	<u>\$4,871.3</u>	<u>\$4,643.7</u>

See notes to consolidated financial statements.

## Consolidated Balance Sheets

### ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, shares in thousands)

	December 31	2011	2010
<b>Assets</b>			
<i>Current Assets</i>			
Cash and cash equivalents (Note 6) .....	\$ 5,922.5	\$ 5,993.2	
Short-term investments (Note 6) .....	974.6	733.8	
Accounts receivable, net of allowances of \$110.1 (2011) and \$79.9 (2010) .....	3,597.7	3,493.8	
Other receivables (Note 10) .....	640.2	664.3	
Inventories .....	2,299.8	2,517.7	
Prepaid taxes .....	158.5	828.3	
Prepaid expenses and other (Note 10) .....	654.9	608.9	
Total current assets .....	<u>14,248.2</u>	<u>14,840.0</u>	
<i>Other Assets</i>			
Investments (Note 6) .....	4,029.8	1,779.5	
Goodwill and other intangibles—net (Note 7) .....	5,128.1	4,818.8	
Sundry (Note 10) .....	2,493.4	1,622.4	
Total other assets .....	<u>11,651.3</u>	<u>8,220.7</u>	
Property and Equipment, net .....	7,760.3	7,940.7	
Total assets .....	<u>\$33,659.8</u>	<u>\$31,001.4</u>	
<b>Liabilities and Shareholders' Equity</b>			
<i>Current Liabilities</i>			
Short-term borrowings and current maturities of long-term debt (Note 8) .....	\$ 1,522.3	\$ 156.0	
Accounts payable .....	1,125.2	1,072.2	
Employee compensation .....	804.7	851.8	
Sales rebates and discounts .....	1,771.3	1,372.6	
Dividends payable .....	542.3	540.0	
Income taxes payable (Note 13) .....	261.6	457.5	
Other current liabilities (Note 10) .....	2,903.5	2,476.8	
Total current liabilities .....	<u>8,930.9</u>	<u>6,926.9</u>	
<i>Other Liabilities</i>			
Long-term debt (Note 8) .....	5,464.7	6,770.5	
Accrued retirement benefits (Note 14) .....	3,068.5	1,887.4	
Long-term income taxes payable (Note 13) .....	1,086.3	1,234.8	
Other noncurrent liabilities (Note 10) .....	1,573.8	1,769.0	
Total other liabilities .....	<u>11,193.3</u>	<u>11,661.7</u>	
Commitments and contingencies (Note 15)			
<i>Shareholders' Equity</i> (Notes 9 and 11)			
Common stock—no par value			
Authorized shares: 3,200,000			
Issued shares: 1,158,644 (2011) and 1,154,018 (2010) .....	724.1	721.3	
Additional paid-in capital .....	4,886.8	4,798.5	
Retained earnings .....	14,897.8	12,732.6	
Employee benefit trust .....	(3,013.1)	(3,013.2)	
Deferred costs—ESOP .....	—	(52.4)	
Accumulated other comprehensive loss (Note 16) .....	(3,858.6)	(2,670.1)	
Noncontrolling interests .....	(6.1)	(7.5)	
Cost of common stock in treasury, 853 shares (2011) and 864 shares (2010) .....	(95.3)	(96.4)	
Total shareholders' equity .....	<u>13,535.6</u>	<u>12,412.8</u>	
Total liabilities and shareholders' equity .....	<u>\$33,659.8</u>	<u>\$31,001.4</u>	

See notes to consolidated financial statements.

## Consolidated Statements of Cash Flows

ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions)	Year Ended December 31		
	2011	2010	2009
<b>Cash Flows from Operating Activities</b>			
Net income	\$ 4,347.7	\$ 5,069.5	\$ 4,328.8
<b>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities</b>			
Depreciation and amortization	1,373.6	1,328.2	1,297.8
Change in deferred income taxes	(268.5)	559.7	189.9
Stock-based compensation expense	147.4	231.0	368.5
Impairment charges, indefinite lived intangibles	151.5	—	—
Acquired in-process research and development, net of tax	252.2	32.5	58.5
Net marketing investigation charges paid (Note 15)	—	(112.3)	(1,313.6)
Other operating activities, net	(17.8)	(66.3)	362.5
Changes in operating assets and liabilities, net of acquisitions			
Receivables—increase	(188.8)	(319.1)	(492.9)
Inventories—decrease (increase)	203.1	157.0	(179.0)
Other assets—decrease (increase)	642.7	340.5	(84.9)
Accounts payable and other liabilities—increase (decrease)	591.4	(363.9)	(200.1)
<b>Net Cash Provided by Operating Activities</b>	<b>7,234.5</b>	<b>6,856.8</b>	<b>4,335.5</b>
<b>Cash Flows from Investing Activities</b>			
Purchases of property and equipment	(672.0)	(694.3)	(765.0)
Disposals of property and equipment	25.3	24.6	17.7
Net change in short-term investments	(250.9)	(686.5)	399.1
Proceeds from sales and maturities of noncurrent investments	2,138.5	584.7	1,107.8
Purchases of noncurrent investments	(4,459.4)	(1,067.2)	(432.3)
Purchase of product rights	(632.9)	(442.4)	—
Purchases of in-process research and development	(388.0)	(50.0)	(90.0)
Cash paid for acquisitions, net of cash acquired	(307.8)	(609.4)	—
Loan to collaboration partner	(165.0)	—	—
Other investing activities, net	(112.2)	(219.3)	(94.5)
<b>Net Cash (Used for) Provided by Investing Activities</b>	<b>(4,824.4)</b>	<b>(3,159.8)</b>	<b>142.8</b>
<b>Cash Flows from Financing Activities</b>			
Dividends paid	(2,180.1)	(2,165.3)	(2,152.1)
Net change in short-term borrowings	(141.2)	123.9	(5,824.2)
Proceeds from issuance of long-term debt	—	1.2	2,400.0
Repayments of long-term debt	(54.6)	(1.1)	—
Other financing activities, net	6.0	19.4	42.6
<b>Net Cash Used for Financing Activities</b>	<b>(2,369.9)</b>	<b>(2,021.9)</b>	<b>(5,533.7)</b>
Effect of exchange rate changes on cash and cash equivalents	(110.9)	(144.8)	21.6
Net (decrease) increase in cash and cash equivalents	(70.7)	1,530.3	(1,033.8)
Cash and cash equivalents at beginning of year	5,993.2	4,462.9	5,496.7
<b>Cash and Cash Equivalents at End of Year</b>	<b>\$ 5,922.5</b>	<b>\$ 5,993.2</b>	<b>\$ 4,462.9</b>

See notes to consolidated financial statements.

## Segment Information

We operate in one significant business segment—human pharmaceutical products. Operations of the animal health business segment are not material and share many of the same economic and operating characteristics as human pharmaceutical products. Therefore, they are included with pharmaceutical products for purposes of segment reporting.

<b>ELI LILLY AND COMPANY AND SUBSIDIARIES</b> (Dollars in millions)	<b>Year Ended December 31</b>		
	<b>2011</b>	<b>2010</b>	<b>2009</b>
Revenue—to unaffiliated customers			
Neuroscience	\$ 9,723.8	\$ 9,419.0	\$ 8,976.4
Endocrinology	6,806.7	6,135.4	6,015.0
Oncology	3,322.2	3,744.5	3,460.0
Cardiovascular	2,486.4	2,171.3	1,971.1
Animal health	1,678.6	1,391.4	1,207.2
Other pharmaceuticals	268.8	214.4	206.3
Revenue	<u>\$24,286.5</u>	<u>\$23,076.0</u>	<u>\$21,836.0</u>
<b>Geographic Information</b>			
Revenue—to unaffiliated customers <sup>1</sup>			
United States	\$12,977.2	\$12,865.6	\$12,294.4
Europe	5,290.9	5,106.4	5,227.2
Japan	2,104.1	1,616.6	1,224.8
Other foreign countries	3,914.3	3,487.4	3,089.6
Revenue	<u>\$24,286.5</u>	<u>\$23,076.0</u>	<u>\$21,836.0</u>
Long-lived assets			
United States	\$ 5,485.3	\$ 5,333.9	\$ 5,310.0
Europe	2,220.2	2,250.7	2,313.3
Japan	102.9	101.2	90.9
Other foreign countries	1,564.0	1,588.4	1,632.4
Long-lived assets	<u>\$ 9,372.4</u>	<u>\$ 9,274.2</u>	<u>\$ 9,346.6</u>

<sup>1</sup> Revenue is attributed to the countries based on the location of the customer.

Our neuroscience group of products includes Zyprexa, Cymbalta, Strattera, and Prozac. Endocrinology products consist primarily of Humalog, Humulin, Evista, Forteo, Humatrope, Byetta, and Actos. Oncology products consist primarily of Alimta, Gemzar, and Erbitux. Cardiovascular products consist primarily of Cialis, Effient, and ReoPro. Animal health products include Rumensin, Tylan, Posilac, Paylean, and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The other pharmaceuticals category includes anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services.

Most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2011, 2010, and 2009, our three largest wholesalers each accounted for between 11 percent and 17 percent of consolidated total revenue. Further, they each accounted for between 9 percent and 15 percent of accounts receivable as of December 31, 2011 and 2010. Animal health products are sold primarily to wholesale distributors.

Our business segments are distinguished by the ultimate end user of the product: humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. The accounting policies of the individual segments are substantially the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements. Income before income taxes for the animal health business was approximately \$301 million, \$251 million, and \$217 million for the years ended December 31, 2011, 2010, and 2009, respectively.

The assets of the animal health business are intermixed with those of the pharmaceutical products business. Long-lived assets disclosed above consist of property and equipment and certain sundry assets.

We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

## Selected Quarterly Data (unaudited)

### ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, except per-share data)

	2011	Fourth	Third	Second	First
Revenue	\$6,046.6	\$6,147.9	\$6,252.8	\$5,839.2	
Cost of sales	1,321.7	1,338.1	1,228.0	1,180.1	
Operating expenses	3,488.7	3,198.7	3,303.6	2,909.7	
Acquired in-process research and development	—	—	—	388.0	
Asset impairments, restructuring, and other special charges	167.6	25.2	132.3	76.3	
Other—net, expense	26.8	83.4	57.6	11.2	
Income before income taxes	1,041.8	1,502.5	1,531.3	1,273.9	
Net income	858.2	1,236.3	1,197.3	1,055.9	
Earnings per share—basic and diluted	0.77	1.11	1.07	.95	
Dividends paid per share	.49	.49	.49	.49	
Common stock closing prices					
High		41.75	39.32	39.15	35.84
Low		35.58	34.49	34.99	33.63
	2010	Fourth	Third	Second	First
Revenue	\$6,187.0	\$5,654.8	\$5,748.7	\$5,485.5	
Cost of sales	1,232.2	987.6	1,023.9	1,122.5	
Operating expenses	3,426.8	2,914.7	2,942.6	2,653.5	
Acquired in-process research and development	—	—	—	50.0	
Asset impairments, restructuring, and other special charges	79.0	59.5	27.3	26.2	
Other—net, expense (income)	39.4	21.7	18.4	(74.5)	
Income before income taxes	1,409.6	1,671.3	1,736.5	1,707.8	
Net income	1,169.6	1,302.9	1,348.9	1,248.1	
Earnings per share—basic and diluted	1.05	1.18	1.22	1.13	
Dividends paid per share	.49	.49	.49	.49	
Common stock closing prices					
High		38.06	37.77	36.92	37.41
Low		33.66	33.12	32.25	33.95

Our common stock is listed on the New York, London, and Swiss stock exchanges.

## Selected Financial Data (unaudited)

### ELI LILLY AND COMPANY AND SUBSIDIARIES

(Dollars in millions, except revenue per employee and per-share data)

	2011	2010	2009	2008	2007
<b>Operations</b>					
Revenue	\$ 24,286.5	\$ 23,076.0	\$ 21,836.0	\$ 20,371.9	\$ 18,633.5
Cost of sales	5,067.9	4,366.2	4,247.0	4,376.7	4,248.8
Research and development	5,020.8	4,884.2	4,326.5	3,840.9	3,486.7
Marketing, selling, and administrative	7,879.9	7,053.4	6,892.5	6,626.4	6,095.1
Other	968.4	247.0	1,012.2	6,835.5 <sup>1</sup>	926.1
Income (loss) before income taxes	5,349.5	6,525.2	5,357.8	(1,307.6)	3,876.8
Income taxes	1,001.8	1,455.7	1,029.0	764.3	923.8
Net income (loss)	4,347.7	5,069.5	4,328.8	(2,071.9)	2,953.0
Net income as a percent of revenue	17.9%	22.0%	19.8%	NM	15.8%
Net income (loss) per share— diluted	3.90	4.58	3.94	(1.89)	2.71
Dividends declared per share	1.96	1.96	1.96	1.90	1.75
Weighted-average number of shares outstanding – diluted (thousands)	1,113,967	1,105,813	1,098,367	1,094,499	1,090,750
<b>Financial Position</b>					
Current assets	\$ 14,248.2	\$ 14,840.0	\$ 12,486.5	\$ 12,453.3	\$ 12,316.1
Current liabilities	8,930.9	6,926.9	6,568.1	13,109.7	5,436.8
Property and equipment – net	7,760.3	7,940.7	8,197.4	8,626.3	8,575.1
Total assets	33,659.8	31,001.4	27,460.9	29,212.6	26,874.8
Long-term debt	5,464.7	6,770.5	6,634.7	4,615.7	4,593.5
Shareholders' equity	13,535.6	12,412.8	9,525.3	6,737.7	13,510.3
<b>Supplementary Data</b>					
Return on shareholders' equity	31.4%	46.1%	51.0%	(16.3)%	24.3%
Return on assets	13.4%	17.7%	15.8%	(7.5)%	12.1%
Capital expenditures	\$ 672.0	\$ 694.3	\$ 765.0	\$ 947.2	\$ 1,082.4
Depreciation and amortization	1,373.6	1,328.2	1,297.8	1,122.6	1,047.9
Effective tax rate	18.7%	22.3%	19.2%	NM <sup>2</sup>	23.8%
Revenue per employee	\$ 638,000	\$ 602,000	\$ 540,000	\$ 504,000	\$ 459,000
Number of employees	38,080	38,350	40,360	40,450	40,600
Number of shareholders of record	35,200	36,700	38,400	39,800	41,700

NM—Not Meaningful

<sup>1</sup> The increase reflects the in-process research and development (IPR&D) expense of \$4.69 billion associated with the ImClone acquisition and \$1.48 billion associated with the Zyprexa investigation settlements.


<sup>2</sup> We incurred tax expense of \$764.3 million in 2008, despite having a loss before income taxes of \$1.31 billion. Our net loss was driven by the \$4.69 billion acquired IPR&D charge for ImClone and the \$1.48 billion Zyprexa investigation settlements. The IPR&D charge was not tax deductible, and only a portion of the Zyprexa investigation settlements was deductible. In addition, we recorded tax expense associated with the ImClone acquisition, as well as a discrete income tax benefit of \$210.3 million for the resolution of a substantial portion of the 2001–2004 IRS audit.

## PERFORMANCE GRAPH

This graph compares the return on Lilly stock with that of the Standard & Poor's 500 Stock Index and our peer group for the years 2007 through 2011. The graph assumes that, on December 31, 2006, a person invested \$100 each in Lilly stock, the S&P 500 Stock Index, and the peer group's common stock. The graph measures total shareholder return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are reinvested in that company's stock.

### Value of \$100 Invested on Last Business Day of 2006

### Comparison of Five-Year Cumulative Total Return Among Lilly, S&P 500 Stock Index, Peer Group<sup>1</sup>, and Peer Group (Previous)<sup>2</sup>



	Lilly	Peer Group	Peer Group (Previous)	S&P 500
Dec-06	\$100.00	\$100.00	\$100.00	\$100.00
Dec-07	\$105.68	\$100.43	\$100.12	\$105.48
Dec-08	\$ 83.08	\$ 86.51	\$ 85.77	\$ 66.52
Dec-09	\$ 77.99	\$ 96.90	\$ 97.75	\$ 84.07
Dec-10	\$ 80.87	\$ 97.81	\$ 97.91	\$ 96.71
Dec-11	\$101.01	\$109.47	\$112.59	\$ 98.76

<sup>1</sup> We constructed the peer group as the industry index for this graph. It comprises the companies in the pharmaceutical industry that we used to benchmark the compensation of executive officers for 2011: Abbott Laboratories; Amgen Inc.; AstraZeneca PLC; Baxter International Inc.; Bristol-Myers Squibb Company; Genzyme Corporation (prior to the company's acquisition by Sanofi-Aventis); GlaxoSmithKline plc; Johnson & Johnson; Merck & Co., Inc.; Novartis AG.; Pfizer Inc.; Sanofi-Aventis; and Takeda Pharmaceuticals Company.

<sup>2</sup> Due to changes in the pharmaceutical industry, we revised our peer group for 2011 by adding Baxter International Inc., Genzyme Corporation (prior to the company's acquisition by Sanofi-Aventis), and Takeda Pharmaceuticals Company.

## Notes to Consolidated Financial Statements

ELI LILLY AND COMPANY AND SUBSIDIARIES

(Dollars in millions, except per-share data)

### Note 1: Summary of Significant Accounting Policies

**Basis of presentation:** The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected in shareholders' equity. All intercompany balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.

All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of dilutive stock options and other incremental shares.

**Cash equivalents:** We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.

**Inventories:** We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental United States, or approximately 45 percent of our total inventories. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories at December 31 consisted of the following:

	2011	2010
Finished products . . . . .	\$ 786.4	\$ 800.8
Work in process . . . . .	1,518.2	1,714.2
Raw materials and supplies . . . . .	205.8	220.8
	<u>2,510.4</u>	<u>2,735.8</u>
Reduction to LIFO cost . . . . .	(210.6)	(218.1)
Inventories . . . . .	<u>\$2,299.8</u>	<u>\$2,517.7</u>

**Investments:** Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other—net, expense. We own no investments that are considered to be trading securities.

**Risk-management instruments:** Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.

We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are

principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other—net, expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.

In the normal course of business, our operations are exposed to fluctuations in interest rates. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt or investments to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating rate debt or investments to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements.

We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.

**Goodwill and other intangibles:** Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized.

Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years.

The cost of in-process research and development (IPR&D) projects acquired directly in a transaction other than a business combination is capitalized if the projects have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects acquired in business combinations are capitalized as other intangible assets. There are several methods that can be used to determine the estimated fair value of the IPR&D acquired in a business combination. We utilized the "income method," which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets will be amortized over the remaining useful life or written off, as appropriate. We also capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing and amortize those amounts over the remaining estimated useful life of the underlying asset.

Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present.

**Property and equipment:** Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 18 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.

At December 31, property and equipment consisted of the following:

	2011	2010
Land .....	\$ 202.5	\$ 207.8
Buildings .....	6,135.7	6,029.3
Equipment .....	7,219.9	7,355.7
Construction in progress .....	1,036.0	893.8
	<u>14,594.1</u>	<u>14,486.6</u>
Less accumulated depreciation .....	(6,833.8)	(6,545.9)
Property and equipment, net .....	<u>\$ 7,760.3</u>	<u>\$ 7,940.7</u>

Depreciation expense for the years ended December 31, 2011, 2010, and 2009 was \$732.4 million, \$749.1 million, and \$813.5 million, respectively. Interest costs of \$25.7 million, \$26.0 million, and \$30.2 million were capitalized as part of property and equipment for the years ended December 31, 2011, 2010, and 2009, respectively. Total rental expense for all leases, including contingent rentals (not material), amounted to \$353.4 million, \$339.3 million, and

\$337.8 million for the years ended December 31, 2011, 2010, and 2009, respectively. Assets under capital leases included in property and equipment in the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

**Litigation and environmental liabilities:** Litigation accruals and environmental liabilities and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when probable and reasonably estimable. A portion of the costs associated with defending and disposing of these suits is covered by insurance. We record receivables for insurance-related recoveries when it is probable they will be realized. These receivables are classified as a reduction of the litigation charges on the statement of operations. We estimate insurance recoverables based on existing deductibles, coverage limits, our assessment of any defenses to coverage that might be raised by the carriers, and the existing and projected future level of insolvencies among the insurance carriers. However, for substantially all of our currently marketed products, we are completely self-insured for future product liability losses.

**Revenue recognition:** We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recorded.

We also generate income as a result of collaboration agreements. Revenue from co-promotion services is based upon net sales reported by our co-promotion partners and, if applicable, the number of sales calls we perform. Initial fees we receive from the partnering of our compounds under development where we have continuing involvement are generally amortized through the expected product approval date. Initial fees received from out-licensing agreements that include both the sale of marketing rights to our commercialized products and a related commitment to supply the products are generally recognized in net product sales over the term of the supply agreement. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is substantive, is objectively determinable, and represents an important point in the development life cycle of the pharmaceutical product. Milestone payments earned by us are generally recorded in other—net, expense. If the payment to us is a commercialization payment that is part of a multiple-element collaborative commercialization arrangement and is a result of the initiation of the commercialization period (e.g., payments triggered by regulatory approval for marketing or launch of the product), we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details.

Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue.

Following is the composition of revenue:

	2011	2010	2009
Net product sales . . . . .	\$23,604.8	\$22,442.2	\$21,171.5
Collaboration and other revenue (Note 4) . . . . .	681.7	633.8	664.5
Total revenue . . . . .	<u>\$24,286.5</u>	<u>\$23,076.0</u>	<u>\$21,836.0</u>

**Research and development expenses and acquired research and development:** Research and development expenses include the following:

- Research and development costs, which are expensed as incurred.
- Milestone payments incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.

Acquired IPR&D expense includes the initial costs of IPR&D projects acquired directly in asset acquisitions, unless they have an alternative future use.

**Income taxes:** Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the United States and be taxable.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

**Earnings per share:** We calculate basic earnings per share based on the weighted-average number of outstanding common shares and incremental shares. We calculate diluted earnings per share based on the weighted-average number of outstanding common shares plus the effect of dilutive stock options and other incremental shares. See Note 12 for further discussion.

**Stock-based compensation:** We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. Under our policy all stock-based awards are approved prior to the date of grant. The compensation committee of the board of directors approves the value of the award and date of grant. Stock-based compensation that is awarded as part of our annual equity grant is made on a specific grant date scheduled in advance.

**Reclassifications:** Certain reclassifications have been made to the December 31, 2010 and 2009 consolidated financial statements and accompanying notes to conform with the December 31, 2011 presentation.

### Note 2: Implementation of New Financial Accounting Pronouncements

In 2010, the Financial Accounting Standards Board (FASB) issued an Accounting Standard Update (ASU) that applies to the annual fee imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs as part of U.S. health care reform. This fee is allocated to companies based on their prior-calendar-year market share for branded prescription drug sales into these government programs. This guidance clarifies how pharmaceutical manufacturers should recognize and classify in their income statements fees mandated by U.S. health care reform. This fee is recorded as selling, general, and administrative expense in our consolidated results of operations and is amortized on a straight-line basis for the year. This guidance was effective for us January 1, 2011. In accordance with this guidance, for the year ended December 31, 2011 we recorded \$178.0 million related to this fee, which is not deductible for tax purposes.

In 2009, the FASB issued an ASU related to Revenue Recognition that amends the previous guidance on arrangements with multiple deliverables. This guidance provides principles and application guidance on whether multiple deliverables exist, how the arrangements should be separated, and how the consideration should be allocated. It also clarifies the method to allocate revenue in an arrangement using the estimated selling price. This guidance was effective for us January 1, 2011, and did not have a material impact on our consolidated financial position or results of operations.

### Note 3: Acquisitions

During 2011 and 2010, we completed the acquisitions of the animal health business of Janssen Pharmaceutica NV (Janssen), Avid Radiopharmaceuticals, Inc. (Avid), Alnara Pharmaceuticals, Inc. (Alnara), and a group of animal health product lines. These acquisitions were accounted for as business combinations under the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the date of acquisition. None of these acquisitions were material to our consolidated financial statements.

Most of these acquisitions included IPR&D, which represented compounds, new indications, or line extensions under development that had not yet achieved regulatory approval for marketing. As discussed in Note 1, the fair values of IPR&D assets acquired as part of the acquisition of a business are capitalized as intangible assets. Accordingly, we capitalized IPR&D assets acquired in business combinations totaling \$30.9 million and \$598.0 million for the years ended December 31, 2011 and 2010, respectively. Once the Avid and Alnara products are launched, the amortization of the respective acquired IPR&D assets will not be deductible for tax purposes. The ongoing expenses with respect to each of these assets in development are not material to our total research and development expense currently and are not expected to be material to our total research and development expense on an annual basis in the future.

Some of these acquisitions included contingent consideration, which is recorded at fair value in other liabilities as of the acquisition date. The fair value of the contingent consideration was determined by utilizing a probability weighted estimated cash flow stream discounted for the expected timing of each payment. Subsequent to the acquisition date, on a quarterly basis we remeasure the contingent consideration at current fair value with changes recorded in other—net, expense in the statement of operations.

In addition to the acquisitions of businesses, we also acquired several assets in development which are discussed below in Product Acquisitions and in Note 4. The acquired IPR&D related to these products of \$388.0 million, \$50.0 million, and \$90.0 million for the years ended December 31, 2011, 2010, and 2009, respectively, was written off by a charge to income immediately upon acquisition because the products had no alternative future use.

### Acquisition of Businesses

#### *Janssen*

On July 7, 2011, we acquired the animal health business of Janssen, a Johnson & Johnson company, for total purchase consideration of \$307.8 million in cash. We obtained a portfolio of more than 50 marketed animal health products. In connection with this acquisition, we preliminarily recorded \$223.5 million of marketed product assets and \$30.9 million of acquired IPR&D assets, with \$53.4 million of other net assets. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts, it is not expected that those differences will be material to our financial results.

**Avid**

On December 20, 2010, we acquired all of the outstanding stock of Avid, a company focusing on developing molecular radiopharmaceutical tracers in positron emission topography (PET) scan imaging, for total purchase consideration of \$346.1 million, which included an upfront payment of \$286.3 million and up to \$550 million in additional payments contingent upon potential future regulatory and commercial milestones. The fair value of the contingent consideration at the acquisition date was \$59.8 million. In connection with this acquisition, we recorded \$334.0 million of acquired IPR&D assets, \$119.6 million of goodwill, and \$116.9 million of deferred tax liability, with \$9.4 million of other net assets. Avid's lead product under development, florbetapir, is a PET agent indicated for imaging amyloid plaque pathology in the brain to aid the evaluation of patients with signs or symptoms of cognitive impairment. The New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in the third quarter of 2010. In March 2011, we received a complete response letter that was primarily focused on the need to establish a reader training program for market implementation that helps to ensure reader accuracy and consistency of interpretations of existing Amyvid™ scans. During the year ended December 31, 2011 we recorded impairment charges related to the partial impairment of the IPR&D asset related to Amyvid, as discussed further in Note 7. We submitted our response to the complete response letter in 2011.

**Alnara**

On July 20, 2010, we acquired all of the outstanding stock of Alnara, a privately-held company developing protein therapeutics for the treatment of metabolic diseases, for total purchase consideration of \$291.7 million, which included an upfront payment of \$188.7 million and up to \$200 million in additional payments contingent upon potential future regulatory and commercial milestones. The fair value of the contingent consideration at the acquisition date was \$103.0 million. In connection with this acquisition, we recorded \$264.0 million of acquired IPR&D assets, \$100.5 million of goodwill, and \$92.4 million of deferred tax liability, with \$19.6 million of other net assets. Alnara's lead product in development is lipotamase, a non-porcine pancreatic enzyme replacement therapy. The NDA was submitted to the FDA in the first quarter of 2010. In April 2011, we received a complete response letter that communicated the need for us to conduct an additional clinical trial prior to a re-submission. During the year ended December 31, 2011 we recorded impairment charges related to the partial impairment of the IPR&D asset related to lipotamase, as discussed further in Note 7. We are currently finalizing the study design and anticipate starting a clinical study in 2012.

**Animal Health Product Lines**

On May 28, 2010, we acquired the European marketing rights to several animal health product lines divested by Pfizer Inc. as part of its acquisition of Wyeth, Inc., for total purchase consideration of \$148.4 million paid in cash. These products, including vaccines, parasiticides, and feed additives, serve both the production animal and companion animal markets. We also acquired a manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines. In connection with this acquisition, we recorded \$76.2 million of marketed product intangible assets, with \$72.2 million of other net assets.

**Product Acquisitions**

In March 2010, we entered into a license agreement with Acrux Limited to acquire the exclusive rights to commercialize its proprietary testosterone solution Axiron. At the time of the licensing, the product had not been approved and had no alternative future use. The charge of \$50.0 million for acquired IPR&D related to this arrangement was included as expense in the first quarter of 2010 and is deductible for tax purposes. In the fourth quarter of 2010, Axiron was approved by the FDA for the treatment of testosterone deficiency in men. In the first quarter of 2011, the product was available in pharmacies in the U.S.

In December 2009, we entered into a licensing and collaboration agreement with Incyte Corporation (Incyte) to acquire rights to its compound, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. The lead compound was in the development stage (Phase II clinical trials for rheumatoid arthritis) and had no alternative future use. The charge of \$90.0 million for acquired IPR&D related to this arrangement was included in expense in the fourth quarter of 2009 and is deductible for tax purposes. As part of this agreement, Incyte has the option to co-develop these compounds and the option to co-promote in the U.S.

In connection with these arrangements, our partners are generally entitled to future milestones and royalties based on sales should these products be approved for commercialization.

**Note 4: Collaborations**

We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products sold by us pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit share payments) are included in collaboration and other revenue. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below.

**Erbix**

We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Japan, and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). The agreements are expected to expire in 2018, upon which all of the rights with respect to Erbitux in the U.S. and Canada return to us and certain rights with respect to Erbitux outside the U.S. and Canada (excluding Japan) remain with Merck KGaA (Merck). The following table summarizes the revenue recognized with respect to Erbitux:

	2011	2010	2009
Net product sales	\$ 87.6	\$ 71.9	\$ 92.5
Collaboration and other revenue	321.6	314.2	298.3
Total revenue	<u>\$409.2</u>	<u>\$386.1</u>	<u>\$390.8</u>

**Bristol-Myers Squibb Company**

Pursuant to a commercial agreement with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), relating to Erbitux, we are co-developing Erbitux in the U.S. and Canada with BMS, exclusively, and in Japan with BMS and Merck. The companies have jointly agreed to expand the investment in the ongoing clinical development plan for Erbitux to further explore its use in additional tumor types. Under this arrangement, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.

Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreement. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.

We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the territory, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.

**Merck KGaA**

A development and license agreement with Merck with respect to Erbitux granted Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and co-exclusive rights with BMS and us in Japan. Merck also has rights to manufacture Erbitux for supply in its territory. We also receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for research and for development; and marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated statement of operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.

**Necitumumab**

The commercial agreement with BMS described above includes the co-development and co-commercialization of necitumumab, which is currently in Phase III clinical testing for squamous non-small cell lung cancer. We and BMS share the cost of developing and potentially commercializing necitumumab in the U.S., Canada, and Japan. We maintain exclusive rights to necitumumab in all other markets. We will fund 45 percent of the development costs for studies that will be used only in the U.S., and 72.5 percent for global studies. We will be responsible for the manufacturing of API, and BMS will be responsible for manufacturing the finished product. We could receive a payment of \$250.0 million upon approval in the U.S. In the U.S. and Canada, BMS will record sales and we will receive 45 percent of the profits for necitumumab, while we will provide 50 percent of the selling effort. In Japan, we and BMS will share costs and profits evenly.

**Exenatide**

In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta (exenatide injection) and other forms of exenatide such as Bydureon (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of \$250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15 percent of their global net sales of exenatide products until Amylin has made aggregate payments to us of \$1.20 billion plus interest, which will accrue at 9.5 percent. Amylin issued a secured note in the amount of \$1.20 billion to us under which any revenue-sharing payments made to us will reduce amounts outstanding under the note. In general, Amylin's obligation for the revenue-sharing payments and the secured note will terminate if all exenatide products are withdrawn from the market due to safety or efficacy issues and are not sold for a period of four years. Amylin will also pay a \$150.0 million milestone to us contingent upon FDA approval of a once-monthly suspension version of exenatide that is currently in Phase II clinical trials.

Commercial operations were transferred to Amylin in the U.S. at the end of November 2011, although we will continue to provide certain transition services. Outside the U.S., we will transfer responsibility for commercialization of exenatide to Amylin on a market-by-market basis over a period beginning no earlier than the second half of 2012 and that will not extend beyond December 31, 2013.

Payments received from Amylin are allocated 65 percent to the U.S., which is treated as a contract termination, and 35 percent to the business outside the U.S., which will be treated as the disposition of a business. The allocation is based upon relative fair values. Revenue-sharing payments will be recognized as income as Amylin records sales. The income allocated to the U.S. is recognized as collaboration and other revenue and the income allocated to the business outside the U.S. will be recognized as proceeds from the disposition of a business in other-net, expense in our consolidated income statement beginning at the time control of the business transfers to Amylin. The amounts we may receive pursuant to the revenue-sharing arrangement represent contingent consideration and, therefore, do not qualify for recognition as income until the contingency is resolved and the amount becomes fixed or determinable. As a consequence, the note has not been recognized in our consolidated balance sheet. The income recognized from this transaction was not material for the year ended December 31, 2011, as the income recognized from the upfront payment was substantially offset by the derecognition of amounts previously capitalized related to certain supply arrangements and approval milestones.

Prior to termination of the collaboration, we and Amylin were co-promoting Byetta in the U.S. Amylin was responsible for manufacturing and primarily utilized third-party contract manufacturers to supply Byetta. We supplied Byetta pen delivery devices for Amylin and will continue to do so for a period that will not extend beyond December 31, 2013, unless we and Amylin agree otherwise. We are responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial operations are transferred to Amylin.

Under the terms of our prior arrangement, we reported as collaboration and other revenue our 50 percent share of gross margin on Amylin's net product sales in the U.S. We reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. will continue until those operations transfer to Amylin. Prior to its termination, under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide's gross margin, we also recorded approximately 50 percent of U.S. related research and development costs and marketing and selling costs in the respective line items on the consolidated statements of operations.

In June 2011, the European Commission granted marketing authorization to Bydureon for the once-weekly treatment of type 2 diabetes in combination with certain oral therapies. European launches began in the third quarter of 2011, starting with the United Kingdom and Germany. Net product sales of Bydureon were not material for the year ended December 31, 2011. In January 2012, the FDA approved Bydureon for marketing in the U.S.

The following table summarizes the revenue recognized with respect to exenatide:

	2011	2010	2009
Net product sales	\$179.6	\$168.1	\$147.7
Collaboration and other revenue	243.1	262.5	300.8
Total revenue	<u>\$422.7</u>	<u>\$430.6</u>	<u>\$448.5</u>

In accordance with the prior arrangement and pursuant to Amylin's request, in the second quarter of 2011 we loaned Amylin \$165.0 million. Interest on this loan is to be received quarterly and all outstanding principal and interest is due five years from the date of the advance.

### Cymbalta

We were in a collaborative arrangement with Boehringer Ingelheim (Boehringer) to jointly develop, market, and promote Cymbalta (duloxetine), outside the U.S. and Japan. Pursuant to the terms of the agreement, we generally shared equally in development, marketing, and selling expenses, and paid Boehringer a commission on sales in the co-promotion territories. We manufactured the product for all territories. Reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses were recorded in the respective expense line items in the consolidated statements of operations. The commission paid to Boehringer was recorded in marketing, selling, and administrative expenses. In March 2010, the parties agreed to terminate this agreement, and we reacquired the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan. In connection with the termination, we paid Boehringer approximately \$400 million and will also pay to Boehringer a

percentage of our sales of duloxetine in these countries through 2012 as consideration for the rights acquired. We record these costs as intangible assets, which will be amortized to marketing, selling, and administrative expenses using the straight-line method over the life of the original agreement, which is through 2015.

### Effient

We are in a collaborative arrangement with Daiichi Sankyo Company, Limited (D-S) to develop, market, and promote Effient. We and D-S have agreed to co-promote in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. D-S has exclusive marketing rights in Japan. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay D-S a royalty specific to these territories. Profit share payments made to D-S are recorded as marketing, selling, and administrative expenses. All royalties paid to D-S and the third-party manufacturer are recorded in cost of sales. Worldwide Effient sales were \$302.5 million, \$115.0 million, and \$27.0 million for the years ended December 31, 2011, 2010, and 2009, respectively.

### Diabetes Collaboration

In January 2011, we and Boehringer entered into a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Included are Boehringer's two oral diabetes agents, linagliptin and empagliflozin (BI 10773). Subsequently in 2011, linagliptin was approved and launched in the U.S. (tradename Tradjenta), Japan (tradename Trazenta), Europe (tradename Trajenta), and other countries. Empagliflozin is currently in Phase III clinical testing. Also included in the agreement is our new insulin glargine product and our novel basal insulin analog, both of which began Phase III clinical testing in the second half of 2011; and an option granted to Boehringer to co-develop and co-commercialize our anti-TGF-beta monoclonal antibody, which is currently in Phase II clinical testing. Under the terms of the agreement, we made an initial one-time payment to Boehringer of \$388.0 million and recorded an acquired IPR&D charge, which was included as expense in the first quarter of 2011 and is deductible for tax purposes.

In connection with the approval of linagliptin in the U.S., Japan, and Europe, in 2011 we paid \$478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We may pay up to approximately €300 million in additional success-based regulatory milestones for empagliflozin. We will be eligible to receive up to a total of \$650.0 million in success-based regulatory milestones on our two insulin products. Should Boehringer elect to opt in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, we would be eligible for up to \$525.0 million in opt-in and success-based regulatory milestone payments. The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Revenue related to this collaboration has not been significant to date.

### Solanezumab

We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby both we and TPG were obligated to fund the Phase III development of solanezumab. Under the agreement, TPG's obligation to fund solanezumab costs are not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately \$70.0 million and mid-single digit royalties that are contingent upon the successful development of solanezumab. The royalties relating to solanezumab would be paid for approximately eight years after launch of a product. Reimbursements received from TPG for its portion of research and development costs incurred were recorded as a reduction to the research and development expense line item on the consolidated statements of operations. The reimbursement from TPG was not material in any period.

### Summary of Collaboration-Related Commission and Profit Share Payments

The aggregate amounts of commissions and profit share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above were \$219.2 million, \$174.5 million, and \$319.2 million for the years ended December 31, 2011, 2010, and 2009, respectively.

### Note 5: Asset Impairments, Restructuring, and Other Special Charges

The components of the charges included in asset impairments, restructuring, and other special charges in our consolidated statements of operations are described below.

	2011	2010	2009
Severance . . . . .	\$251.8	\$142.0	\$ 99.0
Asset impairments and other special charges . . . . .	149.6	50.0	363.7
Product liability and other special charges – legal settlement . . . . .	—	—	230.0
Asset impairments, restructuring, and other special charges . . . . .	<u>\$401.4</u>	<u>\$192.0</u>	<u>\$692.7</u>

### Severance

Severance costs listed above, substantially all of which have been paid, are primarily the result of the 2009 initiative to reorganize global operations, streamline various functions of the business, and reduce total employees, as well as other previously announced strategic actions to reduce our cost structure and global workforce. Included in the 2009 severance charges is \$61.1 million related to the sale of our Tippecanoe Laboratories manufacturing site, which is further described below.

### Asset Impairments and Other Special Charges

For the year ended December 31, 2011, we incurred \$149.6 million of asset impairments and other special charges primarily consisting of \$85.0 million for returned product and contractual commitments related to the withdrawal of Xigris from the market and \$56.1 million related to our decision to vacate certain leased premises, a decision that was as a result of our 2009 initiative to reorganize global operations, streamline various functions of the business, and reduce total employees.

For the year ended December 31, 2010, we incurred \$50.0 million of asset impairments and other special charges primarily consisting of lease termination costs and asset impairments outside the United States.

In 2009, we recognized non-cash asset impairments and other special charges of \$363.7 million primarily due to the sale of our Tippecanoe Laboratories manufacturing site to an affiliate of Evonik Industries AG (Evonik) in early 2010. In connection with the sale of the site, we entered into a nine-year supply and services agreement, whereby Evonik will manufacture final and intermediate step API for certain of our human and animal health products. The fair value of assets used in determining impairment charges was based on contracted sales prices.

### Product Liability and Other Special Charges

In 2009, we incurred other special charges of \$230.0 million related to advanced discussions with the attorneys general for several states, seeking to resolve their Zyprexa-related claims. The charges represented the then-current probable and estimable exposures in connection with the states' claims. Refer to Note 15 for additional information.

### Note 6: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we limit the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

At December 31, 2011, we had outstanding foreign currency forward commitments to purchase 494.3 million British pounds and sell 583.4 million euro, and commitments to purchase 1.61 billion euro and sell 2.11 billion U.S. dollars, which will all settle within 30 days.

At December 31, 2011, approximately 90 percent of our total debt is at a fixed rate. We have converted approximately 70 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.

### The Effect of Risk Management Instruments on the Statement of Operations

The following effects of risk-management instruments were recognized in other—net, expense:

	2011	2010	2009
Fair value hedges			
Effect from hedged fixed-rate debt	\$ 259.6	\$ 149.6	\$(369.5)
Effect from interest rate contracts	(259.6)	(149.6)	369.5
Cash flow hedges			
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	9.0	9.0	10.2
Net losses on foreign currency exchange contracts not designated as hedging instruments	97.4	12.0	82.6

The effective portion of net gains (losses) on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was \$35.6 million, \$(35.6) million, and \$0.0 million for the years ended December 31, 2011, 2010, and 2009, respectively. The effective portion of net gains on interest rate contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was \$0.0 million, \$0.0 million, and \$38.0 million for the years ended December 31, 2011, 2010, and 2009 respectively.

We expect to reclassify \$9.0 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on floating rate debt from accumulated other comprehensive loss to earnings during the next 12 months.

During the years ended December 31, 2011, 2010, and 2009, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.

### Fair Value of Financial Instruments

The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:

Description	Carrying Amount	Amortized Cost	Fair Value Measurements Using			Fair Value
			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	
<b>December 31, 2011</b>						
Cash and cash equivalents	\$5,922.5	\$5,922.5	\$5,264.6	\$ 657.9	\$	\$5,922.5
Short-term investments						
U.S. government and agencies	\$ 362.3	\$ 362.3	\$ 362.3	\$	\$	\$ 362.3
Corporate debt securities	600.7	601.1		600.7		600.7
Other securities	11.6	11.6		11.6		11.6
Short-term investments	<u>\$ 974.6</u>	<u>\$ 975.0</u>				
Noncurrent investments						
U.S. government and agencies	\$ 908.8	\$ 901.3	\$ 908.8	\$	\$	\$ 908.8
Corporate debt securities	2,081.3	2,093.3		2,081.3		2,081.3
Mortgage-backed	443.8	479.1		443.8		443.8
Asset-backed	245.0	253.2		245.0		245.0
Other securities	10.0	11.9		8.7	1.3	10.0
Marketable equity	180.8	107.5	180.8			180.8
Equity method and other investments <sup>(1)</sup>	160.1	160.1				
Investments	<u>\$4,029.8</u>	<u>\$4,006.4</u>				
<b>December 31, 2010</b>						
Cash and cash equivalents	\$5,993.2	\$5,993.2	\$2,138.6	\$3,854.6	\$	\$5,993.2
Short-term investments						
Commercial paper	\$ 540.8	\$ 540.8	\$	\$ 540.8	\$	\$ 540.8
U.S. government and agencies	128.9	128.9	128.9			128.9
Corporate debt securities	63.4	63.9		63.4		63.4
Other securities	0.7	0.7		0.7		0.7
Short-term investments	<u>\$ 733.8</u>	<u>\$ 734.3</u>				
Noncurrent investments						
U.S. government and agencies	\$ 359.2	\$ 361.8	\$ 359.2	\$	\$	\$ 359.2
Corporate debt securities	367.9	368.9		367.9		367.9
Mortgage-backed	315.5	350.7		315.5		315.5
Asset-backed	132.4	140.8		132.4		132.4
Other securities	6.4	8.3		3.3	3.1	6.4
Marketable equity	433.7	182.6	433.7			433.7
Equity method and other investments <sup>1</sup>	164.4	164.4				
Investments	<u>\$1,779.5</u>	<u>\$1,577.5</u>				

<sup>1</sup> Fair value not applicable

Description	Carrying Amount	Fair Value Measurements Using			Fair Value
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	
<b>Long-term debt, including current portion</b>					
December 31, 2011	\$(6,981.5)	\$	\$(7,451.5)	\$	\$(7,451.5)
December 31, 2010	(6,788.7)		(7,030.0)		(7,030.0)

Description	Carrying Amount	Fair Value Measurements Using			Fair Value
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	
<b>December 31, 2011</b>					
Risk-management instruments					
Interest rate contracts designated as hedging instruments					
Other receivables	\$ 6.1	\$	\$ 6.1	\$	\$ 6.1
Sundry	531.7		531.7		531.7
Foreign exchange contracts not designated as hedging instruments					
Other receivables	16.2		16.2		16.2
Other current liabilities	(25.9)		(25.9)		(25.9)
<b>December 31, 2010</b>					
Risk-management instruments					
Interest rate contracts designated as hedging instruments					
Sundry	\$ 278.3	\$	\$ 278.3	\$	\$ 278.3
Foreign exchange contracts not designated as hedging instruments					
Other receivables	13.7		13.7		13.7
Other current liabilities	(31.6)		(31.6)		(31.6)
Equity contracts designed as hedging instruments					
Other current liabilities	(35.6)		(35.6)		(35.6)

The fair value of the contingent consideration liability related to the Avid and Alnara acquisitions (Note 3), a Level 3 measurement in the fair value hierarchy, was \$121.6 million and \$163.5 million as of December 31, 2011 and 2010, respectively.

We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.

Approximately \$4.03 billion of our investments in debt securities, measured at fair value, will mature within five years.

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:

	2011	2010
Unrealized gross gains	\$ 103.0	\$ 262.6
Unrealized gross losses	80.0	61.1
Fair value of securities in an unrealized gain position	2,498.9	1,031.8
Fair value of securities in an unrealized loss position	2,164.4	758.1

Other-than-temporary impairment losses on fixed income securities of \$26.8 million, \$12.0 million, and \$22.4 million were recognized in the statement of operations for the years ended December 31, 2011, 2010, and 2009, respectively. These losses primarily relate to credit losses on other securities for the year ended December 31, 2011 and on certain mortgage-backed securities for the years ended December 31, 2010 and 2009. The amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.

The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed income securities is sensitive to changes in the yield curve and other market conditions. Approximately 90 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of December 31, 2011.

The net adjustment to unrealized gains and losses (net of tax) on available-for-sale securities decreased other comprehensive income (loss) by \$114.1 million for the year ended December 31, 2011 and increased other comprehensive income (loss) by \$53.5 million and \$186.6 million for the years ended December 31, 2010 and 2009, respectively. Activity related to our available-for-sale investment portfolio was as follows:

	2011	2010	2009
Proceeds from sales	\$2,268.3	\$760.3	\$1,227.4
Realized gross gains on sales	140.0	110.7	68.9
Realized gross losses on sales	9.9	4.8	6.8

#### Note 7: Goodwill and Other Intangibles

Goodwill at December 31 was as follows:

	2011	2010
Goodwill	<u>\$1,434.7</u>	\$1,423.9

Substantially all of our goodwill balance is attributable to the human pharmaceutical business segment. See Note 3 for a further discussion of goodwill resulting from recent business combinations. No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2011, 2010, or 2009.

The components of other intangible assets at December 31 were as follows:

Description	2011			2010		
	Carrying Amount—Gross	Accumulated Amortization	Carrying Amount—Net	Carrying Amount—Gross	Accumulated Amortization	Carrying Amount—Net
Finite-lived intangible assets						
Marketed products	\$4,624.9	\$(1,481.2)	\$3,143.7	\$3,789.1	\$(1,023.4)	\$2,765.7
Other	117.3	(42.5)	74.8	62.5	(31.3)	31.2
Total finite-lived intangible assets	<u>4,742.2</u>	<u>(1,523.7)</u>	<u>3,218.5</u>	<u>3,851.6</u>	<u>(1,054.7)</u>	<u>2,796.9</u>
Indefinite-lived intangible assets						
In-process research and development	474.9	0.0	474.9	598.0	0.0	598.0
Total other intangible assets	<u>\$5,217.1</u>	<u>\$(1,523.7)</u>	<u>\$3,693.4</u>	<u>\$4,449.6</u>	<u>\$(1,054.7)</u>	<u>\$3,394.9</u>

Marketed products consists of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. Other intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. IPR&D consists of the acquisition date fair value of intangible assets acquired in business combinations that have not yet achieved regulatory approval for marketing. See Note 3 for a further discussion of indefinite-lived intangible assets acquired in recent business combinations.

The remaining weighted-average amortization period for finite-lived intangible assets is approximately 9 years. Amortization expense for 2011, 2010, and 2009 was \$469.0 million, \$385.7 million, and \$277.0 million, respectively. The estimated amortization expense for our current finite-lived intangible assets for each of the five succeeding years approximates \$530 million in 2012, \$460 million in 2013, \$410 million in 2014, \$380 million in 2015, and \$330 million in 2016. Amortization expense is included in either cost of sales or marketing, selling, and administrative depending on the nature of the intangible asset being amortized.

During 2011, we recorded impairment charges of \$151.5 million due primarily to the partial impairment of the IPR&D assets related to Amyvid and liprotamase. The impairment of Amyvid was due to a delay in product launch and lower sales projections during the early part of the product's expected life cycle. In April 2011, we received a complete response letter from the FDA for the NDA for liprotamase, which communicated the need for us to conduct an additional clinical trial prior to a re-submission, resulting in an impairment of liprotamase.

No impairments occurred with respect to the carrying value of other intangible assets for the years ended December 31, 2010 and 2009.

### Note 8: Borrowings

Long-term debt at December 31 consisted of the following:

	2011	2010
3.55 to 7.13 percent notes (due 2012-2037) .....	\$ 6,387.4	\$6,387.4
Other, including capitalized leases .....	37.6	97.2
Fair value adjustment .....	556.5	304.1
	<u>6,981.5</u>	<u>6,788.7</u>
Less current portion .....	(1,516.8)	(18.2)
Long-term debt .....	<u>\$ 5,464.7</u>	<u>\$6,770.5</u>

In March 2009, we issued \$2.40 billion of fixed-rate notes with interest to be paid semi-annually.

The 6.55 percent Employee Stock Ownership Plan (ESOP) debentures were repaid in full during the year ended December 31, 2011. The balance was \$63.7 million at December 31, 2010, and is included in Other in the table above.

The aggregate amounts of maturities on long-term debt for the next five years are as follows: 2012, \$1.51 billion; 2013, \$10.2 million; 2014, \$1.01 billion; 2015, \$5.3 million; and 2016, \$201.2 million.

At December 31, 2011 and 2010, short-term borrowings included \$5.5 million and \$137.8 million, respectively, of notes payable to banks. At December 31, 2011, we have \$1.24 billion of unused committed bank credit facilities, \$1.20 billion of which backs our commercial paper program and matures in April 2015. There were no amounts outstanding under the facility as of or during the year ended December 31, 2011. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.

In September 2010, we borrowed \$125.0 million of short-term floating-rate debt, which was repaid in full during the year ended December 31, 2011.

We have converted approximately 70 percent of all fixed-rate debt to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on debt obligations and interest rates at December 31, 2011 and 2010, including the effects of interest rate swaps for hedged debt obligations, were 3.00 percent and 2.87 percent, respectively.

For the years ended December 31, 2011, 2010, and 2009, cash payments of interest on borrowings totaled \$167.4 million, \$176.3 million, and \$205.9 million, respectively, net of capitalized interest.

In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

### Note 9: Stock-Based Compensation

Stock-based compensation expense in the amount of \$147.4 million, \$231.0 million, and \$368.5 million was recognized for the years ended December 31, 2011, 2010, and 2009, respectively, as well as related tax benefits of \$51.6 million, \$80.8 million, and \$128.9 million, respectively. Our stock-based compensation expense consists primarily of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize the stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares and treasury stock to satisfy stock option exercises and for the issuance of PA, SVA, and RSU shares. We classify tax benefits resulting from tax deductions in excess of the compensation cost recognized for exercised stock options as a financing cash flow in the consolidated statements of cash flows.

At December 31, 2011, additional stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 93.0 million shares.

### Performance Award Program

PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. In 2009, we granted both a one-year and a two-year award to all global management

as a transition to a two-year performance period for all PAs granted beginning in 2010. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement periods. The fair values of PAs granted for the years ended December 31, 2011 and 2010 were \$31.90 and \$30.88, respectively. The fair values of PAs granted in 2009 were \$36.17 for the one-year award and \$34.12 for the two-year award. The number of shares ultimately issued for the PA program is dependent upon the earnings achieved during the vesting period. Pursuant to this plan, approximately 3.9 million shares, 3.8 million shares, and 2.8 million shares were issued during the years ended December 31, 2011, 2010, and 2009, respectively. Approximately 1.6 million shares are expected to be issued in 2012. As of December 31, 2011, the total remaining unrecognized compensation cost related to nonvested PAs amounted to \$16.7 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.

### Shareholder Value Award Program

SVAs are granted to officers and management and are payable in shares of common stock at the end of a three-year period. The number of shares actually issued varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2011, 2010, and 2009 were \$28.33, \$25.97, and \$33.97, respectively, determined using the following assumptions:

(Percents)	2011	2010	2009
Expected dividend yield	4.90	4.50	4.00
Risk-free interest rate	.20–1.36	.10–1.36	.44–1.48
Range of volatilities	27.61–29.10	28.00–28.69	24.34–24.92

A summary of the SVA activity is presented below:

	Units Attributable to SVAs (in thousands)
Outstanding at January 1, 2009	1,903
Granted	1,416
Forfeited or expired	(559)
Outstanding at December 31, 2009	2,760
Granted	1,987
Issued	(365)
Forfeited or expired	(745)
Outstanding at December 31, 2010	3,637
Granted	1,830
Issued	(428)
Forfeited or expired	(740)
Outstanding at December 31, 2011	4,299

The maximum number of shares that could ultimately be issued upon vesting of the SVA units outstanding at December 31, 2011, is 5.6 million. Approximately 1.0 million shares are expected to be issued in 2012. As of December 31, 2011, the total remaining unrecognized compensation cost related to nonvested SVAs amounted to \$45.9 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.

### Restricted Stock Units

RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December 31, 2011, 2010, and 2009 were \$35.80, \$34.78, and \$38.12, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this plan, 1.5 million, 1.5 million and 0.5 million shares were granted during the years ended December 31, 2011, 2010, and 2009, respectively, and approximately 0.2 million and 0.2 million shares were issued during the years ended December 31, 2011 and 2010, respectively. Approximately 0.3 million shares are expected to be issued in 2012. As of December 31, 2011, the total remaining unrecognized compensation cost related to nonvested RSUs amounted to \$52.0 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.

### Stock Option Program

Stock options were granted prior to 2007 to officers, management, and board members at exercise prices equal to the fair market value of our stock price at the date of grant. Options fully vest three years from the grant date and have a term of 10 years.

Stock option activity during the year ended December 31, 2011 is summarized below:

	Shares of Common Stock Attributable to Options (in thousands)	Weighted-Average Exercise Price of Options	Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2011	55,507	\$69.04		
Exercised	(18)	24.33		
Forfeited or expired	(18,933)	74.56		
Outstanding at December 31, 2011	36,556	66.22	1.8	\$1.2
Exercisable at December 31, 2011	36,556	66.22	1.8	1.2

All options were vested as of December 31, 2011.

The intrinsic value of options exercised during the years ended December 31, 2011, 2010, and 2009 amounted to \$0.2 million, \$0.1 million, and \$0.3 million, respectively. The total grant date fair value of options vested during the year ended December 31, 2009 amounted to \$68.5 million. We received cash of \$0.4 million, \$0.1 million, and \$0.2 million from exercises of stock options during the years ended December 31, 2011, 2010, and 2009, respectively. The recognized related tax benefits for all three years were not material.

### Note 10: Other Assets and Other Liabilities

Other receivables include receivables from our collaboration partners, tax receivables, interest receivable on the interest rate swaps, and a variety of other items.

Prepaid expenses and other includes global prepaid operating expenses and deferred taxes (Note 13).

Sundry assets primarily include deferred tax assets (Note 13), capitalized computer software, receivables from our collaboration partners, the fair value of the interest rate swaps, and prepaid retirement plan outside the U.S. The increase in sundry asset is attributable to the increase in deferred tax assets, the increase in the fair value of the interest rate swaps, the increase in the prepayment of a retirement plan outside the U.S. (Note 14), and the increase relating to the loan made to Amylin in the second quarter of 2011 (Note 4).

Other current liabilities include product litigation, other taxes payable, deferred tax liabilities (Note 13), deferred income and liabilities from our collaboration arrangements, the current portion of our estimated product return liabilities, and a variety of other items. The increase in other current liabilities is primarily attributable to the increase in deferred income relating to the termination of the collaboration agreement with Amylin (Note 4) and, to a lesser extent, an increase in liabilities from our collaboration arrangements, product liabilities, and deferred taxes.

Other noncurrent liabilities include deferred income from our collaboration and out-licensing arrangements, deferred tax liabilities (Note 13), the fair value of contingent consideration from business combinations (Note 3), the long-term portion of our estimated product return liabilities, product litigation, and a variety of other items. The decrease in other noncurrent liabilities was primarily due to the decrease in deferred tax liabilities and, to a lesser extent, the decrease in contingent consideration, and the decrease in deferred income. The decreases were offset by the increase in the long-term portion of the estimated product return liabilities.

**Note 11: Shareholders' Equity**

Changes in certain components of shareholders' equity were as follows:

	Additional Paid-in Capital	Retained Earnings	Deferred Costs - ESOP	Common Stock in Treasury	
				Shares (in thousands)	Amount
Balance at January 1, 2009	\$3,976.6	\$ 7,654.9	\$(86.3)	889	\$99.2
Net income		4,328.8			
Cash dividends declared per share: \$1.96		(2,153.3)			
Retirement of treasury shares	(3.3)			(132)	(3.3)
Issuance of stock under employee stock plans-net	(85.0)			125	2.6
Stock-based compensation	368.5				
ESOP transactions	6.9		8.9		
Employee benefit trust contribution	371.9				
Balance at December 31, 2009	4,635.6	9,830.4	(77.4)	882	98.5
Net income		5,069.5			
Cash dividends declared per share: \$1.96		(2,167.3)			
Retirement of treasury shares	(1.0)			(28)	(1.0)
Issuance of stock under employee stock plans-net	(87.6)			10	(1.1)
Stock-based compensation	231.0				
ESOP transactions	20.5		25.0		
Balance at December 31, 2010	4,798.5	12,732.6	(52.4)	864	96.4
Net income		4,347.7			
Cash dividends declared per share: \$1.96		(2,182.5)			
Retirement of treasury shares	(0.1)			(1)	(0.1)
Issuance of stock under employee stock plans-net	(108.7)			(10)	(1.0)
Stock-based compensation	147.4				
ESOP transactions	49.7		52.4		
Balance at December 31, 2011	\$4,886.8	\$14,897.8	\$ 0.0	853	\$95.3

As of December 31, 2011, we have purchased \$2.58 billion of our announced \$3.00 billion share repurchase program. No shares were repurchased during the years ended December 31, 2011, 2010, or 2009.

We have 5 million authorized shares of preferred stock. As of December 31, 2011 and 2010, no preferred stock has been issued.

We have an employee benefit trust that held 50.0 million and 50.0 million shares of our common stock at December 31, 2011 and 2010, respectively, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was \$3.01 billion and \$3.01 billion at December 31, 2011 and 2010, respectively, and is shown as a reduction in shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of earnings per share. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2011, 2010, or 2009.

We have an ESOP as a funding vehicle for the existing employee savings plan. The ESOP used the proceeds of a loan from us to purchase shares of common stock from the treasury. The ESOP issued third-party debt, repayment of which was guaranteed by us (Note 8). The proceeds were used to purchase shares of our common stock on the open market. As of December 31, 2011, all shares of common stock held by the ESOP were allocated to participating employees as part of our savings plan contribution. The fair value of shares allocated each period was recognized as compensation expense.

**Note 12: Earnings Per Share**

Following is a reconciliation of the denominators used in computing earnings per share:

	2011	2010	2009
	(Shares in thousands)		
Income available to common shareholders	\$ 4,347.7	\$ 5,069.5	\$ 4,328.8
Basic earnings per share			
Weighted-average number of common shares outstanding, including incremental shares	1,113,923	1,105,788	1,098,338
Basic earnings per share	\$ 3.90	\$ 4.58	\$ 3.94
Diluted earnings per share			
Weighted-average number of common shares outstanding	1,107,112	1,099,310	1,094,623
Stock options and other incremental shares	6,855	6,503	3,744
Weighted-average number of common shares outstanding—diluted	1,113,967	1,105,813	1,098,367
Diluted earnings per share	\$ 3.90	\$ 4.58	\$ 3.94

**Note 13: Income Taxes**

Following is the composition of income tax expense:

	2011	2010	2009
Current			
Federal	\$ 671.4	\$ 376.2	\$ 45.7
Foreign	759.5	513.9	772.2
State	(22.9)	23.3	49.2
Total current tax expense	1,408.0	913.4	867.1
Deferred			
Federal	(398.5)	624.4	82.5
Foreign	(34.7)	(55.2)	79.8
State	27.0	(26.9)	(0.4)
Total deferred tax expense (benefit)	(406.2)	542.3	161.9
Income taxes	\$1,001.8	\$1,455.7	\$1,029.0

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:

	2011	2010
Deferred tax assets		
Compensation and benefits .....	\$ 1,286.5	\$ 890.4
Tax credit carryforwards and carrybacks .....	695.3	503.1
Asset purchases .....	428.5	275.1
Tax loss carryforwards and carrybacks .....	406.1	414.0
Intercompany profit in inventories .....	277.2	316.7
Debt .....	214.9	114.6
Sale of intangibles .....	207.1	112.8
Product return reserves .....	146.2	84.0
Contingencies .....	94.5	106.6
Other .....	301.3	363.4
Total gross deferred tax assets .....	4,057.6	3,180.7
Valuation allowances .....	(611.9)	(473.1)
Total deferred tax assets .....	3,445.7	2,707.6
Deferred tax liabilities		
Unremitted earnings .....	(940.2)	(741.8)
Intangibles .....	(839.9)	(954.9)
Inventories .....	(489.2)	(525.6)
Property and equipment .....	(451.0)	(505.2)
Financial instruments .....	(196.9)	(160.9)
Other .....	(8.5)	(19.1)
Total deferred tax liabilities .....	(2,925.7)	(2,907.5)
Deferred tax assets (liabilities)—net .....	\$ 520.0	\$ (199.9)

At December 31, 2011 and 2010, no individually significant items were classified as "Other" deferred tax assets or liabilities.

The deferred tax asset and related valuation allowance amounts for U.S. and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings. At December 31, 2011, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. income tax purposes of \$780.8 million: \$335.5 million will expire within 5 years; \$404.8 million will expire between 5 and 20 years; and \$40.5 million of the carryforwards will never expire. The remaining balance of the deferred tax asset for tax loss carryforwards and carrybacks is related to net operating losses for state income tax purposes that are substantially reserved.

Based on filed tax returns, we also have tax credit carryforwards and carrybacks of \$1.01 billion available to reduce future income taxes; \$514.4 million will be carried back; \$53.0 million of the tax credit carryforwards will expire between 10 and 20 years; and \$1.3 million of the tax credit carryforwards will never expire. The remaining portion of the tax credit carryforwards is related to federal tax credits of \$93.8 million and state tax credits of \$349.4 million, both of which are fully reserved.

Domestic and Puerto Rican companies contributed approximately 24 percent, 45 percent, and 39 percent for the years ended December 31, 2011, 2010, and 2009, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant. The current tax incentive grant will not expire prior to 2017.

At December 31, 2011, we had an aggregate of \$20.60 billion of unremitted earnings of foreign subsidiaries that have been or are intended to be permanently reinvested for continued use in foreign operations and that, if distributed, would result in additional income tax expense at approximately the U.S. statutory rate.

Cash payments of income taxes totaled \$943.0 million, \$861.0 million, and \$1.14 billion, for the years ended December 31, 2011, 2010, and 2009, respectively.

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:

	2011	2010	2009
Income tax at the U.S. federal statutory tax rate	\$1,872.3	\$2,283.8	\$1,875.2
Add (deduct)			
International operations, including Puerto Rico	(796.7)	(823.3)	(741.1)
U.S. health care reform	62.9	85.1	0.0
General business credits	(80.8)	(83.2)	(79.4)
IRS audit conclusion	(85.3)	0.0	(54.4)
Other	29.4	(6.7)	28.7
Income taxes	\$1,001.8	\$1,455.7	\$1,029.0

In October 2010, Puerto Rico enacted excise tax legislation that affected our operations beginning with the year ended December 31, 2011. The excise tax is imposed on the purchase of goods and services from a related manufacturer in Puerto Rico, and is therefore included in costs of sales in our consolidated statement of operations rather than income taxes. The Internal Revenue Service (IRS) has stated it would not challenge a taxpayer's position that this excise tax is creditable for U.S. income tax purposes, pending the resolution of numerous legal and factual issues. As a result, the 2011 benefit on international operations reported in the effective tax rate reconciliation above includes the benefit from the foreign tax credit related to the excise tax.

The U.S. health care legislation (both the primary "Patient Protection and Affordable Care Act" and the "Health Care and Education Reconciliation Act") eliminated the tax-free nature of the subsidy we receive for sponsoring retiree drug coverage that is "actuarially equivalent" to Medicare Part D. This provision is effective January 1, 2013. While this change has a future impact on our net tax deductions related to retiree health benefits, we were required to record a one-time charge to adjust our deferred tax asset for this change in the law in the quarter of enactment. Accordingly, we recorded a non-cash charge of \$85.1 million in the first quarter of 2010. In addition, U.S. health care reform mandated an annual industry fee effective January 1, 2011, which is not deductible for tax purposes.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

	2011	2010	2009
Beginning balance at January 1	\$1,619.6	\$1,351.2	\$1,223.2
Additions based on tax positions related to the current year	89.4	186.2	179.1
Additions for tax positions of prior years	390.0	117.0	170.4
Reductions for tax positions of prior years	(492.3)	(30.2)	(128.9)
Lapses of statutes of limitation	(2.6)	(7.0)	(3.3)
Settlements	(326.3)	(0.1)	(95.0)
Changes related to the impact of foreign currency translation	(3.0)	2.5	5.7
Balance at December 31	\$1,274.8	\$1,619.6	\$1,351.2

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was \$812.3 million and \$1.07 billion at December 31, 2011 and 2010, respectively.

We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in major taxing jurisdictions for years before 2007.

During 2011, we settled the U.S. examinations of tax years 2005-2007, along with certain matters related to tax years 2008-2009. The examination of the remainder of 2008-2009 commenced in the fourth quarter of 2011. Considering this current examination cycle, as well as the settlement of 2005-2007 and certain matters related to 2008-2009, our consolidated results of operations benefited from a reduction in tax expense of \$85.3 million in 2011. We made cash payments totaling approximately \$300 million for tax years 2005-2007. Because the examination of the remainder of 2008-2009 is still in the early stages, the resolution of all issues in this audit period will likely extend beyond the next 12 months.

During 2009, we settled an IRS administrative appeals matter from the 2001-2004 IRS audit. Considering the status of the 2005-2007 IRS examination at that time and the settlement of the IRS administrative appeals matter from the 2001-2004 audit, our income tax expense was reduced by \$54.4 million, and a cash payment of approximately \$50 million was paid, after utilization of applicable tax credit carryovers.

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2011, 2010, and 2009, we recognized income tax expense (benefit) of \$(47.3) million, \$38.3 million, and \$(1.9) million, respectively, related to interest and penalties. At December 31, 2011 and 2010, our accruals for the payment of interest and penalties totaled \$145.1 million and \$221.0 million, respectively. Substantially all of the expense (benefit) and accruals relate to interest.

**Note 14: Retirement Benefits**

We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:

	Defined Benefit Pension Plans		Retiree Health Benefit Plans	
	2011	2010	2011	2010
Change in benefit obligation				
Benefit obligation at beginning of year	\$ 8,115.0	\$ 7,553.9	\$2,088.5	\$2,032.8
Service cost	236.3	219.2	72.4	56.5
Interest cost	447.9	431.6	118.0	121.4
Actuarial loss	794.7	342.2	110.2	10.0
Benefits paid	(400.1)	(387.8)	(77.9)	(98.0)
Plan amendments	10.0	0.3	1.1	(64.2)
Foreign currency exchange rate changes and other adjustments	(12.6)	(44.4)	(3.7)	30.0
Benefit obligation at end of year	9,191.2	8,115.0	2,308.6	2,088.5
Change in plan assets				
Fair value of plan assets at beginning of year	6,983.0	6,008.5	1,327.7	1,180.7
Actual return on plan assets	209.2	818.3	16.6	152.2
Employer contribution	402.4	563.5	72.6	92.8
Benefits paid	(400.1)	(387.8)	(77.9)	(98.0)
Foreign currency exchange rate changes and other adjustments	(8.2)	(19.5)	0.0	0.0
Fair value of plan assets at end of year	7,186.3	6,983.0	1,339.0	1,327.7
Funded status	(2,004.9)	(1,132.0)	(969.6)	(760.8)
Unrecognized net actuarial loss	4,857.5	3,796.6	1,367.4	1,235.3
Unrecognized prior service cost (benefit)	57.3	56.1	(215.1)	(261.1)
Net amount recognized	\$ 2,909.9	\$ 2,720.7	\$ 182.7	\$ 213.4
Amounts recognized in the consolidated balance sheet consisted of				
Prepaid expenses and other	\$ 160.8	\$ 58.5	\$ 0.0	\$ 0.0
Other current liabilities	(57.5)	(54.7)	(9.3)	(9.2)
Accrued retirement benefit	(2,108.2)	(1,135.8)	(960.3)	(751.6)
Accumulated other comprehensive loss before income taxes	4,914.8	3,852.7	1,152.3	974.2
Net amount recognized	\$ 2,909.9	\$ 2,720.7	\$ 182.7	\$ 213.4

The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2011.

For the year ended December 31, 2012, we expect to recognize from accumulated other comprehensive loss as components of net periodic benefit cost, \$285.3 million of unrecognized net actuarial loss and \$3.3 million of unrecognized prior service loss related to our defined benefit pension plans, and \$95.7 million of unrecognized net actuarial loss and \$35.1 million of unrecognized prior service benefit related to our retiree health benefit plans. We do not expect any plan assets to be returned to us in 2012.

The following represents our weighted-average assumptions as of December 31:

(Percents)	Defined Benefit Pension Plans			Retiree Health Benefit Plans		
	2011	2010	2009	2011	2010	2009
Weighted-average assumptions as of December 31						
Discount rate for benefit obligation	5.0	5.6	5.9	5.1	5.8	6.0
Discount rate for net benefit costs	5.6	5.9	6.7	5.8	6.0	6.9
Rate of compensation increase for benefit obligation	3.7	3.7	3.7			
Rate of compensation increase for net benefit costs	3.7	3.7	4.1			
Expected return on plan assets for net benefit costs	8.5	8.8	8.8	8.8	9.0	9.0

In evaluating the expected return on plan assets annually we consider numerous factors, including our historical assumptions compared with actual results, an analysis of current and future market conditions, our current and expected asset allocations, historical returns, and the views of leading financial advisers and economists for future asset class returns. As noted, historical returns are just one of several factors considered and are not the starting point for determining the expected return. Health-care-cost trend rates are assumed to increase at an annual rate of 7.4 percent for the year ended December 31, 2012, decreasing by approximately 0.3 percent per year to an ultimate rate of 5.0 percent by 2020.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:

	2012	2013	2014	2015	2016	2017-2021
Defined benefit pension plans	\$416.1	\$424.2	\$437.2	\$449.9	\$464.2	\$2,609.2
Retiree health benefit plans-gross	\$118.7	\$119.1	\$123.6	\$127.3	\$135.2	\$ 790.8
Medicare rebates	(11.7)	(9.9)	(11.0)	(12.4)	(13.5)	(91.7)
Retiree health benefit plans-net	\$107.0	\$109.2	\$112.6	\$114.9	\$121.7	\$ 699.1

The total accumulated benefit obligation for our defined benefit pension plans was \$8.20 billion and \$7.23 billion at December 31, 2011 and 2010, respectively. The projected benefit obligation and fair value of the plan assets for the defined benefit pension plans with projected benefit obligations in excess of plan assets were \$8.12 billion and \$5.96 billion, respectively, as of December 31, 2011, and \$7.12 billion and \$5.93 billion, respectively, as of December 31, 2010. The accumulated benefit obligation and fair value of the plan assets for the defined benefit pension plans with accumulated benefit obligations in excess of plan assets were \$7.03 billion and \$5.75 billion, respectively, as of December 31, 2011, and \$1.10 billion and \$136.3 million, respectively, as of December 31, 2010.

Net pension and retiree health benefit expense included the following components:

	Defined Benefit Pension Plans			Retiree Health Benefit Plans		
	2011	2010	2009	2011	2010	2009
Components of net periodic benefit cost						
Service cost	\$ 236.3	\$ 219.2	\$ 242.1	\$ 72.4	\$ 56.5	\$ 53.7
Interest cost	447.9	431.6	417.5	118.0	121.4	119.6
Expected return on plan assets	(685.9)	(638.2)	(584.9)	(129.4)	(122.6)	(117.9)
Amortization of prior service cost (benefit)	8.6	8.8	8.0	(42.9)	(37.2)	(36.0)
Recognized actuarial loss	200.4	163.0	84.5	88.7	85.0	71.8
Net periodic benefit cost	\$ 207.3	\$ 184.4	\$ 167.2	\$ 106.8	\$ 103.1	\$ 91.2

If the health-care-cost trend rates were to be increased by one percentage point each future year, the December 31, 2011, accumulated postretirement benefit obligation would increase by \$209.4 million and the aggregate of the service cost and interest cost components of the 2011 annual expense would increase by \$15.1 million. A one percentage point decrease in these rates would decrease the December 31, 2011, accumulated postretirement benefit obligation by \$187.1 million and the aggregate of the 2011 service cost and interest cost by \$12.3 million.

The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2011:

	Defined Benefit Pension Plans	Retiree Health Benefit Plans
Actuarial loss arising during period	\$ 1,266.0	\$ 221.3
Plan amendments during period	10.0	1.1
Amortization of prior service cost (benefit) included in net income	(8.6)	42.9
Amortization of net actuarial loss included in net income	(200.4)	(88.7)
Foreign currency exchange rate changes	(4.9)	1.5
Total other comprehensive loss during period	\$ 1,062.1	\$ 178.1

We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these defined contribution plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plan are based on employee contributions and the level of our match. Expenses under the plans totaled \$117.6 million, \$119.8 million, and \$127.6 million for the years ended December 31, 2011, 2010, and 2009, respectively.

We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2011, 2010, and 2009 were not significant.

### **Benefit Plan Investments**

Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent 81 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.

We manage our portfolio to minimize any concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.

Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.

The defined benefit pension and retiree health benefit plan allocation strategy for the U.S. and Puerto Rico currently comprises approximately 81 percent growth investments and 19 percent fixed income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.

Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.

Fixed income investments primarily consist of fixed income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities and commercial mortgage-backed obligations.

Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.

Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund of funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.

Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as Level 3. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.

Other assets include cash and cash equivalents and mark-to-market value of derivatives.

The cash value of the trust-owned insurance contract is invested in investment grade publicly traded equity and fixed income securities.

Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2011 by asset category are as follows:

Asset Class	Total	Fair Value Measurements Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Defined Benefit Pension Plans</b>				
Public equity securities				
U.S. ....	\$ 454.5	\$ 317.2	\$ 137.3	\$
International .....	1,462.4	505.9	956.5	
Fixed income				
Developed markets .....	929.1	100.9	828.2	
Emerging markets .....	341.5	0.1	341.4	
Private alternative investments				
Hedge funds .....	2,312.6		1,064.2	1,248.4
Equity-like funds .....	870.2			870.2
Real estate .....	409.2	271.2		138.0
Other .....	406.8	177.7	229.1	
<b>Total</b> .....	<b>\$7,186.3</b>	<b>\$1,373.0</b>	<b>\$3,556.7</b>	<b>\$2,256.6</b>
<b>Retiree Health Benefit Plans</b>				
Public equity securities				
U.S. ....	\$ 40.9	\$ 28.0	\$ 12.9	\$
International .....	97.1	27.5	69.6	
Fixed income				
Developed markets .....	55.3		55.3	
Emerging markets .....	34.6		34.6	
Private alternative investments				
Hedge funds .....	213.1		107.8	105.3
Equity-like funds .....	79.9			79.9
Cash value of trust owned insurance contract .....	767.9		767.9	
Real estate .....	27.5	27.5		
Other .....	22.7	8.6	14.1	
<b>Total</b> .....	<b>\$1,339.0</b>	<b>\$91.6</b>	<b>\$1,062.2</b>	<b>\$185.2</b>

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2011.

The activity in the Level 3 investments during the year ended December 31, 2011 was as follows:

	Hedge Funds	Equity-like Funds	Real Estate	Total
<b>Defined Benefit Pension Plans</b>				
Beginning balance at January 1, 2011	\$1,241.9	\$802.9	\$126.5	\$2,171.3
Actual return on plan assets, including changes in foreign exchange rates:				
Relating to assets still held at the reporting date	(8.1)	34.4	3.9	30.2
Relating to assets sold during the period	(18.1)	0.0	0.0	(18.1)
Purchases	217.7	159.1	11.5	388.3
Sales	(25.2)	0.0	(3.9)	(29.1)
Settlements	(159.8)	(126.2)	0.0	(286.0)
Ending balance at December 31, 2011	\$1,248.4	\$870.2	\$138.0	\$2,256.6
<b>Retiree Health Benefit Plans</b>				
Beginning balance at January 1, 2011	\$ 106.6	\$ 74.5		\$ 181.1
Actual return on plan assets, including changes in foreign exchange rates:				
Relating to assets still held at the reporting date	0.5	3.3		3.8
Relating to assets sold during the period	(1.8)	0.0		(1.8)
Purchases	18.2	14.4		32.6
Sales	(2.0)	0.0		(2.0)
Settlements	(16.2)	(12.3)		(28.5)
Ending balance at December 31, 2011	\$ 105.3	\$ 79.9		\$ 185.2

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2010 by asset category are as follows:

Asset Class	Total	Fair Value Measurements Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Defined Benefit Pension Plans</b>				
Public equity securities				
U.S.	\$ 589.4	\$421.4	\$168.0	\$
International	1,868.3	907.1	961.2	
Fixed income				
Developed markets	791.6	77.6	714.0	
Emerging markets	336.2		336.2	
Private alternative investments				
Hedge funds	2,020.3		778.4	1,241.9
Equity-like funds	812.9	10.0		802.9
Real estate	126.5			126.5
Other	437.8	195.9	241.9	
Total	\$6,983.0	\$1,612.0	\$3,199.7	\$2,171.3
<b>Retiree Health Benefit Plans</b>				
Public equity securities				
U.S.	\$ 56.0	\$ 39.7	\$ 16.3	\$
International	131.6	67.8	63.8	
Fixed income				
Developed markets	50.5		50.5	
Emerging markets	33.9		33.9	
Private alternative investments				
Hedge funds	185.2		78.6	106.6
Equity-like funds	74.5			74.5
Cash value of trust owned insurance contract	761.7		761.7	
Other	34.3	12.6	21.7	
Total	\$1,327.7	\$ 120.1	\$ 1,026.5	\$ 181.1

The activity in the Level 3 investments during the year ended December 31, 2010 was as follows:

	Hedge Funds	Equity-like Funds	Inter-national Equity	Fixed Income-Developed Markets	Real Estate	Total
<b>Defined Benefit Pension Plans</b>						
Beginning balance at January 1, 2010	\$1,381.5	\$658.2	\$ 3.9	\$ 3.5	\$ 85.4	\$2,132.5
Actual return on plan assets, including changes in foreign exchange rates:						
Relating to assets still held at the reporting date	106.1	66.2	0.1	0.1	4.2	176.7
Relating to assets sold during the period	0.0	11.3	(0.4)	(0.1)	(5.3)	5.5
Purchases	215.8	131.4	0.1	0.0	41.4	388.7
Sales	(21.4)	0.0	(3.1)	(3.4)	0.0	(27.9)
Settlements	(18.1)	(64.2)	0.0	(0.1)	0.0	(82.4)
Transfers in and/or out of Level 3	(422.0)	0.0	(0.6)	0.0	0.8	(421.8)
Ending balance at December 31, 2010	\$1,241.9	\$802.9	\$ 0.0	\$ 0.0	\$126.5	\$2,171.3
<b>Retiree Health Benefit Plans</b>						
Beginning balance at January 1, 2010	\$ 140.9	\$ 63.6	\$ 0.4	\$ 0.4	\$ 0.0	\$ 205.3
Actual return on plan assets, including changes in foreign exchange rates:						
Relating to assets still held at the reporting date	5.4	4.6	0.0	0.0	0.0	10.0
Relating to assets sold during the period	0.0	0.6	0.0	0.0	0.0	0.6
Purchases	5.3	11.9	0.0	0.0	0.0	17.2
Sales	(0.6)	0.0	(0.4)	(0.4)	0.0	(1.4)
Settlements	(1.8)	(6.2)	0.0	0.0	0.0	(8.0)
Transfers in and/or out of Level 3	(42.6)	0.0	0.0	0.0	0.0	(42.6)
Ending balance at December 31, 2010	\$ 106.6	\$ 74.5	\$ 0.0	\$ 0.0	\$ 0.0	\$ 181.1

Substantially all of the Level 3 transfers are associated with assets that can be redeemed at their NAV per share within a reasonable period of time. This reclassification is in accordance with current accounting guidance.

For the year ended December 31, 2012, we expect to contribute approximately \$75 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. In addition, we expect to contribute approximately \$300 million of additional discretionary funding in the aggregate during the year ended December 31, 2012 to several of our global defined benefit pension and post-retirement health benefit plans.

### Note 15: Contingencies

We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.

#### Patent Litigation

We are engaged in the following U.S. patent litigation matters brought pursuant to procedures set out in the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984):

- Alimta: Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); and Barr Laboratories, Inc. (Barr) each submitted ANDAs seeking approval to market generic versions of Alimta prior to the expiration of the relevant U.S. patents and data-based pediatric exclusivity period (compound patent licensed from the Trustees of Princeton University and expiring in 2017, concomitant nutritional supplement use patent expiring in 2022) and alleging the patents are invalid. We, along with Princeton, filed lawsuits in the U.S. District Court for the District of Delaware against Teva, APP, and Barr seeking rulings that the compound patent is valid and infringed. In July 2011, the district court entered judgment in our favor, upholding that patent's validity. The generic manufacturers have appealed this decision. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our concomitant nutritional supplement use patent is valid and infringed. No trial date has yet been set. In January 2012, we filed a similar lawsuit against Accord Healthcare Inc.

We believe the Hatch-Waxman challenges to Alimta are without merit and expect to prevail in this litigation. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market.

- **Strattera:** Actavis Elizabeth LLC (Actavis), Apotex Inc. (Apotex), Aurobindo Pharma Ltd. (Aurobindo), Mylan Pharmaceuticals Inc. (Mylan), Sandoz Inc. (Sandoz), Sun Pharmaceutical Industries Limited (Sun Ltd.), and Teva Pharmaceuticals USA, Inc. (Teva USA) each submitted an ANDA seeking permission to market generic versions of Strattera prior to the expiration of our relevant U.S. patent and data-based pediatric exclusivity period (expiring in 2017), and alleging that this patent is invalid. In 2007, we brought a lawsuit against Actavis, Apotex, Aurobindo, Mylan, Sandoz, Sun Ltd., and Teva USA in the U.S. District Court for the District of New Jersey. In August 2010, the court ruled that our patent was invalid; however, in July 2011, the Court of Appeals for the Federal Circuit overturned that decision, upholding the patent. The Federal Circuit Court of Appeals denied the generic manufacturers' petition for rehearing en banc in October 2011, and the deadline for any further appeal has passed. Zydus Pharmaceuticals (Zydus) filed an action in the New Jersey district court in October 2010 seeking a declaratory judgment that it has the right to launch a generic atomoxetine product, based on the district court ruling. We believe that Zydus is subject to the injunction issued by the court of appeals in the Actavis case.

### **Zyprexa Litigation**

We are a defendant in approximately 40 Zyprexa product liability lawsuits in the U.S. covering approximately 120 plaintiffs. The lawsuits allege a variety of injuries from the use of Zyprexa, with the majority alleging that the product caused or contributed to diabetes or high blood-glucose levels. The claims seek substantial compensatory and punitive damages and typically accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the claims also allege that we improperly promoted the drug. Approximately 25 of the lawsuits, covering about 30 plaintiffs, are part of a Multi-District Litigation (MDL) proceeding before The Honorable Jack Weinstein in the Federal District Court for the Eastern District of New York (EDNY) (MDL No. 1596). In October 2011, a jury trial in a California state court was decided in our favor. We are prepared to continue our vigorous defense of Zyprexa in all these lawsuits and claims.

We were served with lawsuits filed by 13 states alleging that Zyprexa caused or contributed to diabetes or high blood-glucose levels, and that we improperly promoted the drug. We settled the Zyprexa-related claims of all of these states, incurring pretax charges of \$230.0 million in 2009 and \$15.0 million in 2008.

In 2005 and 2006, four lawsuits were filed in the EDNY purporting to be nationwide class actions on behalf of all consumers and third-party payors, excluding governmental entities, which made or will make payments for their members or insured patients being prescribed Zyprexa. These actions were consolidated into a single lawsuit, brought under certain state consumer-protection statutes, the federal civil Racketeer Influenced and Corrupt Organizations Act, and common law theories, seeking a refund of the cost of Zyprexa, treble damages, punitive damages, and attorneys' fees. As with the product liability suits, these lawsuits allege that we inadequately tested for and warned about side effects of Zyprexa and improperly promoted the drug. In September 2008, Judge Weinstein certified a class consisting of third-party payors, excluding governmental entities and individual consumers, and denied our motion for summary judgment. In September 2010, both decisions were reversed by the Second Circuit Court of Appeals, which found that the case cannot proceed as a class action and entered a judgment in our favor on plaintiffs' overpricing claim. The U.S. Supreme Court denied plaintiffs' petition for certiorari. All remaining claims at issue in these cases have now been resolved.

### **Byetta Litigation**

We have been named as a defendant in approximately 120 lawsuits involving approximately 480 plaintiffs, primarily seeking to recover damages for pancreatitis experienced by patients prescribed Byetta. We are aware of approximately 530 additional claimants who have not yet filed suit. Approximately 100 of these lawsuits are filed in California and coordinated in a Los Angeles Superior Court.

### **Other Product Liability Litigation**

We have been named as a defendant in numerous other product liability lawsuits involving primarily diethylstilbestrol. These claims are covered by insurance, subject to deductibles and coverage limits.

### **Product Liability Insurance**

Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims for other products in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for future product liability losses. In addition, there is no assurance that we will be able to fully collect from our insurance carriers in the future.

**Note 16: Other Comprehensive Income (Loss)**

The accumulated balances related to each component of other comprehensive income (loss) were as follows:

	Foreign Currency Translation Gains (Losses)	Unrealized Net Gains (Losses) on Securities	Defined Benefit Pension and Retiree Health Benefit Plans	Effective Portion of Cash Flow Hedges	Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2011 .....	\$ 510.7	\$ 128.9	\$(3,175.8)	\$(133.9)	\$(2,670.1)
Other comprehensive income (loss) .....	(244.8)	(114.1)	(856.4)	26.8	(1,188.5)
Balance at December 31, 2011 .....	\$ 265.9	\$ 14.8	\$(4,032.2)	\$(107.1)	\$(3,858.6)

The amounts above are net of income taxes. The income taxes associated with the unrecognized net actuarial losses and prior service costs on our defined benefit pension and retiree health benefit plans (Note 14) were a benefit of \$383.8 million for the year ended December 31, 2011. The income taxes associated with the net unrealized losses on securities were a benefit of \$64.4 million for the year ended December 31, 2011. The income taxes related to the other components of comprehensive income (loss) were not significant, as income taxes were not provided for foreign currency translation.

The unrealized gains (losses) on securities is net of reclassification adjustments of net gains (losses) of \$54.7 million, \$27.6 million, and \$19.0 million, net of tax, for the years ended December 31, 2011, 2010, and 2009, respectively, for net realized gains (losses) on sales of securities included in net income. The effective portion of cash flow hedges is net of reclassification adjustments of \$5.8 million, \$5.8 million, and \$6.7 million, net of tax, for the years ended December 31, 2011, 2010, and 2009, respectively, for interest expense on interest rate swaps designated as cash flow hedges.

Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in income.

**Note 17: Other—Net, Expense:**

Other—net, expense consisted of the following:

	2011	2010	2009
Interest expense .....	\$ 186.0	\$ 185.5	\$ 261.3
Interest income .....	(79.9)	(51.9)	(75.2)
Other (income) expense .....	72.9	(128.6)	43.4
Other—net, expense .....	\$ 179.0	\$ 5.0	\$ 229.5

Other expense for the year ended December 31, 2011 primarily consists of the partial impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 7) partially offset by gains on the disposal of investment securities. For the year ended December 31, 2010, other (income) expense primarily consists of damages recovered from generic pharmaceutical companies related to Zyprexa patent litigation in Germany and gains on the disposal of investment securities.

## Management's Reports

### Management's Report for Financial Statements—Eli Lilly and Company and Subsidiaries

Management of Eli Lilly and Company and subsidiaries is responsible for the accuracy, integrity, and fair presentation of the financial statements. The statements have been prepared in accordance with generally accepted accounting principles in the United States and include amounts based on judgments and estimates by management. In management's opinion, the consolidated financial statements present fairly our financial position, results of operations, and cash flows.

In addition to the system of internal accounting controls, we maintain a code of conduct (known as *The Red Book*) that applies to all employees worldwide, requiring proper overall business conduct, avoidance of conflicts of interest, compliance with laws, and confidentiality of proprietary information. All employees must take training annually on *The Red Book* and are required to report suspected violations. A hotline number is published in *The Red Book* to enable employees to report suspected violations anonymously. Employees who report suspected violations are protected from discrimination or retaliation by the company. In addition to *The Red Book*, the CEO, and all financial management must sign a financial code of ethics, which further reinforces their fiduciary responsibilities.

The consolidated financial statements have been audited by Ernst & Young LLP, an independent registered public accounting firm. Their responsibility is to examine our consolidated financial statements in accordance with generally accepted auditing standards of the Public Company Accounting Oversight Board (United States). Ernst & Young's opinion with respect to the fairness of the presentation of the statements is included in Item 8 of our annual report on Form 10-K. Ernst & Young reports directly to the audit committee of the board of directors.

Our audit committee includes five nonemployee members of the board of directors, all of whom are independent from our company. The committee charter, which is available on our web site, outlines the members' roles and responsibilities and is consistent with enacted corporate reform laws and regulations. It is the audit committee's responsibility to appoint an independent registered public accounting firm subject to shareholder ratification, approve both audit and non-audit services performed by the independent registered public accounting firm, and review the reports submitted by the firm. The audit committee meets several times during the year with management, the internal auditors, and the independent public accounting firm to discuss audit activities, internal controls, and financial reporting matters, including reviews of our externally published financial results. The internal auditors and the independent registered public accounting firm have full and free access to the committee.

We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established. We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate. Our culture demands integrity and an unyielding commitment to strong internal practices and policies. Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities and operate under a code of conduct and the highest level of ethical standards.

### Management's Report on Internal Control Over Financial Reporting—Eli Lilly and Company and Subsidiaries

Management of Eli Lilly and Company and subsidiaries is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. We have global financial policies that govern critical areas, including internal controls, financial accounting and reporting, fiduciary accountability, and safeguarding of corporate assets. Our internal accounting control systems are designed to provide reasonable assurance that assets are safeguarded, that transactions are executed in accordance with management's authorization and are properly recorded, and that accounting records are adequate for preparation of financial statements and other financial information. A staff of internal auditors regularly monitors, on a worldwide basis, the adequacy and effectiveness of internal accounting controls. The general auditor reports directly to the audit committee of the board of directors.

We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in *Internal Control—Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, we concluded that our internal control over financial reporting was effective as of December 31, 2011. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The internal control over financial reporting has been assessed by Ernst & Young LLP as of December 31, 2011. Their responsibility is to evaluate whether internal control over financial reporting was designed and operating effectively.

John C. Lechleiter, Ph.D.  
Chairman, President, and Chief Executive Officer

Derica W. Rice  
Executive Vice President, Global Services and Chief Financial Officer

February 24, 2012

## *Report of Independent Registered Public Accounting Firm*

### **The Board of Directors and Shareholders of Eli Lilly and Company**

We have audited the accompanying consolidated balance sheets of Eli Lilly and Company and subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of operations, cash flows, and comprehensive income for each of the three years in the period ended December 31, 2011. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Eli Lilly and Company and subsidiaries at December 31, 2011 and 2010, and the consolidated results of their operations and their cash flows for each of the three years in the period ended December 31, 2011, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Eli Lilly and Company and subsidiaries' internal control over financial reporting as of December 31, 2011, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 24, 2012 expressed an unqualified opinion thereon.

*Ernst + Young LLP*

Indianapolis, Indiana  
February 24, 2012

## *Report of Independent Registered Public Accounting Firm*

### **The Board of Directors and Shareholders of Eli Lilly and Company**

We have audited Eli Lilly and Company and subsidiaries' internal control over financial reporting as of December 31, 2011, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Eli Lilly and Company and subsidiaries' management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Eli Lilly and Company and subsidiaries maintained, in all material respects, effective internal control over financial reporting as of December 31, 2011, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the 2011 consolidated financial statements of Eli Lilly and Company and subsidiaries and our report dated February 24, 2012 expressed an unqualified opinion thereon.

*Ernst + Young LLP*

Indianapolis, Indiana  
February 24, 2012

## **Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

### **Item 9A. Controls and Procedures**

#### **Disclosure Controls and Procedures**

Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's "disclosure controls and procedures," which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-K) is recorded, processed, summarized, and reported on a timely basis.

Our management, with the participation of John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, and Derica W. Rice, executive vice president, global services and chief financial officer, evaluated our disclosure controls and procedures as of December 31, 2011, and concluded that they are effective.

#### **Internal Control over Financial Reporting**

Dr. Lechleiter and Mr. Rice provided a report on behalf of management on our internal control over financial reporting, in which management concluded that the company's internal control over financial reporting is effective at December 31, 2011. In addition, Ernst & Young LLP as of December 31, 2011, the company's independent registered public accounting firm, provided an attestation report on the company's internal control over financial reporting. You can find the full text of management's report and Ernst & Young's attestation report in Item 8, and both reports are incorporated by reference in this Item.

#### **Changes in Internal Controls**

During the fourth quarter of 2011, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We are pursuing a multi-year initiative to outsource some accounting transaction-processing activities, migrating to a consistent enterprise financial system across the organization, and moving certain activities to newly-established captive shared services centers. In addition, we are in the process of reducing financial human resources at various locations around the world. None of these initiatives is in response to any identified deficiency or weakness in our internal control over financial reporting. These initiatives are expected to continue to enhance our internal control over financial reporting, but in the short term may increase our risk.

### **Item 9B. Other Information**

Not applicable.

## **Part III**

### **Item 10. Directors, Executive Officers, and Corporate Governance**

#### **Directors and Executive Officers**

Information relating to our Board of Directors is found in our Proxy Statement to be dated on or about March 5, 2012 (the "Proxy Statement") under "Board of Directors" and is incorporated in this report by reference.

Information relating to our executive officers is found at Item 1 of this Form 10-K under "Executive Officers of the Company."

#### **Code of Ethics**

We have adopted a code of ethics that complies with the applicable SEC and New York Stock Exchange requirements. The code is set forth in:

- *The Red Book*, a comprehensive code of ethical and legal business conduct applicable to all employees worldwide and to our Board of Directors; and
- *Code of Ethical Conduct for Lilly Financial Management*, a supplemental code for our chief executive officer and all members of financial management that focuses on accounting, financial reporting, internal controls, and financial stewardship.

Both documents are online on our web site at <http://www.lilly.com/about/compliance/conduct>. In the event of any amendments to, or waivers from, a provision of the code affecting the chief executive officer, chief financial officer, chief accounting officer, controller, or persons performing similar functions, we intend to post on the above web site within four business days after the event a description of the amendment or waiver as required under applicable SEC rules. We will maintain that information on our web site for at least 12 months. Paper copies of these documents are available free of charge upon request to the company's secretary at the address on the front of this Form 10-K.

### Corporate Governance

In our proxy statements, we describe the procedures by which shareholders can recommend nominees to our board of directors. There have been no changes in those procedures since they were last published in our proxy statement of March 7, 2011.

The board has appointed an audit committee consisting entirely of independent directors in accordance with applicable SEC and New York Stock Exchange rules for audit committees. The members of the committee are Michael L. Eskew (chair), Martin S. Feldstein, R. David Hoover, Douglas R. Oberhelman, and Kathi P. Seifert. The board has determined that Messrs. Eskew, Hoover, and Oberhelman are audit committee financial experts as defined in the SEC rules.

## Item 11. Executive Compensation

Information on director compensation, executive compensation, and compensation committee matters can be found in the Proxy Statement under "Directors' Compensation", "Executive Compensation", and "Compensation Committee Interlocks and Insider Participation." That information is incorporated in this report by reference.

## Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

### Security Ownership of Certain Beneficial Owners and Management

Information relating to ownership of the company's common stock by management and by persons known by the company to be the beneficial owners of more than five percent of the outstanding shares of common stock is found in the Proxy Statement under "Ownership of Company Stock." That information is incorporated in this report by reference.

### Securities Authorized for Issuance Under Equity Compensation Plans

The following table presents information as of December 31, 2011, about our compensation plans under which shares of Lilly stock have been authorized for issuance.

Plan Category	(a) Number of securities to be issued upon exercise of outstanding options, warrants, and rights	(b) Weighted-average exercise price of outstanding options, warrants, and rights	(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in (a))
Equity compensation plans approved by security holders	35,951,135	\$66.07	93,041,299
Equity compensation plans not approved by security holders <sup>1</sup>	604,825	74.89	0
Total	36,555,960	66.22	93,041,299

<sup>1</sup> Represents shares in the Lilly GlobalShares Stock Plan, which permitted the company to grant stock options to non-management employees worldwide. The plan was administered by the senior vice president responsible for human resources. The stock options are nonqualified for U.S. tax purposes. The option price cannot be less than the fair market value at the time of grant. The options shall not exceed 11 years in duration and shall be subject to vesting schedules established by the plan administrator. There are provisions for early vesting and early termination of the options in the event of retirement, disability, and death. In the event of stock splits or other recapitalizations, the administrator may adjust the number of shares available for grant, the number of shares subject to outstanding grants, and the exercise price of outstanding grants.

## Item 13. Certain Relationships and Related Transactions, and Director Independence

### Related Person Transactions

Information relating to two related person transactions and the board's policies and procedures for approval of related person transactions can be found in the Proxy Statement under "Highlights of the Company's Corporate Governance Guidelines—Review and Approval of Transactions with Related Persons." That information is incorporated in this report by reference.

**Director Independence**

Information relating to director independence can be found in the Proxy Statement under “Highlights of the Company’s Corporate Governance Guidelines—Independence Determinations” and is incorporated in this report by reference.

**Item 14. Principal Accountant Fees and Services**

Information related to the fees and services of our principal independent accountants, Ernst & Young LLP, can be found in the Proxy Statement under “Services Performed by the Independent Auditor” and “Independent Auditor Fees.” That information is incorporated in this report by reference.

**Item 15. Exhibits and Financial Statement Schedules****(a)1. Financial Statements**

The following consolidated financial statements of the company and its subsidiaries are found at Item 8:

- Consolidated Statements of Operations—Years Ended December 31, 2011, 2010, and 2009
- Consolidated Statements of Comprehensive Income—Years Ended December 31, 2011, 2010, and 2009
- Consolidated Balance Sheets—December 31, 2011 and 2010
- Consolidated Statements of Cash Flows—Years Ended December 31, 2011, 2010, and 2009
- Segment Information
- Notes to Consolidated Financial Statements

**(a)2. Financial Statement Schedules**

The consolidated financial statement schedules of the company and its subsidiaries have been omitted because they are not required, are inapplicable, or are adequately explained in the financial statements.

Financial statements of interests of 50 percent or less, which are accounted for by the equity method, have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a significant subsidiary.

**(a)3. Exhibits**

- |       |   |
|-------|---|
| 2     | Agreement and Plan of Merger dated October 6, 2008, among Eli Lilly and Company, Alaska Acquisition Corporation and ImClone Systems Incorporated  |
| 3.1   | Amended Articles of Incorporation   |
| 3.2   | By-laws, as amended   |
| 4.1   | Form of Indenture with respect to Debt Securities dated as of February 1, 1991, between Eli Lilly and Company and Citibank, N.A., as Trustee  |
| 4.2   | Agreement dated September 13, 2007 appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed above  |
| 4.3   | Form of Standard Multiple-Series Indenture Provisions dated, and filed with the Securities and Exchange Commission on February 1, 1991  |
| 4.4   | Form of Fiscal Agency Agreement dated May 30, 2001, between Eli Lilly and Company and Citibank, N.A., Fiscal Agent, relating to Resetable Floating Rate Debt Security due 2037 <sup>1</sup> |
| 4.5   | Form of Resetable Floating Rate Debt Security due 2037 <sup>1</sup>   |
| 10.1  | 1998 Lilly Stock Plan, as amended <sup>2</sup>  |
| 10.2  | 2002 Lilly Stock Plan, as amended <sup>2</sup>  |
| 10.3  | Form of two-year Performance Award under the 2002 Lilly Stock Plan <sup>2</sup>   |
| 10.4  | Form of Shareholder Value Award under the 2002 Lilly Stock Plan <sup>2</sup>  |
| 10.5  | Form of Restricted Stock Unit under the 2002 Lilly Stock Plan <sup>2</sup>  |
| 10.6  | The Lilly Deferred Compensation Plan, as amended <sup>2</sup>   |
| 10.7  | The Lilly Directors’ Deferral Plan, as amended <sup>2</sup>   |
| 10.8  | The Eli Lilly and Company Bonus Plan, as amended <sup>2</sup>   |
| 10.9  | The Eli Lilly and Company Executive Officer Incentive Plan <sup>2</sup>   |
| 10.10 | 2007 Change in Control Severance Pay Plan for Select Employees, as amended effective October 20, 2010 <sup>2</sup>  |
| 10.11 | 2007 Change in Control Severance Pay Plan for Select Employees, as amended effective October 18, 2012 <sup>2</sup>  |

- 10.12 Arrangement regarding retirement benefits for Robert A. Armitage<sup>2</sup>
- 10.13 Arrangement regarding severance for Dr. Jan Lundberg<sup>2</sup>
- 10.14 Guilty Plea Agreement in *The United States District Court for the Eastern District of Pennsylvania, United States of America v. Eli Lilly and Company*
- 10.15 Settlement Agreement among the company and the United States of America, acting through the United States Department of Justice, Civil Division, and the United States Attorney's Office of the Eastern District of Pennsylvania, the Office of the Inspector General of the Department of Health and Human Services, TRICARE Management Activity, and the United States Office of Personnel Management, and certain individual relators
- 10.16 Corporate Integrity Agreement between the company and the Office of Inspector General of the Department of Health and Human Services
- 12 Statement re: Computation of Ratio of Earnings (Loss) to Fixed Charges
- 21 List of Subsidiaries
- 23 Consent of Independent Registered Public Accounting Firm
- 31.1 Rule 13a-14(a) Certification of John C. Lechleiter, Ph.D., Chairman of the Board, President, and Chief Executive Officer
- 31.2 Rule 13a-14(a) Certification of Derica W. Rice, Executive Vice President, Global Services and Chief Financial Officer
- 32 Section 1350 Certification
- 101 Interactive Data File

<sup>1</sup> This exhibit is not filed with this report. Copies will be furnished to the Securities and Exchange Commission upon request.

<sup>2</sup> Indicates management contract or compensatory plan.

### Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

*Eli Lilly and Company*

By /s/ John C. Lechleiter

*John C. Lechleiter, Ph.D.,*

Chairman of the Board, President, and Chief Executive Officer

February 24, 2012

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 24, 2012 by the following persons on behalf of the Registrant and in the capacities indicated.

Signature	Title
<u>/s/ John C. Lechleiter, Ph.D.</u> JOHN C. LECHLEITER, Ph.D.	Chairman of the Board, President, and Chief Executive Officer, and a Director (principal executive officer)
<u>/s/ Derica W. Rice</u> DERICA W. RICE	Executive Vice President, Global Services and Chief Financial Officer (principal financial officer)
<u>/s/ Arnold C. Hanish</u> ARNOLD C. HANISH	Vice President, Finance and Chief Accounting Officer (principal accounting officer)
<u>/s/ Ralph Alvarez</u> RALPH ALVAREZ	Director
<u>/s/ Katherine Baicker</u> KATHERINE BAICKER	Director
<u>/s/ Sir Winfried Bischoff</u> SIR WINFRIED BISCHOFF	Director
<u>/s/ Michael L. Eskew</u> MICHAEL L. ESKEW	Director
<u>/s/ Martin S. Feldstein, Ph.D.</u> MARTIN S. FELDSTEIN, Ph.D.	Director
<u>/s/ J. Erik Fyrwald</u> J. ERIK FYRWALD	Director
<u>/s/ Alfred G. Gilman, M.D., Ph.D.</u> ALFRED G. GILMAN, M.D., Ph.D.	Director
<u>/s/ R. David Hoover</u> R. DAVID HOOVER	Director
<u>/s/ Karen N. Horn, Ph.D.</u> KAREN N. HORN, Ph.D.	Director
<u>/s/ Ellen R. Marram</u> ELLEN R. MARRAM	Director
<u>/s/ Douglas R. Oberhelman</u> DOUGLAS R. OBERHELMAN	Director
<u>/s/ Franklyn G. Prendergast, M.D., Ph.D.</u> FRANKLYN G. PRENDERGAST, M.D., Ph.D.	Director
<u>/s/ Kathi P. Seifert</u> KATHI P. SEIFERT	Director



*into advances  
transforming challenges*

*Lilly*

Notice of 2012 Annual Meeting  
Proxy Statement



## 2012 Annual Meeting and Proxy Statement

March 5, 2012

Dear Shareholder:

You are cordially invited to attend our annual meeting of shareholders on Monday, April 16, 2012.

The notice of meeting and proxy statement that follow describe the business we will consider at the meeting. Your vote is very important. I urge you to vote by mail, by telephone, or on the Internet to be certain your shares are represented at the meeting, even if you plan to attend.

Please note the ticket at the back of this proxy statement and our procedures for admission to the meeting described under "Meeting and Voting Logistics" below.

I look forward to seeing you at the meeting.



John C. Lechleiter, Ph.D.  
Chairman, President, and Chief Executive Officer

---

**Important notice regarding the availability of proxy materials for the shareholder meeting to be held April 16, 2012:  
The annual report and proxy statement are available at <http://www.lilly.com/pdf/lillyar2011.pdf>**

---

## Notice of Annual Meeting of Shareholders

April 16, 2012

The annual meeting of shareholders of Eli Lilly and Company will be held at the Lilly Center Auditorium, Lilly Corporate Center, Indianapolis, Indiana, on Monday, April 16, 2012, at 11:00 a.m. EDT for the following purposes:

- to elect four directors of the company to serve three-year terms
- to ratify the appointment by the audit committee of Ernst & Young LLP as principal independent auditor for the year 2012
- to approve, by non-binding vote, compensation paid to the company's named executive officers
- to approve amendments to the articles of incorporation to provide for annual election of all directors
- to approve amendments to the articles of incorporation to eliminate all supermajority voting requirements
- to consider shareholder proposals on establishing a majority vote committee and transparency in animal research.

Shareholders of record at the close of business on February 15, 2012, will be entitled to vote at the meeting and at any adjournment of the meeting.

Attendance at the meeting will be limited to shareholders, those holding proxies from shareholders, and invited guests from the media and financial community. A page at the back of this report contains an admission ticket. If you plan to attend the meeting, please bring this ticket with you.

This combined proxy statement and annual report to shareholders is being posted online and mailed on or about March 5, 2012.

By order of the board of directors,

James B. Lootens  
Secretary

March 5, 2012  
Indianapolis, Indiana

## Proxy Statement Overview

### Annual Meeting of Shareholders

The annual meeting of shareholders will be held at 11:00 a.m. EDT on Monday, April 16, 2012 at:

The Lilly Center Auditorium  
Lilly Corporate Center  
Indianapolis, Indiana 46285

The board of directors of Eli Lilly and Company is soliciting proxies to be voted at the annual meeting and at any adjournment of the annual meeting. The record date for voting is February 15, 2012.

### Meeting Agenda

Shareholders will vote on the following items at the annual meeting:

Agenda Item		Management recommendation	Vote required to pass																									
<b>Item 1</b>	Elect the following nominees for director to serve a three-year term that will expire in 2015:	<b>Vote FOR all</b>	Majority of votes cast																									
	<table><thead><tr><th>Name and principal occupation</th><th>Joined the board</th><th>Age</th><th>Public boards</th><th></th></tr></thead><tbody><tr><td>Katherine Baicker, Ph.D. Professor of Health Economics, Harvard University</td><td>2011</td><td>40</td><td>—</td><td><b>Vote FOR</b></td></tr><tr><td>J. Erik Fyrwald President, Ecolab Inc.</td><td>2005</td><td>52</td><td>—</td><td><b>Vote FOR</b></td></tr><tr><td>Ellen R. Marram President, The Barnegat Group LLC</td><td>2002</td><td>65</td><td>Ford Motor Company The New York Times Company</td><td><b>Vote FOR</b></td></tr><tr><td>Douglas R. Oberhelman Chairman and Chief Executive Officer, Caterpillar Inc.</td><td>2008</td><td>59</td><td>Caterpillar Inc.</td><td><b>Vote FOR</b></td></tr></tbody></table>	Name and principal occupation	Joined the board	Age	Public boards		Katherine Baicker, Ph.D. Professor of Health Economics, Harvard University	2011	40	—	<b>Vote FOR</b>	J. Erik Fyrwald President, Ecolab Inc.	2005	52	—	<b>Vote FOR</b>	Ellen R. Marram President, The Barnegat Group LLC	2002	65	Ford Motor Company The New York Times Company	<b>Vote FOR</b>	Douglas R. Oberhelman Chairman and Chief Executive Officer, Caterpillar Inc.	2008	59	Caterpillar Inc.	<b>Vote FOR</b>		
Name and principal occupation	Joined the board	Age	Public boards																									
Katherine Baicker, Ph.D. Professor of Health Economics, Harvard University	2011	40	—	<b>Vote FOR</b>																								
J. Erik Fyrwald President, Ecolab Inc.	2005	52	—	<b>Vote FOR</b>																								
Ellen R. Marram President, The Barnegat Group LLC	2002	65	Ford Motor Company The New York Times Company	<b>Vote FOR</b>																								
Douglas R. Oberhelman Chairman and Chief Executive Officer, Caterpillar Inc.	2008	59	Caterpillar Inc.	<b>Vote FOR</b>																								
<b>Item 2</b>	Ratify the appointment of Ernst & Young as the company's principal independent auditor.	<b>Vote FOR</b>	Majority of votes cast																									
<b>Item 3</b>	Approve, by non-binding vote, compensation paid to the company's named executive officers.	<b>Vote FOR</b>	Majority of votes cast																									
<b>Item 4</b>	Approve amendments to the articles of incorporation to provide for annual election of all directors.	<b>Vote FOR</b>	80% of out-standing shares																									
<b>Item 5</b>	Approve amendments to the articles of incorporation to eliminate all supermajority voting requirements.	<b>Vote FOR</b>	80% of out-standing shares																									
<b>Item 6</b>	Consider a shareholder proposal on establishing a majority vote committee.	<b>Vote AGAINST</b>	Majority of votes cast																									
<b>Item 7</b>	Consider a shareholder proposal on transparency in animal research.	<b>Vote AGAINST</b>	Majority of votes cast																									

Additional information about these agenda items can be found under "Items of Business" and information on voting and attending the annual meeting can be found under "Meeting and Voting Logistics" below.

### Board of Directors

The company's board is comprised of our chairman, president, and CEO, John Lechleiter, Ph.D. and 13 independent directors. Their biographies and qualifications can be found under "Director Biographies" below.

### Committees of the board of directors

The board has six committees, all of which are staffed by independent directors. Additional information on the functioning of the board and its committees, including director independence, can be found beginning in the section titled "Highlights of the Company's Corporate Governance Guidelines" below.

### Director compensation

Our independent directors receive cash compensation in the form of an annual retainer (\$100,000), with additional annual amounts for the lead director (\$30,000), committee chairs (\$12,000 to \$18,000, depending on the committee), and directors who serve on the audit committee or the science and technology committee (\$3,000). In addition, each independent director receives \$145,000 in shares of company stock each year, payable after service on the board has ended. Additional information about director compensation can be found under "Director Compensation" below.

### **Contacting the board of directors**

You may send written communications to one or more members of the board, addressed to:

Board of Directors  
Eli Lilly and Company  
c/o Corporate Secretary  
Lilly Corporate Center  
Indianapolis, Indiana 46285

All such communications (from shareholders or other interested parties) will be forwarded to the relevant director(s), except for solicitations or other matters unrelated to the company.

### **Executive Compensation**

Our compensation philosophy is designed to attract and retain highly-talented individuals and motivate them to create long-term shareholder value by achieving top-tier corporate performance while embracing the company's values of integrity, excellence, and respect for people. Our programs seek to:

- closely link compensation with company performance and individual performance
- foster a long-term focus
- reflect the market for pharmaceutical talent
- be efficient and egalitarian
- appropriately mitigate risk.

For a detailed discussion of our executive compensation programs and how they reflect our philosophy and are linked to company performance, please read the "Compensation Discussion and Analysis" section of this proxy statement.

## Board of Directors



**Katherine Baicker, Ph.D.**

*Professor of Health Economics, Department of Health Policy and Management, Harvard University School of Public Health; and Research Associate, National Bureau of Economic Research*

Director since 2011

Board committee: public policy and compliance

**Michael L. Eskew**

*Former Chairman and Chief Executive Officer, United Parcel Service, Inc.*

Director since 2008

Board committees: audit (chair); compensation

**Sir Winfried Bischoff**

*Chairman, Lloyds Banking Group plc*

Director since 2000

Board committees: directors and corporate governance; finance (chair)

**Alfred G. Gilman, M.D., Ph.D.**

*Chief Scientific Officer, Cancer Prevention and Research Institute of Texas*

Director since 1995

Board committees: public policy and compliance; science and technology (chair)

**Karen N. Horn, Ph.D.**

*Retired President, Private Client Services, and Managing Director, Marsh, Inc.*

Director since 1987

Board committees: compensation (chair); directors and corporate governance

**Franklyn G. Prendergast, M.D., Ph.D.**

*Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School; and Director, Mayo Clinic Center for Individualized Medicine*

Director since 1995

Board committees: public policy and compliance; science and technology

**J. Erik Fyrwald**

*President, Ecolab Inc.*

Director since 2005

Board committees: public policy and compliance; science and technology



**R. David Hoover**

**John C. Lechleiter, Ph.D.**

**Douglas R. Oberhelman**

**Ellen R. Marram**

**Martin S. Feldstein, Ph.D.**

**Kathi P. Seifert**

**Ralph Alvarez**

*Chairman, Ball Corporation*

*Chairman, President, and Chief Executive Officer*

*Chairman and Chief Executive Officer, Caterpillar Inc.*

*President, The Barnegat Group LLC*

*George F. Baker Professor of Economics, Harvard University*

*Retired Executive Vice President, Kimberly-Clark Corporation*

*Retired President and Chief Operating Officer, McDonald's Corporation*

Director since 2009

Director since 2005

Director since 2008

Director since 2002

Director since 2002

Director since 1995

Director since 2009

Board committees: audit; compensation

Board committees: none

Board committees: audit; finance

Board committees: compensation; directors and corporate governance (chair)

Board committees: audit; finance; public policy and compliance (chair)

Board committees: audit; compensation

Board committees: finance; public policy and compliance; science and technology

## Director Biographies

### Class of 2012

The following five directors' terms will expire at this year's annual meeting. Dr. Feldstein will retire from the board at the end of his current term. Each of the other directors in this class has been nominated and is standing for election to serve a term that will expire in 2015. See "Item 1. Election of Directors" below for more information.

#### **Katherine Baicker, Ph.D.**

Age 40

Director since 2011

**Professor of Health Economics at the Harvard University School of Public Health, Department of Health Policy and Management; and Research Associate at the National Bureau of Economic Research**

Dr. Baicker has been a professor of health economics at the Department of Health Policy and Management, School of Public Health, since 2007. From 2005 to 2007, she served as a Senate-confirmed member of the Council of Economic Advisers. From 1998 to 2005, Dr. Baicker was assistant professor and associate professor of economics at Dartmouth College. In 2001 and 2002 she also served as an economist to the Council of Economic Advisers, Executive Office of the President, and in 2003 was a visiting assistant professor at the University of Chicago Harris School of Public Policy. Dr. Baicker is a commissioner of the Medicare Payment Advisory Board and serves on the Panel of Health Advisers to the Congressional Budget Office. She is a member of the editorial boards of *Health Affairs* and the *Journal of Health Economics*, chair of the board of directors of AcademyHealth, editor of the *Forum for Health Economics and Policy*, and associate editor of the *Journal of Economic Perspectives*. She is an elected member of the Institute of Medicine. Dr. Baicker has been serving under interim election since December 2011.

**Qualifications:** Dr. Baicker is a leading researcher in the fields of health economics, public economics, and labor economics. As a valued advisor to numerous health care-related commissions and committees, her expertise in health care policy and health care delivery is recognized by both academia and government.

**Board committee:** public policy and compliance

#### **Martin S. Feldstein, Ph.D.**

Age 72

Director since 2002

**George F. Baker Professor of Economics, Harvard University**

Dr. Feldstein is the George F. Baker Professor of Economics at Harvard University and president emeritus of the National Bureau of Economic Research. From 1982 through 1984, he served as chairman of the Council of Economic Advisers and President Ronald Reagan's chief economic adviser. Dr. Feldstein served as president and chief executive officer of the National Bureau of Economic Research from 1977 to 1982 and 1984 to 2008. In 2009, President Obama appointed him to the President's Economic Recovery Advisory Board. He is a member of the American Philosophical Society, a corresponding fellow of the British Academy, a fellow of the Econometric Society, and a fellow of the National Association for Business Economics. Dr. Feldstein is a trustee of the Council on Foreign Relations and a member of the Trilateral Commission, the Group of 30, the American Academy of Arts and Sciences, and the Council of Academic Advisors of the American Enterprise Institute, as well as past president of the American Economic Association. He previously served on the boards of American International Group, Inc., TRW, Phoenix Life Insurance, and HCA Inc.

**Qualifications:** Dr. Feldstein is a renowned economist, academic, and adviser to U.S. presidents of both political parties. He has deep economic and public policy expertise, financial acumen, and a global perspective. His background as an academic brings a diversity of experience and perspective to the board's deliberations. He has also served on the boards of several major public companies.

**Board committees:** audit; finance; public policy and compliance (chair)

**J. Erik Fyrwald**

Age 52

Director since 2005

**President of Ecolab Inc.**

J. Erik Fyrwald is president of Ecolab Inc. Prior to the merger of Ecolab and Nalco Company in December 2011, Mr. Fyrwald was chairman and chief executive officer of Nalco from 2008 to 2011. He joined Nalco following a 27-year career at DuPont. From 2003 to 2008, Mr. Fyrwald served as group vice president of the agriculture and nutrition division at DuPont. From 2000 until 2003, he was vice president and general manager of DuPont's nutrition and health business. At DuPont, he held a broad variety of assignments in a number of divisions covering many industries. He has worked in several locations throughout North America and Asia. Mr. Fyrwald serves as a director of the Society of Chemical Industry, the American Chemistry Council, and the Chicago Public Education Fund, and is a trustee of the Field Museum of Chicago.

**Qualifications:** Mr. Fyrwald has a strong record of operational and strategy leadership in two complex worldwide businesses with a focus on technology and innovation. An engineer by training, he has extensive senior executive experience at DuPont, a multinational chemical company, where he led the agriculture and nutrition division, which used chemical and biotechnology solutions to enhance plant health. He served for three years as chairman of the board and CEO of Nalco, a global technology-based water products and services company.

**Board committees:** public policy and compliance; science and technology

**Ellen R. Marram**

Age 65

Director since 2002

**President, The Barnegat Group LLC**

Ms. Marram will serve as the board's lead director beginning April 2012. Ms. Marram is the president of The Barnegat Group LLC, a firm that provides business advisory services. She was a managing director at North Castle Partners, LLC from 2000 to 2005 and served as an advisor to the firm from 2006 to 2010. From 1993 to 1998, Ms. Marram was president and chief executive officer of Tropicana and the Tropicana Beverage Group. From 1988 to 1993, she was president and chief executive officer of the Nabisco Biscuit Company, the largest operating unit of Nabisco, Inc.; from 1987 to 1988, she was president of Nabisco's grocery division; and from 1970 to 1986, she held a series of marketing positions at Nabisco/Standard Brands, Johnson & Johnson, and Lever Brothers. Ms. Marram is a member of the board of directors of Ford Motor Company and The New York Times Company, as well as several private companies. She previously served on the board of Cadbury plc. She also serves on the boards of Wellesley College, Institute for the Future, New York-Presbyterian Hospital, Lincoln Center Theater, and Families and Work Institute.

**Qualifications:** Ms. Marram is a former CEO with a strong marketing and consumer-brand background. Through her nonprofit and private company activities, she has a special focus and expertise in wellness and consumer health. Ms. Marram has extensive corporate governance experience through service on other public company boards in a variety of industries.

**Board committees:** compensation; directors and corporate governance (chair)

**Douglas R. Oberhelman**

Age 59

Director since 2008

**Chairman and Chief Executive Officer, Caterpillar Inc.**

Mr. Oberhelman has been chairman of the board of Caterpillar Inc. since November 2010 and chief executive officer since July 2010. He previously served as vice chairman and chief executive officer-elect of Caterpillar. He joined Caterpillar in 1975 and has held a variety of positions, including senior finance representative based in South America for Caterpillar Americas Co., region finance manager and district manager for the company's North American commercial division, and managing director and vice general manager for strategic planning at Caterpillar Japan Ltd. Mr. Oberhelman was elected a vice president in 1995, serving as Caterpillar's chief financial officer from 1995 to November 1998. In 1998, he became vice president with responsibility for the engine products division and he was elected a group president and member of Caterpillar's executive office in 2002. Mr. Oberhelman serves on the boards of Caterpillar, the National Association of Manufacturers, and the Wetlands America Trust. He previously served on the board of Ameren Corporation. He is a member of the Executive Committee of the Business Roundtable and a member of the Business Council.

**Qualifications:** Mr. Oberhelman has a strong strategic and operational background as a senior executive (and currently as chairman and CEO) of Caterpillar, a leading manufacturing company with worldwide operations and a special focus on emerging markets. He is an audit committee financial expert as a result of his prior experience as CFO of Caterpillar and as a member and chairman of the audit committee of another U.S. public company.

**Board committees:** audit; finance

## Class of 2013

The following five directors will continue in office until 2013.

### Ralph Alvarez

Age 56

Director since 2009

#### Retired President and Chief Operating Officer, McDonald's Corporation

Mr. Alvarez served as president and chief operating officer of McDonald's Corporation from August 2006 until December 2009. Previously, he served as president of McDonald's North America, with responsibility for all the McDonald's restaurants in the U.S. and Canada. Prior to that, he was president of McDonald's USA. Mr. Alvarez joined McDonald's in 1994 and held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald's USA, and president of McDonald's Mexico. Prior to joining McDonald's, he held leadership positions at Burger King Corporation and Wendy's International, Inc. Mr. Alvarez serves on the board of directors of Lowe's Companies, Inc. He also serves on the President's Council, the School of Business Administration Board of Overseers, and the International Advisory Board of the University of Miami. He was previously a member of the boards of McDonald's Corporation and KeyCorp.

**Qualifications:** Through his senior executive positions at McDonald's Corporation and other global restaurant businesses, Mr. Alvarez has extensive experience in consumer marketing, global operations, international business, and strategic planning. His international experience includes a special focus on emerging markets.

**Board committees:** finance; public policy and compliance; science and technology

### Sir Winfried Bischoff

Age 70

Director since 2000

#### Chairman, Lloyds Banking Group plc

Sir Winfried Bischoff has been chairman of the board of Lloyds Banking Group plc since September 2009. He served as chairman of Citigroup Inc. from December 2007 until February 2009 and as interim chief executive officer for a portion of 2007. He served as chairman of Citigroup Europe from 2000 to 2009. From 1995 to 2000, he was chairman of Schroders plc. He joined the Schroder Group in 1966 and held a number of positions there, including chairman of J. Henry Schroder & Co. and group chief executive of Schroders plc. He is also a director of The McGraw-Hill Companies, Inc. He previously served on the boards of Citigroup Inc., Prudential plc, Land Securities plc, and Akbank T.A.S.

**Qualifications:** Sir Winfried Bischoff has a distinguished career in banking and finance, including commercial banking, corporate finance, and investment banking. He has CEO experience both in Europe and the U.S. He is a globalist, with particular expertise in European matters but with extensive experience overseeing worldwide operations. He has broad corporate governance experience from his service on public company boards in the U.S., UK, and other European and Asian countries.

**Board committees:** directors and corporate governance; finance (chair)

### R. David Hoover

Age 66

Director since 2009

#### Chairman, Ball Corporation

Mr. Hoover is chairman of Ball Corporation. Mr. Hoover joined Ball Corporation in 1970 and has held a variety of leadership roles throughout his career, including vice president and treasurer; executive vice president and chief financial officer; vice chairman, president, and chief operating officer; and chairman, president, and chief executive officer. He is a member of the boards of Ball Corporation and Energizer Holdings, Inc. Mr. Hoover previously served on the board of Irwin Financial Corporation. He is a member and past chair of the board of trustees of DePauw University and on the Indiana University Kelley School of Business Dean's Council. He is also a director of Boulder Community Hospital and a member of the Colorado Forum.

**Qualifications:** Mr. Hoover has extensive CEO experience at Ball Corporation, with a strong record of leadership in operations and strategy. He is an audit committee financial expert as a result of his experience as CEO and CFO of Ball. He also has extensive corporate governance experience through his service on other public company boards.

**Board committees:** audit; compensation

**Franklyn G. Prendergast, M.D., Ph.D.**

Age 66

Director since 1995

**Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School; and Director, Mayo Clinic Center for Individualized Medicine**

Dr. Prendergast is the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics at Mayo Medical School and the director of the Mayo Clinic Center for Individualized Medicine. He has held several other teaching positions at the Mayo Medical School since 1975.

**Qualifications:** Dr. Prendergast is a prominent medical clinician, researcher, and academician. He has extensive experience in senior-most administration at Mayo Clinic, a major medical institution, and as director of its renowned cancer center. He has special expertise in two critical areas for Lilly—oncology and personalized medicine. As a medical doctor, he brings an important practicing-physician perspective to the board's deliberations.

**Board committees:** public policy and compliance; science and technology

**Kathi P. Seifert**

Age 62

Director since 1995

**Retired Executive Vice President, Kimberly-Clark Corporation**

Ms. Seifert served as executive vice president for Kimberly-Clark Corporation until June 2004. She joined Kimberly-Clark in 1978 and served in several capacities in connection with both the domestic and international consumer-products businesses. Prior to joining Kimberly-Clark, Ms. Seifert held management positions at Procter & Gamble, Beatrice Foods, and Fort Howard Paper Company. She is chairman of Katapult, LLC. Ms. Seifert serves on the boards of Supervalu Inc.; Revlon Consumer Products Corporation; Lexmark International, Inc.; Appleton Papers Inc.; the U.S. Fund for UNICEF; and the Fox Cities Performing Arts Center.

**Qualifications:** Ms. Seifert is a retired senior executive of Kimberly-Clark, a global consumer products company. She has strong expertise in consumer marketing and brand management, having led sales and marketing for several worldwide brands, with a special focus on consumer health. She has extensive corporate governance experience through her other board positions.

**Board committees:** audit; compensation

**Class of 2014**

The following four directors will continue in office until 2014.

**Michael L. Eskew**

Age 62

Director since 2008

**Former Chairman and Chief Executive Officer, United Parcel Service, Inc.**

Mr. Eskew served as chairman and chief executive officer of United Parcel Service, Inc., from January 2002 until December 2007. He continues to serve on the UPS board of directors. Mr. Eskew began his UPS career in 1972 as an industrial engineering manager and held various positions of increasing responsibility, including time with UPS's operations in Germany and with UPS Airlines. In 1993, Mr. Eskew was named corporate vice president for industrial engineering. Two years later he became group vice president for engineering. In 1998, he was elected to the UPS board of directors. In 1999, Mr. Eskew was named executive vice president and a year later was given the additional title of vice chairman. He serves as chairman of the board of trustees of The Annie E. Casey Foundation. Mr. Eskew also serves on the boards of 3M Corporation and IBM Corporation.

**Qualifications:** Mr. Eskew has CEO experience with UPS, where he established a record of success in managing complex worldwide operations, strategic planning, and building a strong consumer-brand focus. He is an audit committee financial expert, based on his CEO experience and his service on other U.S. company audit committees. He has extensive corporate governance experience through his service on the boards of other companies.

**Board committees:** audit (chair); compensation

**Alfred G. Gilman, M.D., Ph.D.**

Age 70

Director since 1995

**Chief Scientific Officer, Cancer Prevention and Research Institute of Texas**

Dr. Gilman is the chief scientific officer of the Cancer Prevention and Research Institute of Texas and regental professor of pharmacology emeritus at the University of Texas Southwestern Medical Center at Dallas. Dr. Gilman was on the faculty of the University of Virginia School of Medicine from 1971 to 1981 and was named a professor of pharmacology there in 1977. He previously served as executive vice president for academic affairs and provost of the University of Texas Southwestern Medical Center at Dallas, dean of the University of Texas Southwestern Medical School, and professor of pharmacology at the University of Texas Southwestern Medical Center. He held the Raymond and Ellen Willie Distinguished Chair of Molecular Neuropharmacology; the Nadine and Tom Craddock Distinguished Chair in Medical Science; and the Atticus James Gill, M.D., Chair in Medical Science at the university and was named a regental professor in 1995. He is a director of Regeneron Pharmaceuticals, Inc. Dr. Gilman was a recipient of the Nobel Prize in Physiology or Medicine in 1994.

**Qualifications:** Dr. Gilman is a Nobel Prize-winning pharmacologist, researcher, and professor. He has deep expertise in basic science, including mechanisms of drug action, and experience with pharmaceutical discovery research. As the former dean of a major medical school, he brings to the board important perspectives of both the academic and practicing medical communities.

**Board committees:** public policy and compliance; science and technology (chair)

**Karen N. Horn, Ph.D.**

Age 68

Director since 1987

**Retired President, Private Client Services, and Managing Director, Marsh, Inc.**

Ms. Horn will serve as the board's lead director until April 2012. She served as president of private client services and managing director of Marsh, Inc. from 1999 until her retirement in 2003. Prior to joining Marsh, she was senior managing director and head of international private banking at Bankers Trust Company; chairman and chief executive officer of Bank One, Cleveland, N.A.; president of the Federal Reserve Bank of Cleveland; treasurer of Bell Telephone Company of Pennsylvania; and vice president of First National Bank of Boston. Ms. Horn serves as director of T. Rowe Price Mutual Funds; Simon Property Group, Inc.; and Norfolk Southern Corporation and vice chairman of the U.S. Russia Foundation. She previously served on the board of Fannie Mae and Georgia-Pacific Corporation. Ms. Horn has been senior managing director of Brock Capital Group since 2004.

**Qualifications:** Ms. Horn is a former CEO with extensive experience in various segments of the financial industry, including banking and financial services. Through her for-profit and her public-private partnership work, she has significant experience in international economics and finance. Ms. Horn has extensive corporate governance experience through service on other public company boards in a variety of industries.

**Board committees:** compensation (chair); directors and corporate governance

**John C. Lechleiter, Ph.D.**

Age 58

Director since 2005

**Chairman, President, and Chief Executive Officer**

Dr. Lechleiter is chairman, president, and chief executive officer of Eli Lilly and Company. He served as president and chief operating officer from 2005 to 2008. He joined Lilly in 1979 as a senior organic chemist and has held management positions in England and the U.S. He was named vice president of pharmaceutical product development in 1993 and vice president of regulatory affairs in 1994. In 1996, he was named vice president for development and regulatory affairs. Dr. Lechleiter became senior vice president of pharmaceutical products in 1998 and executive vice president for pharmaceutical products and corporate development in 2001. He was named executive vice president for pharmaceutical operations in 2004. He is a member of the American Chemical Society and the Business Roundtable. Dr. Lechleiter serves as chairman-elect of Pharmaceutical Research and Manufacturers of America (PhRMA), and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the board of Nike, Inc.

**Qualifications:** Dr. Lechleiter is our chairman, president, and chief executive officer. Under our corporate governance guidelines, the CEO is expected to serve on the board of directors. Dr. Lechleiter, a Ph.D. chemist, has over 30 years of experience with the company in a variety of roles of increasing responsibility in research and development, sales and marketing, and corporate administration. As a result, he has a deep understanding of pharmaceutical research and development, sales and marketing, strategy, and operations. He also has significant corporate governance experience through service on other public company boards.

**Board committees:** none

## *Highlights of the Company's Corporate Governance Guidelines*

The following summary provides highlights of the company's guidelines established by the board of directors. A complete copy of the guidelines is available online at <http://investor.lilly.com/governance.cfm> or in paper form upon request to the company's corporate secretary.

### **I. Role of the Board**

The directors are elected by the shareholders to oversee the actions and results of the company's management. Their responsibilities include:

- providing general oversight of the business
- approving corporate strategy
- approving major management initiatives
- providing oversight of legal and ethical conduct
- overseeing the company's management of significant business risks
- selecting, compensating, and evaluating directors
- evaluating board processes and performance
- selecting, compensating, evaluating, and, when necessary, replacing the chief executive officer, and compensating other senior executives
- ensuring that a succession plan is in place for all senior executives.

### **II. Composition of the Board**

#### **Mix of Independent Directors and Officer-Directors**

There should always be a substantial majority (75 percent or more) of independent directors. The chief executive officer should be a board member. Other officers may, from time to time, be board members, but no officer other than the chief executive officer should expect to be elected to the board by virtue of his or her position in the company.

#### **Selection of Director Candidates**

The board selects candidates for board membership and establishes the criteria to be used in identifying potential candidates. The board delegates the screening process to the directors and corporate governance committee. For more information on the director nomination process, including the current selection criteria, see "Directors and Corporate Governance Committee Matters."

#### **Independence Determinations**

The board annually determines the independence of directors based on a review by the directors and corporate governance committee. No director is considered independent unless the board has determined that he or she has no material relationship with the company, either directly or as a partner, significant shareholder, or officer of an organization that has a material relationship with the company. Material relationships can include commercial, industrial, banking, consulting, legal, accounting, charitable, and familial relationships, among others. To evaluate the materiality of any such relationship, the board has adopted categorical independence standards consistent with the New York Stock Exchange (NYSE) listing standards, except that the "look-back period" for determining whether a director's prior relationship with the company impairs independence is extended from three to four years.

Specifically, a director is not considered independent if (i) the director or an immediate family member is a current partner of the company's independent auditor (currently Ernst & Young LLP); (ii) the director is a current employee of such firm; (iii) the director has an immediate family member who is a current employee of such firm and who participates in the firm's audit, assurance, or tax compliance (but not tax planning) practice; or (iv) the director or an immediate family member was within the last four years (but is no longer) a partner or employee of such firm and personally worked on our audit within that time.

In addition, a director is not considered independent if any of the following relationships existed within the previous four years:

- a director who is an employee of the company, or whose immediate family member is an executive officer of the company. Temporary service by an independent director as interim chairman or chief executive officer will not disqualify the director from being independent following completion of that service.
- a director who receives any direct compensation from the company other than the director's normal director compensation, or whose immediate family member receives more than \$120,000 per year in direct compensation from the company other than for service as a nonexecutive employee.

- a director who is employed (or whose immediate family member is currently employed as an executive officer) by another company where any Lilly executive officer serves on the compensation committee of that company's board.
- a director who is currently employed by, who is a 10 percent shareholder of, or whose immediate family member is currently employed as an executive officer of a company that makes payments to or receives payments from Lilly for property or services that exceed the greater of \$1 million or 2 percent of that company's consolidated gross revenue in a single fiscal year.
- a director who is a current executive officer of a nonprofit organization that receives grants or contributions from the company exceeding the greater of \$1 million or 2 percent of that organization's consolidated gross revenue in a single fiscal year.

Members of board committees must meet all applicable independence tests of the NYSE, Securities and Exchange Commission (SEC), and Internal Revenue Service (IRS).

The directors and corporate governance committee determined that all 13 nonemployee directors listed below are independent, and that the members of each committee also meet the independence standards referenced above. The committee recommended this conclusion to the board and explained the basis for its decision, and this conclusion was adopted by the board. The committee and the board determined that none of the 13 directors has had during the last four years (i) any of the relationships listed above or (ii) any other material relationship with the company that would compromise his or her independence. In reaching this conclusion, the directors and corporate governance committee reviewed directors' responses to a questionnaire asking about their relationships with the company and other potential conflicts of interest, as well as information provided by management related to transactions, relationships, or arrangements between the company and the directors or parties related to the directors. The table below includes a description of categories or types of transactions, relationships, or arrangements considered by the board in reaching its determinations. All of these transactions were entered into at arm's length in the normal course of business and, to the extent they are commercial relationships, have standard commercial terms. None of these transactions exceeded the thresholds described above or otherwise compromises the independence of the named directors.

Name	Independent	Transactions/Relationships/Arrangements
Mr. Alvarez	Yes	None
Dr. Baicker	Yes	Payments to Harvard University totalling approximately \$2.3 million (less than 0.1 percent of Harvard's consolidated gross revenue), primarily for medical research
Sir Winfried Bischoff	Yes	None
Mr. Eskew	Yes	None
Dr. Feldstein	Yes	Payments to Harvard University totalling approximately \$2.3 million (less than 0.1 percent of Harvard's consolidated gross revenue), primarily for medical research
Mr. Fyrwald	Yes	Purchases of products and services from Ecolab totalling approximately \$1.0 million (less than 0.1 percent of Ecolab's consolidated gross revenue)
Dr. Gilman	Yes	None
Mr. Hoover	Yes	None
Ms. Horn	Yes	None
Ms. Marram	Yes	None
Mr. Oberhelman	Yes	None
Dr. Prendergast	Yes	Payments to the Mayo Clinic and the Mayo Foundation totalling approximately \$2.2 million (less than 0.1 percent of Mayo's consolidated gross revenue), primarily for medical research
Ms. Seifert	Yes	None

### Director Tenure

Subject to the company's charter documents, the following are the board's expectations for director tenure:

- A company officer-director, including the chief executive officer, will resign from the board at the time he or she retires or otherwise ceases to be an active employee of the company.
- Nonemployee directors will retire from the board not later than the annual meeting of shareholders that follows their seventy-second birthday.
- Directors may stand for reelection even though the board's retirement policy would prevent them from completing a full three-year term.
- A nonemployee director who retires or changes principal job responsibilities will offer to resign from the board. The directors and corporate governance committee will assess the situation and recommend to the board whether to accept the resignation.
- The directors and corporate governance committee also considers the contributions of individual directors at least every three years when considering whether to recommend nominating the director to a new three-year term.

### **Other Board Service**

Effective November 1, 2009, no new director may serve on more than three other public company boards, and no incumbent director may accept new positions on public company boards that would result in service on more than three other public company boards. The directors and corporate governance committee or the chair of that committee may approve exceptions to this limit upon a determination that such additional service will not impair the director's effectiveness on the board.

### **Voting for Directors**

In an uncontested election, any nominee for director who fails to receive a majority of the votes cast shall promptly tender his or her resignation following certification of the shareholder vote. The directors and corporate governance committee will consider the resignation offer and recommend to the board whether to accept it. The board will act on the committee's recommendation within 90 days following certification of the shareholder vote. Board action on the matter will require the approval of a majority of the independent directors.

The company will disclose the board's decision on a Form 8-K within four business days after the decision, including a full explanation of the process by which the decision was reached and, if applicable, the reasons why the board rejected the director's resignation. If the resignation is accepted, the directors and corporate governance committee will recommend to the board whether to fill the vacancy or reduce the size of the board.

Any director who tenders his or her resignation under this provision will not participate in the committee or board deliberations regarding the resignation offer. If all members of the directors and corporate governance committee fail to receive a majority of the votes cast at the same election, the independent directors who did receive a majority of the votes cast will appoint a committee amongst themselves to consider the resignation offers and recommend to the board whether to accept them.

### **III. Director Compensation and Equity Ownership**

The directors and corporate governance committee annually reviews board compensation. Any recommendations for changes are made to the board by the committee.

Directors should hold meaningful equity ownership positions in the company; accordingly, a significant portion of director compensation is in the form of Lilly stock. Directors are required to hold Lilly stock valued at not less than five times their annual cash retainer; new directors are allowed five years to reach this ownership level.

### **IV. Key Board Responsibilities**

#### **Selection of Chairman and Chief Executive Officer; Succession Planning**

The board currently combines the role of chairman of the board with the role of chief executive officer, coupled with a lead director position to further strengthen the governance structure. The board believes this provides an efficient and effective leadership model for the company. Combining the chairman and CEO roles fosters clear accountability, effective decision-making, and alignment on corporate strategy. To assure effective independent oversight, the board has adopted a number of governance practices, including:

- a strong, independent, clearly-defined lead director role (see below for a full description of the role)
- executive sessions of the independent directors after every regular board meeting
- annual performance evaluations of the chairman and CEO by the independent directors.

However, no single leadership model is right for all companies and at all times. Depending on the circumstances, other leadership models, such as a separate independent chairman of the board, might be appropriate. Accordingly, the board periodically reviews its leadership structure.

The lead director recommends to the board an appropriate process by which a new chairman and CEO will be selected. The board has no required procedure for executing this responsibility because it believes that the most appropriate process will depend on the circumstances surrounding each such decision.

A key responsibility of the CEO and the board is ensuring that an effective process is in place to provide continuity of leadership over the long term. Each year, succession-planning reviews culminate in a detailed review of top leadership talent by the compensation committee and a summary review by the independent directors as a whole. During this review, the CEO and the independent directors discuss future candidates for senior leadership positions, succession timing, and development plans for the highest-potential candidates.

In addition, the CEO maintains in place at all times, and reviews with the independent directors, a confidential plan for the timely and efficient transfer of his or her responsibilities in the event of an emergency or his or her sudden departure, incapacitation, or death.

#### **Evaluation of Chief Executive Officer**

The lead director is responsible for leading the independent directors in executive session to assess the performance of the chief executive officer at least annually. The results of this assessment are reviewed with the chief

executive officer and considered by the compensation committee in establishing the chief executive officer's compensation for the next year.

### **Corporate Strategy**

Once each year, the board devotes an extended meeting with senior management to discuss the strategic issues and opportunities facing the company, allowing the board an opportunity to provide direction for the corporate strategic plan. These strategy sessions also provide the board an opportunity to interact extensively with the company's senior leadership team. This assists the board in its succession-management responsibilities.

Throughout the year, significant corporate strategy decisions are brought to the board in a timely way for its consideration.

### **Code of Ethics**

The board approves the company's code of ethics. This code is set out in:

- *The Red Book*, a comprehensive code of ethical and legal business conduct applicable to all employees worldwide and to our board of directors
- *Code of Ethical Conduct for Lilly Financial Management*, a supplemental code for our chief executive officer and all members of financial management that recognizes the unique responsibilities of those individuals in assuring proper accounting, financial reporting, internal controls, and financial stewardship.

Both documents are available online at <http://www.lilly.com/about/compliance/conduct/> or in paper form upon request to the company's corporate secretary.

The audit committee and public policy and compliance committee assist in the board's oversight of compliance programs with respect to matters covered in the code of ethics.

### **Risk Oversight**

The company has an enterprise risk management program overseen by its chief ethics and compliance officer and senior vice president of enterprise risk management, who reports directly to the CEO and is a member of the company's top leadership committee. Enterprise risks are identified and prioritized by management, and the top prioritized risks are assigned to a board committee or the full board for oversight. For example, strategic risks are typically overseen by the full board; financial risks are overseen by the audit or finance committee; compliance and reputational risks are typically overseen by the public policy and compliance committee; and scientific risks are overseen by the science and technology committee. Management periodically reports on each such risk to the relevant committee or the board. The enterprise risk management program as a whole is reviewed annually at a joint meeting of the audit and public policy and compliance committees, and enterprise risks are also addressed at the annual board strategy session. Additional review or reporting on enterprise risks is conducted as needed or as requested by the board or committee. Also, the compensation committee periodically reviews the most important enterprise risks to ensure that compensation programs do not encourage excessive risk-taking. The board's role in the oversight of risk had no effect on the board's leadership structure.

## **V. Functioning of the Board**

### **Executive Sessions of Directors**

The independent directors meet alone in executive session and in private session with the CEO at every regularly scheduled board meeting.

### **Lead Director**

The board annually appoints a lead director from among the independent directors. Currently the lead director is Ms. Horn, but effective in April 2012, Ms. Marram will become lead director. The board has no set policy for rotation of the lead director role but believes that periodic rotation is appropriate. The lead director:

- leads the board's processes for selecting and evaluating the CEO;
- presides at all meetings of the board at which the chairman is not present, including executive sessions of the independent directors unless the directors decide that, due to the subject matter of the session, another independent director should preside;
- serves as a liaison between the chairman and the independent directors;
- approves meeting agendas and schedules and generally approves information sent to the board;
- has the authority to call meetings of the independent directors; and
- has the authority to retain advisors to the independent directors.

## Conflicts of Interest

Occasionally a director's business or personal relationships may give rise to an interest that conflicts, or appears to conflict, with the interests of the company. Directors must disclose to the company all relationships that create a conflict or an appearance of a conflict. The board, after consultation with counsel, takes appropriate steps to identify actual or apparent conflicts and ensure that all directors voting on an issue are disinterested. A director will be excused from discussions on the issue, as appropriate.

To avoid any conflict or appearance of a conflict, board decisions on certain matters of corporate governance are made solely by the independent directors. These include executive compensation and the selection, evaluation, and removal of the CEO.

## Review and Approval of Transactions with Related Persons

The board has adopted a written policy and written procedures for review, approval, and monitoring of transactions involving the company and related persons (directors and executive officers, their immediate family members, or shareholders of 5 percent or greater of the company's outstanding stock). The policy covers any related-person transaction that meets the minimum threshold for disclosure in the proxy statement under the relevant SEC rules (generally, transactions involving amounts exceeding \$120,000 in which a related person has a direct or indirect material interest).

- *Policy.* Related-person transactions must be approved by the board or by a committee of the board consisting solely of independent directors, who will approve the transaction only if they determine that it is in the best interests of the company. In considering the transaction, the board or committee will consider all relevant factors, including:

- the company's business rationale for entering into the transaction;
- the alternatives to entering into a related-person transaction;
- whether the transaction is on terms comparable to those available to third parties, or in the case of employment relationships, to employees generally;
- the potential for the transaction to lead to an actual or apparent conflict of interest and any safeguards imposed to prevent such actual or apparent conflicts; and
- the overall fairness of the transaction to the company.

The board or relevant committee will periodically monitor the transaction to ensure that there are no changed circumstances that would render it advisable for the company to amend or terminate the transaction.

- *Procedures.*
  - Management or the affected director or executive officer will bring the matter to the attention of the chairman, the lead director, the chair of the directors and corporate governance committee, or the secretary.
  - The chairman and the lead director shall jointly determine (or, if either is involved in the transaction, the other shall determine in consultation with the chair of the directors and corporate governance committee) whether the matter should be considered by the board or by one of its existing committees consisting only of independent directors.
  - If a director is involved in the transaction, he or she will be recused from all discussions and decisions about the transaction.
  - The transaction must be approved in advance whenever practicable, and if not practicable, must be ratified as promptly as practicable.
  - The board or relevant committee will review the transaction annually to determine whether it continues to be in the company's best interests.

The board has approved only the following related-party transactions. Dr. John Bamforth, senior director, global cardiovascular and urology, Lilly Bio-Medicines, is the spouse of Dr. Susan Mahony, senior vice president and president, Lilly Oncology, and has been employed by the company for over 20 years. In 2011, he was paid approximately \$390,000 in cash compensation, and he received grants under the company's performance-based equity program valued at approximately \$56,000 based upon the fair value computed in accordance with stock-based compensation accounting rules (FASB ASC Topic 718). Similarly, Mr. Myles O'Neill, senior vice president, global drug products, is the spouse of Dr. Fionnuala Walsh, senior vice president, global quality, and has been employed by the company for approximately 10 years. His cash compensation in 2011 was approximately \$450,000 and his equity grants were valued at approximately \$130,000. Both Dr. Bamforth and Mr. O'Neill participate in the company's benefit programs generally available to U.S. employees, and their compensation was established in accordance with the company's compensation practices applicable to employees with equivalent qualifications and responsibilities and holding similar positions.

### **Orientation of New Directors; Director Education**

A comprehensive orientation process is in place for new directors. In addition, directors receive ongoing continuing education through educational sessions at meetings, the annual strategy retreat, and periodic communications between meetings. We hold periodic mandatory training sessions for the audit committee, to which other directors and executive officers are invited. We also afford directors the opportunity to attend external director education programs.

### **Director Access to Management and Independent Advisors**

Independent directors have direct access to members of management whenever they deem it necessary. The company's executive officers attend at least part of each regularly scheduled board meeting. The independent directors and committees are also free to retain their own independent advisors, at company expense, whenever they feel it would be desirable to do so. In accordance with NYSE listing standards, the audit, compensation, and directors and corporate governance committees have sole authority to retain independent advisors to their respective committees.

### **Assessment of Board Processes and Performance**

The directors and corporate governance committee annually assesses the performance of the board, its committees, and board processes based on inputs from all directors.

## *Committees of the Board of Directors*

### **Number, Structure, and Independence**

The duties and membership of the six board-appointed committees are described below. Only independent directors may serve on the committees.

Committee membership and selection of committee chairs are recommended to the board by the directors and corporate governance committee after consulting the chairman of the board and after considering the backgrounds, skills, and desires of the board members. The board has no set policy for rotation of committee members or chairs but annually reviews committee memberships and chair positions, seeking the best blend of continuity and fresh perspectives on the committees.

### **Functioning of Committees**

Each committee reviews and approves its own charter annually, and the directors and corporate governance committee reviews and approves all committee charters annually. The chair of each committee determines the frequency and agenda of committee meetings. In addition, the audit, compensation, and public policy and compliance committees meet alone in executive session on a regular basis; all other committees meet in executive session as needed.

All six committee charters are available online at <http://investor.lilly.com/governance.cfm>.

### **Audit Committee**

The duties of the audit committee are described in the "Audit Committee Report" below.

### **Compensation Committee**

The duties of the compensation committee are described in the "Compensation Committee Matters" section, and the "Compensation Committee Report" below.

### **Directors and Corporate Governance Committee**

The duties of the directors and corporate governance committee are described in the "Directors and Corporate Governance Committee Matters" section below.

### **Finance Committee**

The finance committee reviews and makes recommendations regarding capital structure and strategies, including dividends, stock repurchases, capital expenditures, investments, financings and borrowings, financial risk management, and significant business-development projects.

### **Public Policy and Compliance Committee**

The public policy and compliance committee:

- oversees the processes by which the company conducts its business so that the company will do so in a manner that complies with laws and regulations and reflects the highest standards of integrity
- reviews and makes recommendations regarding policies, practices, and procedures of the company that relate to public policy and social, political, and economic issues.

### Science and Technology Committee

The science and technology committee:

- reviews and makes recommendations regarding the company’s strategic research goals and objectives
- reviews new developments, technologies, and trends in pharmaceutical research and development
- oversees matters of scientific and medical integrity and risk management.

### Membership and Meetings of the Board and Its Committees

In 2011, each director attended more than 82 percent of the total number of meetings of the board and the committees on which he or she serves. In addition, all board members are expected to attend the annual meeting of shareholders, and all the directors attended in 2011. Current committee membership and the number of meetings of the board and each committee in 2011 are shown in the table below.

Name	Board	Audit	Compensation	Directors and Corporate Governance	Finance	Public Policy and Compliance	Science and Technology
Mr. Alvarez	Member				Member	Member	Member
Dr. Baicker	Member					Member	
Sir Winfried Bischoff	Member			Member	Chair		
Mr. Eskew	Member	Chair	Member				
Dr. Feldstein	Member	Member			Member	Chair	
Mr. Fyrwald	Member					Member	Member
Dr. Gilman	Member					Member	Chair
Mr. Hoover	Member	Member	Member				
Ms. Horn	Lead Director		Chair	Member			
Dr. Lechleiter	Chair						
Ms. Marram <sup>1</sup>	Member		Member	Chair			
Mr. Oberhelman	Member	Member			Member		
Dr. Prendergast	Member					Member	Member
Ms. Seifert	Member	Member	Member				
Number of 2011 Meetings	10	11	7	6	7	8	7

<sup>1</sup> Ms. Marram will take over as lead director in April 2012.

## Director Compensation

Director compensation is reviewed and approved annually by the board, on the recommendation of the directors and corporate governance committee. Directors who are employees receive no additional compensation for serving on the board or its committees.

### Cash Compensation

In 2011, the company provided nonemployee directors with an annual retainer of \$100,000 (payable in monthly installments). In addition, certain board roles receive additional annual retainers:

- \$3,000 for audit committee and science and technology committee members
- \$12,000 for committee chairs (\$18,000 for audit committee chair and \$15,000 for science and technology committee chair)
- \$30,000 for the lead director.

Directors are reimbursed for customary and usual travel expenses.

### Stock Compensation

Stock compensation for nonemployee directors consists of shares of company stock equaling \$145,000, deposited annually in a deferred stock account in the Lilly Directors' Deferral Plan (as described below), payable after service on the board has ended.

### Lilly Directors' Deferral Plan

This plan allows nonemployee directors to defer receipt of all or part of their cash compensation until after their service on the board has ended. Each director can choose to invest the funds in one or both of two accounts:

- *Deferred Stock Account.* This account allows the director, in effect, to invest his or her deferred cash compensation in company stock. In addition, the annual award of shares to each director noted above (3,990 shares in 2011) is credited to this account on a pre-set annual date. Funds in this account are credited as hypothetical shares of company stock based on the market price of the stock at the time the compensation would otherwise have been earned. Hypothetical dividends are "reinvested" in additional shares based on the market price of the stock on the date dividends are paid. Actual shares are issued or transferred after the director ends his or her service on the board.
- *Deferred Compensation Account.* Funds in this account earn interest each year at a rate of 120 percent of the applicable federal long-term rate, compounded monthly, as established the preceding December by the U.S. Treasury Department under Section 1274(d) of the Internal Revenue Code. The aggregate amount of interest that accrued in 2011 for the participating directors was \$155,178, at a rate of 4.2 percent. The rate for 2012 is 3.3 percent.

Both accounts may be paid in a lump sum or in annual installments for up to 10 years, beginning the second January following the director's departure from the board. Amounts in the deferred stock account are paid in shares of company stock.

## Director Compensation

In 2011, we provided the following compensation to directors who are not employees:

Name	Fees Earned or Paid in Cash (\$) <sup>1</sup>	Stock Awards (\$) <sup>2</sup>	All Other Compensation and Payments (\$) <sup>3</sup>	Total (\$) <sup>4</sup>
Mr. Alvarez	\$107,500	\$145,000	\$0	\$252,500
Dr. Baicker	\$8,333	—	\$0	\$8,333
Sir Winfried Bischoff	\$112,000	\$145,000	\$0	\$257,000
Mr. Eskew	\$121,000	\$145,000	\$0	\$266,000
Dr. Feldstein	\$115,000	\$145,000	\$18,000	\$278,000
Mr. Fyrwald	\$103,000	\$145,000	\$15,000	\$263,000
Dr. Gilman	\$118,000	\$145,000	\$12,000	\$275,000
Mr. Hoover	\$107,500	\$145,000	\$30,000	\$282,500
Ms. Horn	\$142,000	\$145,000	\$6,575	\$293,575
Ms. Marram	\$112,000	\$145,000	\$30,000	\$287,000
Mr. Oberhelman	\$107,500	\$145,000	\$25,000	\$277,500
Dr. Prendergast	\$103,000	\$145,000	\$0	\$248,000
Ms. Seifert	\$103,000	\$145,000	\$4,150	\$252,150

<sup>1</sup> In 2011, Mr. Hoover deferred \$107,500 in cash compensation into his deferred stock account (2,921 shares) under the “Lilly Directors’ Deferral Plan” (further described above).

<sup>2</sup> Each nonemployee director received an award of stock valued at \$145,000 (3,990 shares). This stock award and all prior stock awards are fully vested in that they are not subject to forfeiture; however, the shares are not issued until the director ends his or her service on the board, as further described above under “Lilly Directors’ Deferral Plan.” The column shows the grant date fair value for each director’s stock award. Aggregate outstanding stock awards are shown in the “Common Stock Ownership by Directors and Executive Officers” table in the “Directors’ Deferral Plan Shares” column. Aggregate outstanding stock options as of December 31, 2011 are shown in the table below. Nonemployee directors received no stock options in 2011. The company discontinued granting stock options to nonemployee directors in 2005. All outstanding stock options are currently under water, meaning they have no realizable value.

Name	Outstanding Stock Options (Exercisable)	Weighted Average Exercise Price
Mr. Alvarez	—	—
Dr. Baicker	—	—
Sir Winfried Bischoff	8,400	\$68.96
Mr. Eskew	—	—
Dr. Feldstein	8,400	\$68.96
Mr. Fyrwald	—	—
Dr. Gilman	8,400	\$68.96
Mr. Hoover	—	—
Ms. Horn	8,400	\$68.96
Ms. Marram	5,600	\$65.48
Mr. Oberhelman	—	—
Dr. Prendergast	8,400	\$68.96
Ms. Seifert	8,400	\$68.96

<sup>3</sup> This column consists of amounts donated by the Eli Lilly and Company Foundation, Inc. under its matching gift program, which is generally available to U.S. employees as well as the outside directors. Under this program, the foundation matched 100 percent of charitable donations over \$25 made to eligible charities, up to a maximum of \$30,000 per year for each individual. The foundation matched these donations via payments made directly to the recipient charity.

<sup>4</sup> Directors do not participate in a company pension plan or non-equity incentive plan.

## *Directors and Corporate Governance Committee Matters*

### **Overview**

The directors and corporate governance committee recommends to the board candidates for membership on the board and board committees and for lead director. The committee also oversees matters of corporate governance, including board performance, director independence and compensation, and the corporate governance guidelines. The committee's charter is available online at <http://investor.lilly.com/governance.cfm> or in paper form upon request to the company's corporate secretary.

All committee members are independent as defined in the NYSE listing requirements.

### **Director Qualifications**

The board seeks independent directors who represent a mix of backgrounds and experiences that will enhance the quality of the board's deliberations and decisions. Candidates shall have substantial experience with one or more publicly-traded national or multinational companies or shall have achieved a high level of distinction in their chosen fields.

Board membership should reflect diversity in its broadest sense, including persons diverse in geography, gender, and ethnicity. The board is particularly interested in maintaining a mix that includes the following backgrounds:

- active or retired chief executive officers and senior executives, particularly those with experience in operations, finance, accounting, banking, marketing, and sales
- international business
- medicine and science
- government and public policy
- health care system (public or private).

Finally, board members should display the personal attributes necessary to be an effective director: unquestioned integrity; sound judgment; independence in fact and mindset; ability to operate collaboratively; and commitment to the company, its shareholders, and other constituencies.

Our board members represent a desirable mix of backgrounds, skills, and experiences, and they all share the personal attributes of effective directors described above. The board monitors the effectiveness of this approach via an annual internal board assessment as well as ongoing director succession planning discussions by the directors and corporate governance committee. Specific experiences and skills of our independent directors are included in "Director Biographies" above.

### **Director Nomination Process**

The board delegates the screening process to the directors and corporate governance committee, which receives direct input from other board members. Potential candidates are identified through recommendations from several sources, including:

- incumbent directors
- management
- shareholders
- independent executive search firms that may be retained by the committee to assist in locating and screening candidates meeting the board's selection criteria.

The committee employs the same process for evaluating all candidates, including those submitted by shareholders. The committee initially evaluates a candidate based on publicly available information and any additional information supplied by the party recommending the candidate. If the candidate appears to satisfy the selection criteria and the committee's initial evaluation is favorable, the committee, assisted by management or the search firm, gathers additional data on the candidate's qualifications, availability, probable level of interest, and any potential conflicts of interest. If the committee's subsequent evaluation continues to be favorable, the candidate is contacted by the chairman of the board and one or more of the independent directors for direct discussions to determine the mutual levels of interest in pursuing the candidacy. If these discussions are favorable, the committee makes a final recommendation to the board to nominate the candidate for election by the shareholders (or to select the candidate to fill a vacancy, as applicable). Dr. Baicker, who is standing for election, was referred to the committee by an independent incumbent director.

### **Process for Submitting Recommendations and Nominations**

A shareholder who wishes to recommend a director candidate for evaluation by the committee should forward the candidate's name and information about the candidate's qualifications to the chair of the directors and corporate governance committee, in care of the corporate secretary, at Lilly Corporate Center, Indianapolis, Indiana 46285. The candidate must meet the selection criteria described above and must be willing and expressly interested in serving on the board.

Under Section 1.9 of the company's bylaws, a shareholder who wishes to directly nominate a director candidate at the 2013 annual meeting (i.e., to propose a candidate for election who is not otherwise nominated by the board through the recommendation process described above) must give the company written notice by November 5, 2012 and no earlier than September 6, 2012. The notice should be addressed to the corporate secretary at Lilly Corporate Center, Indianapolis, Indiana 46285. The notice must contain prescribed information about the candidate and about the shareholder proposing the candidate as described in more detail in Section 1.9 of the bylaws. A copy of the bylaws is available online at <http://investor.lilly.com/governance.cfm>. The bylaws will also be provided by mail without charge upon request to the corporate secretary.

## *Audit Committee Matters*

### **Audit Committee Membership**

All members of the audit committee are independent as defined in the SEC regulations and NYSE listing standards applicable to audit committee members. The board of directors has determined that Mr. Eskew, Mr. Hoover, and Mr. Oberhelman are audit committee financial experts, as defined in the rules of the SEC.

### **Audit Committee Report**

The audit committee ("we" or "the committee") reviews the company's financial reporting process on behalf of the board. Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls and disclosure controls. In this context, we have met and held discussions with management and the independent auditor. Management represented to us that the company's consolidated financial statements were prepared in accordance with generally accepted accounting principles (GAAP), and we have reviewed and discussed the audited financial statements and related disclosures with management and the independent auditor, including a review of the significant management judgments underlying the financial statements and disclosures.

The independent auditor reports to us. We have sole authority to appoint and to replace the independent auditor.

We have discussed with the independent auditor matters required to be discussed by Statement on Auditing Standards No. 61 (Communication with Audit Committees), as amended and as adopted by the Public Company Accounting Oversight Board (PCAOB) in Rule 3200T, including the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, and the clarity of the disclosures in the financial statements. In addition, we have received the written disclosures and the letter from the independent auditor required by applicable requirements of the PCAOB regarding communications with the audit committee concerning independence, and have discussed with the independent auditor the auditor's independence from the company and its management. In concluding that the auditor is independent, we determined, among other things, that the nonaudit services provided by Ernst & Young LLP (as described below) were compatible with its independence. Consistent with the requirements of the Sarbanes-Oxley Act of 2002, we have adopted policies to avoid compromising the independence of the independent auditor, such as prior committee approval of nonaudit services and required audit partner rotation.

We discussed with the company's internal and independent auditors the overall scope and plans for their respective audits, including internal control testing under Section 404 of the Sarbanes-Oxley Act. We periodically meet with the internal and independent auditors, with and without management present, and in private sessions with members of senior management (such as the chief financial officer and the chief accounting officer) to discuss the results of their examinations, their evaluations of the company's internal controls, and the overall quality of the company's financial reporting. We also periodically meet in executive session.

In reliance on the reviews and discussions referred to above, we recommended to the board (and the board subsequently approved the recommendation) that the audited financial statements be included in the company's annual report on Form 10-K for the year ended December 31, 2011, for filing with the SEC. We have also appointed the company's independent auditor, subject to shareholder ratification, for 2012.

## Audit Committee

Michael L. Eskew, Chair  
Martin S. Feldstein, Ph.D.  
R. David Hoover  
Douglas R. Oberhelman  
Kathi P. Seifert

## Services Performed by the Independent Auditor

The audit committee preapproves all services performed by the independent auditor, in part to assess whether the provision of such services might impair the auditor's independence. The committee's policy and procedures are as follows:

- The committee approves the annual **audit services** engagement and, if necessary, any changes in terms, conditions, and fees resulting from changes in audit scope, company structure, or other matters. Audit services include internal controls attestation work under Section 404 of the Sarbanes-Oxley Act. The committee may also preapprove other audit services, which are those services that only the independent auditor reasonably can provide.
- **Audit-related services** are assurance and related services that are reasonably related to the performance of the audit, and that are traditionally performed by the independent auditor. The committee believes that the provision of these services does not impair the independence of the auditor.
- **Tax services.** The committee believes that, in appropriate cases, the independent auditor can provide tax compliance services, tax planning, and tax advice without impairing the auditor's independence.
- The committee may approve **other services** to be provided by the independent auditor if (i) the services are permissible under SEC and PCAOB rules, (ii) the committee believes the provision of the services would not impair the independence of the auditor, and (iii) management believes that the auditor is the best choice to provide the services.
- **Process.** At the beginning of each audit year, management requests prior committee approval of the annual audit, statutory audits, and quarterly reviews for the upcoming audit year as well as any other engagements known at that time. Management will also present at that time an estimate of all fees for the upcoming audit year. As specific engagements are identified thereafter, they are brought forward to the committee for approval. To the extent approvals are required between regularly scheduled committee meetings, preapproval authority is delegated to the committee chair.

For each engagement, management provides the committee with information about the services and fees, sufficiently detailed to allow the committee to make an informed judgment about the nature and scope of the services and the potential for the services to impair the independence of the auditor.

After the end of the audit year, management provides the committee with a summary of the actual fees incurred for the completed audit year.

## Independent Auditor Fees

The following table shows the fees incurred for services rendered on a worldwide basis by the company's independent auditor in 2011 and 2010. All such services were preapproved by the committee in accordance with the preapproval policy.

	2011 (millions)	2010 (millions)
Audit Fees	\$9.1	\$8.7
• Annual audit of consolidated and subsidiary financial statements, including Sarbanes-Oxley 404 attestation		
• Reviews of quarterly financial statements		
• Other services normally provided by the auditor in connection with statutory and regulatory filings		
Audit-Related Fees	\$1.3	\$0.8
• Assurance and related services reasonably related to the performance of the audit or reviews of the financial statements		
— 2011 and 2010: primarily related to employee benefit plan and other ancillary audits, and due diligence services on potential and completed acquisitions		
Tax Fees	\$2.9	\$0.9
• 2011 and 2010: primarily related to consulting and compliance services		
All Other Fees	\$0.9	\$0.1
• 2011: primarily related to integration services for an acquisition		
• 2010: primarily related to compliance services outside the U.S.		
Total	\$14.2	\$10.5

## Compensation Committee Matters

### Scope of Authority

The compensation committee oversees the company's global compensation philosophy and establishes the compensation of executive officers. The committee also acts as the oversight committee with respect to the company's deferred compensation plans, management stock plans, and other management incentive compensation programs. The committee may delegate authority to company officers for day-to-day plan administration and interpretation, including selecting participants, determining award levels within plan parameters, and approving award documents. However, the committee may not delegate any authority for matters affecting the executive officers.

### The Committee's Processes and Procedures

The committee's primary processes for establishing and overseeing executive compensation can be found in the "Compensation Discussion and Analysis" section under "The Committee's Processes and Analyses" below. Additional processes and procedures include:

- *Meetings.* The committee meets several times each year (7 times in 2011). Committee agendas are approved by the committee chair in consultation with the committee's independent compensation consultant. The committee meets in executive session after each meeting.
- *Role of independent consultant.* The committee has retained Cimi B. Silverberg of Frederic W. Cook & Co., Inc., as its independent compensation consultant to assist the committee. Ms. Silverberg reports directly to the committee, and neither she nor her firm is permitted to perform any services for management. The consultant's duties include the following:
  - review committee agendas and supporting materials in advance of each meeting and raise questions with the company's global compensation group and the committee chair as appropriate
  - review the company's total compensation philosophy, peer group, and target competitive positioning for reasonableness and appropriateness
  - review the company's executive compensation program and advise the committee of plans or practices that might be changed in light of evolving best practices
  - provide independent analyses and recommendations to the committee on the CEO's pay
  - review draft "Compensation Discussion and Analysis" and related tables for the proxy statement
  - proactively advise the committee on best practices for board governance of executive compensation
  - undertake special projects at the request of the committee chair.

The consultant interacts directly with members of company management only on matters under the committee's oversight and with the knowledge and permission of the committee chair.

- *Role of executive officers and management.* With the oversight of the CEO and the senior vice president of human resources, the company's global compensation group formulates recommendations on compensation philosophy, plan design, and the specific compensation recommendations for executive officers (other than the CEO, as noted below). The CEO gives the committee a performance assessment and compensation recommendation for each of the other executive officers. The committee considers those recommendations with the assistance of its compensation consultant. The CEO and the senior vice president of human resources attend committee meetings but are not present for executive sessions or for any discussion of their own compensation. (Only non-employee directors and the committee's consultant attend executive sessions.)

The CEO normally does not participate in the formulation or discussion of his pay recommendations; however, as he did for the past two years, Dr. Lechleiter requested that no increases be made to his base salary or incentive targets for 2012. The CEO has no prior knowledge of the recommendations that the consultant makes to the committee.

- *Risk assessment.* With the help of its compensation consultant, in 2011 the committee reviewed the company's compensation policies and practices for all employees, including executive officers. The committee concluded that the company's compensation programs will not have a material adverse effect on the company, after reviewing the business risks identified in the annual enterprise risk management assessment process. The committee noted several design features of the company's cash and equity incentive programs that reduce the likelihood of inappropriate risk-taking:
  - cash and equity and short-term and long-term incentive compensation are balanced
  - incentive plans include a range of payout opportunities below and above target
  - incentive payouts are capped at appropriate levels
  - multiple measures/goals and different measurement periods are used across our incentive plans
  - company performance targets and individual incentive payment targets are set using multiple inputs

- a blend of internal and external measures is used across multiple incentive plans
- the cost of incentive program payouts is included when determining payout results
- performance objectives are appropriately difficult
- the bonus program has a continuum of payout levels for individual performance
- meaningful share ownership requirements exist for all members of senior management.

The committee concluded that, for all employees, the company's compensation programs do not encourage excessive risk and instead encourage behaviors that support sustainable value creation.

#### **Compensation Committee Interlocks and Insider Participation**

None of the compensation committee members:

- has ever been an officer or employee of the company
- is or was a participant in a related-person transaction in 2011 (see "Review and Approval of Transactions with Related Persons" for a description of our policy on related-person transactions)
- is an executive officer of another entity, at which one of our executive officers serves on the board of directors.


# Compensation Discussion and Analysis

## Summary

Executive compensation for 2011 aligned well with the objectives of our compensation philosophy and with our performance, driven by these factors:

- The company exceeded corporate goals for revenue and earnings per share (EPS) as well as pipeline progress. Strong revenues of \$24.3 billion against a goal of \$23.2 billion and adjusted non-GAAP earnings per share (EPS) of \$4.36 against a goal of \$4.31 demonstrated good operational performance, as the company entered a challenging era of significant patent expirations. The pipeline also progressed well, with approvals of Tradjenta®, Bydureon®, and Cialis® for the treatment of benign prostatic hyperplasia, as well as several other milestones, five new molecular entities entered Phase III, and 61 percent of project milestones were met or accelerated. As a result, the annual cash incentive bonus paid out at 125 percent of target.
- Two-year EPS growth fell in the middle range of our peer companies. Three-year stock price growth to \$38.64 was under our target of \$39.50. For the 2010-2011 Performance Award (PA), the annual cumulative compounded EPS growth rate was 9.0 percent, resulting in a payout of 109 percent of target to all participants. The company's 2009-2011 Shareholder Value Award (SVA) fell short of its target payout price of \$39.50; as a result, awards granted to executive officers and all other participants paid at 80 percent of target.

- Highlights:**
- With the expiration of the Zyprexa® patent, the company enters a period of patent expirations
  - Very strong performance in advancing the pipeline
  - New bonus metrics include a pipeline progress metric and sales and EPS growth measured against corporate goals
  - No increase to CEO salary or incentive targets for 2010, 2011, or 2012



- A balanced program fosters employee achievement, retention, and engagement. We delivered a total compensation package composed of salary, performance-based cash and equity incentives, and a competitive employee benefits program. We implemented new bonus-plan metrics to drive innovation and retain and motivate employees during the next few years of patent expirations and business challenges. The new bonus metrics measure our revenue, EPS, and pipeline performance against internal goals. At the same time, we retained the external metrics of EPS growth versus our peers and stock price performance versus expected large-cap returns for our equity program. Together these elements reinforced pay-for-performance, provided balance between short- and long-term performance and between internal and external metrics, and encouraged employee retention and engagement.

In addition:

- *No increase in CEO target compensation since 2009.* As he did for the past two years, and in light of the business challenges the company currently faces, Dr. Lechleiter requested, and the compensation committee approved, no increases to his 2012 salary or incentive targets.
- *The compensation committee reviewed the connection between compensation and risk.* The committee reviewed our compensation programs and policies for features that may encourage excessive risk taking and found the overall program to be sound.

## The Committee's Processes and Analyses

### Linking Business Strategy and Compensation Program Design

At Lilly, we aim to discover, develop, and acquire innovative new therapies—medicines that make a real difference for patients and deliver clear value for payers. In addition, we must continually improve productivity in all that we do. To achieve these goals, we must attract, engage, and retain highly-talented individuals who are committed to the company's core values of integrity, excellence, and respect for people. Our compensation and benefits programs are based on these objectives:

#### Executive Compensation Philosophy:

- *Individual and company performance*
- *Long-term focus*
- *Consideration of both internal relativity and competitive pay*
- *Efficient and egalitarian*

- *Reflect individual and company performance.* We link employees' pay to individual and company performance.

—As employees assume greater responsibilities, more of their pay is linked to company performance and shareholder returns through increased participation in equity programs.

—We seek to deliver above-market compensation given top-tier individual and company performance, but below-market compensation where individual performance falls short of expectations or company performance lags the industry.

—Our 2011 incentive programs used a combination of corporate financial goals and a pipeline metric (annual bonus), relative EPS growth as measured against the performance of our peer companies (PA), and TSR growth as measured by stock price goals (SVA). We design our programs to be simple and clear, so that employees can understand how their efforts affect their pay.

—We balance the objectives of pay-for-performance and employee retention. Even during downturns in company performance, the program should continue to motivate and engage successful, high-achieving employees.

- *Foster a long-term focus.* In our industry, long-term focus is critical to success and is consistent with our goal of retaining highly-talented employees as they build their careers. A competitive benefits program aids retention. As employees progress to higher levels of the organization, a greater portion of compensation is tied to long-term performance through our equity programs.
- *Provide compensation consistent with the level of job responsibility and reflective of the market.* We seek internal pay relativity, meaning that pay differences among jobs should be commensurate with differences in job responsibility and impact. In addition, the committee compares the company's programs with a peer group of global pharmaceutical companies. Pharmaceutical companies' needs for scientific and sales and marketing talent are unique to the industry and we compete with these companies for talent.
- *Provide efficient and egalitarian compensation.* We seek to deliver superior long-term shareholder returns and to share value created with employees in a cost-effective manner. While the amount of compensation reflects differences in job responsibilities, geographies, and marketplace considerations, the overall structure of compensation and benefits programs should be broadly similar across the organization.
- *Appropriately mitigate risk.* The compensation committee reviews the company's compensation policies and practices annually and works with management to ensure that program design does not inadvertently create inappropriate incentives.
- *Shareholder input.* In establishing 2012 compensation, the committee considered the shareholder vote in 2011 on the compensation paid to named executive officers—more than 88 percent in favor. The committee viewed this vote as supportive of the company's overall approach to executive compensation.

### Setting Compensation

The compensation committee uses several tools to set compensation targets that meet company objectives. Among those are:

- *Assessment of individual performance.* Individual performance has a strong impact on compensation.
  - The independent directors, under the direction of the lead director, meet with the CEO at the beginning of the year to agree upon the CEO's performance objectives for the year. At the end of the year, the independent directors meet with the CEO and in executive session to assess the CEO's performance based on his achievement of the objectives, contribution to the company's performance, ethics and integrity, and

other leadership accomplishments. This evaluation is shared with the CEO by the lead director and is used by the compensation committee in setting the CEO's compensation for the following year.

—For the other executive officers, the committee receives performance assessments and compensation recommendations from the CEO and also exercises its judgment based on the board's interactions with the executive officers. As with the CEO, an executive officer's performance assessment is based on his or her achievement of objectives established between the executive officer and the CEO, contribution to the company's performance, ethics and integrity, and other leadership attributes and accomplishments.

- *Assessment of company performance.* The committee considers company performance measures in two ways:
  - In establishing total compensation ranges, the committee uses as a reference the performance of the company and the public companies in its peer group with respect to revenue, EPS, return on assets, and 1- and 5-year TSR.
  - The committee establishes specific company performance goals that determine payouts under the company's cash and equity incentive programs.
- *Peer-group analysis.* The committee reviews peer-group data as a market check for compensation decisions, but does not base compensation targets on peer-group data only.
  - Overall competitiveness.* The committee uses aggregated market data as a reference point to ensure that executive compensation is competitive, meaning within the broad middle range of comparative pay at peer companies when the company achieves the targeted performance levels. The committee does not target a specific position within the range.
  - Individual competitiveness.* The committee compares the overall pay of individual executives if the jobs are sufficiently similar to make the comparison meaningful. The individual's pay is driven primarily by individual and company performance and internal relativity; the peer-group data is used as a market check to ensure that individual pay remains within the broad middle range of peer-group pay. The committee does not target a specific position within the range.

#### Compensation Considerations:

- Individual metrics
- Company metrics
- Peer-group analysis
- External advisor
- Internal relativity

The peer group consists of Abbott Laboratories; Amgen Inc.; AstraZeneca plc; Baxter International, Inc.; Bristol-Myers Squibb Company; Genzyme Corporation (prior to its acquisition by Sanofi-Aventis); GlaxoSmithKline plc; Hoffmann-La Roche Inc.; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi-Aventis; and Takeda Pharmaceuticals Company. The committee reviews the peer group for appropriateness at least every three years, and the committee considered the current peer group at the end of 2010 when considering 2011 compensation opportunities. The peer companies are direct competitors for our products, operate in a similar business model, and employ people with the unique skills required to operate an established biopharmaceutical company. The committee also considers market cap and revenue as measures of size. With the exception of Johnson & Johnson and Pfizer, peer companies were no greater than three times our size with regard to both measures. The committee included Johnson & Johnson and Pfizer despite their size because both compete directly with Lilly for management and scientific talent.

- *CEO compensation.* To provide further assurance of independence, the compensation recommendation for the CEO is developed by the committee's independent consultant with limited support from company staff. The consultant prepares analyses showing competitive CEO compensation among the peer group for the individual elements of compensation and total direct compensation. Normally, the consultant develops a range of recommendations for any change in the CEO's base salary, annual cash incentive target, equity grant value, and equity mix. The CEO has no prior knowledge of the recommendations and normally takes no part in the recommendations, committee discussions, or decisions. For 2011, no such recommendation was prepared, since Dr. Lechleiter requested that no increases be made to his base salary or incentive targets. He made the same request for 2012, as he had for 2010 and 2011, and the committee granted this request for all three years.

## Executive Compensation for 2011

### Overview

In setting target compensation for 2011, the committee reviewed 2010 individual and company performance and peer-group data as discussed above, and also considered expected competitive trends in executive pay. That review included:

- *Company performance.* In 2010, the company performed in the upper tier of the peer group in revenue growth, in the middle tier in non-GAAP EPS growth and one-year TSR, and in the lower tier in five-year TSR. Company performance against corporate operating goals was at target for revenue growth, net cash flow, and pipeline progress. Growth in EPS, return on assets, and operating income per employee exceeded corporate goals.
- *Individual performance.* As described above under "Setting Compensation," base salary increases were driven largely by individual performance assessments. In assessing the 2010 performance of executive officers, the independent directors (for the CEO) and the compensation committee (with regard to all executive officers) considered the company's and the executive officer's accomplishment of objectives established at the beginning of the year and their own subjective assessment of the executive officer's performance.

—In assessing Dr. Lechleiter's performance, the independent directors noted that under Dr. Lechleiter's leadership in 2010, the company:

- delivered strong revenue growth (6 percent actual vs. 2.5 percent expected industry growth) and earnings growth that exceeded analysts' expectations for the company
- effectively reorganized into four pharmaceutical business areas plus Elanco Animal Health, supported by a new global services organization
- made measurable progress toward the goals of eliminating 5,500 positions and \$1 billion in costs by the end of 2011
- continued to demonstrate progress in the development of molecules in its late-stage pipeline, with 8 potential medicines in Phase III testing by the end of the year.

The committee also noted Dr. Lechleiter's continued leadership in the implementation of the company's Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services and his efforts to reinforce ethics and compliance across the company. Dr. Lechleiter was an active public advocate for the company and the industry. In addition, he strengthened key practices within the company for talent development and succession management.


Despite Dr. Lechleiter's strong performance, the committee agreed with Dr. Lechleiter's request that his base salary and incentive plan targets not be increased for 2011.

- Dr. Lundberg had a strong first full year in his position. He demonstrated decisive leadership in moving the pipeline forward, simplifying LRL governance, prioritizing research projects, and closing or repurposing underutilized facilities, and he collaborated very effectively with the business units.
- Mr. Rice's responsibilities expanded in 2010 to include IT and Six Sigma®. He led the transformation of the financial component and the creation and implementation of the global services organization. He provided important contributions to the company's strategic decision making and served effectively as CFO.
- Mr. Carmine reorganized the sales and marketing functions and collaborated effectively with other business unit leaders. Lilly Biomedicines operating results exceeded target. Mr. Carmine retired from the company on December 31, 2011.
- Mr. Armitage provided outstanding support to his internal clients and continued industry leadership in external influence regarding intellectual property matters. The legal organization helped achieve positive outcomes in key patent litigation (wins for Alimta, Strattera, and Evista; a loss for Gemzar).
- *Pay relative to peer group.* The company's total compensation to executive officers, in the aggregate, for 2010 was in the broad middle range of the peer group.

The committee determined the following:

- *Program elements.* The 2011 program consisted of base salary, a cash incentive bonus, and two forms of performance-based equity grants: PAs and SVAs. Executives also received the company employee benefits package. This total compensation program balances the mix of cash and equity compensation, the mix of current and longer-term compensation, the mix of financial and market goals, and the security of foundational benefits in a way that furthers the compensation objectives discussed above.
- *Targets.* The company generally maintained pay ranges and a balance of pay elements similar to 2010. The committee believes this overall program continues to provide cost-effective delivery of total compensation that:
  - encourages employee retention and engagement by delivering competitive cash and equity components
  - maintains a strong link to company performance and shareholder returns through a balanced equity incentive program without encouraging excessive risk-taking
  - maintains appropriate internal pay relativity
  - provides opportunity for total pay within the broad middle range of expected peer-group pay given company performance comparable to that of our peers.

The graph below shows the balance of fixed and performance-based target compensation determined by the committee and actual compensation received for 2011. The target compensation reflects decisions made by the compensation committee for 2011. This includes the 2011-2012 PA and the 2011-2013 SVA. For comparison purposes, actual compensation includes base salary and cash incentive bonus earned in 2011 and the equity awards that completed their performance periods in 2011: the 2010-2011 PA and the 2009-2011 SVA.



Actual base salary and bonus amounts are shown in the "Summary Compensation Table." The PA payout for 2010-2011 performance period paid out at 109 percent of target, as shown in the "Outstanding Equity Awards at December 31, 2011" table. The SVA payout for 2009-2011 performance was 80 percent of target for all participants as shown in the "Options Exercised and Stock Vested in 2011" table. Since Dr. Lundberg joined the company after the SVA award was granted, he was not eligible for the payout. The graph above includes the vesting of one-third of the award of restricted stock units that Dr. Lundberg received upon joining the company.

**Base Salary**

In setting base salaries for 2011, in addition to the considerations described above, the committee considered the corporate budget for salary increases, which was established at 3 percent based on company performance for 2010, expected performance for 2011, and general external trends. The objective of the budget is to allow salary increases to retain, motivate, and reward successful performers while maintaining affordability within the company's business plan. Individual pay increases can be more or less than the budget amount depending on individual performance, but aggregate increases must stay within the budget. The aggregate increases for the named executive officers and the other executive officers were within this budget. Mr. Rice's base salary reflects his increased responsibilities. In setting 2011 compensation, peer-group data confirmed that the proposed salaries were within the broad middle range of competitive pay.

**Annualized Base Salary (thousands)**

Name	2010	2011	Percentage Increase
Dr. Lechleiter	\$1,500	\$1,500	0%
Mr. Rice	\$955	\$990	4%
Mr. Carmine	\$952	\$952	0%
Dr. Lundberg	\$950	\$979	3%
Mr. Armitage	\$841	\$841	0%

**Cash Incentive Bonuses**

The company's annual cash bonus program aligns employees' goals with the company's financial plans and pipeline delivery objectives for the current year. For executive officers, cash incentive bonuses are made under the Executive Officer Incentive Plan (EOIP), which operates by establishing a maximum annual incentive bonus and granting the committee discretion to reduce the bonus from the maximum. Under the EOIP, the maximum bonuses are based on non-GAAP net income (as defined under "Non-GAAP Results" below) for the year. For the chief executive officer, chief operating officer (if any), and executive chairman (if any), the maximum

**Bonus Weighting:**

- 25% revenue goals
- 50% non-GAAP EPS goals
- 25% pipeline progress

**2011 Targets:**

- \$23.2 billion revenue
- \$4.31 adjusted non-GAAP EPS
- achievement of pipeline milestones

is 0.3 percent of non-GAAP net income. For other executive officers, the maximum is 0.15 percent of non-GAAP net income. No payments can be made unless the company has a positive non-GAAP net income for the year. The committee has discretion to reduce, but not increase, the annual incentive bonus.

In exercising this discretion, the committee intends generally to award executive officers the lesser of (i) the bonuses they would have received under the Eli Lilly and Company Bonus Plan (the bonus plan) or (ii) the EOIP maximum amounts. Each year the committee establishes target bonuses for the executive officers based on a percentage of salary. At the end of the year, the committee will reduce the bonuses from the EOIP maximum based on the company's achievement relative to performance-based goals (as described below) set by the committee in a manner consistent with the committee's administration of the bonus plan. Accordingly, actual payouts under the EOIP are expected to be less than the EOIP maximum amounts. The committee retains further discretion to reduce the bonuses below the results that would have been yielded under the bonus plan.

All other management employees worldwide, as well as a substantial number of nonmanagement employees in the U.S., participate in the bonus plan. Under the plan, participants' targets and pre-established company goals are set at the beginning of each year. Bonus-payouts range from zero to 200 percent of target amounts depending on the company's performance in regard to these goals. At the end of the performance period, the committee has discretion to adjust a bonus-payout downward (but not upward) from the amount yielded by the formula.

The committee considered the following when establishing the 2011 awards:

- *Bonus targets.* Consistent with our compensation objectives, as employees assume greater responsibilities, more of their pay is linked to company performance. Bonus targets (expressed as a percentage of base salary) were based on job responsibilities, internal relativity, individual performance, and peer-group data. For each named executive officer, the committee maintained the same bonus targets as 2010.

**Bonus Targets (as a percentage of base salary)**

Name	2010	2011
Dr. Lechleiter	140%	140%
Mr. Rice	90%	90%
Mr. Carmine	90%	90%
Dr. Lundberg	90%	90%
Mr. Armitage	80%	80%


- *Company performance measures.* A bonus program's goals should be challenging, yet achievable, in order to motivate and retain employees. Beginning in 2011, performance goals under our bonus plan are tied directly to our internal annual operating goals. The committee established 2011 corporate goals with a 25 percent weighting on revenue growth, 50 percent weighting on non-GAAP EPS growth, and 25 percent weighting on our pipeline progress. These goals replace the prior years' goals of 25 percent revenue growth versus peer expectations and 75 percent non-GAAP EPS growth versus peer expectations. Revenue and non-GAAP EPS goals that reflect anticipated median peer group year-on-year growth would likely not be achievable in years with patent losses, such as 2011, and would likely result in artificially-inflated payouts in subsequent near-term growth years. The new performance measures were designed to be achievable yet challenging, focusing employees appropriately on achieving or exceeding the company's top-line sales and bottom-line earnings objectives in a difficult period for the company while delivering a robust pipeline of medicines at all stages of development, which is critical to our long-term success.

In establishing the 2011 goals, the committee used the company's 2011 annual operating plan to set goals of \$23.2 billion in revenue and \$4.31 in adjusted EPS and measures of both the output and sustainability of the pipeline. Payouts were determined by this formula:

$$(0.25 \times \text{revenue multiple}) + (0.50 \times \text{adjusted EPS multiple}) + (0.25 \times \text{pipeline multiple}) = \text{bonus multiple}$$

$$\text{bonus multiple} \times \text{bonus target} \times \text{base salary earnings} = \text{payout}$$

2011 revenue, EPS, and pipeline multiples are illustrated by this chart:



2011 adjusted revenue of \$24.3 billion represented 5.1 percent growth over 2010, exceeding the goal of \$23.2 billion, and resulted in a revenue multiple of 1.41. 2011 adjusted non-GAAP EPS of \$4.36 represented a reduction of 8 percent from 2010, exceeding the 2011 goal of \$4.31 and resulting in an EPS multiple of 1.10.

The pipeline output and sustainability metrics were set consistent with corporate goals. The science and technology committee of the board of directors assessed the company’s progress toward achieving these goals at 3.8 (on a scale of 1 to 5), noting 3 major product approvals (plus 4 other approvals) versus a goal of 3, and 5 new molecular entities (NMEs) moved into Phase III versus a goal of 3 NMEs. Additionally, 61 percent of pipeline projects met their milestone goals, which was below the target of 70 percent. The science and technology committee also performed a subjective assessment of the quality of the pipeline. Based on the recommendation of the science and technology committee, the compensation committee certified a pipeline score of 3.8 resulting in a pipeline multiple of 1.40.


Combined, the sales, EPS, and pipeline progress multiples yielded a bonus multiple of 1.25.

$$(0.25 \times 1.41) + (0.50 \times 1.10) + (0.25 \times 1.40) = 1.25 \text{ bonus multiple}$$

### Equity Incentives—Total Equity Program

We employ two forms of equity incentives granted under the 2002 Lilly Stock Plan: performance awards (PAs) and shareholder value awards (SVAs). These incentives are designed to focus company leaders on long-term shareholder value. For executive officers, SVAs have a three-year performance period followed by a one-year holding requirement; PAs have a two-year performance period and pay out in restricted stock units (RSUs) that vest one year after the performance period. The following chart shows the performance and holding periods for PA and SVA grants over time:

**Performance and Holding Periods for PAs and SVAs**



*Target grant values.* For 2011, the committee set the aggregate target grant values for the named executive officers based on internal relativity, individual performance, and aggregated peer-group data. Mr. Rice and Dr. Lundberg's target grant values were increased, reflecting Mr. Rice's increased responsibilities and implementation of the global services organization and Dr. Lundberg's successful first year. The target grant values for the remaining named executive officers were maintained. Consistent with the company's compensation objectives, individuals at higher levels received a greater proportion of total compensation in the form of equity. The committee determined that for members of senior management, a 50/50 split between PAs and SVAs appropriately balances the company financial performance and shareholder equity return metrics of the two programs. Target values for 2010 and 2011 equity grants for the named executive officers were as follows:

#### Equity Compensation:

- Performance metrics of growth in non-GAAP EPS and share price are objective and align with shareholder interests
- Target grant values set based on internal relativity, performance, and peer data

#### Target Grant Values (thousands)

Name	2010-2011 PA	2011-2012 PA	2010-2012 SVA	2011-2013 SVA	Percentage Increase (total)
Dr. Lechleiter	\$3,750	\$3,750	\$3,750	\$3,750	0%
Mr. Rice	\$1,500	\$1,900	\$1,500	\$1,900	27%
Mr. Carmine	\$1,500	\$1,500	\$1,500	\$1,500	0%
Dr. Lundberg	\$1,250	\$1,375	\$1,250	\$1,375	10%
Mr. Armitage	\$1,000	\$1,000	\$1,000	\$1,000	0%

#### Equity Incentives—Performance Awards

PAs provide employees with shares of company stock if certain company performance goals are achieved. The awards are structured as a schedule of potential shares of company stock earned based on cumulative, compounded annual growth in non-GAAP EPS over a two-year period. In 2011, the company granted a two-year award to global management (approximately 15 percent of our employee population). Possible payouts for the 2011-2012 PA range from 0 to 150 percent of the target depending on non-GAAP EPS growth over the performance period. No dividends are accrued or paid on the awards during the performance period.


#### Performance Awards:

- Target 2-year EPS growth was 4.6%, slightly above expected peer-group performance
- Payout in restricted stock for executive officers

*Company performance measure.* For the 2011 grants, the committee established the performance measure as non-GAAP EPS growth. The committee believes non-GAAP EPS growth is an effective motivator because it is closely linked to shareholder value, is broadly communicated to the public, is easily understood by employees, and allows for objective comparisons to peer-group performance. The target compounded growth percentage of 4.6 percent per year slightly exceeded the median expected non-GAAP EPS of companies in our peer group, based on investment analysts' published estimates. Accordingly, consistent with our compensation objectives, company performance exceeding the expected peer-group median will result in above-target payouts, while company performance lagging the expected peer-group median will result in below-target payouts. The measure of non-GAAP EPS used in the PA program differs from the non-GAAP EPS measure used in our annual bonus program in two ways. First, the annual bonus program measures EPS over a one-year period, while the PA program measures EPS over a two-year period. Second, the target EPS goal in the annual bonus program is set with reference to our internal operating plan for the year, while the target EPS goal in the PA program is set relative to expected growth rates for other companies in our industry.

Payouts for 2011-2012 PAs are illustrated by the chart below:

#### 2011-2012 PA



## Equity Incentives—Shareholder Value Awards

In 2007, the company replaced its stock option program with the SVA program. SVAs are structured as a schedule of potential shares of company stock based on the company's share price performance over a three-year period. No dividends are accrued or paid on the awards during the performance period. Payouts range from 0 to 140 percent of the target amount, depending on stock performance over the period. At the end of the performance period, the committee has discretion to adjust an award payout downward (but not upward) from the amount yielded by the formula. The SVA program delivers equity compensation that is strongly linked to 3-year TSR. It is more cost-effective than the stock option program it replaced because the SVA program delivers, at a lower cost to the company, an equity incentive that is equally or more effective in aligning employee interests with long-term shareholder returns.

### Shareholder Value Awards:

- Three-year performance period
- Target is determined by applying an expected three-year rate of return for large-cap companies
- Shares earned by executive officers must be held one year

*Company performance measure.* For the 2011 grants, the SVA will pay above target if company stock outperforms an expected compounded annual rate of return for large-cap companies and below target if company stock underperforms that rate of return. The expected rate of return was determined considering total return that a reasonable investor would consider appropriate for investing in a large-cap U.S. company (based on input from external money managers). The resulting share price payout schedule was developed using this expected rate of return, less the company's dividend yield applied to the starting share price. Executive officers receive no payout if the stock price, less three years of dividends at the current rate, does not grow over the three-year performance period—in other words, if total shareholder return for the three-year period is zero or negative.

The starting price for the 2011-2013 SVAs is \$34.81 per share, representing the average of the closing prices of company stock for all trading days in November and December 2010, and an assumed dividend yield of 5.6 percent. The ending price to determine payouts will be the average of the closing prices of company stock for all trading days in November and December 2013.

The 2011-2013 SVA will be paid out to executive officers according to the grid below in early 2014:

### 2011-2013 SVA

Ending Stock Price	Less than \$28.94	\$28.94-\$33.02	\$33.03-\$37.09	\$37.10-\$39.59	\$39.60-\$42.09	\$42.10-\$44.59	Greater than \$44.59
Compounded Annual Growth Rate (excluding dividends)	Less than (6.0%)	(6.0%)-(1.7%)	(1.7%)-2.1%	2.1%-4.4%	4.4%-6.5%	6.5% -8.6%	Greater than 8.6%
Percent of Target	0%	40%	60%	80%	100%	120%	140%

## Restricted Stock Units

No one-time restricted stock units were awarded to any of the named executive officers in 2011.

## Stock Options

The company stopped granting stock options in 2007. All outstanding stock options are currently under water. The stock options granted in 2001 expired in 2011, and the named executive officers who held them forfeited the award having realized no value. These awards (and other expired stock options) were not replaced.

## Non-GAAP Results

Consistent with past practice, the committee adjusted the results on which 2010-2011 PAs and the 2011 bonus were determined to eliminate the distorting effect of certain unusual income or expense items on year-over-year growth percentages. The adjustments are intended to:

- align award payments with the underlying performance of the core business
- avoid volatile, artificial inflation or deflation of awards due to the unusual items in either the award year or the previous (comparator) year
- eliminate certain counterproductive short-term incentives—for example, incentives to refrain from acquiring new technologies, to defer disposing of underutilized assets, or to defer settling legacy legal proceedings to protect current bonus payments.


To assure the integrity of the adjustments, the committee establishes adjustment guidelines at the beginning of the year. These guidelines are generally consistent with the company guidelines for reporting non-GAAP earnings to the investment community, which are reviewed by the audit committee of the board. The adjustments apply equally to income and expense items. The compensation committee reviews all adjustments and retains downward discretion—i.e., discretion to reduce compensation below the amounts that are yielded by the adjustment guidelines.

When the committee set 2010-2011 PA goals for two-year EPS growth in 2010, U.S. health care reform legislation had not yet passed. Given the scope and uncertainty of the legislation, the committee decided not to include the potential impact of U.S. health care reform when the targets were set, and to adjust results based on the actual impact of U.S. health care reform in 2010 and 2011. The committee also adjusted 2011 EPS to eliminate the first-year impact of the company's collaboration with Boehringer Ingelheim (BI) and the acquisition of Avid Radio-pharmaceuticals (Avid), which were not contemplated when performance targets were set. These costs were not adjusted for the 2011 bonus. In addition, although the company excluded the impact of the Xigris<sup>®</sup> product withdrawal that occurred in 2011 in its published non-GAAP earnings, the committee chose to include the negative impact on sales and EPS for both the 2010-2011 PA and the 2011 bonus.

For the 2010-2011 PA payout calculations, the committee made the following adjustments to EPS:

- For 2011: (i) Eliminated the first-year impact of the BI collaboration and the Avid acquisition; (ii) included the negative impact of the Xigris product withdrawal
- For 2010 and 2011: Eliminated the impact of U.S. health care reform
- For 2009, 2010, and 2011: Eliminated the impact of (i) significant asset impairments and restructuring charges and (ii) one-time accounting charges for the acquisition of in-process research and development
- For 2009: Eliminated the impact of special charges related to Zyprexa litigation.

The adjustments were intended to align award payments more closely with underlying business growth trends and eliminate volatile swings (up or down) caused by the unusual items. This is demonstrated by the 2009, 2010, and 2011 adjustments:



Reconciliations of these adjustments to our reported earnings per share are below. The shaded numbers are the growth percentages used to calculate the 2010-2011 PA payout.

	2011	2010	% Growth 2011 vs. 2010	2009	% Growth 2010 vs. 2009
EPS as reported	\$ 3.90	\$4.58	-14.8%	\$3.94	16.2%
Eliminate IPR&D charges for acquisitions and in-licensing transactions	\$ 0.23	\$0.03		\$0.05	
Eliminate asset impairments, restructuring and other special charges (including Xigris withdrawal)	\$ 0.29	\$0.13		\$0.42	
Non-GAAP EPS*	\$ 4.41	\$4.74	-7.0%	\$4.42	7.2%
Health care reform adjustment	\$ 0.45	\$0.24		—	
Acquisitions and collaboration first year impact adjustment	\$ 0.28	—		—	
Xigris withdrawal adjustment	(\$0.05)	—		—	
EPS—adjusted	\$ 5.09	\$4.98	2.2%	\$4.42	12.7%

\*Numbers may not add due to rounding.

Similarly, for the 2011 bonus-payout calculations, the committee adjusted EPS to (i) eliminate the impact of significant asset impairments and restructuring charges, (ii) eliminate the impact of one-time accounting charges for the acquisition of in-process research and development, and (iii) include the negative impact of the Xigris product withdrawal.

Reconciliations of these adjustments to our reported earnings per share are below. The shaded numbers are the growth percentages used to calculate the 2011 bonus payout.

	2011	2010	% Growth 2011
Revenue as reported (\$ millions)	\$24,286.5	\$23,076.0	5.2%
Impact of Xigris withdrawal	(\$32.9)	—	
Revenue—adjusted	\$24,253.6	\$23,076.0	5.1%
EPS as reported	\$3.90	\$4.58	-14.8%
Eliminate IPR&D charges for acquisitions and in-licensing transactions	\$0.23	\$0.03	
Eliminate asset impairments, restructuring and other special charges (including Xigris withdrawal in 2011)	\$0.29	\$0.13	
Non-GAAP EPS*	\$4.41	\$4.74	-7.0%
Xigris withdrawal adjustment	(\$0.05)	—	
EPS—adjusted	\$4.36	\$4.74	-8.0%

\*Numbers may not add due to rounding.

### Equity Incentive Grant Mechanics and Timing

The committee approves target grant values for equity incentives prior to the grant date. On the grant date, those values are converted to shares based on:

- the closing price of company stock on the grant date
- the same valuation methodology the company uses to determine the accounting expense of the grants under Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) Topic 718.

The committee's procedure for the timing of equity grants assures that grant timing is not being manipulated for employee gain. The annual equity grant date for all eligible employees is in the first half of February. The committee establishes this date in October. The February grant date timing is driven by these considerations:

- It coincides with the company's calendar-year-based performance management cycle, allowing supervisors to deliver the equity awards close in time to performance appraisals, which increases the impact of the awards by strengthening the link between pay and performance.
- It follows the annual earnings release, so that the stock price at that time can reasonably be expected to fairly represent the market's collective view of our then-current results and prospects.

Grants to new hires and other off-cycle grants are effective on the first trading day of the following month.

### Employee and Post-Employment Benefits

The company offers core employee benefits coverage to:

- provide our global workforce with a reasonable level of financial support in the event of illness, injury, and retirement
- enhance productivity and job satisfaction through programs that focus on work/life balance.

The benefits available are the same for all U.S. employees and include medical and dental coverage, disability insurance, and life insurance.

In addition, the 401(k) plan and The Lilly Retirement Plan (the retirement plan) provide U.S. employees a reasonable level of retirement income reflecting employees' careers with the company. To the extent that any employee's retirement benefit exceeds IRS limits for amounts that can be paid through a qualified plan, the company also offers a nonqualified pension plan and a nonqualified savings plan. These plans provide only the difference between the calculated benefits and the IRS limits, and the formula is the same for all U.S. employees.

The cost of both employee and post-employment benefits is partially borne by the employee, including each executive officer.

### Perquisites

The company provides very limited perquisites to executive officers. Executive officers generally do not have access to the corporate aircraft for personal use; however, the aircraft is made available for the personal use of Dr. Lechleiter when the security and efficiency benefits to the company outweigh the expense. Dr. Lechleiter did not use the corporate aircraft for personal flights during 2011, nor did he receive any other perquisites. Until March 2009, the company aircraft was made available to other executive officers for the limited purpose of travel to outside board meetings. However, the company no longer allows this use. Depending on seat availability, family members and personal guests of executive officers may travel on the company aircraft to accompany executives who are traveling on business. There is no incremental cost to the company for these trips.

## The Lilly Deferred Compensation Plan

Executives may defer receipt of part or all of their cash compensation under The Lilly Deferred Compensation Plan (the deferred compensation plan), which allows executives to save for retirement in a tax-effective way at minimal cost to the company. Under this unfunded plan, amounts deferred by the executive are credited at an interest rate of 120 percent of the applicable federal long-term rate, as described in more detail following the “Nonqualified Deferred Compensation in 2011” table.

## Severance Benefits

Except in the case of a change in control of the company, the company is not obligated to pay severance to named executive officers upon termination of their employment; any such payments are at the discretion of the compensation committee.

### Change in Control Severance:

- All regular employees covered
- Double trigger
- Two-year cash pay protection for executives
- 18-month benefit continuation
- Tax gross-up eliminated effective October 2012

The company has adopted a change-in-control severance pay plan for nearly all employees of the company, including the executive officers. The plan is intended to preserve employee morale and productivity and encourage retention in the face of the disruptive impact of an actual or rumored change in control. In addition, for executives, the plan is intended to align executive and shareholder interests by enabling executives to consider corporate transactions that are in the best interests of the shareholders and other constituents of the company without undue concern over whether the transactions may jeopardize the executives' own employment.

Although benefit levels may differ depending on the employee's job level and seniority, the basic elements of the plan are comparable for all regular employees:

- *Double trigger.* Unlike “single trigger” plans that pay out immediately upon a change in control, the company plan generally requires a “double trigger”—a change in control followed by an involuntary loss of employment within two years thereafter. This is consistent with the purpose of the plan, which is to provide employees with financial protection upon loss of employment. A partial exception is made for outstanding PAs, a portion of which would be paid out upon a change in control on a pro-rated basis for time worked based on the forecasted payout level at the time of the change in control. The committee believes this partial payment is appropriate because of the difficulties in converting the company EPS targets into an award based on the surviving company's EPS. Likewise, if Lilly is not the surviving entity, a portion of outstanding SVAs is paid out on a pro-rated basis for time worked up to the change in control based on the merger price for company stock.
- *Covered terminations.* Employees are eligible for payments if, within two years of the change in control, their employment is terminated (i) without cause by the company or (ii) for good reason by the employee, each as is defined in the plan. See “Potential Payments Upon Termination or Change in Control” for a more detailed discussion, including a discussion of what constitutes a change in control.
- Employees who suffer a covered termination receive up to two years of pay and 18 months of benefits protection. These provisions assure employees a reasonable period of protection of their income and core employee benefits upon which they depend for financial security.
  - Severance payment.* Eligible terminated employees would receive a severance payment ranging from six months' to two years' base salary. Executives are all eligible for two years' base salary plus two times the then-current year's target bonus.
  - Benefit continuation.* Basic employee benefits such as health and life insurance would be continued for 18 months following termination of employment, unless the individual becomes eligible for coverage with a new employer. All employees would receive an additional 2 years of both age and years-of-service credit for purposes of determining eligibility for retiree medical and dental benefits.
- *Accelerated vesting of equity awards.* Any unvested equity awards at the time of termination of employment would vest.
- *Excise tax.* In some circumstances, the payments or other benefits received by the employee in connection with a change in control could exceed limits established under Section 280G of the Internal Revenue Code. The employee would then be subject to an excise tax on top of normal federal income tax. Because of the way the excise tax is calculated, it can impose a large burden on some employees while similarly compensated employees will not be subject to the tax. The costs of this excise tax and associated gross-ups would be borne by the company. (Employees would pay income tax resulting from severance payments.) To avoid triggering the excise tax, payments that would otherwise be due under the plan that are up to 5 percent over the IRS limit will be cut back to the limit. Effective October 2012, this tax gross-up will be eliminated.

### Share Ownership and Retention Guidelines; Hedging Prohibition

Share ownership and retention guidelines help to foster a focus on long-term growth. The committee has adopted a guideline requiring the CEO to own company stock valued at least six times his or her annual base salary. Other executive officers are required to own a fixed number of shares based on their position. The fixed number of shares eliminates volatility in the share ownership requirements that can occur with sharp movements in share price. Until the guideline level is reached, the executive officer must retain all existing holdings as well as 50 percent of net shares resulting from new equity payouts. Our executives have a long history of maintaining extensive holdings in company stock, and all named executive officers already meet or exceed the guideline. All new executive officers are on track to meet or exceed the guideline within the next few years. As of February 1, 2012, Dr. Lechleiter held shares valued at approximately 17 times his salary. The following table shows the required share levels for the named executive officers:

Name	Revised Share Requirement	Meets Requirement
Dr. Lechleiter	six times base salary	Yes
Mr. Rice	75,000	Yes
Mr. Carmine	Retired	—
Dr. Lundberg	75,000	Yes
Mr. Armitage	60,000	Yes

Executive officers are also required to retain all shares received from the company equity programs, net of acquisition costs and taxes, for at least one year, even once share requirements have been met. For PAs, this requirement is met by paying the award in the form of restricted stock units. Employees are not permitted to hedge their economic exposures to company stock through short sales or derivative transactions.

### Tax Deductibility Cap on Executive Compensation

U.S. federal income tax law prohibits the company from taking a tax deduction for non-performance based compensation paid in excess of \$1,000,000 to named executive officers. However, performance-based compensation is fully deductible if the programs are approved by shareholders and meet other requirements. Our policy is to qualify our incentive compensation programs for full corporate deductibility to the extent feasible and consistent with our overall compensation objectives.

We have taken steps to qualify all incentive awards (bonuses, PAs, and SVAs) for full deductibility as performance-based compensation. The committee may make payments that are not fully deductible if, in its judgment, such payments are necessary to achieve the company's compensation objectives and to protect shareholder interests. For 2011, the non-deductible compensation was approximately \$400,000 for Dr. Lechleiter, less than the portion of his base salary that exceeded \$1,000,000, and approximately \$1,140,000 for Dr. Lundberg, primarily attributable to the vesting of restricted stock units received when he joined the company.

### Executive Compensation Recovery Policy and Other Risk Mitigation Tools

All incentive awards are subject to forfeiture upon termination of employment prior to the end of the performance period or for disciplinary reasons. In addition, under the company's executive officer compensation recovery policy, the company can recover incentive compensation (cash or equity) that was based on achievement of financial results that were subsequently the subject of a restatement if the executive officer engaged in intentional misconduct that caused or partially caused the need for the restatement and the effect of the wrongdoing was to increase the amount of bonus or incentive compensation. The company can also recover or "claw back" all or a portion of any incentive compensation in the case of materially inaccurate financial statements or material errors in the performance calculation, whether or not they result in a restatement and whether or not the executive officer has engaged in wrongful conduct. Recoveries under this "no-fault" provision cannot extend back more than two years.

The recovery policy applies to any incentive compensation awarded or paid to an employee at a time when he or she is an executive officer. Subsequent changes in status, including retirement or termination of employment, do not affect the company's rights to recover compensation under the policy.

In addition to the executive compensation recovery policy, the committee and management have implemented compensation-program design features to mitigate the risk of compensation programs encouraging misconduct or imprudent risk-taking. First, incentive programs are designed using a diversity of meaningful financial metrics (growth in stock price measured over three years, net revenue, EPS (measured over one and two years), and pipeline progress), providing a balance between short- and long-term performance. The committee reviews incentive programs each year against the objectives of the programs, assesses any features that could encourage excessive risk-taking, and makes changes as necessary. Second, management has implemented effective controls that minimize unintended and willful reporting errors.

The committee does not believe it is practical to apply a specific claw-back policy to SVAs in the event of misstated financial results since it is very difficult to isolate the amount, if any, by which the stock price might benefit from misstated financial results over a three-year performance period.

### **Looking Ahead to 2012 Compensation**

Several changes to the company's executive compensation program will take effect in 2012:

- In light of the business challenges the company faces, Dr. Lechleiter requested that he receive no increase in base salary or incentive targets in 2012. The committee agreed to maintain his 2011 compensation package for 2012.
- Similarly, employees in most countries worldwide, including the named executive officers, will not receive base pay increases in 2012.
- Amendments to the change-in-control severance pay plans to eliminate tax gross-ups are effective October 2012.
- All members of senior management (approximately 150 employees) are subject to share ownership requirements, correlated to their level of responsibility.

### **Compensation Committee Report**

The compensation committee ("we" or "the committee") evaluates and establishes compensation for executive officers and oversees the deferred compensation plan, the company's management stock plans, and other management incentive, benefit, and perquisite programs. Management has the primary responsibility for the company's financial statements and reporting process, including the disclosure of executive compensation. With this in mind, we have reviewed and discussed with management the "Compensation Discussion and Analysis" above. The committee is satisfied that the "Compensation Discussion and Analysis" fairly and completely represents the philosophy, intent, and actions of the committee with regard to executive compensation. We recommended to the board of directors that the "Compensation Discussion and Analysis" be included in this proxy statement for filing with the SEC.

### **Compensation Committee**

Karen N. Horn, Ph.D., Chair  
Michael L. Eskew  
R. David Hoover  
Ellen R. Marram  
Kathi P. Seifert

## Executive Compensation

### Summary Compensation Table

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Stock Awards (\$) <sup>3</sup>	Option Awards (\$)	Non-Equity Incentive Plan Compensation (\$) <sup>4</sup>	Change in Pension Value (\$) <sup>5</sup>	All Other Compensation (\$) <sup>6</sup>	Total Compensation (\$)
John C. Lechleiter, Ph.D. <sup>1</sup> Chairman, President, and Chief Executive Officer	2011	\$1,500,000	\$ 0	\$ 5,625,000	\$0	\$2,625,000	\$6,530,094	\$90,000	\$16,370,094
	2010	\$1,500,000	\$ 0	\$ 8,175,000	\$0	\$2,982,000	\$3,757,545	\$90,000	\$16,504,545
	2009	\$1,483,333	\$ 0	\$11,250,000	\$0	\$3,551,100	\$4,553,125	\$90,091	\$20,927,649
Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer	2011	\$ 984,167	\$ 0	\$ 2,850,000	\$0	\$1,107,188	\$ 940,589	\$59,050	\$5,940,993
	2010	\$ 955,000	\$ 0	\$ 3,270,000	\$0	\$1,220,490	\$ 996,723	\$57,300	\$6,499,513
	2009	\$ 892,500	\$ 0	\$ 4,500,000	\$0	\$1,220,940	\$ 977,741	\$54,838	\$7,646,019
Bryce D. Carmine Retired Executive Vice President and President, Lilly Bio-Medicines	2011	\$ 951,700	\$ 0	\$ 2,250,000	\$0	\$1,070,663	\$2,243,789	\$57,102	\$6,573,254
	2010	\$ 947,083	\$ 0	\$ 3,270,000	\$0	\$1,210,373	\$2,252,560	\$56,825	\$7,736,841
	2009	\$ 916,667	\$ 0	\$ 4,500,000	\$0	\$1,410,750	\$1,776,537	\$57,001	\$8,660,955
Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories	2011	\$ 973,750	\$ 0	\$ 2,062,500	\$0	\$1,095,469	\$ 232,128	\$58,425	\$4,422,272
	2010	\$ 946,401	\$1,000,000 <sup>2</sup>	\$ 6,225,000 <sup>2</sup>	\$0	\$1,209,501	\$ 83,150	\$87,833	\$9,551,885
Robert A. Armitage Senior Vice President and General Counsel	2011	\$ 840,900	\$ 0	\$ 1,500,000	\$0	\$840,900	\$ 595,293	\$50,454	\$3,827,547
	2010	\$ 836,817	\$ 0	\$ 2,180,000	\$0	\$950,624	\$ 521,237	\$50,209	\$4,538,886
	2009	\$ 811,167	\$ 0	\$ 3,000,000	\$0	\$1,109,676	\$ 775,287	\$49,902	\$5,746,032

<sup>1</sup> Supplement to the Summary Compensation Table. In 2009, we granted both a one-year and a two-year PA as part of our transition to a two-year award, which was implemented in response to shareholder feedback. The two grants in 2009 provided the opportunity for participants to receive *one and only one* PA payout each year—without skipping a year. In 2010, we returned to our regular grant cycle and granted a single two-year PA. As a result, the amount in the “Stock Awards” column decreased. The 2010-2011 PA and the 2011-2012 PA grant values shown respectively in 2010 and 2011 in this column are based on the probable payout outcome anticipated at the time of grant. For purposes of comparison, the supplemental table below shows target compensation for Dr. Lechleiter (with one rather than two PA grants in 2009), approved by the compensation committee, given target company performance.

Name	Year	Annualized Salary	Target Stock Awards	Target Cash Incentive Bonus	Total
John C. Lechleiter, Ph.D.	2011	\$1,500,000	\$7,500,000	\$2,100,000	\$11,100,000
	2010	\$1,500,000	\$7,500,000	\$2,100,000	\$11,100,000
	2009	\$1,500,000	\$7,500,000	\$2,100,000	\$11,100,000

<sup>2</sup> The one-time bonus compensation Dr. Lundberg received upon joining the company in January 2010 included a signing bonus and an award of restricted stock units.

<sup>3</sup> This column shows the grant date fair value of awards computed in accordance with stock-based compensation accounting rules (FASB ASC Topic 718). Values for awards subject to performance conditions (PAs) are computed based upon the probable outcome of the performance condition as of the grant date. (See the “Target Grant Values” table above for target grant values for the 2010 and 2011 equity awards.) A discussion of assumptions used in calculating award values may be found in Note 9 to our 2011 audited financial statements in our Form 10-K.

The table below shows the minimum, target, and maximum payouts for the 2011-2012 PA grant included in this column of the Summary Compensation Table.

Name	Payout Date	Minimum Payout	Target Payout	Maximum Payout
Dr. Lechleiter	January 2013	\$0	\$3,750,000	\$5,625,000
Mr. Rice	January 2013	\$0	\$1,900,000	\$2,850,000
Mr. Carmine	January 2013	\$0	\$1,500,000	\$2,250,000
Dr. Lundberg	January 2013	\$0	\$1,375,000	\$2,062,500
Mr. Armitage	January 2013	\$0	\$1,000,000	\$1,500,000

<sup>4</sup> Payments for 2011 performance were made in March 2012 under the bonus plan. All bonuses paid to named executive officers were part of a non-equity incentive plan.

<sup>5</sup> The amounts in this column are the change in pension value for each individual, calculated by our actuary. No named executive officer received preferential or above-market earnings on deferred compensation.

<sup>6</sup> The table below shows the components of the “All Other Compensation” column for 2009 through 2011, which includes the company match for each individual’s savings plan contributions, tax reimbursements, and perquisites.

Name	Year	Savings Plan Match	Tax Reimbursements <sup>1</sup>	Perquisites	Other	Total “All Other Compensation”
Dr. Lechleiter	2011	\$90,000	\$0	\$0	\$0	\$90,000
	2010	\$90,000	\$0	\$0	\$0	\$90,000
	2009	\$89,000	\$1,091	\$0	\$0	\$90,091
Mr. Rice	2011	\$59,050	\$0	\$0	\$0	\$59,050
	2010	\$57,300	\$0	\$0	\$0	\$57,300
	2009	\$53,550	\$1,288	\$0	\$0	\$54,838
Mr. Carmine	2011	\$57,102	\$0	\$0	\$0	\$57,102
	2010	\$56,825	\$0	\$0	\$0	\$56,825
	2009	\$55,000	\$2,001	\$0	\$0	\$57,001
Dr. Lundberg	2011	\$58,425	\$0	\$0	\$0	\$58,425
	2010	\$56,784	\$12,876	\$0	\$18,173 <sup>2</sup>	\$87,833
Mr. Armitage	2011	\$50,454	\$0	\$0	\$0	\$50,454
	2010	\$50,209	\$0	\$0	\$0	\$50,209
	2009	\$48,670	\$1,232	\$0	\$0	\$49,902

<sup>1</sup> These amounts reflect tax reimbursements for expenses for each executive’s spouse to attend certain company functions involving spouse participation. Beginning in 2010, the company no longer reimburses executive officers for these taxes. For Mr. Rice, these amounts include taxes on income imputed for use of the corporate aircraft to attend outside board meetings in 2009. For Dr. Lundberg, these amounts include taxes on income imputed for relocation expenses.

<sup>2</sup> Relocation expenses reimbursed under a company policy available to any employee asked to relocate by the company.

We have no employment agreements with our named executive officers.

## Grants of Plan-Based Awards During 2011

The compensation plans under which the grants in the following table were made are described in the “Compensation Discussion and Analysis” and include the bonus plan (a non-equity incentive plan) and the 2002 Lilly Stock Plan (which provides for PAs, SVAs, stock options, restricted stock grants, and stock units).

Name	Award	Grant Date	Compensation Committee Action Date	Estimated Possible Payouts Under Non-Equity Incentive Plan Awards <sup>1</sup>			Estimated Possible and Future Payouts Under Equity Incentive Plan Awards			All Other Stock or Option Awards: Number of Shares of Stock, Options, or Units	Grant Date Fair Value of Equity Awards
				Threshold (\$)	Target (\$)	Maximum (\$)	Threshold (# shares)	Target (# shares)	Maximum (# shares)		
Dr. Lechleiter	2011-2012 PA	02/07/2011 <sup>2</sup>	12/13/2010	\$52,500	\$2,100,000	\$4,200,000	58,778	117,555	176,333	0	\$1,875,000
	2011-2013 SVA	02/07/2011 <sup>3</sup>	12/13/2010				59,809	149,522	209,331		\$3,750,000
Mr. Rice	2011-2012 PA	02/07/2011 <sup>2</sup>	12/13/2010	\$22,144	\$885,750	\$1,771,500	29,781	59,561	89,342	0	\$950,000
	2011-2013 SVA	02/07/2011 <sup>3</sup>	12/13/2010				30,303	75,758	106,061		\$1,900,000
Mr. Carmine	2011-2012 PA	02/07/2011 <sup>2</sup>	12/13/2010	\$21,413	\$856,530	\$1,713,060	23,511	47,022	70,533	0	\$750,000
	2011-2013 SVA	02/07/2011 <sup>3</sup>	12/13/2010				23,924	59,809	83,733		\$1,500,000
Dr. Lundberg	2011-2012 PA	02/07/2011 <sup>2</sup>	12/13/2010	\$21,909	\$876,375	\$1,752,750	21,552	43,103	64,655	0	\$687,500
	2011-2013 SVA	02/07/2011 <sup>3</sup>	12/13/2010				21,930	54,825	76,755		\$1,375,000
Mr. Armitage	2011-2012 PA	02/07/2011 <sup>2</sup>	12/13/2010	\$16,818	\$672,720	\$1,345,440	15,674	31,348	47,022	0	\$500,000
	2011-2013 SVA	02/07/2011 <sup>3</sup>	12/13/2010				15,949	39,872	55,821		\$1,000,000

<sup>1</sup> These columns show the threshold, target, and maximum payouts for performance under the bonus plan. As described in the section titled “Cash Incentive Bonuses” in the “Compensation Discussion and Analysis,” bonus-payouts range from 0 to 200 percent of target. The bonus payment for 2011 performance was based on the metrics described, at 125 percent of target, and is included in the “Summary Compensation Table” in the column titled “Non-Equity Incentive Plan Compensation.”

<sup>2</sup> This row shows the range of payouts for 2011-2012 PA grants as described in the section titled “Equity Incentives—Performance Awards” in the “Compensation Discussion and Analysis.” The 2011-2012 PA will pay out in January 2013 based on cumulative EPS for 2011 and 2012. Payouts will range from 0 to 150 percent of target and will be in the form of restricted stock units, vesting in February 2014.

<sup>3</sup> This row shows the range of payouts for 2011-2013 SVA grants as described in the section titled “Equity Incentives—Shareholder Value Awards” in the “Compensation Discussion and Analysis.” The 2011-2013 SVA payout will be determined in January 2014. SVA payouts range from 0 to 140 percent of target.

To receive a payout under the PA or the SVA, a participant must remain employed with the company through the end of the relevant performance period (except in the case of death, disability, or retirement). In addition, an employee who was an executive officer at the time of grant will receive payment in restricted stock units according to the chart titled “Performance and Holding Periods for PAs and SVAs” in the “Compensation Discussion and Analysis.” SVAs granted in 2011 will pay out in common stock at the end of the three-year performance period according to the grid in the section of the “Compensation Discussion and Analysis” titled “Equity Incentives—Shareholder Value Awards,” provided the participant is still employed with the company (except in the case of death, disability, or retirement). No dividends accrue on either PAs or SVAs during the performance period. Non-preferential dividends accrue on earned PA’s one-year restriction period following the two-year performance period and these accrued dividends are paid upon vesting.

## Outstanding Equity Awards at December 31, 2011

Name	Option Awards			Stock Awards				
	Number of Securities Underlying Unexercised Options (#) <sup>1</sup> Exercisable	Option Exercise Price (\$)	Option Expiration Date	Award	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested (\$)	Equity Incentive Plan Awards: Number of Unearned Shares, Units, or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units, or Other Rights That Have Not Vested (\$)
Dr. Lechleiter	140,964 127,811 200,000 120,000 120,000 <sup>7</sup>	\$56.18 \$55.65 \$73.11 \$57.85 \$75.92	02/09/2016 02/10/2015 02/14/2014 02/15/2013 02/17/2012	2011-2013 SVA 2010-2012 SVA 2011-2012 PA 2010-2011 PA 2009-2010 PA	132,367 <sup>5</sup> 219,812 <sup>6</sup>	\$5,501,173 \$9,135,387	149,522 <sup>2</sup> 170,145 <sup>3</sup> 117,555 <sup>4</sup>	\$6,214,134 \$7,071,226 \$4,885,586
Mr. Rice	30,000 27,108 23,077 25,000 11,200 10,000	\$52.54 \$56.18 \$55.65 \$73.11 \$57.85 \$75.92	04/29/2016 02/09/2016 02/10/2015 02/14/2014 02/15/2013 02/17/2012	2011-2013 SVA 2010-2012 SVA 2011-2012 PA 2010-2011 PA 2009-2010 PA	52,947 <sup>5</sup> 87,924 <sup>6</sup>	\$2,200,477 \$3,654,121	75,758 <sup>2</sup> 68,058 <sup>3</sup> 59,561 <sup>4</sup>	\$3,148,502 \$2,828,490 \$2,475,355
Mr. Carmine	37,651 42,604 55,000 57,000 50,000	\$56.18 \$55.65 \$73.11 \$57.85 \$75.92	02/09/2016 02/10/2015 02/14/2014 02/15/2013 02/17/2012	2011-2013 SVA 2010-2012 SVA 2011-2012 PA 2010-2011 PA 2009-2010 PA	52,947 <sup>5</sup> 87,924 <sup>6</sup>	\$2,200,477 \$3,654,121	59,809 <sup>2</sup> 68,058 <sup>3</sup> 47,022 <sup>4</sup>	\$2,485,662 \$2,828,490 \$1,954,234
Dr. Lundberg				2011-2013 SVA 2010-2012 SVA 2011-2012 PA 2010-2011 PA Grant upon hire	44,122 <sup>5</sup> 66,667 <sup>8</sup>	\$1,833,710 \$2,770,681	54,825 <sup>2</sup> 56,715 <sup>3</sup> 43,103 <sup>4</sup>	\$2,278,527 \$2,357,075 \$1,791,361
Mr. Armitage	54,217 53,254 80,000 80,000 23,800	\$56.18 \$55.65 \$73.11 \$57.85 \$75.92	02/09/2016 02/10/2015 02/14/2014 02/15/2013 02/17/2012	2011-2013 SVA 2010-2012 SVA 2011-2012 PA 2010-2011 PA 2009-2010 PA	35,297 <sup>5</sup> 58,616 <sup>6</sup>	\$1,466,943 \$2,436,081	39,872 <sup>2</sup> 45,372 <sup>3</sup> 31,348 <sup>4</sup>	\$1,657,080 \$1,885,660 \$1,302,823

<sup>1</sup> These options vested as listed in the table below by expiration date.

Expiration Date	Vesting Date
04/29/2016	05/01/2009
02/09/2016	02/10/2009
02/10/2015	02/11/2008

Expiration Date	Vesting Date
02/14/2014	02/19/2007
02/15/2013	02/17/2006
02/17/2012	02/18/2005

<sup>2</sup> SVAs granted for the 2011-2013 performance period that will end December 31, 2013. The number of shares reported in the table reflects the target payout, which will be made if the average closing stock price in November and December 2013 is between \$39.60 and \$42.09. Actual payouts may vary from 0 to 140 percent of target. Had the performance period ended at year-end 2011, the payout would have been 80 percent of target.

<sup>3</sup> SVAs granted for the 2010-2012 performance period that will end December 31, 2012. The number of shares reported in the table reflects the target payout, which will be made if the average closing stock price in November and December 2012 is between \$41.00 and \$43.49. Actual payouts may vary from 0 to 140 percent of target. Had the performance period ended at year-end 2011, the payout would have been 80 percent of target.

<sup>4</sup> Target number of PA shares that could pay out in January 2013 for 2011-2012 performance, provided performance goals are met. Any shares resulting from this award will pay out in the form of restricted stock units, vesting February 2014. Actual payouts may vary from 0 to 150 percent of target.

<sup>5</sup> The 2010-2011 PA paid out at 109 percent of target in January 2012 in the form of restricted stock units, vesting February 2013.

<sup>6</sup> PA shares paid out in January 2011 for 2009-2010 performance. These shares vested in February 2012.

<sup>7</sup> 50,734 shares of this option are held in trust for the benefit of Dr. Lechleiter's children.

<sup>8</sup> Dr. Lundberg's restricted stock unit award was granted February 1, 2010; one third vested on February 1, 2011, one third vested February 1, 2012, and the remaining shares will vest February 1, 2013.

### Options Exercised and Stock Vested in 2011

Name	Option Awards		Stock Awards	
	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise (\$) <sup>1</sup>	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting (\$) <sup>2</sup>
Dr. Lechleiter	0	\$0	207,354 <sup>3</sup> 97,498 <sup>4</sup>	\$ 7,300,934 \$ 4,052,017
Mr. Rice	0	\$0	82,942 <sup>3</sup> 38,999 <sup>4</sup>	\$ 2,920,388 \$ 1,620,798
Mr. Carmine	0	\$0	82,942 <sup>3</sup> 38,999 <sup>4</sup>	\$ 2,920,388 \$ 1,620,798
Dr. Lundberg	0	\$0	33,333 <sup>5</sup> — <sup>6</sup>	\$ 1,173,655 —
Mr. Armitage	0	\$0	55,294 <sup>3</sup> 25,999 <sup>4</sup>	\$ 1,946,902 \$ 1,080,518

<sup>1</sup> All outstanding stock options are currently under water.

<sup>2</sup> Amounts reflect the market value of the stock on the day the stock vested.

<sup>3</sup> PAs issued in January 2010 (as restricted stock units) for company performance in 2009 and subject to forfeiture until they vested in February 2011.

<sup>4</sup> Payout of the 2009-2011 SVA at 80 percent of target.

<sup>5</sup> One third of a one-time grant of restricted stock units awarded to Dr. Lundberg when he joined the company in 2010.

<sup>6</sup> The 2009-2011 SVA was granted prior to Dr. Lundberg joining the company.

### Retirement Benefits

We provide retirement income to U.S. employees, including executive officers, through the following plans:

- *The 401(k) plan*, a defined contribution plan qualified under Sections 401(a) and 401(k) of the Internal Revenue Code. Participants may elect to contribute a portion of their salary to the plan, and the company provides matching contributions on employees' contributions, in the form of company stock, up to 6 percent of base salary. The employee contributions, company contributions, and earnings thereon are paid out in accordance with elections made by the participant. See the footnotes to "Summary Compensation Table" for information about company contributions for the named executive officers.
- *The retirement plan*, a tax-qualified defined benefit plan that provides monthly benefits to retirees. See the "Pension Benefits in 2011" table below for additional information about the value of these pension benefits.

Sections 401 and 415 of the Internal Revenue Code generally limit the amount of annual pension that can be paid from a tax-qualified plan (\$195,000 in 2011) as well as the amount of annual earnings that can be used to calculate a pension benefit (\$245,000 in 2011). However, since 1975, the company has maintained a nonqualified pension plan that pays retirees the difference between the amount payable under the retirement plan and the amount they would have received without the Internal Revenue Code limits. The nonqualified pension plan is unfunded and subject to forfeiture in the event of bankruptcy.

The following table shows benefits that the named executive officers are entitled to under the retirement plan and the nonqualified pension plan.

### Pension Benefits in 2011

Name	Plan	Number of Years of Credited Service	Present Value of Accumulated Benefit (\$) <sup>1</sup>	Payments During Last Fiscal Year (\$)
Dr. Lechleiter <sup>2</sup>	retirement plan (pre-2010)	30	\$1,381,238	\$0
	retirement plan (post-2009)	2	\$46,990	
	nonqualified plan (pre-2010)	30	\$23,737,164	
	nonqualified plan (post-2009)	2	\$737,386	
	total		\$25,902,778	
Mr. Rice	retirement plan (pre-2010)	20	\$528,761	\$0
	retirement plan (post-2009)	2	\$27,159	
	nonqualified plan (pre-2010)	20	\$3,963,000	
	nonqualified plan (post-2009)	2	\$190,047	
	total		\$4,708,967	
Mr. Carmine <sup>4</sup>	retirement plan (pre-2010)	34	\$1,509,446	\$0
	retirement plan (post-2009)	2	\$51,915	
	nonqualified plan (pre-2010)	34	\$10,636,274	
	nonqualified plan (post-2009)	2	\$335,084	
	total		\$12,532,719	
Dr. Lundberg <sup>3</sup>	retirement plan (post-2009)	2	\$50,844	\$0
	nonqualified plan (post-2009)	2	\$273,897	
	total		\$324,741	
Mr. Armitage <sup>5</sup>	retirement plan (pre-2010)	10	\$385,046	\$0
	retirement plan (post-2009)	2	\$63,368	
	nonqualified plan (pre-2010)	10	\$2,903,057	
	nonqualified plan (post-2009)	2	\$404,168	
	total		\$3,755,639	

<sup>1</sup> The following standard actuarial assumptions were used to calculate the present value of each individual's accumulated pension benefit:

Discount rate:	5.11 percent
Mortality (post-retirement decrement only):	RP 2000CH
Pre-2010 joint and survivor benefit (% of pension):	50% until age 62; 25% thereafter
Post-2009 benefit payment form:	life annuity

<sup>2</sup> Dr. Lechleiter is currently eligible for full retirement benefits under the old plan formula (pre-2010 benefits) and qualifies for early retirement under the new plan formula (post-2009 benefits, as described below).

<sup>3</sup> Dr. Lundberg joined the company in January 2010. He is covered under our retirement plans and has no special retirement arrangement or enhanced benefits.

<sup>4</sup> Mr. Carmine retired December 31, 2011, with full retirement benefits under the old plan formula and early retirement benefits under the new plan formula.

<sup>5</sup> Mr. Armitage is currently eligible for full retirement benefits under the old plan formula and qualifies for early retirement under the new plan formula. His additional service credit, described below, applies only to benefits calculated under the old plan formula and increases the present value of his nonqualified pension benefit by \$211,289.

The retirement plan benefits shown in the table are net present values. The benefits are not payable as a lump sum; they are generally paid as a monthly annuity for the life of the retiree and, if elected, any qualifying survivor. The annual benefit under the retirement plan is calculated using years of service and the average of the annual earnings for the highest five out of the last 10 calendar years of service (final average earnings). Annual earnings covered by the retirement plan consist of salary and bonus paid in those calendar years. For calendar years prior to 2003, the calculation includes PA payouts.

Following amendment of our retirement plan formulae, employees hired on or after February 1, 2008 have accrued retirement benefits only under the new plan formula. Employees hired before that date have accrued benefits under both the old and new plan formulae. All eligible employees, including those hired on or after February 1, 2008, can retire at age 65 with at least five years of service and receive an unreduced benefit. The annual benefit under the new plan formula is equal to 1.2 percent of final average earnings multiplied by years of service. Early retirement benefits under this plan formula are reduced 6 percent for each year under age 65. Transition benefits were afforded to employees with 50 points (age plus service) or more as of December 31, 2009. These benefits were intended to ease the transition to the new retirement formula for those employees who are closer to retirement or have been with the company longer. For the transition group, early retirement benefits are reduced 3 percent for each year from age 65 to age 60 and 6 percent for each year under age 60. With the exception of Dr. Lundberg, all of the named executive officers are in this transition group.

Employees hired prior to February 1, 2008 accrued benefits under both plan formulae. Benefits accrued before January 1, 2010 under the old plan formula. The amount of the benefit is calculated using actual years of service through December 31, 2009, while total years of service is used to determine eligibility and early retirement reductions. The benefit amount is increased (but not decreased) proportionately, based on final average earnings at termination compared to final average earnings at December 31, 2009. Full retirement benefits are earned by employees with 90 or more points (the sum of his or her age plus years of service). Employees electing early retirement receive reduced benefits as described below:

- The benefit for employees with between 80 and 90 points is reduced by 3 percent for each year under 90 points or age 62.
- The benefit for employees who have less than 80 points, but who reached age 55 and have at least 10 years of service, is reduced as described above and is further reduced by 6 percent for each year under 80 points or age 65.

For retirees with spouses, domestic partners, or unmarried dependents, the plan will pay survivor annuity benefits upon the retiree's death at 25, 50, or 75 percent of the retiree's annuity benefit, depending on the employee's elections. Election of the higher survivor benefit will result in a lower annuity payment during the retiree's life. All U.S. retirees, or their eligible survivors, are entitled to medical insurance under the company's plans.

When Mr. Armitage joined the company in 1999, the company agreed to provide him with a retirement benefit based on his actual years of service and earnings at age 60. Since Mr. Armitage reached age 60 with 8.75 years of service, for purposes of determining eligibility and calculating his early retirement reduction, he has been treated as though he has 20 years of service. The additional service credit made him eligible to begin reduced benefits 15 months early, but did not change the timing or amount of his unreduced benefits (shown in the "Pension Benefits in 2011" table). A grant of additional years of service credit to any employee must be approved by the compensation committee of the board of directors.

### Nonqualified Deferred Compensation in 2011

Name	Plan	Executive Contributions in Last Fiscal Year (\$) <sup>1</sup>	Registrant Contributions in Last Fiscal Year (\$) <sup>2</sup>	Aggregate Earnings in Last Fiscal Year (\$)	Aggregate Withdrawals/Distributions in Last Fiscal Year (\$)	Aggregate Balance at Last Fiscal Year End (\$) <sup>3</sup>
Dr. Lechleiter	nonqualified savings	\$75,300	\$75,300	\$84,287	\$0	\$1,484,653
	deferred compensation	\$1,491,000	—	\$344,797		\$8,886,684
	total	\$1,566,300	\$75,300	\$429,083		\$10,371,337
Mr. Rice	nonqualified savings	\$44,350	\$44,350	\$33,794	\$0	\$553,967
	deferred compensation	\$0	—	\$0		\$0
	total	\$44,350	\$44,350	\$33,794		\$553,967
Mr. Carmine	nonqualified savings	\$42,402	\$42,402	\$25,156	\$0	\$607,956
	deferred compensation	\$0	—	\$67,130		\$1,680,836
	total	\$42,402	\$42,402	\$92,285		\$2,288,793
Dr. Lundberg	nonqualified savings	\$43,725	\$43,725	\$13,931	\$0	\$190,496
	deferred compensation	\$0	—	\$0		\$0
	total	\$43,725	\$43,725	\$13,931		\$190,496
Mr. Armitage	nonqualified savings	\$35,754	\$35,754	\$33,292	\$0	\$657,693
	deferred compensation	\$0	—	\$254,676		\$6,376,759
	total	\$35,754	\$35,754	\$287,969		\$7,034,451

<sup>1</sup> The amounts in this column are also included in the "Summary Compensation Table," in the "Salary" column (nonqualified savings) or the "Non-Equity Incentive Plan Compensation" column (deferred compensation).

<sup>2</sup> The amounts in this column are also included in the “Summary Compensation Table,” in the “All Other Compensation” column as a portion of the savings plan match.

<sup>3</sup> Of the totals in this column, the following amounts have previously been reported in the “Summary Compensation Table” for this year and for previous years:

Name	2011 (\$)	Previous Years (\$)	Total (\$)
Dr. Lechleiter	\$1,641,600	\$6,421,031	\$8,062,631
Mr. Rice	\$88,700	\$345,504	\$434,204
Mr. Carmine	\$84,804	\$1,078,713	\$1,163,517
Dr. Lundberg	\$87,450	\$84,168	\$171,618
Mr. Armitage	\$71,508	\$5,864,427	\$5,935,935

The Nonqualified Deferred Compensation in 2011 table above shows information about two company programs: the nonqualified savings plan and the deferred compensation plan. The nonqualified savings plan is designed to allow each employee to contribute up to 6 percent of his or her base salary, and receive a company match, beyond the contribution limits prescribed by the IRS with regard to 401(k) plans. This plan is administered in the same manner as the 401(k) plan, with the same participation and investment elections. Executive officers and other U.S. executives may also defer receipt of all or part of their cash compensation under the deferred compensation plan. Amounts deferred by executives under this plan are credited with interest at 120 percent of the applicable federal long-term rate as established the preceding December by the U.S. Treasury Department under Section 1274(d) of the Internal Revenue Code with monthly compounding, which was 4.2 percent for 2011 and is 3.3 percent for 2012. Participants may elect to receive the funds in a lump sum or in up to 10 annual installments following retirement, but may not make withdrawals during their employment, except in the event of hardship as approved by the compensation committee. All deferral elections and associated distribution schedules are irrevocable. Both plans are unfunded and subject to forfeiture in the event of bankruptcy.

#### **Potential Payments Upon Termination or Change in Control**

The following table describes the potential payments and benefits under the company’s compensation and benefit plans and arrangements to which the named executive officers would be entitled upon termination of employment. Except for (i) certain terminations following a change in control of the company, as described below, and (ii) the pension arrangement for Mr. Armitage described under “Retirement Benefits” above, there are no agreements, arrangements, or plans that entitle named executive officers to severance, perquisites, or other enhanced benefits upon termination of their employment. Any agreement to provide such payments or benefits to a terminating executive officer (other than following a change in control) would be at the discretion of the compensation committee.

## Potential Payments Upon Termination of Employment (as of December 31, 2011)

	Cash Severance Payment	Incremental Pension Benefit (present value)	Continuation of Medical / Welfare Benefits (present value) <sup>1</sup>	Value of Acceleration of Equity Awards <sup>2</sup>	Excise Tax Gross-Up <sup>3</sup>	Total Termination Benefits
<b>Dr. Lechleiter</b>						
• Voluntary retirement	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary retirement or termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary or good reason termination after change in control	\$7,200,000	\$0	\$17,100	\$5,800,170	\$0	\$13,017,270
<b>Mr. Rice</b>						
• Voluntary termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary retirement or termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary or good reason termination after change in control	\$3,762,000	\$0	\$33,300	\$2,918,881	\$0	\$6,714,181
<b>Mr. Carmine <sup>4</sup></b>						
• Voluntary retirement	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary retirement or termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary or good reason termination after change in control	\$0	\$0	\$0	\$0	\$0	\$0
<b>Dr. Lundberg</b>						
• Voluntary termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary retirement or termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary or good reason termination after change in control	\$3,718,300	\$0	\$17,100	\$2,439,245	\$2,129,702	\$8,304,348
<b>Mr. Armitage <sup>5</sup></b>						
• Voluntary retirement	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary retirement or termination	\$0	\$0	\$0	\$0	\$0	\$0
• Involuntary or good reason termination after change in control	\$3,027,240	\$0	\$17,100	\$1,546,706	\$0	\$4,591,046

<sup>1</sup> See “Accrued Pay and Regular Retirement Benefits” and “Change-in-Control Severance Pay Plan—Continuation of medical and welfare benefits” below.

<sup>2</sup> Beginning in 2010, equity grants included an individual performance criterion to vest. As a result, even retirement-eligible employees have the possibility of forfeiting their grants.

<sup>3</sup> Beginning in October 2012, the company will eliminate excise tax gross-ups.

<sup>4</sup> Mr. Carmine retired on December 31, 2011.

<sup>5</sup> Mr. Armitage’s incremental pension benefit is described in the “Retirement Benefits” section.

**Accrued Pay and Regular Retirement Benefits.** The amounts shown in the table above do not include certain payments and benefits to the extent they are provided on a non-discriminatory basis to salaried employees generally upon termination of employment. These include:

- accrued salary and vacation pay.
- regular pension benefits under the retirement plan and the nonqualified pension plan. See “Retirement Benefits.”
- welfare benefits provided to all U.S. retirees, including retiree medical and dental insurance. The amounts shown in the table above as “Continuation of Medical / Welfare Benefits” are explained below.
- distributions of plan balances under the 401(k) plan and the nonqualified savings plan. See the narrative following the “Nonqualified Deferred Compensation in 2011” table for information about these plans.

**Deferred Compensation.** The amounts shown in the table do not include distributions of plan balances under the deferred compensation plan. Those amounts are shown in the “Nonqualified Deferred Compensation in 2011” table.

**Death and Disability.** A termination of employment due to death or disability does not entitle named executive officers to any payments or benefits that are not available to salaried employees generally.

**Termination for Cause.** Executives receive no severance or medical benefits and forfeit any unvested equity grants. Mr. Armitage’s pension arrangement is described in the “Retirement Benefits” section; no other executive officer has an enhanced pension arrangement.

**Change-in-Control Severance Pay Plan.** As described in the “Compensation Discussion and Analysis” under “Severance Benefits,” the company maintains a change-in-control severance pay plan (CIC plan) for nearly all employees, including the named executive officers. The CIC plan defines a change in control very specifically, but

generally the terms include the occurrence of, or entry into, an agreement to do one of the following: (i) acquisition of 20 percent or more of the company's stock; (ii) replacement by the shareholders of one half or more of the board of directors; (iii) consummation of a merger, share exchange, or consolidation of the company; or (iv) liquidation of the company or sale or disposition of all or substantially all of its assets. The amounts shown in the table for "involuntary or good reason termination after change in control" are based on the following assumptions and plan provisions:

- *Covered terminations.* The table assumes a termination of employment that is eligible for severance under the terms of the current plan, based on the named executive officer's compensation, benefits, age, and service credit at December 31, 2011. Eligible terminations include an involuntary termination for reasons other than for cause or a voluntary termination by the executive for good reason, within two years following the change in control.
  - A termination of an executive officer by the company is for cause if it is for any of the following reasons: (i) the employee's willful and continued refusal to perform, without legal cause, his or her material duties, resulting in demonstrable economic harm to the company; (ii) any act of fraud, dishonesty, or gross misconduct resulting in significant economic harm or other significant harm to the business reputation of the company; or (iii) conviction of or the entering of a plea of guilty or *nolo contendere* to a felony.
  - A termination by the executive officer is for good reason if it results from: (i) a material diminution in the nature or status of the executive's position, title, reporting relationship, duties, responsibilities, or authority, or the assignment to him or her of additional responsibilities that materially increase his or her workload; (ii) any reduction in the executive's then-current base salary; (iii) a material reduction in the executive's opportunities to earn incentive bonuses below those in effect for the year prior to the change in control; (iv) a material reduction in the executive's employee benefits from the benefit levels in effect immediately prior to the change in control; (v) the failure to grant to the executive stock options, stock units, performance shares, or similar incentive rights during each 12-month period following the change in control on the basis of a number of shares or units and all other material terms at least as favorable to the executive as those rights granted to him or her on an annualized average basis for the three-year period immediately prior to the change in control; or (vi) relocation of the executive by more than 50 miles.
- *Cash severance payment.* Represents the CIC plan benefit of two times the employee's 2011 annual base salary plus two times the employee's bonus target for 2011 under the bonus plan.
- *Continuation of medical and welfare benefits.* Represents the present value of the CIC plan's guarantee, following a covered termination, for 18 months of continued coverage equivalent to the company's current active employee medical, dental, life, and long-term disability insurance. Similar actuarial assumptions to those used to calculate incremental pension benefits apply to the calculation for continuation of medical and welfare benefits, with the addition of actual COBRA rates based on current benefit elections.
- *Acceleration of equity awards.* Upon a covered termination, any unvested equity awards would vest. Payment of SVAs is accelerated in the case of a change in control in which Lilly is not the surviving entity. The amount in this column represents the value of the acceleration of unvested equity grants.
- *Excise tax reimbursement.* Upon a change in control, employees may be subject to certain excise taxes under Section 280G of the Internal Revenue Code. The company has agreed to reimburse the affected employees for those excise taxes as well as any income and excise taxes payable by the employee as a result of the reimbursement. The amounts in the table are based on a 280G excise tax rate of 20 percent and a 40 percent federal, state, and local income tax rate. To reduce the company's exposure to these reimbursements, the employee's severance will be cut back by up to 5 percent if the effect is to avoid triggering the excise tax under Section 280G. Beginning in October 2012, excise taxes will no longer be reimbursed.

**Payments Upon Change in Control Alone.** In general, the CIC plan is a "double trigger" plan, meaning payments are made only if the employee suffers a covered termination of employment within two years following the change in control. Employees do not receive payments upon a change in control alone, except that upon consummation of a change in control a partial payment of outstanding PAs would be made, reduced to reflect the portion of the performance period worked prior to the change in control. Likewise, in the case of a change in control in which Lilly is not the surviving entity, SVAs will pay out based on the change-in-control stock price and be prorated for the portion of the three-year performance period elapsed.

## Ownership of Company Stock

### Common Stock Ownership by Directors and Executive Officers

The following table sets forth the number of shares of company common stock beneficially owned by the directors, the named executive officers, and all directors and executive officers as a group, as of February 1, 2012.

The table shows shares held by named executive officers in the 401(k) plan, shares credited to the accounts of outside directors in the Lilly Directors' Deferral Plan, and total shares beneficially owned by each individual, including the shares in these two plans. In addition, the table shows restricted stock units that will be issued as shares of common stock at the end of the restriction period and shares that may be purchased pursuant to stock options that are exercisable within 60 days of February 1, 2012. All of the stock options shown are currently under water.

Name	401(k) Plan Shares	Directors' Deferral Plan Shares <sup>1</sup>	Total Shares Owned Beneficially <sup>2</sup>	Restricted Stock Units <sup>3</sup>	Stock Options Exercisable Within 60 Days of February 1, 2012
Ralph Alvarez	—	12,897	12,897	—	—
Robert A. Armitage	3,583	—	134,132	35,297	291,271
Katherine Baicker, Ph.D.	—	0	0	—	—
Sir Winfried Bischoff	—	32,059	34,059	—	8,400
Bryce D. Carmine <sup>4</sup>	6,869	—	58,055	87,924	242,255
Michael L. Eskew	—	18,223	18,223	—	—
Martin S. Feldstein, Ph.D.	—	30,043	31,043	—	8,400
J. Erik Fyrwald	—	35,581	35,681	—	—
Alfred G. Gilman, M.D., Ph.D.	—	39,361	39,361	—	8,400
R. David Hoover	—	17,786	18,786	—	—
Karen N. Horn, Ph.D.	—	55,110	55,110	—	8,400
John C. Lechleiter, Ph.D.	17,989	—	503,939 <sup>5</sup>	132,367	708,775
Jan M. Lundberg, Ph.D.	904	—	34,251	77,456	—
Ellen R. Marram	—	30,043	31,043	—	5,600
Douglas R. Oberhelman	—	12,897	12,897	—	—
Franklyn G. Prendergast, M.D., Ph.D.	—	46,315	46,315	—	8,400
Derica W. Rice	7,872	—	176,512	52,947	126,385
Kathi P. Seifert	—	41,428	44,961	—	8,400
All directors and executive officers as a group [28 people]:			1,554,851 <sup>6</sup>		

<sup>1</sup> See the description of the "Lilly Directors' Deferral Plan."

<sup>2</sup> Unless otherwise indicated in a footnote, each person listed in the table possesses sole voting and sole investment power with respect to their shares. No person listed in the table owns more than 0.10 percent of the outstanding common stock of the company. All directors and executive officers as a group own 0.28 percent of the outstanding common stock of the company.

<sup>3</sup> Except for Mr. Carmine, this column shows, the 2010-2011 PAs paid out in January 2012 in restricted stock units. These shares will vest in February 2013, and have no voting rights until they vest. Mr. Carmine's restricted stock units are shown as of his retirement on December 31, 2011 and they vested on February 1, 2012. Dr. Lundberg's restricted stock units include 33,334 shares from an award granted February 1, 2010 which will vest February 1, 2013. The company considers restricted stock units for purposes of determining whether executive share ownership guidelines are met.

<sup>4</sup> The shares shown for Mr. Carmine are presented as of his retirement on December 31, 2011.

<sup>5</sup> The shares shown for Dr. Lechleiter include 24,405 shares that are owned by a family foundation for which he is a director. Dr. Lechleiter has shared voting power and shared investment power with respect to the shares held by the foundation.

<sup>6</sup> Shares belonging to retired executive officers are shown as of their retirement date.

### Principal Holders of Stock

To the best of the company's knowledge, the only beneficial owners of more than 5 percent of the outstanding shares of the company's common stock are the shareholders listed below:

<u>Name and Address</u>	<u>Number of Shares Beneficially Owned</u>	<u>Percent of Class</u>
Lilly Endowment, Inc. (the "Endowment") 2801 North Meridian Street Indianapolis, Indiana 46208	135,670,804 (as of 2/9/12)	11.7%
BlackRock, Inc. 40 East 52nd Street New York, New York 10022	62,397,499 (as of 12/31/11)	5.4%

The Endowment has sole voting and sole investment power with respect to its shares. The board of directors of the Endowment is composed of Thomas M. Lofton, chairman; N. Clay Robbins, president; Mary K. Lisher; Otis R. Bowen, emeritus director; William G. Enright; Daniel P. Carmichael; Charles E. Golden; Eli Lilly II; and David N. Shane. Each of the directors is, either directly or indirectly, a shareholder of the company.

BlackRock, Inc. provides investment management services for various clients. It has sole voting and sole investment power with respect to its shares.

## *Items of Business To Be Acted Upon at the Meeting*

### **Item 1. Election of Directors**

Under the company's articles of incorporation, the board is divided into three classes with approximately one-third of the directors standing for election each year. The term for directors elected this year will expire at the annual meeting of shareholders held in 2015. Each of the nominees listed below has agreed to serve that term. If any director is unable to stand for election, the board may, by resolution, provide for a lesser number of directors or designate a substitute. In the latter event, shares represented by proxy may be voted for a substitute director.

#### **The board recommends that you vote FOR each of the following nominees:**

- Katherine Baicker, Ph.D.
- J. Erik Fyrwald
- Ellen R. Marram
- Douglas R. Oberhelman

Biographical information about these nominees and a statement of their qualifications may be found in the "Director Biographies" section.

### **Item 2. Proposal to Ratify the Appointment of Principal Independent Auditor**

The audit committee has appointed the firm of Ernst & Young LLP as principal independent auditor for the company for the year 2012. In accordance with the bylaws, this appointment is being submitted to the shareholders for ratification. Ernst & Young served as the principal independent auditor for the company in 2011. Representatives of Ernst & Young are expected to be present at the annual meeting and will be available to respond to questions. Those representatives will have the opportunity to make a statement if they wish to do so.

#### **The board recommends that you vote FOR ratifying the appointment of Ernst & Young LLP as principal independent auditor for 2012.**

### **Item 3. Advisory Vote on Compensation Paid to Named Executive Officers**

Our compensation philosophy is designed to attract and retain highly-talented individuals and motivate them to create long-term shareholder value by achieving top-tier corporate performance while embracing the company's values of integrity, excellence, and respect for people. Our programs seek to:

- closely link compensation with company performance and individual performance
- foster a long-term focus
- reflect the market for pharmaceutical talent
- be efficient and egalitarian
- appropriately mitigate risk.

The compensation committee and the board of directors believe that our executive compensation aligns well with our philosophy and with corporate performance. We urge shareholders to read the "Compensation Discussion and Analysis" section of this proxy statement for a more detailed discussion of our executive compensation programs and how they reflect our philosophy and are linked to company performance.

Executive compensation is an important matter for our shareholders. We have a strong record of engagement with shareholders on compensation matters and have made a number of changes to our programs and disclosures in response to shareholder input, including several enhancements discussed in the "Compensation Discussion and Analysis."

We request shareholder approval, on an advisory basis, of the compensation of the company's named executive officers as disclosed in this proxy statement in the "Compensation Discussion and Analysis," the compensation tables, and related narratives. As an advisory vote, this proposal is not binding on the company. However, the compensation committee values input from shareholders and will consider the outcome of the vote when making future executive compensation decisions.

**The board recommends that you vote FOR the approval, on an advisory basis, of the compensation paid to the named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, the compensation tables, and related narratives in this proxy statement.**

#### **Item 4. Proposal to Amend the Company's Articles of Incorporation to Provide for Annual Election of All Directors**

The company's articles of incorporation provide that the board of directors is divided into three classes, with each class elected every three years. On the recommendation of the directors and corporate governance committee, the board has approved, and recommends that the shareholders approve, amendments to provide for the annual election of all directors. This proposal was brought before shareholders at each of the last five annual meetings, receiving the vote of more than 73 percent of the outstanding shares at each meeting; however, the proposal requires the vote of 80 percent of the outstanding shares to pass.

If approved, this proposal would become effective upon the filing of amended and restated articles of incorporation with the Secretary of State of Indiana, which the company would do promptly after shareholder approval is obtained. Directors elected prior to the effectiveness of the amendments would stand for election for one-year terms once their then-current terms expire. This means that directors whose terms expire at the 2013 and 2014 annual meetings of shareholders would be elected for one-year terms, and beginning with the 2015 annual meeting, all directors would be elected for one-year terms at each annual meeting. In the case of any vacancy on the board occurring after the 2012 annual meeting created by an increase in the number of directors, the vacancy would be filled through an interim election by the board with the new director to serve a term ending at the next annual meeting. Vacancies created by resignation, removal, or death would be filled by interim election of the board for a term until the end of the term of the director being replaced. This proposal would not change the present number of directors or the board's authority to change that number and to fill any vacancies or newly-created directorships.

#### **Background of Proposal**

As part of its ongoing review of corporate governance matters, the board, assisted by the directors and corporate governance committee, considered the advantages and disadvantages of maintaining the classified board structure and eliminating the supermajority voting provisions of the articles of incorporation (see "Item 5" below). The board considered the view of some shareholders who believe that classified boards have the effect of reducing the accountability of directors to shareholders because shareholders are unable to evaluate and elect all directors on an annual basis. The board gave considerable weight to the approval at the 2006 annual meeting of a shareholder proposal requesting that the board take all necessary steps to elect the directors annually, and to the favorable votes of over 73 percent of the outstanding shares for management's proposals in each of the following five years.

The board also considered benefits of retaining the classified board structure, which has a long history in corporate law. A classified structure may provide continuity and stability in the management of the business and affairs of the company because a majority of directors always have prior experience as directors of the company. In some circumstances classified boards may enhance shareholder value by forcing an entity seeking control of the company to initiate discussions at arm's-length with the board of the company, because the entity cannot replace the entire board in a single election. The board also considered that even without a classified board (and without the supermajority voting requirements, which the board also recommends eliminating), the company has defenses that work together to discourage a would-be acquirer from proceeding with a proposal that undervalues the company and to assist the board in responding to such proposals. These defenses include other provisions of the company's articles of incorporation and bylaws as well as certain provisions of Indiana corporation law.

The board believes it is important to maintain appropriate defenses to inadequate takeover bids, but also important to retain shareholder confidence by demonstrating that it is accountable and responsive to shareholders. After balancing these interests, the board has decided to resubmit this proposal to eliminate the classified board structure.

#### **Text of Amendments**

Article 9(b) of the company's amended articles of incorporation contains the provisions that will be affected if this proposal is adopted. This article, set forth in "Appendix A" to this proxy statement, shows the proposed changes with deletions indicated by strike-outs and additions indicated by underlining. The board has also adopted conforming amendments to the company's bylaws, to be effective immediately upon the effectiveness of the amendments to the amended articles of incorporation.

#### **Vote Required**

The affirmative vote of at least 80 percent of the outstanding common shares is needed to pass this proposal.

**The board recommends that you vote FOR amending the company's articles of incorporation to provide for annual election of all directors.**

### **Item 5. Proposal to Amend the Company's Articles of Incorporation to Eliminate All Supermajority Voting Requirements**

Under the company's articles of incorporation, nearly all matters submitted to a vote of shareholders can be adopted by a majority of the votes cast. However, our articles require a few fundamental corporate actions to be approved by the holders of 80 percent of the outstanding shares of common stock (a "supermajority vote"). Those actions are:

- amending certain provisions of the articles of incorporation that relate to the number and terms of office of directors:
  - the company's classified board structure (as described under Item 4)
  - a provision that the number of directors shall be specified solely by resolution of the board of directors
- removing directors prior to the end of their elected term
- entering into mergers, consolidations, recapitalizations, or certain other business combinations with a "related person"—a party who has acquired at least five percent of the company's stock (other than the Lilly Endowment or a company benefit plan) without the prior approval of the board of directors
- modifying or eliminating any of the above supermajority voting requirements.

#### **Background of Proposal**

This proposal is the result of the board's ongoing review of corporate governance matters. In 2007, 2008, and 2009, shareholder proposals requesting that the board take action to eliminate the supermajority voting provisions were supported by a majority of votes cast. In 2010 and 2011, the board responded by submitting proposals seeking shareholder approval to eliminate the provisions. In both years, the proposal received the votes of more than 72 percent of the outstanding shares, falling short of the required 80 percent.

Assisted by the directors and corporate governance committee, the board considered the advantages and disadvantages of maintaining the supermajority voting requirements. The board considered that under certain circumstances, supermajority voting provisions can provide benefits to the company. The provisions can make it more difficult for one or a few large shareholders to take over or restructure the company without negotiating with the board. In the event of an unsolicited bid to take over or restructure the company, supermajority voting provisions may encourage bidders to negotiate with the board and increase the board's negotiating leverage on behalf of the shareholders. They can also give the board time to consider alternatives that might provide greater value for all shareholders.

The board also considered the potential adverse consequences of opposing elimination of the supermajority voting requirements. While it is important to the company's long-term success for the board to maintain appropriate defenses against inadequate takeover bids, it is also important for the board to maintain shareholder confidence by demonstrating that it is responsive and accountable to shareholders and committed to strong corporate governance. This requires the board to carefully balance sometimes competing interests. In this regard, the board gave considerable weight to the fact that a substantial majority of shares voted have supported eliminating the supermajority voting provisions. Many shareholders believe that supermajority voting provisions impede accountability to shareholders and contribute to board and management entrenchment.

The board also considered that even without the supermajority vote (and without the classified board, which the board also recommends eliminating), the company has defenses that work together to discourage a would-be acquirer from proceeding with a proposal that undervalues the company and to assist the board in responding to such proposals. These defenses include other provisions of the company's articles of incorporation and bylaws as well as certain provisions of Indiana corporation law.

Therefore, the board believes the balance of interests is best served by recommending to shareholders that the articles of incorporation be amended to eliminate the supermajority voting provisions. By recommending these amendments, the board is demonstrating its accountability and willingness to take steps that address shareholder-expressed concerns.

#### **Text of Amendments**

Articles 9(c), 9(d), and 13 of the company's amended articles of incorporation contain the provisions that will be affected if this proposal is adopted. These articles, set forth in "Appendix A" to this proxy statement, show the proposed changes with deletions indicated by strike-outs and additions indicated by underlining.

#### **Vote Required**

The affirmative vote of at least 80 percent of the outstanding common shares is needed to pass this proposal.

**The board recommends that you vote FOR amending the company's articles of incorporation to eliminate all supermajority voting requirements.**

#### **Item 6. Shareholder proposal on establishing a majority vote committee**

Rebecca H. Brown, 3213 13<sup>th</sup> Avenue South, Seattle, Washington 98144, beneficial owner of approximately 100 shares, has submitted the following proposal:

##### **Majority Vote Committee**

RESOLVED, Shareholders request that our Board of Directors adopt a bylaw establishing an engagement process with proponents of shareholder proposals that are supported by a majority of the votes cast, excluding abstentions and broker non-votes, at any annual meeting.

This proposal requests our Board to take the following steps if a proposal, submitted by a shareholder for a vote according to Rule 14a-8 of the Securities and Exchange Commission, receives a majority of the votes cast:

- Within four months after the annual meeting, an independent board committee will schedule a meeting (which may be held telephonically and which is coordinated with the timing of a regularly scheduled board meeting) with the proposal proponent, to obtain any additional information for our Board in its consideration of the proposal.
- Following the proponent meeting, the independent board committee will present the proposal with the committee's recommendation, and relevant information, to our full Board, for action consistent with the company's charter and by-laws, which includes a consideration of the interest of shareholders.
- This independent board committee would be able to recommend a budget of \$25,000 or more to spend on special solicitations of shareholders to help adopt shareholder proposals that are supported by a majority of the votes cast.
- In adopting such a policy, our Board can abolish the committee if our company adopts the proposal or the proponent agrees with abolishing the committee.

This proposal would address situations where we give overwhelming support to a proposal and the proposal is not adopted by our company.

##### **Statement in Opposition to the Proposal**

The directors and corporate governance committee of the board has reviewed this proposal and recommends that you vote against it because it is not in the best long-term interests of shareholders. It is unnecessary, is overly prescriptive, and could divert board members' attention from other critical oversight duties.

**Lilly is already responsive to shareholder majority votes.** The shareholder proposal purports to address situations in which shareholders give overwhelming support to a proposal and the company thereafter fails to take the actions requested by shareholders. That is not the case at Lilly. In our history, we have received majority votes in favor of shareholder proposals concerning only two topics. In both cases, the Lilly board has responded by adopting the very actions requested by the shareholders:

- *Eliminate classified board.* In 2006, a majority of shareholders recommended that the board take the necessary actions to seek shareholder approval of amendments to the articles of incorporation to eliminate the classified board and provide for annual election of directors. Beginning in 2007 and every year thereafter, the board has recommended shareholder approval of just such amendments. Despite the board's recommendations, those proposals failed because they fell short of the necessary level of shareholder support (80 percent of the outstanding shares). The board is seeking shareholder approval again this year (see Item 4).
- *Eliminate supermajority voting provisions.* In 2007, 2008, and 2009, a majority of shareholders recommended that the board take the necessary actions to seek shareholder approval of amendments to the articles of incorporation to eliminate the 80 percent supermajority voting provisions. In 2010 and 2011, after dialogue with shareholders, the board did exactly that, submitting management proposals to eliminate the provisions. As with the classified board proposal, the supermajority proposals fell short of the necessary 80 percent vote of the outstanding shares. And as with the classified board proposal, the board is seeking shareholder approval again this year (see Item 5).

**Lilly already actively engages with shareholders on important matters irrespective of voting results.** We do not need the artifice of a special board committee to encourage us to talk with our shareholders. In addition to our extensive investor relations efforts, we actively engage with shareholders on matters of importance, including corporate governance, company operations, and social issues affecting the company. We have had extensive dialogue with shareholders on the two governance issues noted above, and that dialogue continues. We also engage in shareholder dialogue on many other important issues whether or not they would receive substantial voting support.

In addition, shareholders can communicate directly with the board of directors by writing to them in care of the corporate secretary.

**The independent directors already exercise oversight over shareholder issues.** We do not need a special board committee to inform the board of shareholder concerns. The independent directors are kept advised of shareholder views and concerns through regular reports by management to the board and relevant committees, particularly the directors and corporate governance committee and the compensation committee. The board and committees also periodically receive advice from outside advisors on shareholder relations issues.

**The proposal is too prescriptive and could divert the board's attention from other oversight issues.** Maintaining relations with shareholders is primarily a management function, subject to board oversight. In appropriate but limited circumstances, it can be beneficial for independent board members to meet directly with shareholders to discuss important issues. In fact, this has occurred at Lilly. However, involving board members in direct interactions should not be mandated in a one-size-fits-all fashion. If adopted, the shareholder proposal would require directors to engage unnecessarily in management tasks that could distract them from their primary role of providing oversight over company operations and strategy.

**The board recommends that you vote AGAINST this proposal.**

#### **Item 7. Shareholder proposal on transparency in animal research**

People for the Ethical Treatment of Animals (PeTA), 501 N. Front Street, Norfolk, Virginia 23510, on behalf of Meredith Page, beneficial owner of approximately 100 shares, has submitted the following proposal:

RESOLVED, to promote transparency and minimize the use of animals, the Board should issue an annual report to shareholders disclosing procedures to ensure proper animal care, including measures to improve the living conditions of all animals used in-house and at contract laboratories, as well as plans to promote alternatives to animal use.

#### **Supporting Statement**

As shown below, our Company has not been in compliance with its animal welfare policy.

In 2008, our Company's in-house laboratories used more than 3,000 animals, including 300 primates and almost 800 dogs. More than two-thirds of these animals were used in painful experiments. Vast numbers of others were used who are not required to be counted. The U.S. government cited our Company for the death of a dog who strangled in his cage.

A comparison of these figures to 2010 numbers shows that our Company is outsourcing much of its animal experimentation to U.S. and overseas laboratories, including to China, where there are few animal protection laws and enforcement is near non-existent.

In one U.S. contract laboratory used by our Company, Covance, Inc., an undercover investigator videotaped workers striking primates and throwing them against cages. Primates circled frantically in their cages, pulled out their hair, and chewed at their own flesh.

At other Covance facilities, a primate became trapped in his cage bars, unable to reach food or water for days, while others suffered frostbite from inadequate weather protection. The government has cited and fined Covance for improper care and failure to provide pain relief to suffering animals.

Documentation of abusive conditions at another contract laboratory used by our Company, Professional Laboratory and Research Services (PLRS), resulted this year in 14 felony cruelty charges against its employees. The government issued a report confirming the appalling conditions at the facility and PLRS is now out of business. The abuses included:

- Sick and injured animals—including dogs with ear and eye infections, diseased gums, facial lacerations, and inflamed feet—were routinely denied veterinary care;
- An untrained worker used pliers to pull a tooth from a struggling, under-sedated dog;
- Dogs and cats were slammed into cages, thrown, kicked and dragged;

- Dogs and cats were pressure-hosed with a bleach solution;
- A worker attempted to rip out a cat's nails by forcing the cat to clutch a chain-link fence and then violently pulling her away.

According to Food and Drug Administration documentation, our Company contracted PLRS to conduct experiments on more than 100 dogs.

Given that 92% of drugs deemed safe and effective when tested on animals fail in human clinical trials, there is also a clear scientific imperative for improving testing methods.

Shareholders cannot monitor what goes on behind the closed doors of animal testing laboratories, so the Company must. The Board must ensure that animal welfare and replacement measures are an integral part of our Company's corporate stewardship. We urge shareholders to vote in favor of this socially and ethically important proposal.

### **Statement in Opposition to the Proposal Regarding Transparency in Animal Research**

We share the concerns raised in this shareholder proposal. We abhor mistreatment of animals and we are committed to the appropriate treatment of animals in research. However, the public policy and compliance committee of the board has reviewed this proposal and recommends a vote against it.

We are committed to quality research-animal care and use, the responsible use of animals in medical research, and the use of alternative methods whenever possible and appropriate. We do not condone, in any form, the mistreatment of research animals, and we recognize our fundamental ethical and scientific obligation to ensure the appropriate treatment of animals used in research. We have processes and procedures in place to ensure humane treatment of animals, including programs for oversight by an Institutional Animal Care and Use Committee, or an equivalent ethical review board, as well as veterinary oversight at every site—both ours and contract laboratories.

We have been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). AAALAC accreditation rules and standards can be found on the AAALAC website ([www.aaalac.org](http://www.aaalac.org)). This accreditation is a voluntary process that includes a detailed, comprehensive review of our research animal program including animal care and use policies and procedures, animal environment, housing and management, veterinary medical care, and physical plant operations. We currently publish our animal care and use principles on our website ([www.lilly.com](http://www.lilly.com)).

For safe and effective medicines to be available to patients, U.S. and foreign regulatory agencies have mandated that a defined amount of research be performed in animals. Where animals must be used, we take every measure to assure that the lowest number of animals is used and that discomfort and distress are either eliminated or minimized.

As a global company, we develop contractual relationships with select laboratory-animal research and animal-supply companies inside and outside the U.S. We seek to do business only with those companies that share our commitment to animal welfare. We require these companies to maintain a quality animal care and use program. To ensure animal welfare, we assess third-party organization adherence to these expectations. If events suggest a laboratory has failed to meet our standards, we promptly investigate and act upon the allegations. These actions may include termination of a business relationship.

Given the information on animal care and use already published on our website, we believe an annual report is unnecessary.

**The board recommends that you vote AGAINST this proposal.**

## Meeting and Voting Logistics

### Additional items of business

We do not expect any items of business other than those above because the deadline for shareholder proposals and nominations has already passed. Nonetheless, if necessary, the accompanying proxy gives discretionary authority to the persons named on the proxy with respect to any other matters that might be brought before the meeting. Those persons intend to vote that proxy in accordance with their best judgment.

### Voting

Shareholders as of the close of business on February 15, 2012 (the record date) may vote at the annual meeting. You have one vote for each share of common stock you held on the record date, including shares:

- held directly in your name as the shareholder of record
- held for you in an account with a broker, bank, or other nominee
- attributed to your account in The Eli Lilly and Company Employee 401(k) Plan (the 401(k) plan).

If you are a shareholder of record, you may vote your shares in person at the meeting. However, we encourage you to vote by mail, by telephone, or on the Internet even if you plan to attend the meeting.

### Required vote

There are differing vote requirements for the various proposals.

- The four nominees for director will be elected if the votes cast for the nominee exceed the votes cast against the nominee. Abstentions will not count as votes cast either for or against a nominee.
- The following items of business will be approved if the votes cast for the proposal exceed those cast against the proposal:
  - ratification of the appointment of principal independent auditor
  - advisory approval of executive compensation
  - shareholder proposals.

Abstentions will not be counted either for or against these proposals.

- The proposals to amend the articles of incorporation to provide for annual election of all directors and to eliminate all supermajority voting requirements require the vote of 80 percent of the outstanding shares. For these items, abstentions and broker nonvotes have the same effect as a vote against the proposals.

### Quorum

A majority of the outstanding shares, present or represented by proxy, constitutes a quorum for the annual meeting. As of the record date, 1,160,406,840 shares of company common stock were issued and outstanding.

### Voting by proxy

If you are a shareholder of record, you may vote your proxy by any one of the following methods:

**On the Internet.** You may vote online at [www.proxyvote.com](http://www.proxyvote.com). Follow the instructions on your proxy card or notice. If you received these materials electronically, follow the instructions in the e-mail message that notified you of their availability. Voting on the Internet has the same effect as voting by mail. If you vote on the Internet, do not return your proxy card. Internet voting will be available until 11:59 p.m. EDT, April 15, 2012.

You have the right to revoke your proxy at any time before the meeting by (i) notifying the company's secretary in writing or (ii) delivering a later-dated proxy via the Internet, by mail, or by telephone. If you are a shareholder of record, you may also revoke your proxy by voting in person at the meeting.

**By mail.** Sign and date each proxy card you receive and return it in the prepaid envelope. Sign your name exactly as it appears on the proxy. If you are signing in a representative capacity (for example, as an attorney-in-fact, executor, administrator, guardian, trustee, or the officer or agent of a corporation or partnership), please indicate your name and your title or capacity. If the stock is held in custody for a minor (for example, under the Uniform Transfers to Minors Act), the custodian should sign, not the minor. If the stock is held in joint ownership, one owner may sign on behalf of all owners. If you return your signed proxy but do not indicate your voting preferences, we will vote on your behalf with the board's recommendations.

If you did not receive a proxy card in the materials you received from the company and you wish to vote by mail rather than by telephone or on the Internet, you may request a paper copy of these materials and a proxy card by calling 317-433-5112. If you received a notice or an e-mail message notifying you of the electronic availability of these materials, please provide the control number, along with your name and mailing address.

**By telephone.** Shareholders in the U.S., Puerto Rico, and Canada may vote by telephone by following the instructions on your proxy card or notice. If you received these materials electronically, follow the instructions in the e-mail message that notified you of their availability. Voting by telephone has the same effect as voting by mail. If you vote by telephone, do not return your proxy card. Telephone voting will be available until 11:59 p.m. EDT, April 15, 2012.

#### **Voting shares held by a broker**

If your shares are held by a broker, the broker will ask you how you want your shares to be voted. You may instruct your broker or other nominee to vote your shares by following instructions that the broker or nominee provides to you. Most brokers offer voting by mail, by telephone, and on the Internet.

If you give the broker instructions, your shares will be voted as you direct. If you do not give instructions, one of two things can happen, depending on the type of proposal. For the ratification of the auditor, the broker may vote your shares in its discretion. For all other proposals, the broker may not vote your shares at all.

#### **Voting shares held in the 401(k) plan**

You may instruct the plan trustee on how to vote your shares in the 401(k) plan via the Internet, by mail, or by telephone as described above, except that, if you vote by mail, the card that you use will be a voting instruction card rather than a proxy card.

In addition, unless you decline, your vote will apply to a proportionate number of other shares held in the 401(k) plan for which voting directions are not received. These undirected shares include:

- shares credited to the accounts of participants who do not return their voting instructions (except for a small number of shares from a prior stock ownership plan, which can be voted only on the directions of the participants to whose accounts the shares are credited)
- shares held in the plan that are not yet credited to individual participants' accounts.

All participants are named fiduciaries under the terms of the 401(k) plan and under the Employee Retirement Income Security Act (ERISA) for the limited purpose of voting shares credited to their accounts and the portion of undirected shares to which their vote applies. Under ERISA, fiduciaries are required to act prudently in making voting decisions.

If you do not want to have your vote applied to the undirected shares, you must so indicate when you vote. Otherwise, the trustee will automatically apply your voting preferences to the undirected shares proportionally with all other participants who elected to have their votes applied in this manner.

If you do not vote, your shares will be voted by other plan participants who have elected to have their voting preferences applied proportionally to all shares for which voting instructions are not otherwise received.

#### **Proxy cards and notices**

If you received more than one proxy card, notice, or e-mail related to proxy materials, you hold shares in more than one account. To ensure that all your shares are voted, sign and return each card. Alternatively, if you vote by telephone or on the Internet, you will need to vote once for each proxy card, notice, or e-mail you receive. If you do not receive a proxy card, you may have elected to receive your proxy statement electronically, in which case you should have received an e-mail with directions on how to access the proxy statement and how to vote your shares. If you wish to request a paper copy of these materials and a proxy card, please call 317-433-5112.

#### **Vote tabulation**

Votes are tabulated by an independent inspector of election, IVS Associates, Inc.

#### **Attending the annual meeting**

All shareholders as of the record date may attend by presenting the admission ticket that appears at the end of this proxy statement. Please fill it out and bring it with you to the meeting. The meeting will be held at the Lilly Center Auditorium. Please use the Lilly Center entrance to the south of the fountain at the intersection of Delaware and McCarty streets. You will need to pass through security, including a metal detector. Present your ticket to an usher at the meeting.

Parking will be available on a first-come, first-served basis in the garage indicated on the map at the end of this report. If you have questions about admittance or parking, you may call 317-433-5112.

#### **The 2013 annual meeting**

The company's 2013 annual meeting is currently scheduled for May 6, 2013.

**Shareholder proposals**

If a shareholder wishes to have a proposal considered for inclusion in next year's proxy statement, he or she must submit the proposal in writing so that we receive it by November 5, 2012. Proposals should be addressed to the company's corporate secretary, Lilly Corporate Center, Indianapolis, Indiana 46285. In addition, the company's bylaws provide that any shareholder wishing to propose any other business at the annual meeting must give the company written notice by November 5, 2012 and no earlier than September 6, 2012. That notice must provide certain other information as described in the bylaws. Copies of the bylaws are available online at <http://investor.lilly.com/governance.cfm> or in paper form upon request to the company's corporate secretary.

## *Other Matters*

### **Section 16(a) Beneficial Ownership Reporting Compliance**

Under SEC rules, our directors and executive officers are required to file with the SEC reports of holdings and changes in beneficial ownership of company stock. We have reviewed copies of reports provided to the company, as well as other records and information. Based on that review, we concluded that all reports were timely filed, except that, due to administrative errors, Dr. Fionnuala Walsh was late in reporting the vesting of an equity award received by her husband; Ms. Anne Nobles was late in reporting a stock sale; and Mr. Hoover was late in reporting the deferral of one month's compensation into the Lilly Directors' Deferral Plan. Each filing was made promptly after the issue was discovered.

### **Other Information Regarding the Company's Proxy Solicitation**

We will pay all expenses in connection with our solicitation of proxies. We will pay brokers, nominees, fiduciaries, or other custodians their reasonable expenses for sending proxy material to and obtaining instructions from persons for whom they hold stock of the company. We expect to solicit proxies primarily by mail, but directors, officers, and other employees of the company may also solicit in person or by telephone, fax, or electronic mail. We have retained Georgeson Inc. to assist in the distribution and solicitation of proxies. Georgeson may solicit proxies by personal interview, telephone, fax, mail, and electronic mail. We expect that the fee for those services will not exceed \$17,500 plus reimbursement of customary out-of-pocket expenses.

By order of the board of directors,

James B. Lootens  
Secretary

March 5, 2012

## Appendix A

### Proposed Amendments to the Company's Articles of Incorporation

Proposed changes to the company's articles of incorporation are shown below related to Items 4 and 5, "Items of Business To Be Acted Upon at the Meeting." The changes shown to Article 9(b) will be effective if "Item 4. Proposal to Amend the Company's Articles of Incorporation to Provide for Annual Election of All Directors" receives the vote of at least 80 percent of the outstanding shares. The changes to Articles 9(c), 9(d), and 13 will be effective if "Item 5. Proposal to Amend the Company's Articles of Incorporation to Eliminate All Supermajority Voting Requirements" receives the vote of at least 80 percent of the outstanding shares. Additions are indicated by underlining and deletions are indicated by strike-outs.

.....

9. The following provisions are inserted for the management of the business and for the conduct of the affairs of the Corporation, and it is expressly provided that the same are intended to be in furtherance and not in limitation or exclusion of the powers conferred by statute:

(a) The number of directors of the Corporation, exclusive of directors who may be elected by the holders of any one or more series of Preferred Stock pursuant to Article 7(b) (the "Preferred Stock Directors"), shall not be less than nine, the exact number to be fixed from time to time solely by resolution of the Board of Directors, acting by not less than a majority of the directors then in office.

(b) ~~The Prior to the 2013 annual meeting of directors, the Board of Directors (exclusive of Preferred Stock Directors) shall be divided into three classes, with the term of office of one class expiring each year. At the annual meeting of shareholders in 1985, five directors of the first class shall be elected to hold office for a term expiring at the 1986 annual meeting, five directors of the second class shall be elected to hold office for a term expiring at the 1987 annual meeting, and six directors of the third class shall be elected to hold office for a term expiring at the 1988 annual meeting. Commencing with the annual meeting of shareholders in 1986~~2013, each class of directors whose term shall then expire shall be elected to hold office for a three one-year term expiring at the next annual meeting of shareholders. In the case of any vacancy on the Board of Directors, ~~including a vacancy created by an increase in the number of directors,~~ the vacancy shall be filled by election of the Board of Directors with the director so elected to serve for the remainder of the term of the director being replaced or, in the case of an additional director, ~~for the remainder of the term of the class to which the director has been assigned.~~ until the next annual meeting of shareholders. All directors shall continue in office until the election and qualification of their respective successors in office. ~~When the number of directors is changed, any newly created directorships or any decrease in directorships shall be so assigned among the classes by a majority of the directors then in office, though less than a quorum, as to make all classes as nearly equal in number as possible. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Election of directors need not be by written ballot unless the By-laws so provide.~~

(c) Any director or directors (exclusive of Preferred Stock Directors) may be removed from office at any time, but only for cause and only by the affirmative vote of ~~at least 80%~~a majority of the votes ~~entitled to be cast by the holders of all the outstanding shares~~ of Voting Stock (as defined in Article 13 hereof), voting together as a single class.

(d) ~~Notwithstanding any other provision of these Amended Articles of Incorporation or of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class of Voting Stock required by law or these Amended Articles of Incorporation, the affirmative vote of at least 80% of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock, voting together as a single class, shall be required to alter, amend or repeal this Article 9.~~

.....

13. In addition to all other requirements imposed by law and these Amended Articles ~~and except as otherwise expressly provided in paragraph (c) of this Article 13~~, none of the actions or transactions listed in paragraph (a) below shall be effected by the Corporation, or approved by the Corporation as a shareholder of any majority-owned subsidiary of the Corporation if, as of the record date for the determination of the shareholders entitled to vote thereon, any Related Person (as hereinafter defined) exists, unless the applicable requirements of paragraphs (b), (c), (d), (e), and (f) of this Article 13 are satisfied.

(a) The actions or transactions within the scope of this Article 13 are as follows:

- (i) any merger or consolidation of the Corporation or any of its subsidiaries into or with such Related Person;
- (ii) any sale, lease, exchange, or other disposition of all or any substantial part of the assets of the Corporation or any of its majority-owned subsidiaries to or with such Related Person;
- (iii) the issuance or delivery of any Voting Stock (as hereinafter defined) or of voting securities of any of the Corporation's majority-owned subsidiaries to such Related Person in exchange for cash, other assets or securities, or a combination thereof;
- (iv) any voluntary dissolution or liquidation of the Corporation;
- (v) any reclassification of securities (including any reverse stock split), or recapitalization of the Corporation, or any merger or consolidation of the Corporation with any of its subsidiaries, or any other transaction (whether or not with or otherwise involving a Related Person) that has the effect, directly or indirectly, of increasing the proportionate share of any class or series of capital stock of the Corporation, or any securities convertible into capital stock of the Corporation or into equity securities of any subsidiary, that is beneficially owned by any Related Person; or
- (vi) any agreement, contract, or other arrangement providing for any one or more of the actions specified in the foregoing clauses (i) through (v).

(b) The actions and transactions described in paragraph (a) of this Article 13 shall have been authorized by the affirmative vote of ~~at least 80% of all~~ a majority of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock, voting together as a single class.

~~(c) Notwithstanding paragraph (b) of this Article 13, the 80% voting requirement shall not be applicable if any action or transaction specified in paragraph (a) is approved by the Corporation's Board of Directors and by a majority of the Continuing Directors (as hereinafter defined).~~

~~(d)~~ Unless approved by a majority of the Continuing Directors, after becoming a Related Person and prior to consummation of such action or transaction:

- (i) the Related Person shall not have acquired from the Corporation or any of its subsidiaries any newly issued or treasury shares of capital stock or any newly issued securities convertible into capital stock of the Corporation or any of its majority-owned subsidiaries, directly or indirectly (except upon conversion of convertible securities acquired by it prior to becoming a Related Person or as a result of a pro rata stock dividend or stock split or other distribution of stock to all shareholders pro rata);
- (ii) such Related Person shall not have received the benefit directly or indirectly (except proportionately as a shareholder) of any loans, advances, guarantees, pledges, or other financial assistance or tax credits provided by the Corporation or any of its majority-owned subsidiaries, or made any major changes in the Corporation's or any of its majority-owned subsidiaries' businesses or capital structures or reduced the current rate of dividends payable on the Corporation's capital stock below the rate in effect immediately prior to the time such Related Person became a Related Person; and
- (iii) such Related Person shall have taken all required actions within its power to ensure that the Corporation's Board of Directors included representation by Continuing Directors at least proportionate to the voting power of the shareholdings of Voting Stock of the Corporation's Remaining Public Shareholders (as hereinafter defined), with a Continuing Director to occupy an additional Board position if a fractional right to a director results and, in any event, with at least one Continuing Director to serve on the Board so long as there are any Remaining Public Shareholders.

(e) A proxy statement responsive to the requirements of the Securities Exchange Act of 1934, as amended, whether or not the Corporation is then subject to such requirements, shall be mailed to the shareholders of the Corporation for the purpose of soliciting shareholder approval of such action or transaction and shall contain at the front thereof, in a prominent place, any recommendations as to the advisability or inadvisability of the action or transaction which the Continuing Directors may choose to state and, if deemed advisable by a majority of the Continuing Directors, the opinion of an investment banking firm selected by a majority of the Continuing Direc-

tors as to the fairness (or not) of the terms of the action or transaction from a financial point of view to the Remaining Public Shareholders, such investment banking firm to be paid a reasonable fee for its services by the Corporation. The requirements of this paragraph (ed) shall not apply to any such action or transaction which is approved by a majority of the Continuing Directors.

(fe) For the purpose of this Article 13

(i) the term "Related Person" shall mean any other corporation, person, or entity which beneficially owns or controls, directly or indirectly, 5% or more of the outstanding shares of Voting Stock, and any Affiliate or Associate (as those terms are defined in the General Rules and Regulations under the Securities Exchange Act of 1934) of a Related Person; *provided, however*, that the term Related Person shall not include (a) the Corporation or any of its subsidiaries, (b) any profit-sharing, employee stock ownership or other employee benefit plan of the Corporation or any subsidiary of the Corporation or any trustee of or fiduciary with respect to any such plan when acting in such capacity, or (c) Lilly Endowment, Inc.; and *further provided*, that no corporation, person, or entity shall be deemed to be a Related Person solely by reason of being an Affiliate or Associate of Lilly Endowment, Inc.;

(ii) a Related Person shall be deemed to own or control, directly or indirectly, any outstanding shares of Voting Stock owned by it or any Affiliate or Associate of record or beneficially, including without limitation shares

a. which it has the right to acquire pursuant to any agreement, or upon exercise of conversion rights, warrants, or options, or otherwise or

b. which are beneficially owned, directly or indirectly (including shares deemed owned through application of clause a. above), by any other corporation, person, or other entity with which it or its Affiliate or Associate has any agreement, arrangement, or understanding for the purpose of acquiring, holding, voting, or disposing of Voting Stock, or which is its Affiliate (other than the Corporation) or Associate (other than the Corporation);

(iii) the term "Voting Stock" shall mean all shares of any class of capital stock of the Corporation which are entitled to vote generally in the election of directors;

(iv) the term "Continuing Director" shall mean a director who is not an Affiliate or Associate or representative of a Related Person and who was a member of the Board of Directors of the Corporation immediately prior to the time that any Related Person involved in the proposed action or transaction became a Related Person or a director who is not an Affiliate or Associate or representative of a Related Person and who was nominated by a majority of the remaining Continuing Directors; and

(v) the term "Remaining Public Shareholders" shall mean the holders of the Corporation's capital stock other than the Related Person.

(ff) A majority of the Continuing Directors of the Corporation shall have the power and duty to determine for the purposes of this Article 13, on the basis of information then known to the Continuing Directors, whether (i) any Related Person exists or is an Affiliate or an Associate of another and (ii) any proposed sale, lease, exchange, or other disposition of part of the assets of the Corporation or any majority-owned subsidiary involves a substantial part of the assets of the Corporation or any of its subsidiaries. Any such determination by the Continuing Directors shall be conclusive and binding for all purposes.

(fg) Nothing contained in this Article 13 shall be construed to relieve any Related Person or any Affiliate or Associate of any Related Person from any fiduciary obligation imposed by law.

(fh) The fact that any action or transaction complies with the provisions of this Article 13 shall not be construed to waive or satisfy any other requirement of law or these Amended Articles of Incorporation or to impose any fiduciary duty, obligation, or responsibility on the Board of Directors or any member thereof, to approve such action or transaction or recommend its adoption or approval to the shareholders of the Corporation, nor shall such compliance limit, prohibit, or otherwise restrict in any manner the Board of Directors, or any member thereof, with respect to evaluations of or actions and responses taken with respect to such action or transaction. The Board of Directors of the Corporation, when evaluating any actions or transactions described in paragraph (a) of this Article 13, shall, in connection with the exercise of its judgment in determining what is in the best interests of the Corporation and its shareholders, give due consideration to all relevant factors, including without limitation the social and economic effects on the employees, customers, suppliers, and other constituents of the Corporation and its subsidiaries and on the communities in which the Corporation and its subsidiaries operate or are located.

(j) Notwithstanding any other provision of these Amended Articles of Incorporation or of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class of Voting Stock required by law or these Amended Articles of Incorporation, the affirmative vote of the holders of at least 80% of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock, voting together as a single class, shall be required to alter, amend, or repeal this Article 13.

*transforming challenges  
into advances*

*Lilly*

Corporate Information



## *Executive Committee*

**John C. Lechleiter, Ph.D.**

*Chairman, President, and Chief Executive Officer*

**Robert A. Armitage**

*Senior Vice President and General Counsel*

**Enrique A. Conterno**

*Senior Vice President, and President, Lilly Diabetes*

**Maria Crowe**

*President, Manufacturing Operations*

**Stephen F. Fry**

*Senior Vice President, Human Resources and Diversity*

**Jan M. Lundberg, Ph.D.**

*Executive Vice President, Science and Technology, and  
President, Lilly Research Laboratories*

**Susan Mahony, Ph.D.**

*Senior Vice President, and President, Lilly Oncology*

**Anne Nobles**

*Senior Vice President, Enterprise Risk Management, and Chief  
Ethics and Compliance Officer*

**Barton R. Peterson**

*Senior Vice President, Corporate Affairs and Communications*

**Derica W. Rice**

*Executive Vice President, Global Services, and  
Chief Financial Officer*

**David A. Ricks**

*Senior Vice President, and President, Lilly Bio-Medicines*

**Jeffrey N. Simmons**

*Senior Vice President, and President, Elanco Animal Health*

**Jacques Tapiero**

*Senior Vice President, and President, Emerging Markets*

**Fionnuala Walsh, Ph.D.**

*Senior Vice President, Global Quality*

## *Senior Leadership*

**E. Paul Ahern, Ph.D.**

*Senior Vice President, Global API and Dry Products  
Manufacturing*

**Alex M. Azar II**

*President, Lilly USA*

**Jeffrey A. Balagna**

*Senior Vice President and Chief Information Officer*

**Robert B. Brown**

*Senior Vice President, Marketing, and Chief Marketing Officer*

**Timothy J. Garnett, M.D.**

*Senior Vice President, Development Center of Excellence,  
Lilly Research Laboratories, and Chief Medical Officer*

**Thomas W. Grein**

*Senior Vice President, Finance, and Treasurer*

**William F. Heath Jr., Ph.D.**

*Senior Vice President, Product Research and Development,  
Lilly Research Laboratories*

**Elizabeth G. O'Farrell**

*Senior Vice President, Policy and Finance*

**Myles O'Neill**

*Senior Vice President, Global Parenteral Drug Product and  
Delivery Devices Manufacturing*

**Joshua L. Smiley**

*Senior Vice President, Finance, and Chief Financial Officer,  
Lilly Research Laboratories*

**Thomas R. Verhoeven, Ph.D.**

*Senior Vice President, Development Center of Excellence,  
Lilly Research Laboratories*

**J. Anthony Ware, M.D.**

*Group Vice President, Neuroscience/Cardiovascular Acute  
Care/Urology Product Development*

**Alfonso G. Zulueta**

*President and General Manager, Lilly Japan*

## Corporate Information

### Annual meeting

The annual meeting of shareholders will be held at the Lilly Center Auditorium, Lilly Corporate Center, Indianapolis, Indiana, on Monday, April 16, 2012, at 11:00 a.m. EDT. For more information, see the proxy statement section of this report.

### 10-K and 10-Q reports

Paper copies of the company's annual report to the Securities and Exchange Commission on Form 10-K and quarterly reports on Form 10-Q are available upon written request to:

Eli Lilly and Company  
c/o Corporate Secretary  
Lilly Corporate Center  
Indianapolis, Indiana 46285

To access these reports more quickly, you can find all of our SEC filings online at: <http://investor.lilly.com/sec.cfm>

### Stock listings

Eli Lilly and Company common stock is listed on the New York, London, and Swiss stock exchanges. NYSE ticker symbol: LLY. Most newspapers list the stock as "Lilly (Eli) and Co."

### CEO and CFO certifications

The company's chief executive officer and chief financial officer have provided all certifications required under Securities and Exchange Commission regulations with respect to the financial information and disclosures in this report. The certifications are available as exhibits to the company's Form 10-K and 10-Q reports.

In addition, the company's chief executive officer has filed with the New York Stock Exchange a certification to the effect that, to the best of his knowledge, the company is in compliance with all corporate governance listing standards of the Exchange.

### Transfer agent and registrar

Wells Fargo Shareowner Services  
Mailing address:

Shareowner Relations Department  
P.O. Box 64854  
St. Paul, Minnesota 55164-0854

Overnight address:

161 North Concord Exchange  
South St. Paul, Minnesota 55075

Telephone: 1-800-833-8699

E-mail: [stocktransfer@wellsfargo.com](mailto:stocktransfer@wellsfargo.com)

Internet:

<https://wellsfargo.com/contactshareownerservices>

### Dividend reinvestment and stock purchase plan

Wells Fargo Shareowner Services administers the Shareowner Service Plus Plan, which allows registered shareholders to purchase additional shares of Lilly common stock through the automatic investment of dividends. The plan also allows registered shareholders and new investors to purchase shares with cash payments, either by check or by automatic deductions from checking or savings accounts. The minimum initial investment for new investors is \$1,000. Subsequent investments must be at least \$50. The maximum cash investment during any calendar year is \$150,000. Please direct inquiries concerning the Shareowner Service Plus Plan to:

Wells Fargo Shareowner Services  
Shareowner Relations Department  
P.O. Box 64854  
St. Paul, Minnesota 55164-0854  
Telephone: 1-800-833-8699

### Online delivery of proxy materials

Shareholders may elect to receive annual reports and proxy materials online. This reduces paper mailed to the shareholder's home and saves the company printing and mailing costs. To enroll, go to <http://investor.lilly.com/services.cfm> and follow the directions provided.

## *Trademarks Used In This Report*

Trademarks or service marks owned by Eli Lilly and Company or its subsidiaries or affiliates, when first used in this report, appear with an initial capital and are followed by the symbol<sup>®</sup> or<sup>™</sup>, as applicable. In subsequent uses of the marks in the report, the symbols are omitted.

Actos<sup>®</sup> is a trademark of Takeda Chemical Industries, Ltd.

Axid<sup>®</sup> is a trademark of Reliant Pharmaceuticals, LLC

Bydureon<sup>™</sup> and Byetta<sup>®</sup> are trademarks of Amylin Pharmaceuticals, Inc.

Darvon<sup>®</sup> is a trademark of Xanodyne Pharmaceuticals, Inc.

Livalo<sup>®</sup> is a trademark of Kowa Company Ltd.

Tradjenta<sup>™</sup>, Trazenta<sup>™</sup>, and Trajenta<sup>®</sup> are trademarks of Boehringer Ingelheim GmbH

Vancocin<sup>®</sup> is a trademark of ViroPharma Incorporated



# Annual Meeting Admission Ticket

Eli Lilly and Company 2012 Annual Meeting of Shareholders  
Monday, April 16, 2012  
11:00 a.m. EDT

Lilly Center Auditorium  
Lilly Corporate Center  
Indianapolis, Indiana 46285

**The top portion of this page will be required for admission to the meeting.**

Please write your name and address in the space provided below and present this ticket when you enter the Lilly Center.

Doors open at 10:15 a.m.


Name

Address

City, State, and Zip Code

Detach here

Detach here



## Directions and Parking

From I-70 take Exit 79B; follow signs to McCarty Street. Turn right (east) on McCarty Street; go straight into Lilly Corporate Center. You will be directed to parking. **Be sure to take the admission ticket (the top portion of this page) with you to the meeting and leave this parking pass on your dashboard.**

**Take the top portion of this page with you to the meeting.**

Detach here

Detach here

Eli Lilly and Company  
Annual Meeting of Shareholders  
April 16, 2012

**Complimentary Parking**  
**Lilly Corporate Center**

**Please place this identifier on the dashboard of your car as you enter Lilly Corporate Center so it can be clearly seen by security and parking personnel.**



**Connecting Hearts Abroad:  
Giving service and gaining insights**

*Re'Nita O'Bannon, senior executive assistant, U.S. oncology business unit, was a 2011 Connecting Hearts Abroad ambassador, working in an elderly day center in Lima, Peru, where a local volunteer knitted this alpaca scarf.*

**For more information on Lilly's commitment to corporate responsibility and transparency**

Corporate Responsibility:

[www.lilly.com/responsibility](http://www.lilly.com/responsibility)

Lilly Clinical Trial Registry:

[www.lillytrials.com](http://www.lillytrials.com)

Lilly Grant Office Registry:

[www.lillygrantoffice.com/pages/grant\\_registry.aspx](http://www.lillygrantoffice.com/pages/grant_registry.aspx)

Lilly Physician Payment Registry:

[www.lillyphysicianpaymentregistry.com](http://www.lillyphysicianpaymentregistry.com)

LillyPAC Report of Political Financial Support:

[www.lilly.com/about/public\\_affairs](http://www.lilly.com/about/public_affairs)

**For more information on Lilly and pharmaceutical industry patient-assistance programs**

Lilly TruAssist:

[www.lillytruassist.com](http://www.lillytruassist.com)

or call toll-free 1.855.LLY.TRUE (1.855.559.8783)

Partnership for Prescription Assistance (industry program):

[www.pparx.org](http://www.pparx.org)

**For perspectives on health care innovation**

LillyPAD, an official blog of Eli Lilly and Company:

[lillypad.lilly.com](http://lillypad.lilly.com)

## *Transforming corporate responsibility to meet global challenges*

For more than 135 years, Lilly has demonstrated its commitment to be a responsible global citizen. Today, our understanding of corporate responsibility is evolving beyond charity and reaching into the core of our business operations.

We're using our business assets and expertise in new ways to create shared value for society and our company where we can have sustainable impact through our corporate responsibility efforts.

Our vision as a company is to make a significant contribution to humanity by improving global health in the 21st century. Lilly's greatest contribution has always been to discover and develop innovative medicines, which we believe will continue to be among the most powerful tools to improve the quality and reduce the cost of health care.

Today, we aim to put a special focus on improving the health of underserved people in low- and middle-income countries around the globe. We'll do this not only by contributing money, but also by applying what we do best, drawing on our scientific, technical, and business expertise.

We will sustain our efforts aimed at serving our local communities and reducing our environmental footprint. And we will continue to apply the energy of Lilly employees in their communities and, through Connecting Hearts Abroad, provide them opportunities to gain understanding by volunteering around the world.

Our commitment to corporate responsibility is also reflected in our ongoing support for the United Nations Global Compact's 10 principles related to human rights, labor, the environment, and anti-corruption.

You can review our performance across all areas of our business in our 2010/2011 Corporate Responsibility Report at [www.lilly.com](http://www.lilly.com).



Answers That Matter.

*Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285 USA  
317-276-2000  
[www.lilly.com](http://www.lilly.com)*